<SEC-DOCUMENT>0001493152-25-011685.txt : 20250807
<SEC-HEADER>0001493152-25-011685.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807085218
ACCESSION NUMBER:		0001493152-25-011685
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		251191881

	BUSINESS ADDRESS:	
		STREET 1:		601 21ST STREET, SUITE 300
		CITY:			VERO BEACH
		STATE:			FL
		ZIP:			32960
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		601 21ST STREET, SUITE 300
		CITY:			VERO BEACH
		STATE:			FL
		ZIP:			32960

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:PCSA="http://processapharmaceuticals.com/20250630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_PCSA_processapharmaceuticals.com_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20250101_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  <ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-06-30" id="xdx2ixbrl0110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:IncreaseDecreaseInDueFromToRelatedParties" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2025-01-01to2025-06-30" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2024-01-012024-06-30" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0672" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0674" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2025-06-30" id="xdx2ixbrl0872" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20250630#OperatingAndFinanceLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2025-06-30" id="xdx2ixbrl0875" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://processapharmaceuticals.com/20250630#OperatingAndFinanceLeaseLiabilityNoncurrent</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20250630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-292025-01-29_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-29</xbrli:startDate>
        <xbrli:endDate>2025-01-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-182025-06-18_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-18</xbrli:startDate>
        <xbrli:endDate>2025-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_JunePOMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:JunePOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-04</xbrli:startDate>
        <xbrli:endDate>2025-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ATMAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-04</xbrli:startDate>
        <xbrli:endDate>2025-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ChiefExecutiveOfficerAndCertainBoardMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_EmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-19_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JanuaryPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:JanuaryPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JunePOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:JunePOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonWarrantsMember_custom_JunePOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:JunePOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PlacementAgentWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:PlacementAgentWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember18079015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-172025-06-17_custom_PCS12852Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">PCSA:PCS12852Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-17</xbrli:startDate>
        <xbrli:endDate>2025-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CROsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:CROsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-242025-07-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-24</xbrli:startDate>
        <xbrli:endDate>2025-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>PCSA:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000898" toRefs="Footnote000937"/>
  <ix:relationship fromRefs="Fact000899" toRefs="Footnote000937"/>
  <ix:relationship fromRefs="Fact000900" toRefs="Footnote000937"/>
  <ix:relationship fromRefs="Fact000901" toRefs="Footnote000937"/>
  <ix:relationship fromRefs="Fact000908" toRefs="Footnote000946"/>
  <ix:relationship fromRefs="Fact000909" toRefs="Footnote000946"/>
  <ix:relationship fromRefs="Fact000910" toRefs="Footnote000946"/>
  <ix:relationship fromRefs="Fact000911" toRefs="Footnote000946"/>
  <ix:relationship fromRefs="Fact000918" toRefs="Footnote000955"/>
  <ix:relationship fromRefs="Fact000919" toRefs="Footnote000955"/>
  <ix:relationship fromRefs="Fact000920" toRefs="Footnote000955"/>
  <ix:relationship fromRefs="Fact000921" toRefs="Footnote000955"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>Securities
and Exchange Commission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20250101__20250630_z6vUwLTam9u4"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000014" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentQuarterlyReport_c20250101__20250630_zUkcHz5tgch6"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_901_edei--DocumentPeriodEndDate_c20250101__20250630_z9sZl7QFYBs2"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_907_edei--DocumentFiscalYearFocus_c20250101__20250630_z2elJ8VFHJqj"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000017" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--DocumentTransitionReport_c20250101__20250630_zAMkvZh2Qm42"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ____ to ____</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_904_edei--EntityFileNumber_c20250101__20250630_zLXt0oXQtdzd"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000019" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20250101__20250630_zpf8jKxULnri"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000020" name="dei:EntityRegistrantName">Processa
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20250101__20250630_znc8l5PQ2iJ8"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20250101__20250630_zp6iSLkgEVJ7"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000022" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20250101__20250630_zoSLDnlQX9yk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000023" name="dei:EntityAddressAddressLine1">601
21<sup>st</sup> Street</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250101__20250630_zYzuknX9GUie"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20250101__20250630_zZzNQKwvL4F3"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000025" name="dei:EntityAddressCityOrTown">Vero
Beach</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250101__20250630_z4oa3ULJfE31"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000026" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250101__20250630_zsBhXRJkz79d"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000027" name="dei:EntityAddressPostalZipCode">32960</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--CityAreaCode_c20250101__20250630_zAvFxxZax9J6"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000028" name="dei:CityAreaCode">(772)</ix:nonNumeric></span>
<span id="xdx_906_edei--LocalPhoneNumber_c20250101__20250630_zsoR137ixU7"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000029" name="dei:LocalPhoneNumber">453-2899</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20250101__20250630_zcb6rSTr6wq5"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000030" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20250101__20250630_zWon5MFWveqh"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000031" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20250101__20250630_zLunFxznQDRh"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20250101__20250630_zmE47AwL2cs4"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20250101__20250630_z0olPmfTSFQ"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20250101__20250630_zRG2kPaZAQxi"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntitySmallBusiness_c20250101__20250630_ztUkS9BxyDD8"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20250101__20250630_zXSwdLTMzEr1"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90A_edei--EntityShellCompany_dbF_c20250101__20250630_zyyCyAUaGvdk"><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding shares of the registrant&#8217;s common stock at August 5, 2025 was <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20250805_zXtFAahlvgB6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-08-05" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,349,149</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
PHARMACEUTICALS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Part I. Financial Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Item 1: Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Item 2: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Item 3. Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Item 4. Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Part II. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Item 1. Legal Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Item 1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Item 3. Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Item 5. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Item 6. Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Part
I: Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1: Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_zX2jomPiYe0f" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250630_zcohdIk3NWvf" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zKyZoDZ7JjP4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsAbstract_iB_zeNp7dtJHChg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zxXVLuX9fjTc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzFTx_zZOPPe8D8xBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,936,620</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,191,325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzFTx_zlOaO7xA1vpd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Prepaid expenses and other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,201</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,294</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzFTx_maCzUWd_zHFuuqNxGU19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,153,821</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,873,619</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PropertyAndEquipmentNet_i01I_maCzUWd_zleqnLNfg1za" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Property and Equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:PropertyAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,414</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:PropertyAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,016</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsNoncurrentAbstract_i01B_zEIUaS6T3Sc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseNoncurrent_i02I_maCznuZ_zMgCXDrvAt7f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2025-06-30" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">993,701</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2024-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274,442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AssetsNoncurrentExcludingPropertyAndEquipmentNet_i02TI_maCzUWd_mtCznuZ_zvETG3bOYrlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Non-current Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">993,701</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274,442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsAbstract_i01B_z9vdmaE6ogX6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzmDx_zLb8FcI8fOub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssets_i02I_maCzmDx_zOfvt7Ux1PX4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_i02TI_mtCzmDx_maCzUWd_zPM7AABbO5Ha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Other Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,853</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,212</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_mtCzUWd_zdFESHfOMiWa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,181,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,229,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zDaz7BF1j2ql" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zCOr7HOvdxu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--OperatingAndFinanceLeaseLiabilityCurrent_i02I_maCzdaF_zxZ7sUJVvZ4e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Current maturities of lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,584</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_i02I_maCzdaF_zH7QCHja0gu5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-06-30" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">785,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">880,880</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzdaF_zAMJ7Kv3NqK3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,263,243</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">578,731</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i01TI_mtCzdaF_maCzqW8_zR7si6LJjEta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,074,581</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,532,631</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zflwODidDuN6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OperatingAndFinanceLeaseLiabilityNoncurrent_i02I_maCzqW8_zXuceOON6fHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Non-current lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtCzqW8_maCzmRU_zflw0wnVGaG3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,074,581</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,533,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommitmentsAndContingencies_i01I_maCzmRU_zst63ishvdSe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0110">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PreferredStockValue_i02I_maCzQm4_zWiJyzm5Nto3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Preferred stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250630_z6KJ7y6VTjP8" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zh3ayOloSZpc" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250630_zsiQDFppE7R2" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z77UqyCtPmQc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20250630_zktzovjLh4r9" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20250630_zBDbuNBRb1qa" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zp3WCy0wb1h" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zOF5SThAOTdb" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000127" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000129" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000133" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued or outstanding at June 30, 2025 or December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maCzQm4_zVUaMlkzRDaj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250630_zds22kd3t2Ag" title="Common stock, par value"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zNcudF4zKf09" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_zVf9upRgBzl4" title="Common stock, shares authorized"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zUxToxQSS3Rl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20250630_zNAREWNVIaek" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,289,356</ix:nonFraction></span> issued and <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250630_zvYr8eeGEPa9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,284,356</ix:nonFraction></span> outstanding at June 30, 2025; and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zi92J39O2wZc" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,707,628</ix:nonFraction></span> issued and <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zJkFBAWX5p96" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,702,628</ix:nonFraction></span> outstanding at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzQm4_zUPDtj2MhGBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2025-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,390,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,214,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TreasuryStockValue_i02NI_di_msCzQm4_zjQned7nmGB6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Treasury stock, <span id="xdx_909_eus-gaap--TreasuryStockCommonShares_iI_pid_c20250630_zTlltUVRUEh5" title="Treasury stock shares"><span id="xdx_902_eus-gaap--TreasuryStockCommonShares_iI_pid_c20241231_zUsyhsdWPPc8" title="Treasury stock shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2025-06-30" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzQm4_zyOYCc33J0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,987,522</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,219,199</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquity_i02TI_maCzmRU_mtCzQm4_zlufO3q8zoVg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,107,208</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,696,171</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzmRU_z4MP5I8qRB8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,181,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,229,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zaLajUcV1jvi" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250401__20250630_zMBiu81MgBwc" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240401__20240630_zFM5j12amiz8" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250630_z8kNcq4ejGWd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20240630_zPEVv77BAUF" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zgm95U13lcH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_i01_msOILzpXC_ztNHi5Irf9A7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-04-012025-06-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,447,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-04-012024-06-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,730,444</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-01to2025-06-30" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,035,767</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,269,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_msOILzpXC_zv6CDW7aROC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-04-012025-06-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,503,497</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,351,580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,762,006</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,622,067</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_mtOILzpXC_maILFCOz7kr_zXeNf8y5WtFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,950,783</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,082,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,797,773</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,891,622</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncome_maILFCOz7kr_zsSbB5bS46A7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other Income (Expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-04-012025-06-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-04-012024-06-30" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,698</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-01to2025-06-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,915</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iT_mtILFCOz7kr_zlcrE9O3SDLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000198" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,933,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,768,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss per Common Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20250401__20250630_zDStyrZyeyj4" title="Net Loss Per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_z84M7VYIkTF3" title="Net Loss Per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-04-012025-06-30" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-012025-06-30" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20240401__20240630_zzfZjemm8H86" title="Net Loss Per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zrwrG5Pml669" title="Net Loss Per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250630_zlU4Hhxuj7sh" title="Net Loss Per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zf3eJnqnFl1k" title="Net Loss Per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-06-30" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.55</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240630_ziMww5lWB1r2" title="Net Loss per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zBkpZe7YCAxc" title="Net Loss per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.11</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zdP74Eoi90Fb" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_z0n3MKElz6J5" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,569,312</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zmnjpOkJ1x66" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_z9EQcoZ3ZbGh" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zntdLzUydswb" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zRcPOTit3Kah" title="Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-06-30" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,401,583</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zNBlBadv8457" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zwpnRTYjvCq7" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zkk5Nba9jlZ4" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z0tbEVZjCZGf" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z7Z7l3SWfxpl" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zpGzRalwOuEg" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z6Ik4epP4DB2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_zM2cXv2ksm7b" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Paid-In</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_z3Sp7HYZ6iT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziMtDjJLpeu7" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,658,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--TreasuryStockCommonShares_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zjzhkO4IMtte" title="Treasury Stock balance, shares" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,989,159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z8KGErCd1w7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwYR13xqj1jj" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zs7xoiq7m7h9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in connection with capital raise, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zC7uTBuKQ1m6" title="Shares issued in connection with capital raises, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,555,555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,282,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,282,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zuAIAqb74jXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in connection with license agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Au7BWqViA3" title="Shares issued in connection with license agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-03-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_zjowV1J42Llh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Settlement of stock award</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zv5Pebq5lsa9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_iN_pid_di_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA8ZXQ7Lkm27" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_ztxv3C6Y0Rld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20240401__20240630_eus-gaap--StockholdersEquity_iS_zhOICsndhe81" style="vertical-align: bottom; background-color: White">
    <td>Balance, March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSbpZ0svK2ji" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,860,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,278,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--TreasuryStockCommonShares_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zIiTZyed3qLc" title="Treasury Stock balance, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,095,462</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,883,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z01J4SfdtPs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5VswpO57nn2" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zOYviK0ENeBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_iN_pid_di_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIPW1gLMxQ8b" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,008</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,008</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zfSBj8wljlA8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20240401__20240630_eus-gaap--StockholdersEquity_iE_zieCGOPUnUAd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgf8IqEwwzQi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000327" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,873,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,429,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--TreasuryStockCommonShares_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zA5e1mzo5YHk" title="Treasury Stock balance, shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000329" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000323" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000324" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,105,788</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,023,664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Paid-In</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_435_c20250101__20250331_eus-gaap--StockholdersEquity_iS_z6egGMvCre2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXrs2DYZ6UJh" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,707,628</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,214,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--TreasuryStockCommonShares_iS_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_ziBlQRUwHXGd" title="Treasury Stock, balance shares" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000339" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,219,199</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,696,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z2FWswDIJaqi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z79XlqAPCRQh" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-01-012025-03-31" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,711</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLCAU2zox1r5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in connection with capital raise, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgNEximMWHJ8" title="Shares issued in connection with capital raise, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,556,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,438,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,438,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zKxLwsVstS4g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziQFZrK1keb7" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-012025-03-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,439</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_ztuIz0b3rSLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,834,405</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,834,405</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20250401__20250630_eus-gaap--StockholdersEquity_iS_zyMTHFv0jMI2" style="vertical-align: bottom; background-color: White">
    <td>Balance, March 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKeYORmVVEMd" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,274,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,879,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--TreasuryStockCommonShares_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zcknpI1OKdb6" title="Treasury Stock, balance shares" style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,053,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20250401__20250630_eus-gaap--StockholdersEquity_iS_zqOnFsphrSS4" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8a2oMLPvyC7" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,274,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,879,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--TreasuryStockCommonShares_iS_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zNkyvKgpRpwl" title="Treasury Stock, balance shares" style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,053,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z2BHL2jPPVP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjPLMz2dM4B8" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">143,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2025-04-012025-06-30" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zJpWAW2jHM44" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in connection with capital raise, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV2AwywPAHgb" title="Shares issued in connection with capital raises, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,894,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,316,743</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-04-012025-06-30" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,320,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zhZHpNMVVCk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_iN_pid_di_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhPUnnAVOGif" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,987</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,963</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-04-012025-06-30" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,965</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zGFvLf4Cqxcb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000418" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,933,918</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30" id="Fact000419" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,933,918</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20250401__20250630_eus-gaap--StockholdersEquity_iE_zpxro6Yb1LS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNJCqE9D6x5a" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,289,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,390,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--TreasuryStockCommonShares_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zpCk5eEdLHv" title="Treasury Stock, balance shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000429" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,987,522</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,107,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20250401__20250630_eus-gaap--StockholdersEquity_iE_zzTlP006yNPh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrJwTfEgISt6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,289,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,029</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,390,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--TreasuryStockCommonShares_iE_pid_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zimVnhadUFm" title="Treasury Stock, balance shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000439" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000433" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,987,522</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,107,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zKul5EhPwLul" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20250630_zeFnVg0Jb2l" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240630_zqgCeTIIiISb" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zqw5txyIhezc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCzKxB_zp6yscFfFTGi" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000444" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,768,323</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30" id="Fact000445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z96vpcCpbeZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_maCzKxB_zKOHDKbKYZ9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-06-30" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-06-30" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OperatingAndFinanceLeaseExpense_i02_maCzKxB_zX6uPwf4ED83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash lease expense for right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseExpense" contextRef="From2024-01-012024-06-30" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maCzKxB_zEDvICtrhnXd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-06-30" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zaa4pqoVT3pa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzKxB_z2xRapjj2hKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-06-30" id="Fact000462" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">745,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-06-30" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,554</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzKxB_zx37qTOXWR2d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-06-30" id="Fact000465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,073</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-06-30" id="Fact000466" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,228</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzKxB_zkLtB86rcXY8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-01-01to2025-06-30" id="Fact000468" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,126</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-06-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">641,469</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInDueFromToRelatedParties_i03N_di_msCzKxB_zi81SQbXONwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:IncreaseDecreaseInDueFromToRelatedParties" contextRef="From2024-01-012024-06-30" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maCzKxB_zSDKvZxI8Zy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-01-01to2025-06-30" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,512</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-012024-06-30" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzKxB_maCzU4u_zn5HogD9F698" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000,253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-06-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,394,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zyOJZhT2WbAb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCzCpQ_z2ahuk1SCCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from issuance of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-06-30" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,758,802</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-06-30" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,282,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_di_msCzCpQ_zzEjmKC6QDWb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares withheld to pay taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2025-01-01to2025-06-30" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,404</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-06-30" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--PaymentsForSettlementOfStockAwards_i01N_di_msCzCpQ_ziIcZFOargC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Settlement of stock award</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2024-01-012024-06-30" id="Fact000490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msCzCpQ_zwG0paXkIzr8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payment of finance lease obligation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2025-01-01to2025-06-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,850</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-012024-06-30" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,301</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzCpQ_maCzU4u_zivMYHFeRwDa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,745,548</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-06-30" id="Fact000496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,259,636</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzU4u_zZITIQ6VC7B4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Decrease in Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-06-30" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,745,295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-06-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z9CUwPzCJ72b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents - Beginning of Period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,191,325</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,706,197</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zh1nyNuF80s5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents - End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-06-30" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,936,620</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-06-30" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,571,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zNycv3nYVUZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaidNet_i01_z7QVqp75E87d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-06-30" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesPaidNet_i01N_di_zr1vRxrAhVZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z1ZbHaFJWpg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-Cash Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_i01_zVldydw7gbfd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEk52NAKdswl" title="Shares issued in connection with license agreement" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENhc2ggRmxvd3MgKFVuYXVkaXRlZCAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000522" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2024-01-012024-06-30" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_i01_zEuXqSsPrHVj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">New right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2024-01-012024-06-30" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,804</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinancingLeaseLiability_i01_zukej4C1Foeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financing lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2024-01-012024-06-30" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,804</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--NonCashLeaseLiabilityNet_i01_zdNDI21P064k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000533" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zIZIjLFBErTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_zFIjwmIv4qfb">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000535" name="PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock"><p id="xdx_84A_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zmQ34fiLtj4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Organization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation Cancer therapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications
of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known
and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments
will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000537" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmc2n4cY4vO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2024, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000539" name="PCSA:LiquidityPolicyTextBlock"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2hdvmOmWDs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all our efforts toward research and development of our NGC drug product candidates, including conducting
clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20250630_zNh9yWsIe164" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000541" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">94.0</ix:nonFraction></span> million
at June 30, 2025. During the six months ended June 30, 2025, we generated a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zFzXmnNyo545" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-06-30" id="Fact000543" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">6.8</ix:nonFraction></span> million and used $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zpQwioDX2aL4" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-06-30" id="Fact000545" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.0</ix:nonFraction></span> million in net cash
for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore
we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We expect that
we will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2025, we closed a public offering where we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2IACKKI10E1" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,030,972</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, pre-funded warrants to purchase
up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z58Do0rJpmlc" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,019,700</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, and accompanying Series A warrants
to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZTmd28bUka4" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,672</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series A Warrants&#8221;)
and Series B warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCXIC3WoAcM9" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,025,336</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series B Warrants&#8221;)
for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zioWwupi64G1" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember" id="Fact000555" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). On June 18, 2025, we closed another public offering where we sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYXePnTaJ6j4" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember" id="Fact000557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,310,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, pre-funded warrants to purchase up
to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--JunePOMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zXWIl4CjZbd2" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-18_custom_JunePOMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,690,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, and common warrants to purchase up
to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrNMa5jWEqYi" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zH31S1JuM2Z3" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember" id="Fact000563" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.2</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). As of June 30, 2025, all Pre-Funded Warrants from both public offerings were exercised.</span>
During the six months ended June 30, 2025, we also received $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6EycM3aubbj" title="Received exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> for the exercise of warrants to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjpAP6rnKIa5" title="Number of warrants exercised during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078109" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares of common
stock from the June PO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On August 4, 2025, we entered
into a Securities Purchase Agreement with an accredited investor and sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGdBVoKFE98" title="Sale of stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,467,181</ix:nonFraction></span> shares for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgX2dT0HbjF3" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000571" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million in gross proceeds. We also
sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxqId1oMYKpi" title="Sale of stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,597,612</ix:nonFraction></span> shares for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaplZhOhCk9j" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember" id="Fact000575" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million in gross proceeds under our ATM agreement. Following these investments, we are exploring options
to pursue a cryptocurrency treasury strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we had cash and cash equivalents totaling $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_z8sFX0LwBso7" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000577" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million. Based on our current business plans, we believe these funds, together with the $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250801__20250831_z7xMLlYVDhXi" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-08-012025-08-31" id="Fact000579" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million in gross proceeds we received in August  2025, will
satisfy our capital needs into the first quarter of 2026. Our ability to execute our longer-term operating plans, including future preclinical
studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or
debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000581" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_z5RcCwaqmVAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000583" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z2Ef04Iwn7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2025 and December 31, 2024, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2025 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000585" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z5mNCpgeT9r" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Concentration
of Credit Risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2025, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000587" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTwDrg7o1fOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

</ix:nonNumeric><p id="xdx_85D_zXPgsjBm4eK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000589" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1ghFS8XDkcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82B_zmiSHmBEamp1">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2025, we issued the following shares of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    January 2<span style="background-color: white">9</span>, 2025, we sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBLWqiaVnxIk" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember" id="Fact000591" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,030,972</ix:nonFraction></span>
    shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDoVJ4mkLeH2" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,019,700</ix:nonFraction></span>
    shares of our common stock, and accompanying Series A Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zdfJbRXL4Yh6" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,672</ix:nonFraction></span>
    shares of our common stock and Series B Warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyfb6yPMQFh2" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,025,336</ix:nonFraction></span>
    shares of our common stock for net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX2n72ca88tc" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember" id="Fact000599" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span>
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#8220;January
    PO&#8221;) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a combined purchase price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAOyKa1uPNf" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.615</ix:nonFraction></span>
    for institutional investors and $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zvFg6aG7Euyl" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7975</ix:nonFraction></span>
    for the Company&#8217;s Chief Executive Officer and certain board members who participated in the offering. The Series A and B
    Warrants both have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zaHPIGUsXnee" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_SeriesAWarrantsAndSeriesBWarrantsMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span>
    per share of common stock, and were subject to stockholder approval, which was obtained at our annual stockholder meeting on July
    18, 2025. The Series A Warrants will expire on July 18, 2030 and the Series B Warrants will expire on January 18, 2027. At June 30,
    2025, all pre-funded warrants sold in this offering were exercised; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    June 18, 2025, we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKTY8byf7pCd" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,310,000</ix:nonFraction></span>
    shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0bWixmHz5u2" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,690,000</ix:nonFraction></span>
    shares of our common stock. and accompanying common warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znWIqShlfNoj" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></span>
    shares of our common stock for net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze4DwWpXikG4" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember" id="Fact000613" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.2</ix:nonFraction></span>
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#8220;June
    PO&#8221;). We sold one share of our common stock and accompanying common warrant at a combined price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaOwSQUNP838" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></span>
    per share, and a pre-funded warrant and accompanying common warrant at a combined price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_ziNBP3SE0hQ6" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2499</ix:nonFraction></span>
    per share. The common warrants have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_ztAFoLaJ5Ki2" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></span>
    per share, are immediately exercisable and expire five years after their original issuance. The pre-funded warrants have an exercise
    price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_z0KRQNVa8MPe" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
    and are also immediately exercisable. We issued placement agent warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zTReL2a8sQV1" title="Number of warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,000</ix:nonFraction></span>
    shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z740UOGCXj95" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>
    per share. During the six months ended June 30, 2025, warrants to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z3yAYDxF8uo3" title="Number of warrants exercised during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span>
    shares of common stock for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_zQ87JitnQVs4" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> and all pre-funded warrants sold in this offering were exercised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__srt--TitleOfIndividualAxis__custom--EmployeeMember_z3Wdm3slowfc" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-06-30_custom_EmployeeMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,804</ix:nonFraction></span>
    shares of common stock to employees, net of <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20250101__20250630_zFSEIzwsIAog" title="Stock withheld for income taxes"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" contextRef="From2025-01-01to2025-06-30" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,768</ix:nonFraction></span> shares of common stock withheld for income and FICA taxes owed upon the distribution
    of the shares; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_ziAFRD2giEmh" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-06-30_custom_ConsultingAgreementsMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,252</ix:nonFraction></span>
    shares of common stock in connection with consulting agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000637" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqJqgJGrTKRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82F_z1bK6Pag2Kml">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20190619__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zg0FAI78MWeh" title="Maximum equity available for issuance under the plan"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2019-06-19_custom_TwoThousandAndNineteenPlanMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></span> shares of our common stock. At June 30, 2025, we have <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zVIDy0G7TP51" title="Shares available for future grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-06-30_custom_TwoThousandAndNineteenPlanMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">357,420</ix:nonFraction></span>
shares available for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000643" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zpg4GeMkaCLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zgJgUxTUru47" style="display: none">Schedule of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250401__20250630_zcVscPdtSXu3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20240630_zNWAg5OJNjBa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250630_zz0NmpJrXoSl" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_zfeZ7cIRtR03" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXLMkInpisw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,613</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,583</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,704</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0KsLz1TPpK1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000650" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,635</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,049</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,626</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,571</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zMEnZuIYZlhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-06-30" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,275</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zfCuakJXxNl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
stock options to purchase shares of common stock were forfeited or expired during the six months ended June 30, 2025. At June 30, 2025,
we had outstanding and exercisable options for the purchase of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdrtciP0MqL8" title="Options exercisable, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,747</ix:nonFraction></span> shares with a weighted average exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znDFGlwvGfZ1" title="Options exercisable weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000662" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">409.09</ix:nonFraction></span> and a weighted
average remaining contractual life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zipkqjoyNXvg" title="Exercisable weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000664" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.2</ix:nonNumeric></span> years. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we did not have any unrecognized stock-based compensation expense related to our granted stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000666" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEpTZk5XqTjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zH7Q6Wk69Jp9" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvWyFtyJZn1" title="Number of shares, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">383,636</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3zFX1wdn3I5" title="Weighted-average grant-date fair value per share, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000670" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.87</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjJztqK9ZQnl" title="Number of shares, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3gRvcQMP6Dj" title="Weighted-average grant-date fair value per share, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGhj3E7NGK11" title="Number of shares, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,547</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyxpE39co2y4" title="Weighted-average grant-date fair value per share, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">53.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zog80YNNHcec" title="Number of shares, issued" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,804</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z95F34UP6Y89" title="Weighted-average grant-date fair value per share, shares issued" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.78</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP4ZmwMHp0d5" title="Number of shares, ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">281,285</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjAH2VNiTWka" title="Weighted-average grant-date fair value per share, ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Vested and unissued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziTIyR2gCLf5" title="Number of shares, vested and unissued" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">229,905</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHaDFq8RaBr3" title="Weighted-average grant-date fair value per share, vested and unissued" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.47</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CjqvEplxCg" title="Number of shares, unvested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,380</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3NRGzVU0gql" title="Weighted-average grant-date fair value per share, unvested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zawHTNnLT6Fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, unrecognized stock-based compensation expense of approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYJI1eVIK85h" title="Unrecognized share based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></span> for RSUs is expected to be fully recognized over
a weighted average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8TpAcBy1Vg" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact000698" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.7</ix:nonNumeric></span> years. The unrecognized expense excludes approximately $<span id="xdx_908_ecustom--UnrecognizedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zw9NujZV6Ctg" title="Unrecognized share based compensation expense"><ix:nonFraction name="PCSA:UnrecognizedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,000</ix:nonFraction></span> of expense related to certain grants
of RSUs with performance milestones that are being accounted for as though the performance milestones are not probable of occurring at
this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. While certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a stockholder
until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock.
The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2025, we sold <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryPOMember_zDVK6ZNgKbx4" title="Number of warrants exercised during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JanuaryPOMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,019,700</ix:nonFraction></span> pre-funded warrants, and accompanying Series A Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zntPkoTrz7t9" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_SeriesAWarrantsMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,050,672</ix:nonFraction></span>
shares of our common stock and Series B Warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zJODoOZVYGG8" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_SeriesBWarrantsMember" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,025,336</ix:nonFraction></span> shares of our common stock in the January PO. We also sold
<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JunePOMember_z9WnlBqm5767" title="Number of warrants exercised during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JunePOMember" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,690,000</ix:nonFraction></span> pre-funded warrants and accompanying common warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JunePOMember_zUy6ePLiIkW3" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_CommonWarrantsMember_custom_JunePOMember" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000,000</ix:nonFraction></span> shares of common stock, as well as issued
placement agent warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantMember_zG9mA6VXD8N8" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_PlacementAgentWarrantMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,000</ix:nonFraction></span> shares of common stock in the June PO. During the six months ended June 30, 2025,
warrants to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJWnN8x1q594" title="Number of warrants exercised during period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span> shares of common stock from the June PO and all pre-funded warrants from the January PO and June PO were
exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we had outstanding exercisable stock purchase warrants excluding the Series A and B Warrants for the purchase of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zZQkbFSvfIDh" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,495,784</ix:nonFraction></span>
<span style="background-color: white">shares with a weighted average exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zcCf964kTF7f" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.35</ix:nonFraction></span> and a weighted average remaining contractual
life of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_z9i5RAp8ze5i" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2025-01-012025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact000720" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.9</ix:nonNumeric></span> years. We have excluded the Series A and B Warrants sold under the January PO from the calculation of the weighted average
remaining contractual life since we did not receive stockholder approval for these warrants until July 18, 2025.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">W</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e
did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000722" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zC4JPyi708qi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211;<span id="xdx_82F_z4HeVi6HFmyl"> Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common stockholders by the weighted average number of shares of
common stock outstanding (which includes vested RSUs and unexercised pre-funded warrants) during the period. Diluted loss per share is
computed by dividing our net loss available to common stockholders by the diluted weighted average number of shares of common stock (which
includes the potentially dilutive effect of stock options, unvested RSUs and warrants) during the period. Since we experienced a net
loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and
six months ended June 30, 2025 and 2024 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000724" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3x6DRAv7bTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2025 and 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zccZWdZJXXg" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630_zBQyRflVH45h" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240401__20240630_zZEaQ7g6xDdd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630_zDGNYNqEkei8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630_z8g5bxqfgZi6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zysC6SZSmFAl" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-04-012025-06-30" id="Fact000726" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,933,918</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-012024-06-30" id="Fact000727" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000728" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,768,323</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-06-30" id="Fact000729" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zCb25uWbxYNc" title="Weighted average number of common shares-basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zTwDq125EzHc" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,569,312</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zNvcgA0igiBk" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zp8zBZE0AUk9" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zF5fdQcoEg1f" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_z7eXylfBtfhl" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-06-30" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,401,583</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zILRm64pui2g" title="Weighted average number of common shares-basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zAw1NI5SyFzl" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250401__20250630_zOIbgKOcOOPe" title="Basic net loss per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_zrFAWidrfQth" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-04-012025-06-30" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-04-012025-06-30" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zeLZqFlt6owg" title="Basic net loss per share"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zI493FwhU0hj" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250630_zxYOMev6ukTj" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zk2QVSTHEkDh" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-06-30" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.55</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zPKr7WdquEI1" title="Basic net loss per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z4ndRW4hLfN8" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.11</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WqXw0ZfFe3" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJknADl25iA" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,545,266</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgkP1uSqdedl" title="Weighted average number of common shares outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWsER6WVKnf" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,849,192</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2zRbvhZdN2" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47QsL2S95J9" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,371,909</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbFuJgrOAz4" title="Weighted-average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVtH5Xkuytz2" title="Weighted-average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,590,530</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpW4HpMsiUr" title="Weighted average number of vested RSUs - basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znCVAMfgSTgi" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,046</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zXOEyX5ulBY" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5dk2uqVHA2b" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,091</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zauaD8l29EEl" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFQYUsMAJ4i" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,674</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zyBHiDAhQWkk" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z48afxRmNlcj" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,373</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zhiqQOUVgcie" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zqX8kaF32rAj" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-04-012025-06-30" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-04-012025-06-30" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,569,312</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zw9Dc8wccNm5" title="Weighted average number of common shares-basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zqursHq06uda" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zn05tG4uxtJl" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zwCe6TGM7vCi" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-06-30" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-06-30" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,401,583</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_ziO6dS7M7U24" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zLjZFflDinS2" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJ6VASJqcMQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000811" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zT9Ny4TA34dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have
had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zRiN2IsB6Ra2" style="display: none">Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250630_zkrQzxy8BfSe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zrXmypGTbojh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhWcCfvVdS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember18079015" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,747</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,747</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zvbHiH5u0Ly2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units (unvested)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zkblzalKdfj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants for common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,495,784</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,778,284</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zKarluVH0ZL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-06-30" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,549,911</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,876,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zbUa6Bcf3lV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not included any potential impact of the Series A and B Warrants from the January PO since they were subject to shareholder
approval as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000825" name="PCSA:LesseeOperatingAndFinancingLeasesTextBlock"><p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zNHpp80gTIe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_828_z6Z4iswNw9S3">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of <span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20250630_zoWTWsGCbHLl" title="Operating and financing lease borrowing rate"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2025-06-30" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% in determining the present value of the lease payments based on
the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_900_eus-gaap--LeaseCost_c20250401__20250630_zlfox7BaWTof" title="Lease cost"><span id="xdx_90A_eus-gaap--LeaseCost_c20240401__20240630_zWC0kftusKs7" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-04-012025-06-30" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-04-012024-06-30" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,461</ix:nonFraction></ix:nonFraction></span></span> for both three months ending June 30, 2025 and
2024 and $<span id="xdx_90D_eus-gaap--LeaseCost_c20250101__20250630_zwvZqTcZ9au2" title="Lease cost"><span id="xdx_900_eus-gaap--LeaseCost_c20240101__20240630_zIUd59PC94S6" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-01-01to2025-06-30" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-012024-06-30" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,922</ix:nonFraction></ix:nonFraction></span></span> for both six months ending June 30, 2025 and 2024. The weighted average remaining lease terms and discount rate for
our operating leases were as follows at June 30, 2025:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000837" name="PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zFAc7SvHu3Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zrMCiHT3pKk8" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zfcTa1j3ilS4" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2025-06-30_custom_FacilityLeaseMember" format="ixt-sec:duryear" id="Fact000839" name="us-gaap:LesseeOperatingLeaseTermOfContract">0.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUwp4wb4Xaq2" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000841" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm">0.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20250630_zO2uCxN12U9h" title="Weighted average discount rate for our facility and equipment leases"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2025-06-30" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zaD75zPXDL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000845" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmVtLUvJNSz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zLnf6mxeVquf" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_496_20250630_zGllg7MuoUrj" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z1RKsd2fhLGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; padding-bottom: 1pt">Remainder of 2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2025-06-30" id="Fact000847" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,347</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zAuyxQzpP0y7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" id="Fact000849" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zRJVVVEdP7uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" id="Fact000851" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zTDc6qM7A6cd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-06-30" id="Fact000853" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,832</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zxEYGDadTbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000855" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,832</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxJf5oAZUB22" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z99fXTTMdHN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000859" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zAcqy1RIXNMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zlq9vwgmocMl" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250630_z6TimV9Ft9Vf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zd98xICrM543" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2025-06-30" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_z5K4N946tx4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_z1PuDZpzRuGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI5BdRRkDQnb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_znuLvlP8E0x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2025-06-30" id="Fact000869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIRPnAxV9MDk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zj5p4XKBN0li" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl0872">Less: current maturities</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,752</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z2lW7IFlz6e6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zpm6BpzM4316" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl0875">Non-current lease liability</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z75UR0DVH30i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000877" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ze9gXe6LDYK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zdqcdT7GGcDa">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. Included in our general and administrative expenses is approximately $<span id="xdx_900_eus-gaap--RecoveryOfDirectCosts_c20250401__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zufJEqvmGxx7" title="Reimbursements received"><ix:nonFraction name="us-gaap:RecoveryOfDirectCosts" contextRef="From2025-04-012025-06-30_custom_CorLystLLCMember" id="Fact000879" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_eus-gaap--RecoveryOfDirectCosts_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zDtc3ZXNNerg" title="Reimbursements received"><ix:nonFraction name="us-gaap:RecoveryOfDirectCosts" contextRef="From2024-04-012024-06-30_custom_CorLystLLCMember" id="Fact000881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of reimbursements from CorLyst during the three months ended
June 30, 2025 and 2024, respectively, and $<span id="xdx_90C_eus-gaap--RecoveryOfDirectCosts_c20250101__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zN4r3uud0nH2" title="Reimbursements received"><ix:nonFraction name="us-gaap:RecoveryOfDirectCosts" contextRef="From2025-01-012025-06-30_custom_CorLystLLCMember" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--RecoveryOfDirectCosts_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zBWYKFW0VEs8" title="Reimbursements received"><ix:nonFraction name="us-gaap:RecoveryOfDirectCosts" contextRef="From2024-01-012024-06-30_custom_CorLystLLCMember" id="Fact000885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the six months ended June 30, 2025 and 2024. At June 30,
2025, we included approximately $<span id="xdx_90D_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpW91teHCuQ5" title="Due from related parties"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-06-30_custom_CorLystLLCMember" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due from CorLyst as a current asset in Prepaid and Other. Our
President, Research and Development is the CEO of CorLyst, and CorLyst is a stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000889" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zyH0kcoMQvy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
7 &#8211; <span id="xdx_826_zmFIvSOykUZ9">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating
decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus
actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations
and comprehensive loss as consolidated net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000891" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"><p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zgLCF8aoESJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zZufT0nPmGGe" style="display: none">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zNWJzZLtLmsd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zlhsxvXSS1G5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_ztcVC35Ts9m6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zgt24ZWuv6g2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PreclinicalClinicalTrialAndOtherCosts_zCeH9ckbKyii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Preclinical, clinical trial and other costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,142,229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,339,263</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="PCSA:PreclinicalClinicalTrialAndOtherCosts" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,293,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zEGqH8EgqzUa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F4B_zhuy8nrNbSYi">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zHOLDxoMw79a" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zaYLf3fhut01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F44_zD8JbZyluxX5">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">628,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,620</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">964,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zfAsZjvssMqa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
personnel expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">628,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,620</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">964,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zxrqkYJC0j6k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4E_zQc48XVSEdv">(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">875,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,459,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,657,658</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zHBW9TZKFWJe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">875,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,459,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:AdministrativeAndFacilitiesExpense" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,657,658</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InvestmentIncomeInterest_di_zI9PgfScKSpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,698</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,915</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iNT_di_zsccqLLBMH54" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,933,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000935" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,768,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zi09RiT0x1C7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zkJPd2W63f79" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000937" xml:lang="en-US">Research
    and development personnel costs include employee stock-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,613</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,583</ix:nonFraction></span> for the three months ended
    June 30, 2025 and 2024, respectively, and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,333</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,704</ix:nonFraction></span> for the six months ended June 30, 2025 and 2024, respectively.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zOEEghvgeZNi">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zC8nYhvS8sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000946" xml:lang="en-US">General
    and administrative personnel costs include employee stock-based compensation expense of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,655</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,309</ix:nonFraction></span> for the three months
    ended June 30, 2025 and 2024, respectively, and $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,310</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,180</ix:nonFraction></span> for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zhvE94uaLy0i">(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z3J02240kkA5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000955" xml:lang="en-US">Administrative
    &amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_z5qUYBLAepgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000957" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_803_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z90mIn0BO6Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_824_zIc9hVjfT3Ji">PCS12852</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2025, we entered into a binding term sheet (&#8220;Term Sheet&#8221;) with Intact Therapeutics (&#8220;Intact&#8221;) granting
Intact the exclusive option to license PCS12852, a highly specific and potent 5HT5 agonist <span style="background-color: white">that
is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients.</span> <span id="xdx_907_ecustom--TermSheetDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zhgmgWiDn9cl" title="Description of term sheet"><ix:nonNumeric contextRef="From2025-06-172025-06-17_custom_PCS12852Member" id="Fact000959" name="PCSA:TermSheetDescription">Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--TermSheetRemainingDiligenceDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zmexDf8czWCc" title="Description of term sheet"><ix:nonNumeric contextRef="From2025-06-172025-06-17_custom_PCS12852Member" id="Fact000961" name="PCSA:TermSheetRemainingDiligenceDescription">The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000.</ix:nonNumeric></span> There can be no assurance that
the Company and Intact will enter into a license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Term Sheet, Yuhan Corporation executed Amendment No. 1 to our existing license agreement dated August 19, 2020 (the
&#8220;Yuhan Agreement&#8221;), effective June 11, 2025, which, among other things, extended the deadline to dose the first patient in
a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial from 48 months to 108 months from the effective date
of the original agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000963" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmZkpPVBp9Sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_825_zUw8WCPkiWB3">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2025, we are contractually obligated to pay up to $<span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zzwPKqury4Vl" title="Purchase obligation"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2025-06-30_custom_CROsMember" id="Fact000965" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.1</ix:nonFraction></span> million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.</span></p>

</ix:nonNumeric><p id="xdx_817_zTd1EBdWlrSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">NGC-Gem
(also identified as PCS3117)</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2025, we provided a 120-day written notice of termination of our licensing agreement with Ocuphire Pharma, Inc. (now Opus Genetics)
dated June 16, 2021, rescinding all rights and licenses previously granted to us for NGC-Gem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-06-30" escape="true" id="Fact000967" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zmh30fozWaJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_826_zgP6ijFNE0Pa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">RSU
Grants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2025, the Compensation Committee of our Board of Directors granted RSUs for the future issuance of up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250724__20250724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn6iguZTRFA5" title="Number of shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-07-242025-07-24_us-gaap_SubsequentEventMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,310</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to our employees and independent directors.
The RSUs vest over a 1-3 year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
Sales</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 4, 2025, we entered into a Securities Purchase Agreement with an accredited investor and sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdcAWabcectf" title="Sale of stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,467,181</ix:nonFraction></span> shares for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc6eJE964wCa" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" id="Fact000973" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span>
million in gross proceeds. We also sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNJJIZeIPJug" title="Sale of stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,597,612</ix:nonFraction></span> shares for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMN5IAtxSOw2" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember" id="Fact000977" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million in gross proceeds under our ATM agreement. Following these
investments, we are exploring options to pursue a cryptocurrency treasury strategy.</span></p>

</ix:nonNumeric><p id="xdx_817_zzbELdTo1rb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; that reflect, when made, the Company&#8217;s expectations
or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the
words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221;
&#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; or other similar words and phrases. Similarly,
statements herein that describe the Company&#8217;s objectives, plans or goals also are forward-looking statements. Actual results could
differ materially from those projected, implied or anticipated by the Company&#8217;s forward-looking statements. Some of the factors
that could cause actual results to differ include: our limited cash and history of losses; our ability to achieve profitability; our
ability to obtain adequate financing to fund our business operations in the future; our ability to secure required FDA or other governmental
approvals for our product candidates and the breadth of the indication sought; the impact of competitive or alternative products, technologies
and pricing; whether we are successful in developing and commercializing our technology, including through licensing; the adequacy of
protections afforded to us and/or our licensors by the anticipated patents that we own or license and the cost to us of maintaining,
enforcing and defending those patents; our and our licensors&#8217; ability to protect non-patented intellectual property rights; our
exposure to and ability to defend third-party claims and challenges to our and our licensors&#8217; anticipated patents and other intellectual
property rights; our ability to remain listed on the Nasdaq Capital Market; and our ability to continue as a going concern. For a discussion
of these and all other known risks and uncertainties that could cause actual results to differ from those contained in the forward-looking
statements, see &#8220;Risk Factors&#8221; herein and in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31,
2024, which is available on the SEC&#8217;s website at www.sec.gov. All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q to reflect
events or circumstances after the date hereof.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the operations of Processa Pharmaceuticals,
Inc. and its direct and indirect subsidiaries for the periods described herein.</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (&#8220;NGC&#8221;) small molecules,
one of which is currently in a Phase 2 trial, while the other is in pre-clinical development. Our risk-mitigated strategy is to identify
existing cancer therapies where the mechanism of action is well understood and that are cornerstones of current treatment regimens, but
are highly toxic, with side effects that are often treatment limiting. We devise technologies to change the way the body metabolizes
them, or the way they are distributed within the body, to improve the therapeutic effect and reduce toxicity. We then efficiently develop
our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach, which we believe will further
increase the likelihood of regulatory approval. Since the underlying active metabolites of these drugs are already commonly used in cancer
therapy, we believe that if our clinical trials are successful and are showing better efficacy and tolerability than the currently used
drugs, the commercial adoption for our NGC therapies will be rapid and broad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
oncology pipeline currently consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology
drugs (PCS12852 and PCS499). We are exploring options for our non-oncology drugs, which may include out-licensing or partnership opportunities.
The current status of our drug pipeline is set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Drug Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last nine months since the first patient was dosed in the NGC-Cap Phase 2 advanced or metastatic breast cancer trial, the study has
been actively adding additional U.S. clinical study sites and screening and enrolling more patients. We plan to obtain preliminary safety-efficacy
data from these breast cancer patients in order to provide insight into the benefit of NGC-Cap over existing treatments. This preliminary
data should provide information that could also help to adaptively modify the protocol to increase the efficiency and/or improve the
information obtained from the study.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
FDA now accepts surrogate endpoints for nephrology diseases, such as primary glomerular diseases (PGDs), we have recently begun to re-evaluate
the potential clinical safety and efficacy of PCS499 in PGDs. These analyses have been based on PCS499 and pentoxifylline (PTX) safety-efficacy
in diabetic nephropathy and, for PTX, in primary glomerular diseases. PTX is a generic drug with similar pharmacological properties to
PCS499 and is approved for the treatment of patients with intermittent claudication. The data suggests that PCS499 may not only be safer,
but also more efficacious in more patients than PTX or other drugs presently used on- and off-label for PGDs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public
Offerings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 2, during the six months ended June 30, 2025, we raised net proceeds of $10.6 million from the January and June POs.
We sold a cumulative 15,340,972 shares of common stock, pre-funded warrants to purchase up to 20,709,700 shares of common stock, accompanying
Series A Warrants to purchase up to 8,050,672 shares of our common stock and Series B Warrants to purchase up to 4,025,336 shares of
common stock in the January PO and common accompanying warrants to purchase up to 28,000,000 shares of common stock in the June PO. During
the six months ended June 30, 2025, all pre-funded warrants were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to use the net proceeds from both financings for continued research and development for NCG-Cap, and for working capital and general
corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PCS12852
Update: Intact Therapeutics and Yuhan Corporation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2025, we entered into a binding term sheet (&#8220;Term Sheet&#8221;) with Intact Therapeutics (&#8220;Intact&#8221;) granting
Intact the exclusive option to license PCS12852, a highly specific and potent 5HT5 agonist <span style="background-color: white">that
is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients.</span> Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000. There can be no assurance that
the Company and Intact will enter into a license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Term Sheet, Yuhan Corporation executed Amendment No. 1 to our existing license agreement dated August 19, 2020
(the &#8220;Yuhan Agreement&#8221;), effective June 11, 2025, which, among other things, extended the deadline to dose the first
patient in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial from 48 months to 108 months from the
effective date of the original agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NGC-Gem
(also identified as PCS3117)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2025, we provided a 120-day written notice of termination of our licensing agreement with Ocuphire Pharma, Inc. (now Opus Genetics)
dated June 16, 2021, rescinding all rights and licenses previously granted to us for NGC-Gem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three and six months ended June 30, 2025 and 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our net loss during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2,447,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,730,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">716,842</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">4,035,767</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">3,269,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">766,212</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,503,497</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,351,580</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">151,917</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,762,006</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,622,067</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">139,939</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,950,783</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,082,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,797,773</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,891,622</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Other Income (Expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,865</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">71,698</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(54,833</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154,915</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(125,465</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,010,326</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,736,707</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any revenue under contract or any immediate sales prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development costs are expensed as incurred. Research and development expenses include (i) program and testing related expenses
including external consulting and professional fees related to the product testing and our development activities and (ii) internal research
and development staff salaries and other payroll costs including stock-based compensation, payroll taxes and employee benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for the three- and six-month periods for the periods ended June 30, 2025 and 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development salaries and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">305,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">468,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">696,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">976,554</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Preclinical, clinical trial and other costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,142,229</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,261,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,339,263</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,293,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,447,286</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,730,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,035,767</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,269,555</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in research and development expenses was due to an increase in preclinical, clinical trial and other costs for our Phase 1B
and Phase 2 clinical trials for NGC-Cap during the three and six months ended June 30, 2025 when compared to the same period in 2024.
During the same period in 2024, the majority of the costs incurred were related to our Phase 1B trial for NGC-Cap, as well as the IND/initiation
of our Phase 2 trial for NGC-Cap. The increase was offset by a decrease in salaries and benefits from the voluntary departures of research
and development employees since March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the
further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include,
but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically
assess the scientific progress and merits of the programs to determine if continued research and development is economically viable.
Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as
estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct
and manage clinical trials on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and
clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees,
we estimate the period over which services will be performed and the level of patient enrollment and activity expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.
Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses
and expensed when the services are rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the three months ended June 30, 2025 increased by approximately $152,000 to $1.5 million from
$1.4 million for the three months ended June 30, 2024. This increase was due primarily to increases in salaries and other-payroll related
costs of $105,000, primarily due to salary increases to our C-suite executives; an increase in employee stock-based compensation of $82,000
(our 2024 stock grant was contingent on receiving stockholder approval to increase the number of shares available for issuance under
our Incentive Plan, so we did not recognize any expense related to grants made during the first quarter of 2024 and awards that were
previously not probable of occurring that vested in 2025); and net increases in taxes and other miscellaneous office expenses of $24,000.
The increases were offset by decreases in office expenses of $32,000; professional fees of $19,000 and travel expenses of $4,000. We
received approximately $4,000 more in reimbursements from CorLyst during the three months ended June 30, 2025 when compared to the same
period in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the six months ended June 30, 2025 increased by approximately $140,000 to $6.8 million from $5.9
million for the three months ended June 30, 2024. This increase was due primarily to increases in salaries and other-payroll related
costs of $182,000, primarily due to salary increases to our C-suite executives; an increase in employee stock-based compensation of $166,000
(our 2024 stock grant was contingent on receiving stockholder approval to increase the number of shares available for issuance under
our Incentive Plan, so we did not recognize any expense related to grants made during the first quarter of 2024 and awards that were
previously not probable of occurring that vested in 2025); and net increases in taxes and other miscellaneous office expenses of $23,000.
The increases were offset by decreases in office expenses of $42,000; professional fees of $170,000; insurance of $5,000; and travel
expenses of $4,000. We received approximately $10,000 more in reimbursements from CorLyst during the six months ended June 30, 2025 when
compared to the same period in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income for the three and six months ended June 30, 2025 includes our portion of the Intact payment of $8,000 along with interest income
of approximately $9,000 and $72,000 for the three months ended June 30, 2025 and 2024, respectively, and approximately $21,000 and $155,000
for the six months ended June 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Benefit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize any income tax benefit for the three or six months ended June 30, 2025 or 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our sources and uses of cash and cash equivalents for the six months ended June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,000,253</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,394,713</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,745,548</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,259,636</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,745,295</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">864,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in our operating activities of $5,000,253 and $5,394,713 during the six months ended June 30, 2025 and 2024, respectively.
The decrease in cash used in operating activities was primarily due to the timing of our use and/or payment of amounts recorded as prepaid
assets with our CROs. During 2024, we continued to incur costs related to our Phase 1B trial for NGC-Cap and, we made a prepayment to
the CRO for our Phase 2 trial for NGC-Cap as we began the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue our development of NGC-Cap and evaluate the other NGC drug in our portfolio, we anticipate our research and development efforts
and ongoing general and administrative costs will continue to generate negative cash flows from operating activities for the foreseeable
future. <span style="background-color: white">As we continue our Phase 2 clinical trial for NGC-Cap in 2025, we anticipate our clinical
trial costs will increase when compared to prior periods since activities in 2024 were primarily related to the completion of our Phase
1B trial and setup of our Phase 2 trial for NGC-Cap.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2025, as described in Note 2, we sold </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
cumulative 15,340,972 shares of common stock, pre-funded warrants to purchase up to 20,709,700 shares of common stock, accompanying Series
A Warrants to purchase up to 8,050,672 shares of our common stock and Series B Warrants to purchase up to 4,025,336 shares of common
stock in the January PO and common accompanying warrants to purchase up to 28,000,000 shares of common stock in the June PO<span style="background-color: white">.
</span>We also received $100,000 from the exercise of warrants to purchase 400,000 shares of common stock sold in the June PO. We used
cash classified as financing activities of approximately $10,000 to pay income taxes owed on stock-based compensation, and $3,000 for
payments owed under a financing lease obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of
common stock in lieu of shares of common stock, all of which were exercised into shares of our common stock, and warrants to purchase
up to 1,555,555 shares of our common stock pursuant to a public offering for net proceeds of $6.3 million.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also used cash classified as financing activities of $12,000 to pay income taxes owed on stock-based compensation, $8,600 for the settlement
of a stock award and $2,300 for payments owed under a financing lease obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2025, we had cash and cash equivalents totaling $6.9 million. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on our current business plans,
we believe these funds, together with the $<span style="background-color: white">2.4</span> million in gross proceeds we received <span style="background-color: white">i</span>n August  2025, will satisfy our capital
needs into the first quarter of 2026</span>. However, absent additional funding, our current cash and cash equivalents will not
be sufficient to fund our planned operations for a period of one year or more after the date that these condensed consolidated financial
statements were available to be issued based on the timing and amount of our projected net loss from continuing operations and the related
amount of cash to be used in operating activities during that period of time. Our ability to execute our longer-term operating plans,
including future preclinical studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding
from the sale of equity and/or debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have incurred losses since inception, currently devoting substantially all our efforts toward research and development of our next generation
cancer therapy drug product candidates, including conducting clinical trials and providing general and administrative support for these
operations, and have an accumulated deficit of $94.0 million at June 30, 2025. During the six months ended June 30, 2025, we generated
a net loss of $6.8 million and used $5.0 million in net cash for operating activities from continuing operations. To date, none of our
drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash
flow from operations in the foreseeable future. We will continue to be dependent upon equity and/or debt financing until we are able
to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 29, 2025, we sold 1,030,972 shares of common stock, pre-funded warrants to purchase up to 7,019,700 shares of common stock, and
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accompanying Series A Warrants to purchase up to 8,050,672
shares of our common stock and Series B Warrants to purchase up to 4,025,336 shares of common stock <span style="background-color: white">for
net proceeds of $4.4 million, after deducting placement agent fees and offering-related expenses. On June 18, 2025, we sold 14,310,000
shares of common stock, pre-funded warrants to purchase up to 13,690,000 shares of common stock, and accompanying common warrants to
purchase up to 28,000,000 shares of common stock for net proceeds of $6.2 million, after deducting placement agent fees and offering-related
expenses. On August 4, 2025, we entered into a Securities Purchase Agreement with an accredited investor and sold 5,467,181 shares for
$1.3 million in gross proceeds. We also sold 4,597,612 shares for $1.1 million in gross proceeds under our ATM agreement. Following these
investments, we are exploring options to pursue a cryptocurrency treasury strategy.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we did not have any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent
assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the estimates, assumptions and judgments involved in the accounting policies described in the &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our most recent Annual Report on Form 10-K
have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results
could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely
events or circumstances that would result in materially different amounts being reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our critical accounting policies from those included in our most recent Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated recently issued accounting pronouncements and determined that there is no material impact on our financial position or
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
3 is not applicable to us as a smaller reporting company and has been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30<span style="background-color: white">, 2025</span>, management, with the participation of the Chief Executive Officer and Chief
Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of its disclosure controls and procedures,
the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at June
30<span style="background-color: white">, 2025</span> to provide reasonable assurance that information required to be disclosed in our
reports under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms and (ii) accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily
applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that have materially affected,
or are reasonably likely to materially affect the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Part
II. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and
Elion as a result of the Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims are without merit and
disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in the Commercial Division
of the Supreme Court of the State of New York, New York County seeking monetary damages, declaratory judgement and injunctive relief.
On August 14, 2024, the Company received Elion&#8217;s answer and counterclaims. On October 10, 2024, the Company filed its response
to Elion&#8217;s counterclaims. The Company intends to enforce its rights under the license agreement and will pursue such other remedies
as it determines are appropriate. The discovery phase of the matter has commenced. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 3, 2024, Jason Assad and Marc Gyimesi, two of the investors in our February 2021 private offering, filed a lawsuit that has
been assigned to the Commercial Division of the Supreme Court of the State of New York, New York County alleging fraud and negligent
misrepresentation in connection therewith regarding alleged company communication and statements and are seeking monetary damages. In
addition to being an investor, Mr. Assad was a former investor relations and communications consultant to the Company from September
1, 2021 through June 30, 2024. On April 25, 2025, the Company filed a motion to dismiss the complaint in its entirety. The motion is
fully submitted to the court and is awaiting decision. The discovery phase of the matter has commenced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to vigorously defend ourselves in these lawsuits and cannot at this time predict the likely outcome of any litigation, reasonably
determine either the probability of a material adverse result or any estimated range of potential exposure, or reasonably determine how
these matters or any future matters might impact our business, our financial condition, or our results of operations, although such impact,
including the costs of defense, as well as any judgments or indemnification obligations, among other things, could be materially adverse
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, there have been no material changes to our risk factors as described in Item 1A of our Annual Report on Form 10-K
for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
at the FDA and other government agencies could hinder new or modified products from being developed, approved, or commercialized in a
timely manner or at all, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory and policy changes, staffing cuts, the FDA&#8217;s ability to hire and retain
key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine
functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government
agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government
funding and the ability to fill key leadership appointments, among various factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
actions by the United States federal government have caused concern in the industry that the FDA will experience staffing reductions
and budget cuts. In addition, some senior FDA employees with responsibility for regulation of drugs and biologics have already resigned
from the FDA. There are also reports that the United States federal government intends to request Congress to reduce FDA funding in upcoming
budgets. Such funding cuts may also delay the development and approval of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
may delist our securities from trading on its exchange which could limit investors&#8217; ability to make transactions in our securities
and subject us to additional trading restrictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
securities are currently listed on Nasdaq. If Nasdaq delists our securities from trading on its exchange, we could face significant material
adverse consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity with respect to our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that shares of our common stock are &#8220;penny stock&#8221; which will require brokers trading in our shares to adhere
    to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, we received a deficiency letter from the Nasdaq Listing Qualifications Department (the &#8220;Staff&#8221;) notifying
us that, for the last 30 consecutive business days, the closing bid price for the Company&#8217;s common stock has been below the minimum
$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (&#8220;Rule 5550(a)(2)&#8221;).
As a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital
Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had been given 180 calendar days, or through August 4, 2025,
to regain compliance with Rule 5550(a)(2). Nasdaq has indicated that they will review our Form 10-Q for the six months
ended June 30, 2025 before making a final determination regarding our extension request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the
sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because our common stock is listed on Nasdaq,
our securities are covered securities. If we are no longer listed on Nasdaq, our securities would not be covered securities and we would
be subject to regulation in each state in which our securities are offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the quarter ended June 30, 2025, we issued a total 50,000 shares of common stock to RedChip Companies, Inc. in connection with a consulting
agreement. The shares were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended,
in reliance on Section 4(a)(2) of the Securities Act, Rule 701 promulgated under the Securities Act or Regulation D promulgated under
the Securities Act, relating to transactions by an issuer not involving a public offering. All of the foregoing securities are deemed
restricted securities for purposes of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the three months ended June 30, 2025, none of our directors or officers <span id="xdx_90B_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250401__20250630_zohGHQXTMbDh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250401__20250630_zaYDYu1ELfPc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-04-012025-06-30" format="ixt:booleanfalse" id="Fact000978" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-04-012025-06-30" format="ixt:booleanfalse" id="Fact000979" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_903_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250401__20250630_zVu1OOYi8f37" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_907_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250401__20250630_z1ZaQpjEqcs5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-04-012025-06-30" format="ixt:booleanfalse" id="Fact000980" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-04-012025-06-30" format="ixt:booleanfalse" id="Fact000981" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221;
or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Ref. No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed June 18, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/ex4-2.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed June 18, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/ex4-3.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed June 18, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/ex10-1.htm" style="-sec-extract: exhibit">Binding Term Sheet by and between Processa Pharmaceuticals and Intact Therapeutics (incorporated by reference to Exhibit 10.1 to Form 8-K filed June 17, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225015654/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated June 17, 2025, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein) (incorporated by reference to Exhibit 10.1 to Form 8-K filed June 18, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225017185/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to License Agreement with Yuhan Corporation (incorporated by reference to Exhibit 10.1 to Form 8-K filed June 30, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000164117225017288/ex10-1.htm" style="-sec-extract: exhibit">Termination of Licensing Agreement dated June 27, 2025 (incorporated by reference to Exhibit 10.1 to Form 8-K filed July 1, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.5</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315225011680/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated August 4, 2025, by and between Processa Pharmaceuticals, Inc. and the Purchaser (as defined therein) (incorporated by reference to Exhibit 10.1 to Form 8-K filed August 7, 2025)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 153-14(a) Certification by Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 153-14(a) Certification by Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of Principal Executive Officer and Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Files</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROCESSA
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 7, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Russell Skibsted</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 7, 2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>




































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJzFWd1uG7cSfoK8w8BXPUCSSjrHQes7SbZTt0ok2GpygKAX9O5IYrsiVZJrW32j85Znhtx/cWU7RWPDgKTlzHzD4fxyT05en7zXlzJDA/+dXM9gidtdJhzCNa7QoEqQKKZXv5wBfV7jWlpnhHL+Z8k41cSDxPPu7VDQc095Jy2mZzD44fvBu+9HpzB4d/bvESw+nLzi9alWK5miclJkIFQKC6N3RqITZh8kLMWDVnq790if0Fip1RkM3w7C8v9gNBiO4KO+E/fa/GFhNpuevHrt/16dvDc63xHVxYNDxZxwkeGW4Gzgrv+9Nklund6esQ5o3H6s0os/c7ljho/oiGAwHI6Gg8F/6GtJ5LWuyF6DQvc2LnZsLTr7UaskN2RRd/GQZHkq1fpJeIEbVMUOWPLDrqkLliKOqDIncuGIlSAvpRJ0vDMUFmdS3MpMuv00YLAKo0qFisvjrAIfZMwIWckJhXpfi1zb52vAa/P0HUL6O33xLrDU4zSVjrxCZAsh0ys1FTvpRHaDzgU3ma9unE7+GN8Lk1p/HqPqPGpB4DSIShTsSBZIBUmQBrYSB3oFlgWC8BKfaaOLhx15Mbb1OGYXDAw9MFcqMUx2juHzSp3neGn0dqmvkWM/XQjjJPqNjypAIoLvVkT2L963CZS0aU/aA7UQe2+pS22OGLfGKOlhpc3z7efFXlmbI5+pVgoTPprP0m1mMuFEQKZdG/QyP29ksvlJpAtDqUrnNttPENU1JtqkmI4tbXepA5s2bS09DkgP5A+8goJ7wiK3LMBAlGhwz3CwEWSxChBuCZEsGSBBWEjJxmTcrIDt2WfwDZLfjqC2khVRN1Z6hFL8TYXddIIyZKNaKlGRf9vNYQD25pxJTqZAa8dkoTvJzkLuPTdroeRfgo220LTf/RIf3CQjwzLggAGnp/S15IaaHYgfmgLgSxABLAO8kN/iuswkJUkK2P1RzIqqR/Bj6wdRkJtkQ+aqfO8Dbm+RnWroQcdc00qihs98CXS/NVfHsdXDQoaXuSKf+iwMV+sKb9DAMwiBCAqqFp7BN+1VewzwBg2fa0kawwskMI7KO7oYB5s8AWxyDCy+2AWbbiSuLh4wycn9cL5aUWgacsAp1V0h1URTPgrcUUU8O1T8UAjwObsQAV4GFEKauvwt5keOiLbwdDs2zoWxn2Ld57Ac2Fxvt5S2j+gVKKLCjix1cS6obdV7xBhCudbkjz07UoPOc8NNHu1cpzcbYdD6RS5HG8xSqolUifUWqdMNtdajD06rCnNfUPpqKD0tOCbuybRU8myeuWaV67FeSVenk44NHyF41q7JgU3C04DXYtjeY1FFU88FO88G1vNRG1Mw9uyXunxrqYlOEFPLDQxrwG3QfBW8wEO02ybPw42zZwLuZ7wOvnuiNiMJ7uO7jb6mJhOJN8l4jT25taQAT9JKrP1LXZzlvV5uqFGg+KFo/Uhl0FG/QAJUrH7QOPQj8GJTZPRhXxhwTihOvi/uKtKQg2riWJgcJTrwID7yCVW4lKdJ6n58ZR9zEK+9vSb7mqRoE30HyZOT218pmktz76dzt0Gz3Ag137GIee4sofO81PE/Fge3LI9PvcIEUYPC7T44Y0G3C8ChDfUTFzUBssYGzeDgCB20h4c7tNwnsylyVfzQtU59rew/ZQ5b9schQjtph0W+eaJJ3nytSWyjdQ4B/82N8MmfA/n7ryro4mPpG7uGbftGUORbm6IRHp9RrjdsljuaLNf4nuvnOQ15l0KaTyLLsYqfyZQzGe0mGICqE6lPM04h4I0IEmBFnHDHrJxaG7ulcb385c3FnaaJu1W9xbcQbk4osQTcwm6utOfLu9FTTDisTfiCflYdFpSHtfYzQMp3f/W59Zj0V8VT65oGMEzj5q3vLIZ18W2ytTbV2nzj9uLZDC+VR58WO6PWwb9Aov17pz6jORzx8JaqvImwffO054P6xooH+Pp+IvDCl0en937kjvnPpU10rtw1batOWpOT+K1ZfUdyYJ20EATE1GeVm2SDaZ5R09nR4hq3NKGVKi7RbLnDaupGI8A8N5VO4tCg4jbDHquWuDQWQokMBTRU2MG64NG93Ut8YAWANABSAZo6xI6G9ejccrw0fvccLkXir6I8T6x5LQkKlRrNaP/K4YhlZnvrZrNpfLDyq6/5ZUR7noo/P5gsKNtlZLZEZNPic2mkyPjCjIN7qq3rXEc3WKD64kz5WiXkhKTgexZxV7lxuiUOfv3DlxEcgsFqkie8yAV1mz7EW8VR5uxn0PWOLccHlehgcuyEr+fxoZmet8608/tAvYy7KxraM72mOpJEtWQaKIlaqvauHKQf7t6sk1lWlC8uufXrk3jO4qFMpj7ktFpSCbArNAarqueQ5m93VbXG9QVwXB6H980G0Z2jTYz01acaT4envXyL6c1w9MPpKDbQPoJUZZhzcpU1v6h8JnZjvC5n6/lWydvc0mnxm8k7bM3ag86sXRBDRR2fvh8n6yr2c65wMY/h8gos5k3myKMDI7fuK45dCXfuJmL3wo+THPpa4zbvn7vMi+7SPt2xfhYqF2bfY/iw2LV99GlXcKFK8xZsWI/cPT0FJrnxCbD/3UHrmrYkh+MvCp5MeJD8lx+OakDrcUG9C5Ha13pnEU3Chy8tWj7xyLKH/D/NpP8N -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
George Ng, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2025;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    7, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Russell Skibsted, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2025;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    7, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. &sect;1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    7, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    7, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form10-q_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %; IX# 2(  A$! Q$!_\0
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MQ^/OQ'9<C.=3PQ9=O4=0"0.?7@C!-/\ ^&I?VGB<CX_?$0DJ,?\ $R!.3QD
M< [0,  >_0UX4)!<@SQ[W7"HC2 1O\I(8M%E3M!7A@O/!R1P7>7GE,%<<':V
M[(S@MVW $8&,8Y P1CH_U>X7Y82?#V%CSPC-?[+0LXRU6CHJ2;5K)*S7:S/!
M?%/$<U!K.>/G4A!4ZKK\4<4T*GM*:<*G-3P7$%7#WYXM*4)-S3;G&,]%[I%^
MU)^T_O /Q_\ B)@2'?G4N-F<%^.?EP/ESQ@GG<<>@?"[]I']H_4OB)H6G:K\
M=_B%JFGW<6L2-;-J7[MVM],GEC63YL@+(H<,3@;3@<9'R4RL$?H&VO@ -GD
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MN\N9"VZYN;F28S7$LA+L\K,<YY!P (IH@8)=F-RV\I>3>C&-#&QWA3)M. %
M7'.<=B#]]EV6T<ERS"98\3"?U:E9U(22C4E4_>2J7C=<\Y>_4=]).,;63/RO
MB;.8\1<09OGLL+F2AF>:U\3AZ7UFAB%1P[E2C2I4ZN#A3H>PI0@X4:<(\U*$
MG&<I3?,>G_$4A/!7P-=6 8>$;=0W0!5N-0!.020N0?7'<UY#?1-<6-W;Q>67
MN -J.H8.X(?D\;N%;&.O!YP<^O\ Q&5E\$? \%8W#>%+<";>H#9N+\$E!(2@
M./NG*D]>O'EYC0 J2O<?>4YY"YPLN<L3@$?Q'H.!771^K5<+7H.JXNI5E::O
M=2=.4?B2OHFWLKNS2Z'/FBY*F7UX8?+74H4Z=:E2SG%XZE7YHU8OVF'IT(R@
MZ:Y5#GE:7.FK;,_4;PM\7_A+H_Q0T7Q;:_$#3-*UC1/V>/!?A;1)+MV@\/WV
MO::T9O\ 0M7OUBEDBFMMI9(U"$DX)XY[/Q[^TQX=FO\ XEQ?#'QIHL>N_$?X
MB_":PL[6" R'5=&FTO2M,\23:?'<^6LD)<7-LTY8!?+;//)_(6)(H\HL-M&I
M9B[(8PSOG+._SGS"Q&"Q.5 ./4I GV9XWMV%M+#M,#V\[136XC<2+]GE23?%
M*DFZ5)8V#J> !Q7Q+\-<KQ&*<GFV(E&&&JSC3JU*<J?.IU9132II2ASSYI0O
MS\RM%Q<F?I$/'#.Z6!H82/#N6SJK$TJN*Q>3?6Z[E1IPIT9>WJXCEG3K1H0<
M:+473]FY2J7:2/WJ^..N?$CX?>%-1#Z=I<_P$T;Q#HVL_$*]O[Q8M?M]&LI=
M,EN;3PYIL:;;Z%(X)#\LCLS2,%+' KQ_6?VJ?!MMX_\ AU=1>//#DO@V/XBW
MNNZ?JNGRR7?B'2M UC1YX[2PU73A;1#3K&WWP+(#YCJ4YYSG\HM8\;^./$%C
M#IVO^-O%&N6$4<<$&G:QXCU#4K,1J00GV:YNI8V&<$[D95(# 5R8@BW1OY4&
M8V5MS,AD^0%5S*9"[@ # )P&R#W%>/EGAG@?9J>*S*,FL16C)8>G.BG&=*5-
MRG[5SYZE]INW+=4W"4?>/HL\^D'6Q%2%?+<GA1D\'1P\99E6Q%.-*5"HIRIX
M2> I3E355**Q%*I_$:=2,XR?*?46B>$[[XL_M6/=GQ58^+="\.^,W^)GB?Q9
M:LL-J? OA6\BU2]=0J'S)Q)=6<$<*KYDAW\<&N)\/_$.SUW]J'1OBOK=Y]E\
M/ZG\8?\ A)FO9D95T[0X-2E_LV[" EP#8B+>CY*@G(!Q7DFEZGJ.B-?/HFIW
MVB/J.GW.E:BVCW[Z>U]IUX5-S8WCVTD;W%M<LJ">%C^]Q'N.U ISC!$(UC'E
M&-8TC" JB^4B%54D/N.U1M&<?WLYK[*GP]@J-;'+GI.AB\KHY91<:<(3BHRG
M+$5I2<7"5:K)4W%Q5H1IN,EJK_F6*X_Q.+H9:\/@LDH8G"9S7SG%.OF&9\E2
MK.E"G2C%+#J:=-J?-*;O)U%R^[S'ZHW?[4NE>%]2L(_"?Q%L++2]5^/?Q"US
MQ*18B;S/"&I;O[+O#YH'EP7%UD*Z\L=W.!FO3/"G[0'PNTWQ!HTOAOXS>'O!
MFFV'QVUOQ)XVL);0NGC#PUK.D36VFI:3$8B4WTT3O*C85HV!  K\8#;P[2KQ
M6Y48B;*1MF)0Q2-B[,9H@26578J"6;&]B2QK:V8;3#:C<L<7R1QQ!(T<-&JA
M20%5OG"J!@_,#GBO"GX<955P<Z7U[,N>I.$I4L$L/6Q$E%/FG*E5]E3E&E%V
ME)S7+&4?9Q<K'V%#QUX@PN-HXJGE/"5>I2C*,:L\3F<I1;=*34).CS1YG32G
M9N4XW5TG<_53PI\>_AEHDVCI:^,-,TKQ%&GQ^TS2->G@EN;?0M<U_P 7WUUX
M9U+4PD;!+&YMIEG,V2BJ0#P<BY^S]\>?"7@BTUB7QI\9= \1^(=1\5ZP/'UU
M=0/8V%]IESX3O;6RO?#,"1,=2AEU=XX9)3(%0D @<9_*3;$PEW>4RL68@E 2
M& R =QX*8)RV,XSR,U&MM; 8$-MY$:2H(F$3Q"&; EA$+2[0KG:W3:2"X 8*
M3T+P]RJ.%K8=XO/J4:L:$9/'X7+Z>&:HI**G6I5IU8V5N50@[U.5R=UH0\;,
MX6/AF>)RSA-SI+%M1>+S:TIXOVEVHNC9.G*MS4VUS171IZ?IO\(/C?HD5Q^S
M?J'B;XO:/I?ACP):^,M(\=>#]2M<7,EU=W%U)H>I1C:0T44#(>#A2W()K<\+
M?'[P19>8?#'Q9T'P?IFA_M!^*O&7Q$T.\L))9/B-\.[^T;[/_83%-KWMRS6E
MO'#$=S+%*<#9D_E7]FM@98C';$,-C!HXR N IX+[02HZXYV@#N1,\:R0I%(T
M1A@=##'\F4"QF)=AW#RDVEE,:[02PD !R:YY^&^46US2I!6;DH2HQ3OS<S<G
M3DN=\W+>W-I%P]])OGI^-_$$:]6I/*^%*L9R3@JN+S:48\OLU"-W26G-3348
M^[).2E[C=OU]TO\ :I^&LOB3P%H^D^-=-TKX6R^ /BY+XQTR[MO)DM[_ %%I
M6\.Z;>[QO$\D;NT4$)WNWR=2*^5_BO\ $O1?%O[,7PM\/:WXST9O%WA'1_">
MCZ!X2\([[K3[K0K?346#4]?2>(3:7J,2*J/ LA5')7:>H^*?+4QPQ,5>* @1
MQ.4:*,@XW[6D;?)SDO(&8@D< XI([>&(9C2"-7V^9L**9@.5\[RW#,02=O.T
M+TXR*TP? >2X+$X?&4\?4J5,)5P]6FY5*<I2EAI2J)2:@F_:-QC5]WFFJ<4N
M7WF\,T\8\[S7+L;EE;*^&(T,=A\9AZD<'B\R=11Q</9RGAX2HQI^VIRN\)&4
ME!5)M-M-.,(:0@9B!+DCN 1G<<D\_P +>G08[@HR,I+>23DG)WMTZA0".Y'!
M%6MB%<JJ@YX&_H 6^7#3+N# G&"  "03R*E"PXYPK'@@S$CWPP<GAL<<#&?J
M/MW4H7<N>]]UI9RZZ6NUK9773RN?C_LJ>DOJV/25E:/M7LDK64N7H^N_,FS-
MVG_G@W)')9OEQC(' R.AR?P-.VG_ )Y?^/-_C5\B(?W&/8B4X (Z<OWP,\CM
MW'* 1?['3KYC#T]9*?M:'_/U?>E_[:QNG2=G]6QZLFKWK+\-=;/7MLKVN4 I
M)SY1'."NX]#W/<8P3U(Z#J14H4H#^Z()0D DE2>FT'/!*YP,$DCG X%K;$>,
MH,<Y\QCQCD [\#/<CD =::4C*@94L<;5WDY8C"Y!FY'.6 P2,@'FAU*#:O45
MEN[II7LE]GOV5UN'LZ*WPN/LK.Z53XDXI--R3OTZ=]KGJOP.(3QU,A 4MX+\
M5D@MG!^PL#R,G&0. /4^AKRF)BDKL/O22S*0,;2=Q&XGCJ&(X QP<9S7K/P-
M7/CZ\VJD@7P7XG0H70!&>S8DAB^<Y ^5B1C ^OD:*2!&Y60I-+N+NH97>7D
M*X0JH4#N"AR #FN:$L.JU2]:2DW+F4I-12CIHG&UDM6D[N^M]CZ!PBLGX4E]
M6S*SX@S1*SDI7=*LUJFW**;LTMV]T?9O[.WQ=^'WPN^!?QALO%.F:7XK\5WG
MB;PUKG@GP5JD\UJFI:EIM]!-'.9X\!! ZF9!GDQX8D$U[-I'[8]^_P"R_P#%
M"\O/%6DZ9\7?%WQ-U#59/#=O"UW+;:!)-I5K]AMXI,>8B:;!-"LOS$[2P.17
MYGM&-O[SR&5BO+^6[+M; :(^8#&RGY5=2#G!!X-1FUB>0S 0B15 #F0$[3EB
M"?,#EOF.226;.?4#Y[$\#\/X_&X['XO$2C7Q^-CCG+G@IJ4(\OL+R@X^R;M*
MI&*YT^67-=6/L<N\6.*<JRG*\CR_!5WA<NRVMP]1Y^>,Y5L9C)YK0KS]ZRQ-
M/"4ZE"G4E\%&4J?+*,G(_5SXH?M*?!W4_ ,MK8WNB:U\/KH_#J^O?"+/._B?
M2K_1=6LIM5N].TCROWGV:16NI/,F(:+<0, 9R-:^/.E72?')?$WQO\/>*]-\
M1^#K^S^'?A[2]*>W;P]I=[<V<NCZ5=W&,O>BUC\NXB()1HW)X%?E^4",SA8$
M:256?;Y>U_E$>'0LR^4R85U)(8DGZ0_9[=662.* .G >+8DI!QMRZR!B%4E<
M98 ' P*\Y>'N3TU)SS"HJ=64HQ?/"HTG4YVH3G'2:M"+DUS2@ES;7/5Q'C=G
M^(JT:JRK(J<N:%1RQ6)Q^'Q*AR1I.-:GA:<Z*A+V-24$IR@VYS]UMI_K1XL_
M:8\&^'1JM]\/_B!I<&MZAXR^#,LNR$36]UX7T[PS;V.NF %2L<EO=Q7<=PR?
M,@6/@[B*R/%WQR^ GF27L^K6^O:;'\<M0\43VNEV<]U=KIES!8LFIK H5F@6
M6.<L0."0,<U^60@B!60QQ*T0/E;"B)#N(WA1O('F##,I!R2S-DC%"1QQ[6 A
M#"(QC:Z@"+<6VL58!P2>X..G'%1'PXR:E9/,J\I7E)MUHJ4HRE>"<HTK.,$W
M&%E[L5R^\FF;3\><[AC<UQ,\JX1E2S#+\!@\/'ZUF?)3K82A.C6E24J/*IU)
MRA*K*#O)J\G&21^K'AKXWZ?HWQ5\4>*/&?Q[\-^)]>M]$N_^%<6<=JUEH.FZ
M)J,UE=PZ/K^HQ1&1+PVP$RPX#@QA=V37G/[5GQ<^&WCKP!\1;#PGKEEJ.I:I
M\3/"?B-K/3X9=MQ9QV$=O?7MD) /-C6]<B1_O",%R.E?G4EM N3&BJ[R"3<S
MHTKS*"$:6?S"TJQ1DQQHXPJ!40!4 #U@C78@BMR!)-(JMY;*KMEI'(,G.2/D
M7Y4C<@J >:[,#P3EF#S/#8^.9UG3PW(W252$:3E1DY1YXQIV4;M2;;?O^]'=
MHXZ_BUGN*X9GDDLFRIUZZJJMB<O6)Q,X>U<K*I7Q<J=6,XQE:$81DG1Y&VW&
MQ#.VVVNL!2XBE!S@[3M(!#8!(';DYSDXXKW;XX?*WP.!Y"? K2L$C/!U6<$$
M<9RQX Y. 01U/AEPA>"?>85 AFRBLA9B%) (,B[V(S\V,L<=>#7N/QRC9&^!
MC$H'?X&Z4Z0,P8R8U:X)9\2#9M!Z%A_#C)KZ;%3H3S+ I5G.,5BU%MN5HO#P
MV=HV2MTOI\C\]P5*NLOS6KBH8RI.KC<@:]G*;Y7+-U&<96;2]I!JF]5&4(\J
M2LF_#656Z@87/4$$9&>.>N< +DCWZ4  J&SMY5"<A1DJ&SD\'J,D#D#H<$U,
M5=AR8]S Y"N!UY(YE8@X!48;.#G ['D[R#NA506 !9. 0 HP7/ QQSG)!Y)R
M>QUXTL3!TZSY59U7&;NH.,7=IP>G,K*6[6G1,XYP<,PP]:&&Q#CAL?GLI0K-
MJFZ<L52HTXQC*<4Y0YI65[0@WH[W5[0Y[:#Q!X1OKJ9[>"T\6Z#(TRQDQVD=
MOK%@\MU.1D,BQQNQ/95)-???B7]J'PQ!\>-:T/P=HOAWP;\,M5^+MCXC\;^-
MH[JXNY?%][I5L@M]5E1B5LX4NHE5BBE&*GD U^>^W 8.\:JR>6RAU\D\D*P0
MR@%E89'RYSQGBD$91BRM"F4*;5\D!E8Y9,L=H5B26&W+$%B03FO%S7AK)\[S
M'^T,=B.9PPM2C055QE3IRG655U4I1_BPMR7U2BVE%M7/J>%^-N)^$,IQ&68*
MAB*56KGBS>-6DZD*[PRPE3"^Q4U5;5"7-&\5&TI\LN:S/U&U_P#:/\(?$35_
M&%C\1O'MKJ'AS1/BAX \3^ KO3;-/MFDVMA:SP:SJ]C($=;B*W?[*DOF*3&'
M=L$X%>@>)OVFO",WC#P-K.A^-O <GBW3-1\2:-JM_>WES+9-X4U(+]DNH;X0
MKY&HM'AW_=M"D@V#CFOQX,:>6\0CB2-U8&(;-K*_WXSB7!5BJ$QXP=H)7*Y#
M'@B;)=;<EE558^7YJH@&T--OWD*  J\J%.".:\-^'N2SJRG#'SA2E&IRTXSI
MQH\TH<JLO9W45:3LVHSD[-*R;^OEXU\1RP53"ULGP+J1=/%RQF9/$TE7GA)2
MJTX5\11<ZTIR=1TZ:]EHU*-TDF?K-X$^/?PC\*6_Q;TCPEXXL9O%6I_&,^-M
M1\2>,7;2;#Q/H,NG6J76GV=[';.EU;VLPGM=/1$22[BC1UP=QKX3\$3^&O$/
M[1-MXLN/%&B^!= TWXA1?$/4K^]N)(=.NM-T_7(KBYL[5\&7_2(E!MX6"NXY
M( 8X\'$:A%3(,<3GRTDD#>620%>%7?$1X!212-I+ 'BF-;1>8\FRW,TAWO(Q
M5Y9)" "SRDLQ?&#G. R@GH!71EO!&3Y91QCABG+$XB*A2G)QE4IQDN2I*ESJ
MT7)+G2Y7&+;LE"5EX^?>+^9\24>'L;F&4<+X19=5=..%P^(S2C]8B_W2Y^2C
M>HH_%K)O:;;D>Y_M,6?ARZ^.7CCQKX:\6^'O%FD^--1>\M)=%ED>6TM0%>);
MR-E&PL&5,C;\P.?6O"2V0Y8[E?*G[V,[2< CH>% &1ZXQG$CPI*[3-M,\BA6
MED=7DD"@##/NYQC"D#H>G6G;%()/E EEP"Y"C:K8(42D$DJ=Q*Y^8@#C!^FP
M%&A@,-3P\<14<:=*%*,Y-<TU3BJ:;48J"4EORVUO8^#SS&Y;F^=5<0\NRBE4
MEAZU9?5<9F<ZWM/XD5AU.E&%2JYM\BJ64I751\MFX,':0T9&V12N&R3DC!SD
M<CIC)'3FNW^&H ^)?@W"E ?$&Y22#_RSDY.>1Z#L0H8XKD!&N8U/EON922'Z
M8(*?Q@AO;!SW /%=I\-@)/B-X-5%B\P>(5"KOY*[9MQR9#@$DE1TSD!>.3$U
M*'U;%/VMK8:NVTV[+V4E=+E3]ZSWUTZ:')ET*7U_ OZMF-WC<*WI52E?$4UJ
MFW9WNW;1\K2MH<EJ)_XF?B,9!(UW6&0<8S]LF/!SR!@G.3W)(P<5CN^5C_=P
M6'(CP<GIP1D]O?H034]W&KZUXD0M&YCUK665)#M /VV=3R)5W8Y&T;2><5$\
M7/RF/:N<IO4*57J/]8"&5N=X)R/Q Z:$J/U?*N6LN7V-*TKWO^[BTERQ2OW;
MN[76ZUZ<8K9EG%Z&9-.=5N2<[J2K5+6=TK)?"DFUJF]"LS/W3> #DJ2I8-C.
M.GW?XQG!45!<I-):7]NB<RPLB(2"6,B\8.X8YS^!//6KX5#DE%Z<_O .JG
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ME@X_XHZ^  Y)U2?  ^;/<DG)].<^E)_P[5_97._=X.N^<=-4GSP-H/)&TMC
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M<DVN:UDY14HMQ6K:36\K.Z1^3'P$_P""P?BKQZO[)^K>,=0M= L=0TSXP/\
MM9Z?=^&;C3]0\'ZC\/?#DFOV5N+1[47:R7=EY=S#_9JSQW"MM!SE1XU\$_V^
M/^"IGQ&_:G\#?$37->_9N\(?L4_&/7=:\:?"KX9>)O$O@S3/C5XC_9Y=+NZ\
M/^.=,T'^U?[:NI[G38;>\N;4;[R*::6*:RB=#&OVMXQ_X(]:+JW[:GA7]HK1
M/&6F:'\$=5^%GBCP7\9O@XUA=R1^-O%FO^';_P .IXQTZ99!'9W9L;N&.Y55
M3>MG'P<L*^?_  3_ ,$6OCM:^-?V>]'^(7Q_^'/C;X+_ ++6NZK;?"G53X ^
MQ?&"W^%US;7UGI'PWU+Q!!(D<FFZ7;7H@:10SS?9XV?# U]5-<-5L3"5*<\'
M05IUH5\/]9ESJ3FL/1C!P4[2DZ-64I0E*BH5(>]%Q?FMYI"C-RHQKU)RY:<J
M-1TX)2?*Y-R3Y)1BE.,;2CSWBW9D?[,?[7W_  5V_:C_ &JM%^-'@+X>_#R+
M_@F7K?Q0\0>&;*]UF;PUIWCZ+P%X<EO=*N?&$MK/J<>J0+-J]I((8)HQ>-;!
M939!'5C]#?\ !3']L_\ :QT3XC_";]CW_@G!8>&?$W[5_C[2=4^(>O7_ (LM
M[*Y\(^$?AGI3/:2:M-K6H2II4EY?ZBHMH+&UEO+Q5#N]O&I5ZP?@/_P3/_;$
M^"&I3?!'2/VN?#6K?L/7'CCQ3K&K_"NZ\&O'X\NO OBTWMQJ/@"U\503P76G
MVSW-XS1:I:3I>P+GRG5@#6G\3/\ @D=XC^'WC3X'?%/_ ()V_&"/]GKQE\']
M"\5^$[FS^(*ZS\3--\8>&O%-S]MN;34M0\17]_JZ/8WX\VU_?E$^XJJ *X*J
MR)XW$06*3ISHUI8*.%P]3V-&?[I4%F4JB]I15.<:CKPHPJ7YTX2D^9KI@L0H
M4E-252*A[2+:<FU?VB5M+VM:4W&VJ>C.Q^'7_!2/Q+^R#\&/#B_\%:6D^%_Q
MGU%;J_DF^'/P]\8>.?"LGA_3;?3TO=<U#6? .D>(]%TB*.[N)))$O[NTE6%=
MYB"@D>E?$3_@M]_P3>^%NOZEX7\7?'/6?[1TKPOX5\::G<Z%\*OBCXET72/#
M'CFTM+WPQK.IZYH'A&_TJPM-0BOK8"2YNXO)F9H)Q',DB+\+?MJ?\$?/VM/V
MT#X"U/XH?M?^'_$.LZ+\-?%?@;Q?X=U+PWJ.E^!/MOB:PM[>/Q5I&BZ)?64=
MSJFFW44CVW]J?:(]KH2F5(;X3@_X(Q_MM>*/CU^T?\%/#?Q \-_#/X'^*/V=
M/@+\(=>^)>J>%;;6[/XEZ?X0MXQK<&@+(S7>DWUND4D:ON&P2@!OD4CK67<-
MXG!U,74SRE1Q_O\ /AL+AY_4DJ$J4%R3G'F_>1O*S?/*HW!J$:BG#"5;'4\1
MR+">TPZBI0JJI:;<G\,HMVO!MMM>[9)W;3B_[&O"GB33?%>EZ/X@T:\BU#1-
M>T;3]7TC4;</Y%_8:E;QW5M<1;PK)'+!<02HKJCKOP5&T@=61A3&@V\8!XP"
M><\\>I[\@X'2O(?A3X,MOAM\/_ _@FVN'O8O!G@_0?"5O/G;(]OH>GV>FPSR
M!C\OGBT,I8@D;\9P!7IT%Q+,[QF,QD(C,X<2)N&0P!!/S*!\V, 9&><8^.4(
M4_:>RK2Q%-RJ252;32UG:$7%>ZHI1Y5J_>:=^2[]35I.4?9M)>[KJOYFWK>3
M;>UM%9V>EBZ601%L*S*O4Y )Q@DX^I)R,<>U?'W[<?@CQO\ $S]DKXX^!? 7
MAAO%_C'Q)X(OK#1/#D$^G6\VK74AC)M89]8N+;3XY63>4:XFB56"X.XKG[&E
M_P!6>0 !G<3WS]T9X/88]017C_QH^*_A'X)?"[QE\4_'#7[>%?!FDS:SK8TJ
MT>[U$VD3HK?9K5&5W<.ZL%&!@;B<YI4:]2G7IU:6$524:E*<9\VJE"2DH235
MVG*Z<8:OFNM5J]'"<&DU)/WG>\5^"M9]>BU:/YN_AS^RI\9-9U.PM/ /P,^+
MV@?!G5M ^ _A[XI+\0/$*V/C+5?%WA/6X(/&<&C7.IZZ-?\ ^$4TS0XTBDM[
M69-%N LW]F),@&/3]%^ O[0.C?%[X\IXYT+XZZI\6M#^)'B;Q_\ LAOX:OQ/
M\)]2^%]AX0M],\#?#[Q3KUK<C3;+1+_6;._AU7P[K=_:DK+'=31HDXE;]M/#
M/[17PQ\4:]X5T#1_$;_VAXU^'$?Q/T:6X: V=EX2;[.[RZM.)FCT^X"W42M'
M/MV_,-Q*FO0V^)GPZC\/C6SX_P#"%IH;R2VD6MGQ'I"Z6ES"O[^!;C[4(2T6
MZ,M"K^:FX,R[6!/U-3B#&RC1A/!NG&G3E!)0E*<U.O/$1<ZBI2E4;?/1E=1=
M6@E12@J?.>8L!",ZDW4<G4E&45>T%R05.7+3C-)*5HSO=VFG.5T[/^>+X.?"
M/]L+Q+X4^,$7Q[^%_P 6_ _PY\9^!-%F^)?A7X?:EI5EK\'Q*LK.];7[?X:6
MFA:G(\NG17RV:"2#SK?4(P^Q[A&.>D^!6@>/_@!\7/ ?[;'[5'[/WBO1M*T+
MX$^,?AW:>+O#^E6VN>(?#_A?PUXZ\03?#B?Q?X;T*ZOM5AUWQ)X#FTF>\CMM
M-,D.LW<MO=Q6TR/$G[RZA\7?AEHUUI6A:M\2/"%KJWB6UM[CP]9S^(;"(ZU:
MSDI;7MG*]PJ2)<,I\GRI"'8!06-<YI/Q\^!/BW5OB=X,M/'WA._NOA%JD&B?
M%#3=4U+3A;:)>S:9I^M#^T4O9/LX26WU2T<RO\HD8H,,A%*KG.,Q:Q'_  G1
M]E4HJ$U"DX6A)*FJE.:C&49\]H2<_:.=U3DHM*1=/!PI)^SJOFO>\Y<^MW*T
MDYZI-WBERVULVM%^<W_!0_PE\4OC+X1_84_:/^"7P<UWXHZ7\*_VC?!7QQ\<
M_#[4(=,A\0:7\,)/#.LOJ?B73?#FNWEF;KQ?HJ362Z7IUDDVLQ7%Y*EM:M(S
M@>,_M)V?Q;^,'Q'U#Q]:?LP_&R+PY\2/@FGA;X& 2Z583^!/C7?:S)=6/BCQ
M)HMEK<=UX<D@_P!$OKO7=6M(!%;6TT$TP9UA?]L;WQ[\/;/1]"UV?QSX1TO0
M=7NK:V\/7DFNZ9#I6L7>UUMK#2KH7"PW#RJHQ#;,=H0 I@&L7XB_&SP+\,/"
M'CKQ;K&N6.K-X"\/7'B36]!T*^L[WQ#'96<)FD:*QAE,^6CP0"H!&#T.*\_#
M9CB*+C'^SE*45*G%OG3<)UJ=7DE[G+SPK4H+FE[WLYU*$U%5;K3ZNTG'VS>S
MUY6[\KC=^]HG%M6CI=1FF^5I_P ^^A_L^?M2_##Q[=^,OV@OA_XP^+?P>N/C
M#=>(?C7X9\$SP:WJ'Q$\82_ WX3>$]&\=6VCZ9<QW6H:%9ZIH&N:4(#$LMO>
MQ27,UFL96:O>/A'^SO\ 'G6Y;:2?X8^-O"GA*36?CYXU^"6C^+?$5O&_P_FU
MRST__A6@UJUAUB::R'VL3OI^G7(D;3#D2P6S@J/U#_9V_:H^''[2]M\0;SPG
M#?:1#X*\9:1X*OXO$ CT^XOM4U7P!X2^(5K'IL4<RM<@:5XLM3-NVSK/'."N
MQ :[37/VA?AYX8^)WASX3:O?L+[Q!H'B+Q#)JHEMCX>T.Q\+/ -0@U?4C(8[
M:[C>XC#Q3,KH.6P<&NZ6>8V+K166TXU'3M-1I0ITZ:I5E65948+EC651SIU*
MJE)UJ4_82BKW)6%5US57RJ3<;R<IR;CR\KD[>YRKF4%\,ESIG\]^F_L]_M53
M? S0!X6T?]HA_P!HCP>_A+2OVHM"UN_32_!WQ"\,6WC&;6OB+#X5OC/:6'B_
MQ)JFFH\6E:G9WEV[6$J6JW*R,T=?3_Q#^&7B;1_CWX6^-/PF_9:\;Q:CXB_8
M?^(GPW^$7]M6EG<MX9^*-O+?ZW9>#_%ZWFIR?V(NK:5%<FUN=8:'2)97-C]J
M%Y-'"_[6#XD_#JXT73_$,7C[PVGA[5KU8=+UV'Q+IG]F:C>;WB^PV5\;@PSS
MO(OEM:1,SH0PP.A\Q_:$_:0\&_LS^ ;+QQXUTW6]9BU[QEX3\#>%M$\+11ZI
MJ_B#7_&&LZ?H>BVMK$TD:$276HQFZE9PL-LKRY. *YY9WCZE:-)X!R5:>(DT
MKJF_:>QJRA4484[^SE0BJ<&TZ%)SIOW7SDU,+1A'VE2JHP@Z;;:3E>+G&#5F
M[/\ >7EI[\^1M)JS_%[]G/X>_%;P*-4^+?BSP/\ $?3/@SX2^,N@?$?2K_QS
M!:6FK:;X6L/AQ/9>,-1TSPA#)'JFG6L7B9I+*VTR#2H+V^.RXM[6>)Q,W[C_
M  %^./AW]H3P?#\2_"&@>+-$\,:EJFL:;I,OC#1;O0+_ %>UTVX:#^U+73-1
MCM]1CL+Z57DLI)X(C)$C/C#(3QOP]_:/^$WQH\/6EQ9:W8Z#<ZMK6M^&9O!?
MC@:=INNQZWX=NC9ZKI$^EW<I%P]O.H&$$BE65N=P)]GM_$O@W1=4T[PPVO\
MABSUQXPFF^&%U73K2^<&$RI'8:9'+&QWQ;I$2./)C!9>#QEG..Q./G"=3+(T
MJJO&+A*7LZ5-5'-U'%Q4?=DTDTW%1LI-I.36%HT*<$X8V<US>U2NDY3Y;)6;
M4N625VF[\[;2T2/1#)*N$!10% W,2.#DYXQDD ;N,_I4ZS.5C.TEW#$=E !&
M"=Q!7<,=<'D9YZ^;S?%CX>0+KR2^-_!T$GAN3[/KJ2^)-+0Z-,X^2+4MUP/L
M<Q 8".7:^5("GFI+#XG^!]1GM;:Q\7>&;BXO-*&NV<,6O:;)/=:*R)(-3B@2
MX+FTD5S(LV-FP!N>E>1*C7:BHTI734I.*E=<JYG)R4;--.7-.RCROFMR>\=S
MG%W?,M7U:O=[)I-ZMZ6WOTO<]/R.O'/&?7_.*:Q.#M(R.3C!/4<$'ID9KYR\
M8_M1_ ;P#X>T;Q3XD^)GA.#P]KGC;P]\.].U>UURRO;-O&7B>_&GZ5HT\\$T
MD=O<7-RZ)B8H &%=-9?&3PM<P>)+W5IXO"^D>')K1+G6O$.HZ;I^E3PW,LJ1
M7$%X]SY8C<Q@QB8QM)D;5)R!7L<6X.7U>IRM.+E[VC3:6KBTY:JUDY.VVJ8O
M:03474CS-72YE=Z=%>_]6/8][87/WN,C:3U[<9Y&#R/4<\U,N2.>N3G\#C^G
M^37,V.OVNI:?:ZII<MIJ6G7D,=S8W]E=P3VEY;S /'+:W$3/'/$\9+Q.A*N!
MA>E;PEQ%&X!)8J64DEAOY(. <$$C Z<]"*RC"5).<W?9<LFU9Z)MWNE+HTDK
M;+4O;^O3U_JY9J$AC(,8 R"<]1\IZ=1GM],BG[P>QQ@YXQSD8 Z=0<Y';O39
M"&!4AN,\@$;2 1DD\8/..",=171=/\/Q5U;Y,32>Z_JY1GDE!,411P&Y4GG'
M#!2!@XZ\]!P"?6M#->"5?-B41 MC!4D=<,<9 *@D$^^.O%))/$9YHV7Y@#AU
M)'0#.<<$@>_<X&14(E, ED+G 0L2P&TDD*JKLY)4*/EQD\XP,T_=IQ4(P4ZE
M1W@IQ?,[O[,XKELFG:]G%+WM1.56#Y94$XSB^6HI?"FFE))M-/7I=7\[(NK-
M.RGY>0<]<$ C:1C/<\J,8R1Q4HDFQM"#*A6VG&0<DDGD CL!ST],9RH]2MH0
MR3W5M V=RK+<0Q28/0NDCAP.<C([>HX<=6T\A?\ B8V0/ /^EVQR"!P6\W.!
MDY'KG!'482UJ3OSQUDK1C>"E9)<LN7WDM;:+6^H1BZ<53YU4<59SE)W=E=MM
M-)N[TM^%K&LLLI8L$)R3R=OL!C)&.!WYYZT>9,3GRNP')3'L0"<9]\=A60-6
ML00?[1L.,8 O+7KCGEGSTR<D^W:@:Q9C!.H:?TQG[9:\ ?\  SZ'MSQCUINR
M7VWMIR[Z)=%MIKIN[6ZCUNM8K3^:7IK9]W\^V]M?S)N,18P/]CIZ<G/;Z_G2
M&2<XRC'TY3^G]:R1J]GR6U*P'/3[9;$'E<G._@ 'IT&#QURO]L6?0:EIY..I
MO+4'/K]_! XR>OIP>79:-N7:ZCIHO*_E_GV3<DW:4=.J;]//3T[FL99C_P L
MCSU(VYH\V;()C)X_V>QZ]>O^<8K+.L66<?VE8'G&?MEKCH#C[YZ9 ]^U)_:]
MD?\ F)6'8_\ 'Y;<$,!CF0#IST[]^,*T=O?^[^OZ[!JUI*'I=K?SOL^NM^UN
MNKYT_P#SS/M]WCZ4>;-@ Q$XZ9V=,8Q61_:UEG(U*PY//^FVV/? \P$=CQD'
MW[']K61Q_P 3*R[9/VVV'/XOTYY&"/QSEKE5FE/M\*?SW_*P]>\?F_\ [;^M
M#6,DQ !C.!R/NC!Y'KV!XX_.CS91G]WC."1\G;GI]!T.2>W6LDZK9=?[2LOP
MOK8>W]_GI_3MP#5K(9']H6'_ (&VO.<CM(!T/<<#/?!IMI])_P#@"7X@O6/_
M ($^_7WK?+\M#7$THY\H_+G/"\<DD#GGVQSU H$TW41G\E!)XY^HY!R/8CBL
MG^V+%<#^T;%AG_G\M@>?I*. >23CG@ "@ZO9%<?VE8#@=+RV!'&?[^>3UP>^
M/6IT?673[.Z]&NO^?F&MGK&^WQ-WZO2^EG^&EC5WR[BPB(8]\+GICU_&E$LV
M23&>>OW>PX[_ )UD'5;,9_XF=EZ\WUMGZ8$AZ_7TXZTG]K60_P"8E9G_ +?K
M8]"..).O],_2GI=OWO3E5M'T)U:^*/WR6]GW\OD;'G3G_EFV".AV]Q]3_.@R
MS8(\H\]SMR1P!GGJ/YUC_P!K61'&I6((  _TRVQQSS^]'3MGW&<]'_VO9G_F
M):>,G_G\M21Q@ ?O,'D9[\'!ZBD[72M/??EV\M+I+9C5UK>+7G*3_6YK&:8X
M_=MP<_P^^/RS[TWS9O\ GF>QS\N<@DY_7\N*RAK%GQ_Q,K YSD&[M1MP#C^/
M!SQTZ=^M']L6??4=/Z\8O+7ISQ_K,9Q@\CUQS3M'^\O^W7;>VGYCN^CA]\O7
MJ[^7H:_G3_\ /,_^._XT>=,>#&<$$$?+S^OY^Q/?%9']L69ZZC88'./MEIVZ
M#._VSQGJ!TYH&K61.?[2L. 3C[;:@>X_UAR3C.#A0?K2LK:.>O\ =_KUZ;+R
M%KWAHOYI>G?7?^K&MYT_&(R!TP-F.#C'7C],#TI#-(VY2I0@$!3M&6P#V/ !
M/7(P>]90U:RY)U&PZCC[;;$Y!&,XDY'?H?3I36U2Q/)U*P)(Y'VRV]!Q@2#G
M@\C)R>#SPI1335Y[I-QA'1NR^:3::?2[UT=DWU;6BU7-+33R>O?J6UEG!+,%
MV=6?.6!+?,2J$_*RY (!.1\QQT?]H3R0ZAB%;.=CC!4D@%2-Y.#Z'C%?'W[0
MO[:?P>_9QOO!/A/7&UCQA\4?B9JUQHOP_P#A3X#ME\0^-?$5Q;VES?7%VNFV
MTA.GZ1:6UM*]UJFH-;VD)94\PR2(I\;7]I;]MV^M+CQ#IO["[PZ/&/M%E::S
M\6O#^GZ]<VA.X//9-;O#:W"Q$220RRY1B8RV16\,/5E24)M0FHI*HG"+=KWO
M=VDU96<=+NR3U,(XG#QE)*K4J25KJ,9S23][WTH7@WWE9\K3Y;6O^D27,[(W
MG*PS@1K@X/7!(&3SD$@ ;1@'!X$JS.(P&!#MMV*006XRW0X4GH Q7D].:_._
MX5?\%%OA'XS^)/\ PI+XJV.I_ 'XU?V)9Z]9>"OB+<65KIGB#3KZ]N=/AD\+
M>+(9CH>NSM?6LL#V5O=&^0B-I+=0X)^__,>2X611E"JNI5U<;2.JX)W9^4@C
M((X!P0:2PR:<O;2DHWDTVM7!JT+/>]FF]$[Z75C6DZM>=5N#H4X0YZ<9-6DN
M1MRCLE=V:3=[]+Z&U:2AE(8C<QS@'Y>.,+G\@!V7H.]S ]!^59=BQV[Y $(=
MA\Q4$=,C )QQD9'7GZG0\V/)_>#GW&!CT^M#DI3FHJR3NER\J2=K):O977KK
MM8*+G[*GSZSY5SO57EK=VW731Z]>I+14?FQ?WU_.CS8O[Z_G3-1^ .@ _"C
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MNB)XETB'4/CKH^J^(#H5E>:*FH6EK#I.FF%_[6EN+B:94M8W9=S1D&G\*?\
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MC-_LG4_^@K>?^!C_ .%']DZG_P!!6\_\#'_PK3_MRU_Y^8O^_D/^-']N6O\
MS\Q?]_(?\:H1F?V3J?\ T%;S_P #'_PH_LG4_P#H*WG_ (&/_A6G_;EK_P _
M,7_?R'_&C^W+7_GYB_[^0_XT 9G]DZG_ -!6\_\  Q_\*/[)U/\ Z"MY_P"!
MC_X5I_VY:_\ /S%_W\A_QH_MRU_Y^8O^_D/^- &9_9.I_P#05O/_  ,?_"C^
MR=3_ .@K>?\ @8_^%:?]N6O_ #\Q?]_(?\:/[<M?^?F+_OY#_C0!F?V3J?\
MT%;S_P #'_PH_LG4_P#H*WG_ (&/_A6G_;EK_P _,7_?R'_&C^W+7_GYB_[^
M0_XT 9G]DZG_ -!6\_\  Q_\*/[)U/\ Z"MY_P"!C_X5I_VY:_\ /S%_W\A_
MQH_MRU_Y^8O^_D/^- &9_9.I_P#05O/_  ,?_"C^R=3_ .@K>?\ @8_^%:?]
MN6O_ #\Q?]_(?\:/[<M?^?F+_OY#_C0!FC2=3'(U:]!'3%W)WX(R.A/'8YQB
MD_LK4,HKZK?MDDY6\E  .  1@ACGCY2"  <<9.G_ &Y:_P#/Q%^$L(Z_4\C
M.?3@XZ4T:S:G:1<0YZ8\V(-]T@$DG!/\.<@C X]0# N8M7LUWV>LZC;LCJ)
MTLDZ.X&^.-BVTHN[(;:&W<# X->T_#WQ?=>(XI+?4D6#4;,+&WDG,<R[2%D=
M2%<%L'@G P,$]:\?OM6M=K>?=016\AWR2NRR1Q,GS1HQB)(:8YVEE^]P#UKN
M/A)I-VUQJ&O3V\T=M<NJ6SR#9YL2JWS)&V&*88D-CF@#WR,!4&!C/S$$YY;D
M\Y.<D]<T^D'3T]O3K^./3V'04M &*/G 9"3L4J"2,Y ()8'J#D8'?).3S7,Z
MC<Z=#!/-J<]I#I]O%<2ZHVHM&E@EK$ICF#B8BW2-25=_-^4DYZ\#K4*E0RIS
M@.HW*I?";0"0VT-QT)(/7. 17YC_ /!4GP?\6/'?[+J>'/AUX&\<^-M'UGXH
M_#S_ (7-X1^&.KQ:9\1M6^#-KXFM+WQK9>$KI;W3WFU&_L;<6]Q;VNH6=S<6
M+W$,4N_ )A90K8B-.4Y4X-J/M()1DI<]W*Z:O>,7RIM<\U&/,EJ957-4I>R2
M<TGRJ6J?NZ*3Z*[3;2>G-:^B7WGX%^(7@CQQIUX_@/Q!IOB&RT>Z>PNVTEX3
M!:W"IYK0?NAY0PI4C'# D\GIWD<[MY<BA]CHLH!Y SA@N0>YP>,X(Y)'%?RN
M?$SP3^U7\+SX0\._\$]OV6OVB_@E\#/%?A#67UW3HKS0=.\<M\5DO;.WT;Q'
MXTO?%/B34KNQ\,:7I1NKB^@@FEFU,KY<4)<*1%\+_BE_P5%^)'Q0^)GQ#^"L
M?QC\=^!_#_C7XK>'O#5KK]SX1TCX7:EX2\!^&H_ FGP>&[B^O/[1UCQ+J7Q&
MT[5]422[M;1H!;.K,T$D;O\ 0KAVIB)PY,SR_#PKKVC>*Q%*FZ*E*46L55A4
MJTX5>:,4XPC*24X/5.4H^?\ VDJ491EAL14E"\7[&E)^U<$I-THRC&;C9MW?
M*FTX7;:O_50)3)YTC)(FU"Q8G P 7. <X  ;L<YZ\\\'X&^)O@GXCPZO)X6U
M>.^CT37+[PY?1SJUK.NK6,45S=P012E9)A%%<1,SH&4[@,C!K^;?X;>'O^"J
M6B^)_P!F\_$_X@_M'>._A/\ $#Q7XRUOXM67AOPAH_A_Q+\/]8L],(\*^"=9
MN[N^CUAO"4VN1B6YURR2:RN+.1[<%8R&KP/PK\'?^"K.D:7;_$/Q!\*OC=H'
MQRT#X=?'CQEX0A\)>*_"#>#KKQUXH\>SV7A73/$NAV&JIH]_KNG> ;>WN-/-
M^KP7,LD<3RQRQD&O]6:4)5:53-LJJ5(1BH3C6YH5).I[.<74=2*<J3?-42BD
MH+GA*HII)PS!S4)QPV,A&4US*4>25*+C*46X.+DU4:23NVF[2Y-3^L/XG?$C
MPC\(O"5QXT\>ZF-&\-PZGH>D2Z@5>1UU#Q)K%EH&C6T:J&;S+S4]0M+53@*O
MG;B0HR(K[X@^%;;QIH/PWEU"6/Q5XCT6YU[2K-8I=\FFV@0SR-=*ICCVEU!1
MB"V[:*_ESUSP9_P4<^-'[,7Q&T'XR?#7]J%M(UWXR?LXS6>@:_+X-UOXA6^C
M>!_&LGC?Q;XI\,:;I&L);V,-Q?Z+X>L!#=7BM9)</<>7+'#(A]-\%_#K_@KA
M\0K>PT#Q9%X]^$'BS3F\/:/I?Q:N;?P1XHU_1O ^J>*-3U[5;$W=K>;;C4D\
M-0:;HVH&- ;>]G58RYB9CG+A:'+B+Y]EE..&Q+JWHXJ*]K[.%%+V%*=*<ZE&
M,I.52*?M*JY_8NZL)YG-<D(X/&3Y[-ITHKEDW-KGFVDG*,;1E?D@VG.S:O\
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M/MS:)I</B+Q?ID,.K>*;S3[>QM;/[1J$S.]NDG(>1G'+?#__ ()5^&OA_P"
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MO+&UM$]7M4T;LNMF]7HK$OA;A>3O/AK(Y-*UWEF&=NN_LEUU^5S\MQ_P1O\
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MU<D_LG_#YN<DYU#G!R, W> #WP>< '@TA_X(X_\ !-XDX_90\ #*K@JVH#/
M '_'VI''S-UR1Z\U^I' .#@^@QSC ZX'MQQP*7 &>/R4''Y#^=://^(K)?VY
MFNC;N\=B'S)VMI[32UOF/_57A9))\,Y$W;?^S,-JNG_+K2RT7SN?EK_PYR_X
M)O8X_90\ '(P-S:D2>O'_'V!QR<Y'?&3R7?\.</^";Q*Y_90^'^ V[KJ/W_E
MR?\ CZY'3@G'7@$U^I!Y.<<=\@>_4$ G\_I[IQQWZY.#D\$>A//N<<<>V?\
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MA ((/<$?3/I[^E & !UQCKUXZ9H %!  )R1QGN?3/OCK[TM%% &.3PQ"\M@
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M#G!VX)R.3CM@5SW_  D]KC(L;WCDC[%,#QVZ=/8'';N12_\ "56Q.387N?\
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M56^>+&\QC./L,O3VX_$>HYI/^$K@X)L;W'?_ $&3/4#T_P Y&.],#KOM$/\
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M &B'_GHO^?PH^T0=Y%/U_P#U5R'_  E=O_SXWO\ X R?X4?\)7;_ //C>_\
M@#)_A2:3W7XOM;OV ZXSP$8,BG\3_2FM+;GGS%R.Y)]<\_YQGG&0*Y/_ (2N
MW_Y\;W_P!D_PI#XKMS_RXWN,$$?89>_N /Y?2BRU\]_NM^0K+Y]^IU DC.,,
MF[V.>#SQQG!/''X<CA?-BX^=&'0@D\] <_KGT/;BN6_X2NVP!]AO>.G^@RGI
M]1^M \56X_Y<;X_]N,N.F.F,>]9^QI?R1^Z_ZBMYNWHNG]?<=7]HCX*LG)7)
M!'(P>"/;ID$].U2"XAX_>+TY^OY?7\ZY+_A*X,9^PWN#_P!.,G^%)_PE=O\
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M4]7RXC17UPU:*Z:7<;"UM[U.K;6SY4]K;I3T:\^MC<$R$A-T9(?&XE1N/S<
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M,KFBI.FW:I%7<.JC>UWTU>RO>VI<&"6X'!P..HP#G/?DGD4[ ]!^0I:*LH3
M]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D
M*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH 88U8@XP5.>.,^Q'<4[ ]!^
M0I:* $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?
MD*,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EH
MH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EH]?:@!NU>NU
M>F.@Z#G^=.P!T&*** ,8,%^9&)79M7((QM(."2"V0,Y!4]<#D&OD;]LK]FB#
M]J[X,S?"@^+[CP6R_$#X8^/8_$-M8_VG-!-\./'FB^-8+$6@EARNH-H_V/[1
MNQ&LY<(^T+7UV0H(ZDLI/(^Z6;@#'1@>2 1MP>,FOSS_ ."F/[2GQ!_9)_9#
M\??&3X1Z-I/B#XKP:_\ #KP5X#T'65=]/O\ Q/\ $'QWH7@VS^U0QR1/<+:Q
MZP]X(1(H80D\<D&&E6IXBC]6A>52=/EE&*]R47+D;4;\SU:LK-.+=GH9R5.5
M-^V23<7=W44KQ:GK?5<M]+:)^IX=XW_X),_"[Q=^VAX$_:W3Q;>Z98:-\+_$
M/PX^(_PDLM'C3PS\2UU_1;W1!K^H(9XHK;4X+2]=&F:VFD=88%,@5:^:O __
M  1:USP_X^^$&F^*/VJ/%/B[]FCX ^*]6\3_  4^$.H>!] C\:^";#68[JTA
M\&ZA\2WDFOM2\+::M]=6L6G>3&!;I;Q*<)FO*OVQ/^"P/[4_[)WQ.T'X8S?#
M;X(^(M3\+?L\Z3\=OBOJ/C'QB?!=W?6ESK$VGWWAGP+:7<PBU+7OL\:OI]@K
M2375PWE*K9 /M&E_\%3_ -HK]J#XL-\+?V#?V;]'\9WGPM\!?#/X@_M&7OQ<
MUBX\*6_AJX^*>A6'B/0O!'AB)(R;WQ$FF2W%U=2W 2"-X?)/SDBOKXT^)Z5/
M#8GZUA8TZM&,Z%>KF%"*H4E3E['WJ[<L+4J04J=+EYJDX7@Z?)JO+C#+JCE2
M5*4^2;YU&46I-2M+W86YH*ZY^9*,7ROFO9'H?P,_X)4>-_V?/B#-H/@_]L;X
M@WW[(,WBSQ)XFNOV5]:\-:-J.GWI\4R75QJOAJ3Q0SB^/AMKN[-Q'I\<*A(\
MQYY)K;_:P_X)#_#O]H77-/?P3XS_ .%*>'=)^"'Q%^$&G^&=#\/Q7FEQ2?$/
MRFNO$=D)+I,W%KY6&MI5(EVJ=Z#FO-_@I_P5!^.WQE_;0\6_ /\ X5'\+/!?
MA'X>ZO>Z!XG\,>,_&7_".?'6[O+'P_+J;>(/"GA"_2/_ (270;W4HFL;2YTO
MSPT:B=V"@X]1_9F_X*%?M ?&;4?VT_#GCC]E^X\*_$O]EZZ\.KX;^%6F>([6
M_P!;\50^*=";6M&BU#4B?L-G>7-NT<LJ(=L,;X;<0*YI+B>GBJ^*C/+Y/"9?
M0KUIX?'X6-:V,QE+"4_;12C"K6<ZD9U:LI3FH*-3FC;3IY< H0A/FY+>ZM7>
M$(R]UR:>BNU&-DIW=E)JYZ;I7_!.G2]%^"_[%WP=A^(EU>)^R-\1O!7Q(36X
M?#]JDOCJ;P1X;U+0?[-N88Y%CL)-0&I?:&.^7:8]GS9X_4&!O-W2A556V.(\
M[7A) PDJ@L01G^'Y1GIUQ_/E^Q-_P4\_;/\ VX?V;_VK_%W@+X _##PE^T1\
M _BS:^"- ^''B/Q#>KX=NK"SU%1XA;7-4MR91J5CHL6I2P"V_=37<$2@;2:\
M;\/?\%>?VW])_9 A_;>^*GP6^#_A;X06OQBT;X>W6F^%M7U+6-;U#3_^$]N?
M 7B74)1.0EDMCJ,#3VV269/O+BN6OD^<XG%_4Y5<+4GE]>-*K!XB,W4Q./E/
M$4XT:E-SC6G5GS:J4DIPG'FLG:H5,/2?/34N6I#FA:*LH4U&GJU:*Y5965ER
MM2:4M3^GVW94D8 8 C(+ <$%AC 4G=[L0 ,CC-:8W9))X[#'/X^^?<\=AVX[
MPOJD6M65GJ]M()+;4]-T[4;,@DJ+;4+2&[5,$Y+CSU;<.J,@/-=A@G'4 -GC
M@D8S@C'(R>>?6OG(RCSSCRR7[ZK%W=_>A)QFWMRVG"<>7=.+3N=<;M+F=WO=
M72M=V7W-7UU>NFA',/W4@)'()).<*HZGCGIQD?TY^6OVNOA!K_Q^_9N^+/P<
M\*:EI>D^(O'GA.]T32-0UV.X?2;:ZF*/$U\;:.2=;:39AGCC9XQEMK8%?4%[
MS;R+A^<<J<'\#_/\3UKPW]H'XY>"?V;/@UX_^-OQ&NY[7P?\/-!N-;UJ2WB\
MZY:*-HXH(8D4$^;/-+'"N.,R=L5I24UB8NG?F2@TM&G-5+PTVDFTM-%T>[M$
MY17Q0;2NTTU:]FFM=FE*3NW:R=KNR/SB\1_L_P#[9FI_"OX4:+I?A?X-Z5XN
M^'?PNU[X-W6G2?$_Q-+X7N+74?#5MHEAXU74[?P;;7J-9W%IYS:,UD92)0BW
MH(#UR4?_  3V^+_DW7B76_$O@C5_%NC_  ^_9P\->&=4L[[Q+)?:5JGPA>^O
M/'LVF/-"K1?V^UT8=+FC)EN@JB^9,X'T9\,?VO/B+8>&/^%C?M0^ _"GP>^'
MOC32]-U/X11:7X@;7?%GBNXUI9+O2?#3>'DC^T77B6XTPPW!M;..1C-(R$80
MD<\__!1SX=7/Q5^$NA^%;S2]:^#'C;PQ\6-9\8_$&6YG@U/P#XC^%Z6AUCP=
MJ.C%?M-OKMI+>1P7>ERQ+=Q2.B)$V]"?>>+SF$*<,+A*5:C&=2I4Y8PY&[?O
M*<:EZCE*TY1Y(VC&3DFW.-H\E:AA*SY:E2496IKW:DHM6?-%N*LU=13N]7'5
M63N_QP\!6VL^%OVX=#^+OB3]G[XV_&3XC:3K?CS_ (0J'P-/>PKX'1KG5SI-
MI\5+#5M TVQFN;R699HKNWU^^6WL&BD02M&(F_;GX\_ GXH?MH?L^? .R\66
ML'PB\;GQ)X$^(_Q'T"T\3:A:ZGX<EM;<W.L>']$UZPL$N'U2SED^R^88+>-F
M1@9!D&O4M+_;1_9NN?AWXI^+][XPE\,>%_!U]#:>)9/$6BZAH>MV,]UY(TT7
M&E3VL>ISG5?/A-@3"QN?-1$SDBLNU_;J_9GU/QQH'PXO/B ^B>+?$>FZ)J2Z
M/K%K<:3=:2WB33AJ6B6&OM<J&TO4]4T\I>V^G7(2<PRQ.ZJ&%7B\1G&*Q%*M
M2RB>%GA8\LE!JIR^RAJE24/9J-.+4YN$JB<FG-J;47%.E@8*<76E4C4:E[\G
M+E<I6NIMW5W[L8RY;*Z^%MKX<_:,_P""<?QL\1:GX,\)_L\:]X \*?!OPA9^
M&M9T6VUO5-4T7QOI?Q3L_&HU_P 5^.=<UJST;6+GQ9;ZYHX-HU@+W2)9KYM\
MUT%;<G/#_@F/\;+2X^(6MV'Q!\$Z%XR\;?$KX[>)(_&%OK_B>;48O"/Q*\./
MIGAS2)87M;=HUL;[,MY9)-)#9Q,TMK</)7U?\8_^"F_P,^#FE>!M6LM$^(?C
M[3?''Q[\(?L_03^'_"FJS16NL>+FU%+;Q-;SW%LD&I^'+632YTEN[%I4,A55
M+%USV7Q6_;B^%_@6R^+&A:2]_<?%GP!X4U7Q9I?@OQ?876AMXLT_2 C7D^A3
M7448OK&-'7S#;D[<_,IP<.&+XAO1B\,W3A-3I^WI0KKW9J2E.\G>+J5*;G>/
MLW=.I&*CRI.CE\5[TXP<TX7BY0O>+NHJR?-R*7*D^9+X?/Y;^&?[!WQ6'A']
MFOP9\3M(^$>F>&?@WJ/VGQWH?AC7?$'B#1OBM>6/AE-#M_'>J7MYI.CS6WB+
M4+QS/-I5W%J2I#;K(=4F<B./!N/^"??QZT[XO?$7QGX8\6>'[V5_%'B_Q]\#
MO%U]XUU.'2?!6HZQX?N-'\/>"O%O@"#P\;C7O!^D2SF0V4'BF"U?"2_8D=*_
M4[X<?%+3?$_P8\&_%W7XK;P_9>(? VD>.M7MH]TJZ3%JFEI>>2@*EGCC&Z)"
M =VWIW'P[\(?V[/'/Q?^+/@^RT7P7\/?#7P6\>>(]?T'P7>^*_&]EH7Q0\8:
M7HT=Z&\;>%_"-ULN-4T>ZN[-HX+:V1YGB#3C"(:PAF>=)UITJ&'4Z--X:I&R
M5/DC5JSDE%N;E-S=3G>JE3O"HXTXQ:U6'PDK+W6KJ47JGS<D5K*T;IQY;:63
M=U[S=_@0_P#!*S]K;Q#/?ZY\1_$OP*UR_E^*O[-_Q0E\)MK&M7'A75O$GPID
MGD\?:GIUBWA>WMO"LGBZXE>?2;2"UU!K?*QW5X[!I#[)X?\ ^"?/[3'@CX^Z
MG\9M7G^#GQ:\):[XY^)FI6OPD\9>-/%MII'ANV\9W>D:AH/BC2Y/["U&TO\
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MR?M&D07"K;ZBMRT#Q1EFP545R][^Q)\6;?PS/XQ73;"V\)P7ZQZ;9:AKK_\
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M (F'B;4M62:6WTCPEH,1-WK>NNLT=O$B0PQ3W$T<;?YJFE^%_P#A(]2T7PW
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M/_\ %4 ?1G]K0?\ /_IG_@2G^-']K0?\_P#IG_@2G^-?.?\ 8,?H_P#WT_\
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MT_\ \50!]&?VM!_S_P"F?^!*?XT?VM!_S_Z9_P"!*?XU\Y_V#'Z/_P!]/_\
M%4?V#'Z/_P!]/_\ %4 ?1G]K0?\ /_IG_@2G^-']K0?\_P#IG_@2G^-?.?\
M8,?H_P#WT_\ \51_8,?H_P#WT_\ \50!]&?VM!_S_P"F?^!*?XT?VM!_S_Z9
M_P"!*?XU\Y_V#'Z/_P!]/_\ %4?V#'Z/_P!]/_\ %4 ?1G]K0?\ /_IG_@2G
M^-']K0?\_P#IG_@2G^-?.?\ 8,?H_P#WT_\ \51_8,?H_P#WT_\ \50!]&?V
MM!_S_P"F?^!*?XT?VM!_S_Z9_P"!*?XU\Y_V#'Z/_P!]/_\ %4?V#'Z/_P!]
M/_\ %4 ?1G]K0?\ /_IG_@2G^-']K0?\_P#IG_@2G^-?.?\ 8,?H_P#WT_\
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MK6G^'_Q*\-:[J]M#;?\ +[*-%M;][6V(!EN(X]IR!C]5RNY7D(&5W%6SC<,
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MR-*3YTFY-J//'FC%)QDVF[:?:7X2ZW_P2N^.WQ6_;5^%/[4GQU^-GPXU>/\
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MD1[O-P)R2Q5X\H(W"K&C ;MN=RL%(R ,YZV+:,?,LBE5908C(&CE**2@:4,
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M2FXRNG3BVVE=;\SNTD9/!8:3BW3O.+<W4NXR<YQ492O%QO)Q2C*2LWJ]%O\
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M_P :H_MJ;_GA-_WQ<_\ QJOJC[#9_P#/K;_]^8__ (FC[#9_\^MO_P!^8_\
MXF@#Y7_MJ;_GA-_WQ<__ !JC^VIO^>$W_?%S_P#&J^J/L-G_ ,^MO_WYC_\
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M'G_!0OX?3?![PPWQ4_:2^(GA?3_ ?Q UWP)K/B_XKZO8:OX9^-FJWTEQI_\
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M[2?RW6C0OFWT=JB:^ZC]^WJ:3(N[..#DDY&<\G'&1SP/]W(/&*?MBX'( S@
MMCGKQTK&_M/&1YD!Y(_UAYQDX'/*\@#Z_C0=24DDM#SR,OPHQQM!/3OW)/&
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M+^TBK<2Q;1D8\TD<#TP#UQT.>1]*?_:7 /FV_/3]Z?\ XJCVC_Z!\3_X+?\
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M=\V[2BD15XKXEIU'2GF_$%.:IQK.,LZXO=J5YQ]HY+.+.TJ<DX[JR=GH>O\
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M&[AN>W3ET4LDTD44.PB:/S(WWD%8W.;=2&&-TL>6;)!5B5YXK-9%D/MYX?\
MLC!.M3@JDZ45AJC47)14G*G3<8J[M\4GLVGJC:7$G$\:=*I/-L]IPJ2JPA.M
MGG%E)3="I[&K&+GG$;RA--23L[-23Y=7[/\ \-%_'[) ^,'C4X P3?29((XP
M-^1R3Q[\$&C_ (:+^/\ CGXP^-,@@X^W2\>N?FZ#UY4^E>.2D0F/SB(V>8Q1
ML1NWL/D)4#LKD=6*G(^7 )J1HIXI)HWCC8VG_'Z0^UK?D8("G;)N+(6P,@L>
M!@5<LBR2+@I9)A4ZLXPIVA0?-.2:C&_)IS--N]DKIMI/3CJ\9Y[1NYY[G7O2
M5-1I9_Q97FW*]O=IYNW%;WG91A>UWT]@_P"&BOC^%8_\+A\:<XX^WRY&,').
MX\>OMR.G+3^T5\?5#,?B_P"-1M(SB_D YY  W9SG /7MG YKQ2_U"UL(XIWD
M+-<3VMK:((Y9?/N+B4)(F$!*1P0GSM[@!B-@*\$WFVLJ3P%I+:=G-O*^4,HB
M=HWW19!7+ A2Q)X4@@$U,\ER*G4E0JY+@XUHQ3G!0P\N5-WU<8O6VNGNK>.E
MT;QXHXE<7*.;9[R*,92G_;G%JBDVE&/.\VY92UU492:W?4]?_P"&C/C_ (P?
MC#XVR,-M_M"7(!Z8 ?DYR"0=N< G%.7]HOX_Y&/C#XUY /\ R$903D<@8<9(
MZ="3W .<^-A7^1AW)VDDG(PO3!]" N0>.!R,T9RP 4KN /WB=I7[Q^]R1V';
M S[8ULER.G1J2IY'A)32]U*E0O=I)WO%7NFYW;]='8VP_&6?X>LJSS[B"$*2
MG.4Z6=<25*D4H--QAC,TJX2<DVKQK4IPEIIU/7;G]HW]H$6TW_%XO&RR)&VX
M_P!IR@[@#@$%QVZYZC![FOZ<OV6]7O\ 7/V>_A7JWBF^DU?5=0\+:?<7.I79
M#W5Y*R,7EF9C\S;B1DY/8'%?R5W!(@N"!D>4RK@YVA$8!CGGF/;ZG/\ =/ _
MK'_9&MW?]FWX0^;Y<X'@_33&K#&U2C8PP!/&" .X/^R*_)?&#"9=EN"RFMEN
M!I4:M2;=6GAX4Z$Y-4TK*<5&#Y+MMO>+22T3/Z8^BKGN<8_/N*:&<9WQ1F4L
M-@J&,6'S#%PK4,/A\942PU7^))-U4GR\KO%Z2M;7\#?^"AVX_M=?$0*I.[3?
M#I!)X(_LYAG&  @R?<#)(Z@_)GAC7]>\)ZL?$'AS5XM'UN>SO-)%U;RIF'3;
MVSEM=1$DDN$BM;BVD>(2[LF9E4#)!KZT_P""AKX_:W^(8< G^SO#N\!N&_XE
MS#&#G[QZD@C;UZ #SW]D7P-X4^)'QOTW2O%NC:?KN@:)X4\2>(QX*O85FT_Q
MCJFG:;<OINENI!,UM:W CO3&5=6EA'R-C%?H>6YA@\#P)E5?%45B:%+@K*L+
M*+2<98BABN>>&YJEX?6%%Q;A)VBDY2ERQ5OP+.\NQF8>+.>Y5@\5]1Q];Q Q
M?+CY\\84EB<1G?L92J4[5.5PK45%17/)3BXWYD>*:3\2/$NF^'=3\ Z;XRU"
MU\*:KK%OX@U32-/NXC%-K-I)&\%PK1O(\-R9(8G0J &V@GH,]QK?Q_\ C7K
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MNWC@+V./EX4$X.#VIQ=V!W!>A].O !/'/&>IXXZXR6"11P0"V/XCPN&PNT*
M>0P)(XR >.25[&K_ ,^VG9I.\;>;^-W?W:#5*IV32:;;E1TM*]E_M&F^^R5G
M>RNOOO\ 9#T/1+WX._%'Q=J"_#:PU'0/&WA>.?Q)\3=*;4=+TW0FO85U.UM0
MD4C+>7ELTD%L#E3<21@XZUV6L_"?]D/Q?\/_ (N?M#6-IXQTWP;;?$2_\+^&
M+'PFJ6]K-J<1T[3I[FTT^0*%TR;6;F27864B N .P_.RU\3^*;#PYK/@[3?$
M6J67A/Q'/:3ZYH=O*GV*]GM94FM[J>VD5@[1/$K$L,-M0C.*2+QAXUM?#3^
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MW7M2\+W7@K4]*M]=FTMC<Z?;:F=/TR*YU!['4(K6^AN))RJW$"22+*,K7?\
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M\6_/R3_PC.MG#8P2"-/ VL<#CZXK^S8Z39#(;3[ 8)^9;*$@D$KU$> 6 S[
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M,Y"V%B'B."19P_+_ '0<QD$,,9[CVXI'TW3TC+R:?8 9;<QLX 0><;1Y74G
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MTDWM?K&SN[WV:M;2]FO^)2<%_P!%UCK7NU_JED]M-M%B4TT[.ZT;2Z'\9?\
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M(.1M\+ZUD@D\K_H(!&/ITY'0U_9M_8UF<C^S;' /:RMQST[Q@?SXH&BV8/\
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MPW'X/T_XQ0Z?:> =+^.%W\13X13QQ?W=GI5E<>%HH;9X;6%T5UM?$B?;+;2
MSQJB1LR[B:J>099'VU*KG=.@J%6FFXOWJO-"?/)*,Y1?*N2I&"E=*?+4Y:JY
M#-8S%KEM@:DFX3GS.5.RG9-1UCS)N[BVURWBY13BT?T5P:]HEW?7VDVVLZ5/
MJ&FQ1MJ5E%?6TE[9!XQ*K7<"L98%>-TD5I4 *,"."#7 :S\1?!MOK'A33(M4
M;4I?$NJWVD6UYH2_VEI\-WI=K)=7<&L:C:L\&GK"B$,URRCS $(!8BOQ3^#7
M["G[0O@S]H+Q]\3/'^M>-/$MZ]A\3]+35-+\?&P\-?$K1O&?B9=7\+/J>EK$
M;^QUOPGHAMM"M8Y<QVUM9!8\QO4GAK]C3]IJS^!ND> [;2+K0K/0_&'Q;FN]
M'TSQU+;>-M4\,>+]!GL]+GN?$4(<'Q$-4G#65[@"VA13, =U1'),FP]6C..>
M0Q"YZ-E:2Y:LXU$IJ,IMR5*:C9>ZTI/F:=[.CC,94FX2P4Z'NU)<\IP?P\MH
MZ1^VKV>VFRV/W4T?5-(U>V:^T;4;75;/[1)!%<V-U!<VIDMI6@:U5X'D3?#(
MIBD&X%74C Y%?*GCK]N+X"^$_BW8_!.6_P#%/B'QG+J6F:)K4W@OPEK7B3P_
MX2UK7[A;'2=,\5:]IEM<:?H-[=22*ZPWTD;I$&ED5%P:^=/V$=,^.GP'\.?"
M']F?XF_#DVYL]!\8^(KCQ7I=[<ZC#H7A32=3MXO#$?CC6GA:TUGXDZ_]K\[6
MWM98X9GCFNHU.7QYW\+OV<_VJ/V<_B5^U!H7@'PGX2^)7@O]J;XR:I\4=-^*
M^I>(5T?6_A9%XATV#3]1LM6TZ>SN;K49?#;6D5[X?%E(BM,[(3%C>,*66X>-
M;,/K&.C4GRT7A_?]G2FG549N,XWBX4J;G6=-\LJBBX)N7+S=7M\1"/,TV]5R
MQ2E.VMD_=MS-N,5*+Y5?FMO;]?K7Q%X>D;4H+77](=]&D1=61-3M&ET]G4-'
M_: $N;9I%92%G6-B !GD5$?%7A>[T[4-3C\3Z#-IFCR$:IJ,6JV+VNG3(@F8
MWLZW!B@\N*2-MLC(VTAN :_FMLO^";?[<TG@UO#1\6V'A[7- ^&OB7P)XY\6
MVOCG6+B;]I'Q;K>K17FC^.M6*#[3I8T2R!C$MS(;N.1GA0F% !TVJ?\ !-W]
MK;PE#K.C>$#8:O\ #K6OV3O 7AK7_!]AX\U2W/B#]I/0OB'_ &OJ7BC41=MY
M>H6+^$X[:PO6G<'4K9#9NH"AJZ(91E;=.,LSC'VDU'X.:-.-_>G4:K**BXM2
MARMM)I27,FC#ZUB[MK"\RC%S=I*/-42;C&'-"\NBDY)*][75C]Q=<_:0^$NC
MW_BK1$\::1XD\0^!M,TSQ#XC\->%I4UKQ19Z'K#?Z!J;Z9:.\TEA/%O>2XCW
MQ1($9CAA7L-KXE\.W4G]GOKFBO>FVDU)[#[?:)J,%G&P8W%U:-+YT2V\3*+E
MF0".3(8BOPJ@_80_:,BU[XL>+[3X:?"_P_\ $WXO_L\^ _!J>._"_B*^TP>%
M?%7A(B#5?"@B^:1M.U>W:-H[F'<JRQ,C?)7@'[,GP3_:9^)WQ=^.WBK0O -A
MH4_@/]K#XSP1_%7Q/XWUY[SQ;X.MH-6T1/ :^&)0!!H%[K>P1>6/L<EM;QWD
M1VR+D_L?*WS\F-3C3BIR=XR3?MHPB_=J_!).4XK^++E2Y5%MD_7,;R\\L#)3
M<OA4H)N/*Y-_#RW35MU&^ZZ']$NN_&3X3^'M/TG4-6^('A:+2O$'B;3_  =I
M&H3:W826^H>)M6G\K3M%LIXIW1KV:<^4D1(<N JKTI/#GQ8\':Q<>,-UW?:%
M!X,O(;76[[Q':'0M,;SY)HXI;2]O62&Z@9K>0"9'VD,,9#U^ OPS_P""=/[2
M^D>$OBE?^/?AKX3\5I;_ +0W[//QB^&WPRO?$L3620^!M6MG^(,^FS#_ $?2
M+F=?.U"R1@R7XMXHITWR-CZI^*?[*G[2NM_\)MK9\*:#\3?"VK>/=$UY_@O?
M>,[_ $/3_$GAJ./6XY=+N=35&2!])FOK*YCB*M;7!C=7!" '6>6Y9&=2-/'^
MTC3E3C&I^[C"NIJ,G[-2JW4N6<H\]51I.:MS)1''%XMJ#>#Y.>$Y.[UI3A*R
M]I:%FIV<E[.\MGR['[$W7C'PI806-[>>)?#]G9ZL('TNZNM7LH8;]+D@6[6C
MR3!;A)BP$+PF0.=@!]>@,P52JB,@D[7/S( 3E,D@ J20Q(. N,;L@G\!)?\
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M:E=V,LL2:KX8\8>#+O2[M0S1FYL+E=?BG6&8<I',B2"-\,H!(&-)_P $G/\
M@I6!$!^QY\4X%CC7RX+?Q%X+6%. <B-/$H"M_NJ"" 2<5^$8?*\UP]&EAZW"
M6,QE2CS4Y8KV5:]6:E-JHFZBNI*UVEK;?:_\@Y9P]Q'E\*^'QGAWF.95W*JJ
MF.5&3CB:LI2E]8YIRDY7]U+I>%TE=%_Q+^PU!X?:STZ/XG)+XNUCP+XF\4^%
M_"ZOX=FN+OQ1X5D:8:%>>))+LIH^GW6F+<7D5_<MOD 6UBY<9\=^-_[/?A/X
M/^!?AAXCTOXFV7CCQ3XZAT6XUCPIHEM;VMOI\.MV$%Z]AI^L6;N9?[/O99--
MO!*P>.<33K@'%>KG_@E)_P %,Y',K?LE?%^1_*,'F3>)_"KRF"0[7@1SXH8K
M%*"5F7[K)P5()J,_\$GO^"ET,,-N/V/_ (H201!H[>!_$'A"6*S4_>-JA\1N
MMNV[G=&%&<X)ZUK]2S#5_P"I>,]ZRE>E6U:WM[[LG>2L[K5.^@WD&=1OS<%\
M58.7/*3PV!P,)X:/-R-N%23<KU.5SJ:VA4LE=:+JO%W[)7@GQGX^\.:/X:D@
M^"4FE?"#PKJ_Q%TRTUVR\6>'-(\97LGB&6PO(K[59DEO(]2T_3T_M6SLOEM;
M\N&?+(#XU\)O!O@&U^!.O_$S4/@P_P ??']WXYU?X?3^&&^(-SX8L_!>F6I,
M=KXN%C:DW5\;AB;N,R*;>.+$"R$+7>C_ ()/_P#!3!0V/V4/C(\KQJKS-XI\
M+EW3<S+!*[^)SYENKR,51SA59N%W&DB_X)0?\%,K622:']DCXL6LLD9B<Z?X
MA\(6BS1#@I.L'B9%DR>Y7/4;L="6#S+FE)<&8R[E=VHU>5W22O[T5=*"NE!*
M^M[MMZK)L^;<UX>YUC'-R;K8[!*%=I6C[&4()0]E!)*FXJ,G>;;NW>QXK_8N
M\ _#F:U;Q/\ 'N6""UFAL_$-Y8:?I,^+.\\-P^*K-O!,]E?2/J%GIOVO^P=8
MN) '&J6\R2 ,I6N]T/\ X)__  Q\7>%KGQGX9_:#\0^(;"VTGQ!?ZKI&E>'-
M+?Q)%'I&K>%]+TX1V!O1;[;K_A)6NIKF<*=FGS')*\>:-_P26_X*52F!)/V0
M/BO(MJ)%M5N/$OA&5($E8R2Q1!_$\BQI,QWR *=S,V<$5UOAW_@FA_P5:\&V
MOB.Q\+_LK?%OP_%XOT*3PUXNFT_Q1X+D;4_#<UW;ZC!8VH?Q(6MYQJ%M ;N:
MW,<S0*5+;>*M8#$N[J<$XWGBVTHTJ^R6B3]I%-N3OUMOT;>D.'LTE*3J>&68
M*RO%+#/1<J]QNZBUS)Z6>\5HKM9K?LA?#'6;);*U^*%MX>'@S3O&\_B?Q1:7
M5EJE[XE31-;>PL]5N=)DG86,$< 7[1IMHSJP#/'D8->@WW[ OP3U"\@O-&_:
M*N/#WA.7P)\/-4-WK.GZ'>R#Q#XH@U.]O-9LH+2X\ZR\,0O8QV=X @N(KJXC
M$P&%KR*'_@D[_P %,H$\B+]D'XK6ZA&C:2#Q)X1C>5'QYL4S#Q*6ECG;F7<S
M"3)+?-S4W_#I[_@I>APG[(GQ=""W^QL%\4>$@HM0SR&U"'Q.5-NK'<L?*JV\
MI'EL55++<7[6+I\&XQ:2UG3Q"3FVK23=5K37L]XK1H4<BSBG4BH>&./2G&7.
MY86=N=*T6WSRL]79IQ725]&<S^T[^S5X+_9Z\&^'KK0/'LOQ*\0:[XFCMI_$
MT0M)= N-!?3!>+_8-JEU,SQ,SK#>O=(@MYON_,!7Q-%)O2,S22(SIND42L[%
MN,(\@(#':$&=N.O. !7WVG_!)S_@I:4CB7]D3XL/!!O^S0WGB#PC<0V[.1Y@
M@AE\3E8BY/WD3#$]@,5;'_!)[_@I9A<?L:?$-B<;F_M[P2@VG(&%_P"$AP/E
MQD  @C&<M7!BLGS2MB:DJ?"F*PZ4+J7L\1RS5_@4HRE]I.?O*ZNE?4\?'\,<
M0U*TG2X"X@RY22?M,LPKG4JW2;IU74FTJ<&O:0:2:F^5:,_/W>^"5E;GIOD(
M &>1PPXP<\X.<Y]@/+SF3CVF?GOG!;)[<=<Y&:_04?\ !)W_ (*79PW[&/Q!
M(;D >(/!>,#.0V?$!SV(QP,\=L*?^"3W_!2W'_)F?Q!'M_PD'@K'0<C_ (J
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M $3N(_\ !6*_^3%_JIQ-_P!$QQC_ .$$/_DS\^]Y_P">C?\ ?QO_ (JC>?\
MGHW_ '\;_P"*K]!/^'3W_!2W_HS/X@?^%!X*_P#F@H_X=/?\%+?^C,_B!_X4
M'@K_ .:"C^P<Y_Z)W$?^"L5_\F'^JG$W_1,<8_\ A!#_ .3/S[WG_GHW_?QO
M_BJ-Y_YZ'/;,I S^+#].:_03_AT]_P %+?\ HS/X@?\ A0>"O_F@H_X=._\
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MU&[R!P,$>;U)!&?3/T*?+IK9:V]^?73>_>ZWMT\@][:[^4IW5E;1WU]'^IH
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M_P#'O\*S/^$5TW_GI?\ _@PN_P#X[1_PBNF_\]+_ /\  ^[_ /CM,#3WQ_\
M/2;_ ,>_PHWQ_P#/2;_Q[_"LS_A%=-_YZ7__ ('W?_QVC_A%=-_YZ7__ ('W
M?_QV@#3WQ_\ /2;_ ,>_PHWQ_P#/2;_Q[_"LS_A%=-_YZ7__ ('W?_QVC_A%
M=-_YZ7__ ('W?_QV@#3WQ_\ /2;_ ,>_PHWQ_P#/2;_Q[_"LS_A%=-_YZ7__
M ('W?_QVC_A%=-_YZ7__ ('W?_QV@#3WQ_\ /2;_ ,>_PHWQ_P!^;]?_ (FL
MS_A%=-_YZ7__ ('W?_QVC_A%=-_YZ7__ ('W?_QV@#3WQY!WS9&<<-^(^[W[
MCO07B*E6+L#CJIXQZ#'_ -;&!T%9G_"*Z;_STO\ _P #[O\ ^.TW_A%M-)9?
M,O\ Y<=-0N\G(S_SUX]N>3Z4 :9:/&Q3* ?F QM0L#D*>!USD@<D8 J*3RB"
M9&:(97!+,H)(;_:ZXZ^AS5(^%=+;;N:_=5?(4ZA>;05)YQYV.2HR,$'H1P,;
M$-A!'$L.'=$)V^8YD( ^4<MGL,YZ\]: (/M+J4<LJAE!/^SDXVL&'& !U.>/
M<"J\DTKI*@.)=WR$@!2=V=PW>N1@'@D$9[4SR75(HP<[=S,N0._4^@'IC!'
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MS\V__?C_ .SH_P"$V\8?\_-O_P!^/_LZ /H#[0__ #TA_7_"C[0__/2']?\
M"OG_ /X3;QA_S\V__?C_ .SH_P"$V\8?\_-O_P!^/_LZ /H#[0__ #TA_7_"
MC[0__/2']?\ "OG_ /X3;Q?_ ,_-O_WX_P#LZ:?&_C $#[1;\_\ 3#\/[Q[D
M=<>V>10!]!BX8%>5<$MN"#.!@$9/&,D$=^2#T!I8IA),P$F0>0A4 ]\<X!R.
M!CG(YSSQ\[2^-_&&4'VNV0AF(9K8D9*G:"=PP2> #QP3GKG;\._%6=)X[+Q/
M#%%/-,L<%W;(!$Y)VD;<DJ3E0V..<8Q0![PIR.W7^$Y!X!.#@=R:=67#/*Q5
M PSE&*XX:,_,"A!P-V<]1E>#CDUJ?E^?_P!;_P#70!@9<Q$J?GQSN7@_+NPI
MR21@C@[<Y!XQ7YL?\%2+BXL/V1M:GAB:43>/_A+$U@+^;3I-26Y^)'AZ.73U
MOX$G>V%XDC0%S$X,;,CKM8D?I<3\J!.-RL"0/X5X!SC@KGC]?4^0_%GPO\,O
M&G@R[T;XLZ?H>H>"+;4--U:\B\27<-GIMK>:3J,-YIE[-<W$L*1O::C#!<1%
MFYD1 @+<5UY%C5EF8Y;F=>FZ].&)HUZF%M=UO9RD_9R22LK-Q;3=HROO&+/F
M.+<EGQ-PQGO#F$KO!5\9@JF%IXA2=/V+KTXJ,N:/,[1UD[)M2M':4C\%?C3\
M)/BW\,/@KXU^,EYIL7PQ^'_B&'P!H^I^"/AUXOU76-5/AZ3653Q!XBO[B>PT
M>"TNGLY/+>.Q>5Y8$8-.&(6O8/CSX2_9\\5?"+0?#O[-_P 2/"?@?QE:7OA'
MQ3>6GB<Z]>^$_&MM8:8MX-#\8+:LTB7=[:RM-#/OG9;A&,RNQK]C&\*>!O''
MA*X\,7.G:3XJ\!ZSI_V#[$3;ZEH]YI^-IA696=9(EQC(/RL<\'FOF?\ X8__
M &0M+M=>\%P?#'P+!97-[:>(M=TU]4F2^@FMF^RV-[=-)?BYL+7EHK="\5O(
MHVHK  5]JN,/K.)CBZCJX:.%Q&(JTJ&$HX=4'2;7LZ.(HXJ$Y8E0CSTW*JVZ
MG,IJ2G"+7X7A? O$9-*MA^%H<+YUA<7E="EF.(X[Q.=5LRP6:0IUEC:N1U</
M"E2P5"M4G1G"E04J<'2]Q24Y1?XE_M!_''6/B'^S#80/\-?B9X2\!^$_"7B1
MWN?!&I6H\$P>/K#5(K>WUG6-2GUFTUT^%K6:W-S816NFSS[)U!@4*0?4OC-I
MOQ,UCQ%%\7=,N] :]\=:)\'].\ ^"M;\1:AIOQ1\$7MC#;P36NB6ME:ZCHZV
M^O0A]1:Z_M-"T<C1W"HXP?W:N_@[\-+WX=7_ ,*1X(T*3X<W^DMID_AE]/23
M2+ZRN%5GAD"X::.;Y7#^8&8X.\DYKB-8^ 7[.$WQ(\+>/]9\*>%C\3M/M[6P
M\)W6I:IY&J/;:-"T-HFE:1)=I%,;%&:*W=+9Y$4 ;B1FNR''."I588C"953H
MPG6Q-2E&=*.*YJ&,IQ=6E5C6LX2G6I^UG4NYTHJ%*G[DI0/*I_1]XFQN6T<+
MGO%#S&K3PV5^UG0C5R*C''Y3F53$X/%8;,<LG4Q>(6!RBI5P&$]OA:?M:4YU
M,3'VT8S7X-?&#P!\8_ ]KXGUJ]^)GA3X@>*O%?QA^%</A76X=<UN+XE_#S5?
M^$]TJ>Y\-:;8SZ<]O/936+75IJ-W;ZE;0M:FY66*:-@I_IQT*&[;1M)34"#>
MII%C]MDYWF[6VA-Q\PXR9<G(')_3YZ7]EOX&CX@6OQ9N/A;HK>.M/OWU.UUF
M<W,J"\F$HEOC:S3M8I>1+++*D[P>9&Q41E'*,/I*TNXI4=E?STD(9)8R)+78
MQ&!#/$3')M8%64-E6&UN0*^5XFXBAG5+"4I4E'%474^L5Z&&I8:+=2</8P5.
MC[D84:$%&T4I2<I3DE)RD_U'PO\ #NKP%C>+L8\;5KX'.,1AZN48&><9EGCP
M$(P7UF=/&YC2IXJ4\3B6ZTXU.:-+6C3DZ7+%;5OM>3')81J9"1E!D@*N"P)/
MRDD@$ 9 )K6QT XX/T[9^N,\9ZGK7,6EZMP\MRL;+\K+&K*T9DBB<X94<*6)
M;S 5 .!AL@,M;,-UYL[Q!6$B1HQ4YVJ'YPQ) +=3P2<?0"OFTXR45%WCR)6D
MFFK.2<6G?5:>MWJ[-+]<A!0C%=TI2?7FE[TFWH]6[NZ7ZEBX;$3,.JL/;C[I
M[-VW$9'MQ7@G[1OQL\/?LX?!;XB?&[Q?;:M?Z!\/O#]YKU[9:-%;SZG<(H$*
M1VT%S<6MLY,\L;!9+F,;0Q+#@5[[-M$9W=R.>>N<]!Z].>W4U\J_MC? R7]I
M?]F;XP_!"WU4:+<>/?"-[I-KJ1 :.VNMR7%L&P5PDDL"QYW<*W7C!BC)?7J<
M:L;89SI>UGHI*\[5(QET_=VEIJGK?H5*_++E=I6E;2Z3L[/7K?\ (^;_  _^
MWO\ #[P58_L_>&?C5K4DOQ2^-GAGP]XC>V\.Z0JZ3X8LO%K))H$NO2S78^S0
ML\\.G*ULEQ(;I6D9!$0U:OPD_P""BO[/_P ;OVD=;_9<\ :AXDUCQ[X?LM:U
M.ZU6?1$M/"MW9:/J5QIFKVMA?27OVQYK*]MI+1YQ8K#(PW1$J21\R>&/^">&
MN>)/%/P^^,_B^#1-1O)_@M\-/ GCOP!XLGOPVDZW\.(4$%[X<DLCY< N[JUA
MF1 T<9FVR,6!:OF[]B[]FG]J/X-_$/QIXCT_X*Z=)\1/$MCX]L=$^)'B]8=,
MC^%VDZGXFNM1TKPQI(B5O^$DM-0GN;G5KZ_=3<YECB+F/BOJH8#(*^#Q-3#9
MA?&T\-SRHN4:$/K,YS<8Q;B^94*"4IIN]1:T_?=EYE/%8NEB84JD'4H2<E&H
MDJG+",(\O/O_ !)<R3M%1:Y7[JN?JA^VU\?/%_P%\&^'!\--+\,+XT\:^(M/
M\*Z'KWC?4;BT\(Z!<WNI6%A'=ZS%:VMU=3VQ:^Y:&(NHCR<\8^9?!G[</QRO
M?VJ/ _[*'BSPM\-=/\1:)\+=(^+'Q0\96^O:A_PBOCW2=5;5!+9?"!ET5FOK
M_0_L$3WB:RVE-=-(Z+$B()6^F/VD/V2+G]IS2?@UH7Q"UO2-1T_P+K>CZUX^
MTR2"YCL/%LMG>:;>7EM#]FEADM0[64@B.\;#(N>A%>6?%3]@CQ%XY^)_PP?P
MKJ?@'P=\(OA=>Z)>^$)['3]2_P"%I^'+2V2Z76]"TSQ+YY>?2=:6YDBDMK^2
MYABAD<)&I537!@ZN43P].E6G2<H?6?:XFI2]K>HER4U%M1G.27,XTK1I+FC5
M<E5IJ^E55Y5JLHSJ>][/DIQJ2IQY$US/;D3D[7DFY.*Y%>#NCP%^T_\ M1^-
M-7O/C#_PJ/X>Z3^SG=Z'XJN/#7@?4?' M_CEJ\?AFZNA%XL@TR'1IM#ECUF"
MQ:"ST5=:WHUY;R2WJ%'1>_\ V$/VE/'W[4WPX\1?%;Q;_P (&GAW4_$EY!X/
MT+PCJ&IS^)_"EO#*RW'A/Q[:ZCIEA%#K^D2+]GO)[&:ZLIYHY6@DDB"N_P I
MZI_P3.^/FL>//@E>W7Q[TF'PU^SY\8[WXC>"/$&G66K:?XRU7P%)]OGM?@SX
MI@L[Z'1]3\*RW=Y%-?W-S;W%U<+9Q*-H)QV_PT_9*_:-^ /Q'\0_$3X:O\-;
M74OBYXM\.1?$CPIX0CO=%\#0Z7;ZE-<>)/B#)I-[+,B>,-3LY3 T6FQVUM)*
M3(R[N33I9-5H8E1JT*-6,8.E.,)<SA3J2M"5W+V<G3DJCQ#:J>UBZ=5.,H-.
M7UV$;T[U6XS_ '<FG&,I)>^G9.UURQIN\>5VCK=/M_CS^WOK7P*_;@^$?[.G
MB'X<I=?"3QY\.!X@\1?%&#5;1+GPEXGU'4]6M=$TZZTB6-99["]AT:[5KNWG
M.RX>-#$ 2PR[O_@HUINE?M;_ !>^$.L>%[;3_@9\&?A&/'>O?%EM1$MY<>(;
M>:$WVDZ=I"6S&2&&"\M81<->!FN#L6(IAZK?M5_\$Z)?VJ?C_K7Q0U3XACP_
MX8F^!VE?"_3]%AM[D:KIOC/0?$^I^(K'Q9!<I(B&&.#4OLZHH#%7D!8AL5\X
M6O\ P1Y\97'POU[P'XF_:%.NZKXK^$E]X-\7^)9-):"^UOQK<>*M,U^VU^:9
M7$@T]K72K32[FV\S$D!?"_-SV82/##PN'CC\76IU9X&<:K<7R/%^WBJ<U/E]
MZI[!S=]4Y-.ZMJ3J9FFXPHQE%3YHNZ2:5.\HZ:V]HTFVFHQ6JVM]?:C_ ,%4
MOV0=+^#6D?&W5O%6OV&@:EXCF\)#1AHLL_B6TUVVM;C4)+34-/LY)X8@-.@:
M^W?:61X" OSDJ/%?B;_P5O\ @MJOP)^+OQ-_9\U&3Q)XC^$]E\.?%MS:^*-'
MO-+LM5\ >*?%^D:'J^IZ, LTMT\.G7.H6]O#)%$YU)(4<(C>8-SPC_P3&TG3
M?#7ARUUC3_AIIFO6_B;5?$WCJYTW2+O6=/\ &-]<>#+CPCIFK3V6L>;!:ZA'
M'*)9_LD$,3*"N"WSGS;QY_P29U77O#4>@>%?'_A'PN\7[/\ 9?"6-;7PS%!8
MW/B/2?BEHWQ%TK7=2M8MB7>GJ-*&EM93([!;F79\LC \[H<,PK.-'&U*D7B:
MJI1G.4;X6E.+C*3<&VYTN97BN:+3GRIJTH57-%'FE2II.G#G47?]ZU+FUVLI
MJ-HNZZ7[?39_X*A?LFZ?X#L/'E]XB\1VUS<^,K7X=)X970KF3Q!%XNN+9+Q-
M->R5VA*/!*+F*9YQ'Y&-S;\K6_I7_!1G]GQO%7B#PCXA;QAX9N-&\%ZS\1Y-
M<\1Z$D&E7.BZ%HPU_65LA#?7-TU[I.D))=2QFUC4A&$#LW!\+\!?\$X=<L/C
MS9_&OXA>*? &JWMQ\24\>^(?"&E^%E_L%Y[#PA%X3T<:9!=*\<5_''%]LN+T
MH)9)GR6W#=6)\4O^":GQ6^+'COQ1KWBKXT:)JNFWL_QIMO#T]UHD,%[H_A'X
MI?#^?P;I/@J;3K&&"SET[PQ+/+=I=R/+/>1-Y<A! I1P_#,ZE12QU2G^XE75
M:-:I.G3K>TM"CRJG#VD:</>E6<8WT]W5HJK5S%0A4IT83DJD.:G)1C*=/E]Y
MIN3C"<IVY4V[6>KN>J>$O^"MW[%WC7X3^.?C5I/C?6CX.\!ZCHFB7J7?AV^@
MU?6-2\6"5?"EOH-F<B['B&:-XK*29H460K]I>%"6KV'X=_MW?L__ !%\.>!_
M%&D:]K(A\>>$/&GC"WL[_2OLVHZ)8^ 5C;Q7I7B&UCGD,&LZ+)*;21(#,DLL
M4ABD>,J[?!NN_P#!'_6/^$'\":#X4^(/@G1]0^'MG^SQ>6%M_P (A OA_P 1
M:_\  RZ:[GD\16$2+%=VOB#"Q&66.6>W4LX+&K=A_P $M/BKX:U74/'W@GXU
M>&[3QSXZ\1?&O5_%^BZIHEQ<>#M)L_C$OEZAIG@^S5DDM(=(9 T8=%6^EW3S
M+N8FA8;ABLN99FW.4'*//.4U1J*?+3I5>2FW*,HKVKJQ:2E)4%%IN23JX^\E
M+#)-2:4THI.+2;JPU2C)2O%TTM;.2D?=GPZ_;M_9T^*_Q=\)?!GP1J^MZQXP
M\6^%O^$BL;R#295TFSLGM)=42QU"ZDDWV=]/I\37"(8A')$502AFVU]KM9P[
MONAGC";&W%6C ;@ YR1G;E,X;&<U^1?P/_X)S_$WX(_M"?!+XG^%OBAX7T3P
M7X&T"XTSXL:-HVA#^V_C%<)X1G\/Z,VL7-W'.+!-#O)$NK1].>T9K>);>99/
MO']?@8X\ER.64%5SU!'(QSSQSC/7!P37D9@L'1JOZMB9RBHI2<)\K<G)I)1D
MD[2C9QC:RO:ZL=5*4^5>TBVV]':.EE%MRLVKN3:O>^BOIH,:R24AF9]ZDLQX
M =PV22".&5<?=RI&0V1BGO;(ZD,'!QM4@ %0@R0 ,8#<*1G!R>@Z:: ,%."=
MPR3N(V$@XP,YYSC(/;/'2I@H4;>2!GJ<GGU/>N*-"FY^UY=;)Q;G-W>Z;3DT
MGTNELVK-;[65[V5_17_K[QD8*HH.W. /E&!TZ8]@.O>I* ,# Z#@4TD+C)QD
M@<YY[ >W)%=%M-'WWUL_PT3OIVT&94W_ !\,3G&X 9.%8@<@84D8R._ODXK^
M2/\ X.D/#.M1V?[%OC\(X\,:'XD^)_A/4YDW2C3]8\7:?X>ET?4)X&VVSP"W
MTG4;5WDECEC^U*(>'8U_7!(P:XD7!.W/WL;0<#IQGU!)S@GH:^=/VCOV8_@]
M^UA\.=<^$OQQ\(:?XS\#ZVJ,=/NS)%<6>IP%C::KIE["Z76GWMHX!CEMW1G&
M%<LN5/F9ME\LURS&X&+5&>)I2I*HY2Y;J2E%]6M4T[+W=[V3/G^)\KGG^09I
ME5.:A+%X:5!3<I146IJ:YG!<S7-!1:5])*]X\R?^;/\ L^?'#3O@C!\7]0U/
M2KW6-;\5?#:[\->#88;9!80^)$O%DLKK7)(;RVN8;&)E21!8R2R,%"L64D5[
M1J_[:%OX]L_"^E_%CPUJ?B/PG:^#'TSQT-(\&^$CJ2^/[K5-7O-1U7P[JE[?
MP:C:V*I=Z8((FG0![:0E"&.[]Y/&W_!L/:7'B2^N_A_^U+K&@^'IY[AK'2-8
M\/6VHW.FVK.QMK2*[9P\ZVB[4663+OL!;DG/,-_P:^Z]]G\I?VMIW#E&N-_A
M>!5E<D-+*RK* TCOO.3T 49P!7X_2X.XLP<(87#X>-2E0O2IU)5,/4YZ=Y6E
M>:YFY<UTV^>-[I['\S9=X:^(^4TG@\%@,-4P=/GI4ZCE@Y2K46YM<]2=ZEVY
M:7=U)W=DK'X\>.OVH/V-=:UR:PL_AOXYNO  ^%5MX4\::;<>"O"EA\1?%?B&
MQUJSU;1Y=$\3V7B"2WTJ-((1;:K=/"UQ<V*O:I&3)O'COQJ^.'P*^)GQ'\ :
MOX6\.>+OA]\,?"U_;W6L:EX7\*Z'HOQ*L?#DB1.=">>S\2&UUB]M$C:ST[4!
M<V4BH3(^&.!^\Y_X->=<#L8_VM7@<_O/,'@VU9PRY"N0\Y$A (3!/W1C%2#_
M (->=1413?\ #5<WVS:L<TO_  C,:)*(T5(IO+$X021."^TJ5+'YN@%7#A+B
MMV]I@J3G=IOGH<LEJTK=K)*_Q-[LZI>'_B%.G3C+)< X4YN4*=1X22C*5I2=
MHRLX\RYKN7,W=M*-D?D/XD_;B\(>*/ 7B_P#XAUKQ)XSEU;QCXCU[3(X_A5X
M3GL=7^'FI_#S1/!OP_\ !^L:KJGB7^T/#WBKP[<Z+-J&OZ[IJWTMPUR'BN+A
MP5'RGH/Q*\#0_ 7P=\-]6^(?Q<^'WB/PEK&M:A>VW@'3[._\-^.(K^:&:*TO
M;R3Q#HFH0W\2QRV=Q/<6US!Y;H8RV#7]$!_X->];C$J+^UM*L+S+,T*^$K=%
MN)0#ODN'CG#AYF8AG0J$5,*!FC_B%XU;S3+)^UC,<1.L"_\ "*P;8F?:2RD3
M*/E8?+D%C_$<U<^%.*W/F^HT$^6":OA^5V7*Y6MS*;C9MK5RU?6Q6X!\2:N(
M55Y1@+RIQIMQC@O9\M."IZQDV^9Q2;:^T[^Z]3\E=:_;<_9H?3=5?X8_";6K
M?5M-T[0C\(K+5OAEX$^S?!>UAL+&R\;V.L7;ZQ<2^,I?&_B2'5O$,-[=1R3:
M<+]8%^4;%T_AS^T[\$]8TKXI_%'Q5H*>$/&GP]T7P9=7VK2_"KP9J-UK7AK4
MOB+HT<_A[PMX>AU5-*.H:AX9_M?2K_59WM;B."^\P%PF*_51?^#7KQ& FS]K
MR8,/,6X:/P?:0K.$V"W5U2496,EV="2'=@QQTJ0_\&OOB-_+5OVMIE597,TO
M_"*0R2RP%2%MIHWN/*GAA8"2W29&$+_/& RY'1#AGBN/.XX/#J[C>$HX64?=
M246HN+4597E&+492?.[R;.K_ %(\0X34Z.29=!-0C.G%X-)2IVC&3CK!PE!)
M<MK2G>I-<[=_QT\2_MA_L_ZII%_::5\+?%.DZ^WAT^&?!7_"3^%O#6MZ)::)
M<WE[>)X0*#7S+INFRQS6\HO+=9&MID\M8R@!/07_ .V7^SKJ>A:Z;KX>7_B7
MQSJ%]X:DO6USX8^$H=%U+P)8>'QHY\"B&T\1C[%J.B:O'>:CIGB",22723QF
MXCC9-M?K3)_P:\:^Y#-^UQ/Y@@:/?)X3MI,1LW,2J\P6-6 R95_>H>$(7BF1
M_P#!KOK >97_ &LYGM98C(8AX6B5UN@VR(_:!.)#;(G(BR LA8Y.XU%3A;BR
M<4OJL+*^G-A8IIZO2--:I/1O5-W[,YWP)XE6?+EF"CHY64L))IINR4GKK?EC
M=V2N]+Z?BC\:?VJOA1\0XOA18_";PMXF\,Z1\*/'W@WQ_>^";CP/X4T72_#D
M&AK:1:XL&IV.M7K^*[S6;J*::TAU&U@CA!0R2@C->C:A^VU\"=?UKXB7_P 0
MO!?B#Q)I7C3QOXV\7ZQX4G^'/@S4+O6DU[Q.NH^!_%=WXRDURWU*PG\)>&8K
M7P]>^&K6![.1[/=#<2+,SU^M<7_!K[X@BA")^UU.CQR!TV^$;=HGVMN\FX43
MAIHBK'_6.V#\PZ4D7_!KQK<,#Q)^UC(K^8GDD^$H'3R]QD>.:)YG\P;B0 7V
ML "PS62X4XMY;/"4G;2SG0D[)/3E:UYM-6]))-)- ^!?$OEE_P ).$DGRQY&
M\$W:2O*5V]O>NUJTTW'7?\'?"?[2'P_TKXM_M'^-_&FA>(=+^'_QK^$GCKX+
M^"SX6\+Z -0\#VWC"P@L?#.J7GAA=6LM/FTW3E62:ZE@U!M0!0*BNSDCTRT_
M:P^#]K8II=]X:\5B#PGX>TGPYX/\7:CX7\.^(8!;:=I&D>';C5#X8NM9C@AN
MO$L&FWD$2-/*^EI=QW!DED5EK]G8?^#7_7(KN:X?]K%YS+:/ L3^$X=L4T@^
M6Y0"8J&AD!,4)4HF0!VJ%?\ @UVU^,/Y/[7$RR;@H=_!]M(&B8%'$BO.49B,
MLKA!B3.W::J'"G%*O? T+W;YG+#R;O9M/HTDK+31N7<FCP#XCT>:5'*<%3J2
MNYUHSP2E/F:NIW4HVBH**Y5'775MV_'/QY^U=^S//JGPLO?A#\#[[PG9^#]9
M.I:QX9U_P5X4U":;Q%-HFOVMIX@TZXAUPV5W8:CJEWILU_I^I0,D*Z>GE(S
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MSF<)C!KFO!_[8'[-_A?2]/A@^&OBGPY(^D6&DZY;W?@#PEXM35]&CN;V._\
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M://>*4.:]U4C*I*[:4;<<1.'NRDTIQLE)0;2DW)\UG9OXMI*UH[79\O?!_\
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MXI^*?"U[;K<)K,\%A:V-M9Z:(84M[8VT5K&(C+$T:D;5<#D?18?'Y#-U)XK
M0]M*I"4)TY_[/2A&%>4OW,5[SE5='DA*24H\U.4E!1MYD\-CN=N.*J<B;:@F
MH2DWR6YI-/EY;3LTM$[V;;/R'^(G[=7[4/B;]M#X%3?#+QM%8W5K\&_%&J^-
MOA9?>(7C^%/B36/ $/BB;Q-JVGVENC7NHV^H1:7*VE7IFVAXX#(<(]?8#?\
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MO>;DWJFTM.EE9+UOO<\\&N:J1D>%=0VG. )(<'/4G&"">,_3CO3CKFKY8_\
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MS6O^A6U#_O\ 0_X5Z%10!Y[_ &YK7_0K:A_W^A_PH_MS6O\ H5M0_P"_T/\
MA7H5% 'GO]N:U_T*VH?]_H?\*/[<UK_H5M0_[_0_X5Z%10!Y[_;FM?\ 0K:A
M_P!_H?\ "C^W-:_Z%;4/^_T/^%>A44 >>_VYK7_0K:A_W^A_PH_MS6O^A6U#
M_O\ 0_X5Z%10!Y[_ &YK7_0K:A_W^A_PH_MS6O\ H5M0_P"_T/\ A7H5% 'G
MO]N:U_T*VH?]_H?\*/[<UK_H5M0_[_0_X5Z%10!Y[_;FM?\ 0K:A_P!_H?\
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1IZ=J< !T&.WOQZGJ?QH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pcsa-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamGebP9z5Z8iekhvWBybYl6/ykkZ+Y8FS8JyV92ARQA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:PCSA="http://processapharmaceuticals.com/20250630" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20250630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" id="StatementsOfCashFlowsUnauditedParenthetical">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999013 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999014 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999015 - Disclosure - Stock-based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
          <link:definition>999016 - Disclosure - Net Loss per Share of Common Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Leases" id="Leases">
          <link:definition>999017 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999018 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999019 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Pcs12852" id="Pcs12852">
          <link:definition>999020 - Disclosure - PCS12852</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999024 - Disclosure - Stock-based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
          <link:definition>999025 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999026 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999027 - Disclosure - Segment Reporting (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999029 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" id="ScheduleOfRestrictedStockUnitsRsusActivityDetails">
          <link:definition>999031 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999032 - Disclosure - Stock-based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" id="ScheduleOfNetLossPerShareBasicAndDilutedDetails">
          <link:definition>999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" id="ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails">
          <link:definition>999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails">
          <link:definition>999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails">
          <link:definition>999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails">
          <link:definition>999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999038 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999039 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" id="ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails">
          <link:definition>999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" id="ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical">
          <link:definition>999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" id="Pcs12852DetailsNarrative">
          <link:definition>999042 - Disclosure - PCS12852 (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999043 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999044 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="PCSA_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JunePOMember" name="JunePOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ATMAgreementMember" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" name="ChiefExecutiveOfficerAndCertainBoardMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" name="SeriesAWarrantsAndSeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeeMember" name="EmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandAndNineteenPlanMember" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JanuaryPOMember" name="JanuaryPOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentWarrantMember" name="PlacementAgentWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CorLystLLCMember" name="CorLystLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PCS12852Member" name="PCS12852Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CROsMember" name="CROsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PropertyAndEquipmentNet" name="PropertyAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" name="AssetsNoncurrentExcludingPropertyAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseExpense" name="OperatingAndFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_IncreaseDecreaseInDueFromToRelatedParties" name="IncreaseDecreaseInDueFromToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PaymentsForSettlementOfStockAwards" name="PaymentsForSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" name="StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FinancingLeaseLiability" name="FinancingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NonCashLeaseLiabilityNet" name="NonCashLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" name="LesseeOperatingAndFinancingLeasesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" name="BusinessActivitiesAndOrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OrganizationTable" name="OrganizationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="PCSA_OrganizationLineItems" name="OrganizationLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" name="StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_UnrecognizedShareBasedCompensationExpense" name="UnrecognizedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" name="OperatingAndFinancingLeaseWeightedAverageDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreclinicalClinicalTrialAndOtherCosts" name="PreclinicalClinicalTrialAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AdministrativeAndFacilitiesExpense" name="AdministrativeAndFacilitiesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TermSheetDescription" name="TermSheetDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TermSheetRemainingDiligenceDescription" name="TermSheetRemainingDiligenceDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesExercised" name="StockIssuedDuringPeriodSharesExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ElionOncologyIncMember" name="ElionOncologyIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandNineteenOmnibusIncentivePlanMember" name="TwoThousandNineteenOmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CommonWarrantMember" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pcsa-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Cover" roleURI="http://processapharmaceuticals.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheets" roleURI="http://processapharmaceuticals.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfOperations" roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlows" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlowsUnauditedParenthetical" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensation" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStock" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Leases" roleURI="http://processapharmaceuticals.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactions" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReporting" roleURI="http://processapharmaceuticals.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852" roleURI="http://processapharmaceuticals.com/role/Pcs12852" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingencies" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEvents" roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationTables" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStockTables" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesTables" roleURI="http://processapharmaceuticals.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReportingTables" roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852DetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:label="loc_PCSAAssetsNoncurrentExcludingPropertyAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PCSAAssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PropertyAndEquipmentNet" xlink:label="loc_PCSAPropertyAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_PCSAPropertyAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_PCSAAssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="loc_PCSAOperatingAndFinanceLeaseExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSAOperatingAndFinanceLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999014 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999016 - Disclosure - Net Loss per Share of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999017 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999019 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852" xlink:title="999020 - Disclosure - PCS12852" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999024 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999025 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999026 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999027 - Disclosure - Segment Reporting (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999031 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999032 - Disclosure - Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999038 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" xlink:title="999042 - Disclosure - PCS12852 (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999044 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pcsa-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Cover" roleURI="http://processapharmaceuticals.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheets" roleURI="http://processapharmaceuticals.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfOperations" roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlows" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlowsUnauditedParenthetical" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensation" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStock" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Leases" roleURI="http://processapharmaceuticals.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactions" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReporting" roleURI="http://processapharmaceuticals.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852" roleURI="http://processapharmaceuticals.com/role/Pcs12852" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingencies" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEvents" roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationTables" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStockTables" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesTables" roleURI="http://processapharmaceuticals.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReportingTables" roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852DetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999014 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999016 - Disclosure - Net Loss per Share of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999017 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999019 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852" xlink:title="999020 - Disclosure - PCS12852" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999024 - Disclosure - Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999025 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999026 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999027 - Disclosure - Segment Reporting (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAOrganizationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ATMAgreementMember" xlink:label="loc_PCSAATMAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAATMAgreementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAJunePOMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSACommonWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantsMember" xlink:label="loc_PCSAPreFundedWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSAPreFundedWarrantsMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSACommonWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ConsultingAgreementsMember" xlink:label="loc_PCSAConsultingAgreementsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantsMember" xlink:label="loc_PCSAPlacementAgentWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPlacementAgentWarrantsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSACommonWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeeMember" xlink:label="loc_PCSAEmployeeMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeeMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSACommonWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_170" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999031 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999032 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesBWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSACommonWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantMember" xlink:label="loc_PCSAPlacementAgentWarrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAPlacementAgentWarrantMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantsMember" xlink:label="loc_PCSAPreFundedWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAJunePOMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JanuaryPOMember" xlink:label="loc_PCSAJanuaryPOMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAJanuaryPOMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAJunePOMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_160" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999038 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaapRecoveryOfDirectCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRecoveryOfDirectCosts_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="loc_PCSAPreclinicalClinicalTrialAndOtherCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAPreclinicalClinicalTrialAndOtherCosts_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="loc_PCSAAdministrativeAndFacilitiesExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAAdministrativeAndFacilitiesExpense_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" xlink:title="999042 - Disclosure - PCS12852 (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PCS12852Member" xlink:label="loc_PCSAPCS12852Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_PCSAPCS12852Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetDescription" xlink:label="loc_PCSATermSheetDescription_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSATermSheetDescription_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetRemainingDiligenceDescription" xlink:label="loc_PCSATermSheetRemainingDiligenceDescription_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSATermSheetRemainingDiligenceDescription_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSACROsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999044 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ATMAgreementMember" xlink:label="loc_PCSAATMAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAATMAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1000" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1001" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesBWarrantsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSACommonWarrantsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantMember" xlink:label="loc_PCSAPlacementAgentWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAPlacementAgentWarrantMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pcsa-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="PCSA_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantMember" xlink:label="PCSA_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="PCSA_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsMember" xlink:to="PCSA_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="PCSA_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantsMember" xlink:to="PCSA_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="PCSA_JunePOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JunePOMember" xlink:to="PCSA_JunePOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_JunePOMember_lbl" xml:lang="en-US">June PO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantsMember" xlink:label="PCSA_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantsMember" xlink:to="PCSA_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="PCSA_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CommonWarrantsMember" xlink:to="PCSA_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="PCSA_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ATMAgreementMember" xlink:label="PCSA_ATMAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMAgreementMember" xlink:to="PCSA_ATMAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:to="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_lbl" xml:lang="en-US">Chief Executive Officer and Certain Board Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:to="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember_lbl" xml:lang="en-US">Series A Warrants and Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantsMember" xlink:label="PCSA_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentWarrantsMember" xlink:to="PCSA_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeeMember" xlink:label="PCSA_EmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeeMember" xlink:to="PCSA_EmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ConsultingAgreementsMember" xlink:label="PCSA_ConsultingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementsMember" xlink:to="PCSA_ConsultingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultingAgreementsMember_lbl" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="PCSA_TwoThousandAndNineteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JanuaryPOMember" xlink:label="PCSA_JanuaryPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryPOMember" xlink:to="PCSA_JanuaryPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_JanuaryPOMember_lbl" xml:lang="en-US">January PO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantMember" xlink:label="PCSA_PlacementAgentWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentWarrantMember" xlink:to="PCSA_PlacementAgentWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PlacementAgentWarrantMember_lbl" xml:lang="en-US">Placement Agent Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_FacilityLeaseMember" xlink:label="PCSA_FacilityLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FacilityLeaseMember_lbl" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CorLystLLCMember" xlink:label="PCSA_CorLystLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CorLystLLCMember_lbl" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:to="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xml:lang="en-US">Reportable Segment, Aggregation before Other Operating Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesMember" xlink:label="PCSA_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesMember" xlink:to="PCSA_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PCS12852Member" xlink:label="PCSA_PCS12852Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PCS12852Member" xlink:to="PCSA_PCS12852Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PCS12852Member_lbl" xml:lang="en-US">P C S 12852 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CROsMember" xlink:label="PCSA_CROsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CROsMember_lbl" xml:lang="en-US">CROs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PropertyAndEquipmentNet" xlink:label="PCSA_PropertyAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PropertyAndEquipmentNet" xlink:to="PCSA_PropertyAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PropertyAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:label="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:to="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_lbl" xml:lang="en-US">Total Non-current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 or December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 100,000,000 shares authorized; 40,289,356 issued and 40,284,356 outstanding at June 30, 2025; and 3,707,628 issued and 3,702,628 outstanding at December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 5,000 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Income (Expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per Common Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per Common Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_2_lbl" xml:lang="en-US">Treasury Stock, balance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raise, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raises, net of transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued in connection with license agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_3_lbl" xml:lang="en-US">Treasury Stock, balance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="PCSA_OperatingAndFinanceLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseExpense" xlink:to="PCSA_OperatingAndFinanceLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense for right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="PCSA_PaymentsForSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease in Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-Cash Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xml:lang="en-US">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">New right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_FinancingLeaseLiability" xlink:label="PCSA_FinancingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FinancingLeaseLiability_lbl" xml:lang="en-US">Financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="PCSA_NonCashLeaseLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NonCashLeaseLiabilityNet_lbl" xml:lang="en-US">Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="PCSA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">PCS12852</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="PCSA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationTable" xlink:label="PCSA_OrganizationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationTable" xlink:to="PCSA_OrganizationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationTable_lbl" xml:lang="en-US">OrganizationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationLineItems" xlink:label="PCSA_OrganizationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationLineItems" xlink:to="PCSA_OrganizationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationLineItems_lbl" xml:lang="en-US">OrganizationLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Sale of stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Received exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants exercised during period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:to="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_lbl" xml:lang="en-US">Stock withheld for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xml:lang="en-US">Number of shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xml:lang="en-US">Number of shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xml:lang="en-US">Number of shares, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xml:lang="en-US">Number of shares, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum equity available for issuance under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of common shares-basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of common shares-diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xml:lang="en-US">Weighted average discount rate for our facility and equipment leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xml:lang="en-US">Operating and financing lease borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="us-gaap_RecoveryOfDirectCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecoveryOfDirectCosts" xlink:to="us-gaap_RecoveryOfDirectCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecoveryOfDirectCosts_lbl" xml:lang="en-US">Reimbursements received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="PCSA_PreclinicalClinicalTrialAndOtherCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:to="PCSA_PreclinicalClinicalTrialAndOtherCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreclinicalClinicalTrialAndOtherCosts_lbl" xml:lang="en-US">Preclinical, clinical trial and other costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_lbl" xml:lang="en-US">Research and development personnel expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative personnel expense</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="PCSA_AdministrativeAndFacilitiesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdministrativeAndFacilitiesExpense" xlink:to="PCSA_AdministrativeAndFacilitiesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AdministrativeAndFacilitiesExpense_lbl" xml:lang="en-US">Administrative and facilities expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_6_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_6_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetDescription" xlink:label="PCSA_TermSheetDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TermSheetDescription" xlink:to="PCSA_TermSheetDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TermSheetDescription_lbl" xml:lang="en-US">Description of term sheet</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetRemainingDiligenceDescription" xlink:label="PCSA_TermSheetRemainingDiligenceDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TermSheetRemainingDiligenceDescription" xlink:to="PCSA_TermSheetRemainingDiligenceDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_TermSheetRemainingDiligenceDescription_lbl" xml:lang="en-US">Description of term sheet</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PropertyAndEquipmentNet" xlink:to="PCSA_PropertyAndEquipmentNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PropertyAndEquipmentNet_doc" xml:lang="en-US">Property and Equipment, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:to="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_doc" xml:lang="en-US">Assets noncurrent excluding property and equipment net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xml:lang="en-US">Operating and finance lease liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xml:lang="en-US">Operating and finance lease liability noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xml:lang="en-US">Adjustments to additional paid in capital settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseExpense" xlink:to="PCSA_OperatingAndFinanceLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseExpense_doc" xml:lang="en-US">Operating and finance lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_doc" xml:lang="en-US">Due (from) to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_doc" xml:lang="en-US">Payments for settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xml:lang="en-US">Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FinancingLeaseLiability_doc" xml:lang="en-US">Financing lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NonCashLeaseLiabilityNet_doc" xml:lang="en-US">Non cash lease liability net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xml:lang="en-US">Business Activities And Organization [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PreFundedWarrantMember_doc" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsMember" xlink:to="PCSA_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesBWarrantsMember" xlink:to="PCSA_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:to="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember_doc" xml:lang="en-US">Chief Executive Officer and Certain Board Members [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:to="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SeriesAWarrantsAndSeriesBWarrantsMember_doc" xml:lang="en-US">Series A Warrants and Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CommonWarrantsMember" xlink:to="PCSA_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeeMember" xlink:to="PCSA_EmployeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EmployeeMember_doc" xml:lang="en-US">Employee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:to="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_doc" xml:lang="en-US">Stock withheld for income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementsMember" xlink:to="PCSA_ConsultingAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultingAgreementsMember_doc" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedDuringPeriodSharesExercised" xlink:label="PCSA_StockIssuedDuringPeriodSharesExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesExercised_doc" xml:lang="en-US">Stock issued during period shares exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentMember" xlink:label="PCSA_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_doc" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesAndConsultantsMember" xlink:label="PCSA_EmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesAndConsultantsMember" xlink:to="PCSA_EmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EmployeesAndConsultantsMember_doc" xml:lang="en-US">Employees and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xml:lang="en-US">Lessee Operating And Financing Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_doc" xml:lang="en-US">Operating and financing lease weighted average discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FacilityLeaseMember_doc" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CorLystLLCMember_doc" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:to="PCSA_PreclinicalClinicalTrialAndOtherCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PreclinicalClinicalTrialAndOtherCosts_doc" xml:lang="en-US">Preclinical clinical trial and other costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdministrativeAndFacilitiesExpense" xlink:to="PCSA_AdministrativeAndFacilitiesExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AdministrativeAndFacilitiesExpense_doc" xml:lang="en-US">Administrative and facilities expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesMember" xlink:to="PCSA_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CROsMember_doc" xml:lang="en-US">CROs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ElionOncologyIncMember" xlink:label="PCSA_ElionOncologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionOncologyIncMember" xlink:to="PCSA_ElionOncologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ElionOncologyIncMember_doc" xml:lang="en-US">Elion Oncology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:label="PCSA_TwoThousandNineteenOmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandNineteenOmnibusIncentivePlanMember" xlink:to="PCSA_TwoThousandNineteenOmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandNineteenOmnibusIncentivePlanMember_doc" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JunePOMember" xlink:to="PCSA_JunePOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JunePOMember_doc" xml:lang="en-US">June PO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentWarrantMember" xlink:to="PCSA_PlacementAgentWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PlacementAgentWarrantMember_doc" xml:lang="en-US">Placement Agent Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantMember" xlink:label="PCSA_CommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CommonWarrantMember" xlink:to="PCSA_CommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CommonWarrantMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryPOMember" xlink:to="PCSA_JanuaryPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JanuaryPOMember_doc" xml:lang="en-US">January PO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecuritiesPurchaseAgreementMember" xlink:to="PCSA_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMAgreementMember" xlink:to="PCSA_ATMAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ATMAgreementMember_doc" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantsMember" xlink:to="PCSA_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:to="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet_3_lbl" xml:lang="en-US">AssetsNoncurrentExcludingPropertyAndEquipmentNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:to="PCSA_IncreaseDecreaseInDueFromToRelatedParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_IncreaseDecreaseInDueFromToRelatedParties_3_lbl" xml:lang="en-US">IncreaseDecreaseInDueFromToRelatedParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_3_lbl" xml:lang="en-US">PaymentsForSettlementOfStockAwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_2_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xml:lang="en-US">LesseeOperatingAndFinancingLeasesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_3_lbl" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TermSheetRemainingDiligenceDescription" xlink:to="PCSA_TermSheetRemainingDiligenceDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TermSheetRemainingDiligenceDescription_2_lbl" xml:lang="en-US">TermSheetRemainingDiligenceDescription</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pcsa-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Cover" roleURI="http://processapharmaceuticals.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheets" roleURI="http://processapharmaceuticals.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#BalanceSheetsParenthetical" roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfOperations" roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlows" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StatementsOfCashFlowsUnauditedParenthetical" roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquity" roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensation" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStock" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Leases" roleURI="http://processapharmaceuticals.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactions" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReporting" roleURI="http://processapharmaceuticals.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852" roleURI="http://processapharmaceuticals.com/role/Pcs12852" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingencies" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEvents" roleURI="http://processapharmaceuticals.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationTables" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#NetLossPerShareOfCommonStockTables" roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesTables" roleURI="http://processapharmaceuticals.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SegmentReportingTables" roleURI="http://processapharmaceuticals.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#LeasesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" roleURI="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#Pcs12852DetailsNarrative" roleURI="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PropertyAndEquipmentNet" xlink:label="loc_PCSAPropertyAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_PCSAPropertyAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:label="loc_PCSAAssetsNoncurrentExcludingPropertyAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_PCSAAssetsNoncurrentExcludingPropertyAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinanceLeaseExpense" xlink:label="loc_PCSAOperatingAndFinanceLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_IncreaseDecreaseInDueFromToRelatedParties" xlink:label="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PCSAIncreaseDecreaseInDueFromToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_FinancingLeaseLiability" xlink:label="loc_PCSAFinancingLeaseLiability" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAFinancingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="loc_PCSANonCashLeaseLiabilityNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSANonCashLeaseLiabilityNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="999014 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="999016 - Disclosure - Net Loss per Share of Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="999017 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="999018 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReporting" xlink:title="999019 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852" xlink:title="999020 - Disclosure - PCS12852">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvents" xlink:title="999022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="loc_PCSALiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSALiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="999024 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="999025 - Disclosure - Net Loss per Share of Common Stock (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="999026 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SegmentReportingTables" xlink:title="999027 - Disclosure - Segment Reporting (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSAOrganizationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_PCSAOrganizationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ATMAgreementMember" xlink:label="loc_PCSAATMAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAATMAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAJunePOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSACommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantsMember" xlink:label="loc_PCSAPreFundedWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSAPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSACommonWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="999029 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="loc_us-gaapClassOfStockDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ConsultingAgreementsMember" xlink:label="loc_PCSAConsultingAgreementsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantsMember" xlink:label="loc_PCSAPlacementAgentWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PCSACommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:label="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAChiefExecutiveOfficerAndCertainBoardMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeeMember" xlink:label="loc_PCSAEmployeeMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PCSACommonWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="999031 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999032 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesBWarrantsMember" xlink:label="loc_PCSASeriesBWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CommonWarrantsMember" xlink:label="loc_PCSACommonWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSACommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PlacementAgentWarrantMember" xlink:label="loc_PCSAPlacementAgentWarrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAPlacementAgentWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SeriesAWarrantsAndSeriesBWarrantsMember" xlink:label="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASeriesAWarrantsAndSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreFundedWarrantsMember" xlink:label="loc_PCSAPreFundedWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAJunePOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JanuaryPOMember" xlink:label="loc_PCSAJanuaryPOMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAJanuaryPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_JunePOMember" xlink:label="loc_PCSAJunePOMember_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAJunePOMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="999038 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999039 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaapRecoveryOfDirectCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRecoveryOfDirectCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails" xlink:title="999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PreclinicalClinicalTrialAndOtherCosts" xlink:label="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAPreclinicalClinicalTrialAndOtherCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_AdministrativeAndFacilitiesExpense" xlink:label="loc_PCSAAdministrativeAndFacilitiesExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_PCSAAdministrativeAndFacilitiesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical" xlink:title="999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative" xlink:title="999042 - Disclosure - PCS12852 (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_PCS12852Member" xlink:label="loc_PCSAPCS12852Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_PCSAPCS12852Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetDescription" xlink:label="loc_PCSATermSheetDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSATermSheetDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_TermSheetRemainingDiligenceDescription" xlink:label="loc_PCSATermSheetRemainingDiligenceDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSATermSheetRemainingDiligenceDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSACROsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative" xlink:title="999044 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_SecuritiesPurchaseAgreementMember" xlink:label="loc_PCSASecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20250630.xsd#PCSA_ATMAgreementMember" xlink:label="loc_PCSAATMAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAATMAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Processa
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601
21st Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vero
Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">453-2899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,349,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,936,620<span></span>
</td>
<td class="nump">$ 1,191,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">217,201<span></span>
</td>
<td class="nump">682,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">7,153,821<span></span>
</td>
<td class="nump">1,873,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PropertyAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">4,414<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">993,701<span></span>
</td>
<td class="nump">1,274,442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet', window );">Total Non-current Assets</a></td>
<td class="nump">993,701<span></span>
</td>
<td class="nump">1,274,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">24,318<span></span>
</td>
<td class="nump">70,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Total Other Assets</a></td>
<td class="nump">29,853<span></span>
</td>
<td class="nump">76,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">8,181,789<span></span>
</td>
<td class="nump">3,229,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent', window );">Current maturities of lease liability</a></td>
<td class="nump">25,584<span></span>
</td>
<td class="nump">73,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">785,754<span></span>
</td>
<td class="nump">880,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,263,243<span></span>
</td>
<td class="nump">578,731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,074,581<span></span>
</td>
<td class="nump">1,532,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,074,581<span></span>
</td>
<td class="nump">1,533,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 or December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 100,000,000 shares authorized; 40,289,356 issued and 40,284,356 outstanding at June 30, 2025; and 3,707,628 issued and 3,702,628 outstanding at December 31, 2024</a></td>
<td class="nump">4,029<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">100,390,701<span></span>
</td>
<td class="nump">89,214,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 5,000 shares</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(93,987,522)<span></span>
</td>
<td class="num">(87,219,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">6,107,208<span></span>
</td>
<td class="nump">1,696,171<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 8,181,789<span></span>
</td>
<td class="nump">$ 3,229,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets noncurrent excluding property and equipment net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and Equipment, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">40,289,356<span></span>
</td>
<td class="nump">3,707,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">40,284,356<span></span>
</td>
<td class="nump">3,702,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 2,447,286<span></span>
</td>
<td class="nump">$ 1,730,444<span></span>
</td>
<td class="nump">$ 4,035,767<span></span>
</td>
<td class="nump">$ 3,269,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,503,497<span></span>
</td>
<td class="nump">1,351,580<span></span>
</td>
<td class="nump">2,762,006<span></span>
</td>
<td class="nump">2,622,067<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(3,950,783)<span></span>
</td>
<td class="num">(3,082,024)<span></span>
</td>
<td class="num">(6,797,773)<span></span>
</td>
<td class="num">(5,891,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other Income (Expense), net</a></td>
<td class="nump">16,865<span></span>
</td>
<td class="nump">71,698<span></span>
</td>
<td class="nump">29,450<span></span>
</td>
<td class="nump">154,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (3,933,918)<span></span>
</td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (6,768,323)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per Common Share - Basic</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per Common Share - Diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic</a></td>
<td class="nump">15,569,312<span></span>
</td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">12,401,583<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted</a></td>
<td class="nump">15,569,312<span></span>
</td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">12,401,583<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 80,658,111<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (75,369,081)<span></span>
</td>
<td class="nump">$ 4,989,159<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">167,642<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">167,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">13,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">6,282,274<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,282,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">188,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(9,923)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(3,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,726,381)<span></span>
</td>
<td class="num">(2,726,381)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">87,278,542<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(78,095,462)<span></span>
</td>
<td class="nump">8,883,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">2,860,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,736,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">87,429,165<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(81,105,788)<span></span>
</td>
<td class="nump">6,023,664<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">87,278,542<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(78,095,462)<span></span>
</td>
<td class="nump">8,883,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">2,860,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">14,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,008)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(1,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,010,326)<span></span>
</td>
<td class="num">(3,010,326)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">87,429,165<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(81,105,788)<span></span>
</td>
<td class="nump">6,023,664<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">89,214,999<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(87,219,199)<span></span>
</td>
<td class="nump">$ 1,696,171<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,707,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">227,710<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 227,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">4,438,414<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,438,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">1,556,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,834,405)<span></span>
</td>
<td class="num">(2,834,405)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">93,879,685<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(90,053,604)<span></span>
</td>
<td class="nump">3,526,608<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">5,274,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">89,214,999<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(87,219,199)<span></span>
</td>
<td class="nump">$ 1,696,171<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">3,707,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,768,323)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 4,029<span></span>
</td>
<td class="nump">100,390,701<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(93,987,522)<span></span>
</td>
<td class="nump">$ 6,107,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">40,289,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">93,879,685<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(90,053,604)<span></span>
</td>
<td class="nump">$ 3,526,608<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="nump">5,274,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">203,236<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">203,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">143,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs</a></td>
<td class="nump">$ 3,489<span></span>
</td>
<td class="nump">6,316,743<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,320,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raises, net of transaction costs, shares</a></td>
<td class="nump">34,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(8,963)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(21,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,933,918)<span></span>
</td>
<td class="num">(3,933,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 4,029<span></span>
</td>
<td class="nump">$ 100,390,701<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (93,987,522)<span></span>
</td>
<td class="nump">$ 6,107,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">40,289,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, balance shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,768,323)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseExpense', window );">Non-cash lease expense for right-of-use assets</a></td>
<td class="nump">46,359<span></span>
</td>
<td class="nump">42,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">430,962<span></span>
</td>
<td class="nump">320,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">745,834<span></span>
</td>
<td class="num">(980,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(45,073)<span></span>
</td>
<td class="num">(41,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(95,126)<span></span>
</td>
<td class="nump">641,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_IncreaseDecreaseInDueFromToRelatedParties', window );">Due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">684,512<span></span>
</td>
<td class="nump">359,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,000,253)<span></span>
</td>
<td class="num">(5,394,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of stock</a></td>
<td class="nump">10,758,802<span></span>
</td>
<td class="nump">6,282,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on stock-based compensation</a></td>
<td class="num">(10,404)<span></span>
</td>
<td class="num">(11,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PaymentsForSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(2,850)<span></span>
</td>
<td class="num">(2,301)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,745,548<span></span>
</td>
<td class="nump">6,259,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="nump">5,745,295<span></span>
</td>
<td class="nump">864,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - Beginning of Period</a></td>
<td class="nump">1,191,325<span></span>
</td>
<td class="nump">4,706,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - End of Period</a></td>
<td class="nump">6,936,620<span></span>
</td>
<td class="nump">5,571,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor', window );">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">New right-of-use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_FinancingLeaseLiability', window );">Financing lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NonCashLeaseLiabilityNet', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_FinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_FinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_IncreaseDecreaseInDueFromToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due (from) to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_IncreaseDecreaseInDueFromToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NonCashLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NonCashLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PaymentsForSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PaymentsForSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,933,918)<span></span>
</td>
<td class="num">$ (2,834,405)<span></span>
</td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (2,726,381)<span></span>
</td>
<td class="num">$ (6,768,323)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zIZIjLFBErTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82D_zFIjwmIv4qfb">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zmQ34fiLtj4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Organization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation Cancer therapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications
of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known
and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments
will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmc2n4cY4vO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2024, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2hdvmOmWDs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all our efforts toward research and development of our NGC drug product candidates, including conducting
clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20250630_zNh9yWsIe164" title="Accumulated deficit">94.0</span> million
at June 30, 2025. During the six months ended June 30, 2025, we generated a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zFzXmnNyo545" title="Net loss">6.8</span> million and used $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zpQwioDX2aL4" title="Net cash used in operating activities">5.0</span> million in net cash
for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore
we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We expect that
we will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2025, we closed a public offering where we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2IACKKI10E1" title="Number of shares sold">1,030,972</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, pre-funded warrants to purchase
up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z58Do0rJpmlc" title="Warrants to purchase common stock">7,019,700</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, and accompanying Series A warrants
to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZTmd28bUka4" title="Warrants to purchase common stock">8,050,672</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series A Warrants&#8221;)
and Series B warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCXIC3WoAcM9" title="Warrants to purchase common stock">4,025,336</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series B Warrants&#8221;)
for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zioWwupi64G1" title="Net proceeds">4.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). On June 18, 2025, we closed another public offering where we sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYXePnTaJ6j4" title="Number of shares sold">14,310,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, pre-funded warrants to purchase up
to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--JunePOMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zXWIl4CjZbd2" title="Warrants to purchase common stock">13,690,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, and common warrants to purchase up
to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrNMa5jWEqYi" title="Warrants to purchase common stock">28,000,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zH31S1JuM2Z3" title="Net proceeds">6.2</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). As of June 30, 2025, all Pre-Funded Warrants from both public offerings were exercised.</span>
During the six months ended June 30, 2025, we also received $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6EycM3aubbj" title="Received exercise of warrants">100,000</span> for the exercise of warrants to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjpAP6rnKIa5" title="Number of warrants exercised during period">400,000</span> shares of common
stock from the June PO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On August 4, 2025, we entered
into a Securities Purchase Agreement with an accredited investor and sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGdBVoKFE98" title="Sale of stock shares">5,467,181</span> shares for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgX2dT0HbjF3" title="Gross proceeds">1.3</span> million in gross proceeds. We also
sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxqId1oMYKpi" title="Sale of stock shares">4,597,612</span> shares for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaplZhOhCk9j" title="Gross proceeds">1.1</span> million in gross proceeds under our ATM agreement. Following these investments, we are exploring options
to pursue a cryptocurrency treasury strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we had cash and cash equivalents totaling $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_z8sFX0LwBso7" title="Cash and cash equivalents">6.9</span> million. Based on our current business plans, we believe these funds, together with the $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250801__20250831_z7xMLlYVDhXi" title="Gross proceeds">2.4</span> million in gross proceeds we received in August  2025, will
satisfy our capital needs into the first quarter of 2026. Our ability to execute our longer-term operating plans, including future preclinical
studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or
debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_z5RcCwaqmVAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z2Ef04Iwn7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2025 and December 31, 2024, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2025 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z5mNCpgeT9r" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Concentration
of Credit Risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2025, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTwDrg7o1fOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

<p id="xdx_85D_zXPgsjBm4eK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1ghFS8XDkcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82B_zmiSHmBEamp1">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2025, we issued the following shares of common stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    January 2<span style="background-color: white">9</span>, 2025, we sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBLWqiaVnxIk" title="Number of shares sold">1,030,972</span>
    shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDoVJ4mkLeH2" title="Warrants to purchase">7,019,700</span>
    shares of our common stock, and accompanying Series A Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zdfJbRXL4Yh6" title="Warrants to purchase shares">8,050,672</span>
    shares of our common stock and Series B Warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyfb6yPMQFh2" title="Warrants to purchase common stock">4,025,336</span>
    shares of our common stock for net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX2n72ca88tc" title="Net proceeds">4.4</span>
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#8220;January
    PO&#8221;) </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a combined purchase price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAOyKa1uPNf" title="Sale of stock price per share">0.615</span>
    for institutional investors and $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zvFg6aG7Euyl" title="Sale of stock price per share">0.7975</span>
    for the Company&#8217;s Chief Executive Officer and certain board members who participated in the offering. The Series A and B
    Warrants both have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zaHPIGUsXnee" title="Warrant exercise price">0.65</span>
    per share of common stock, and were subject to stockholder approval, which was obtained at our annual stockholder meeting on July
    18, 2025. The Series A Warrants will expire on July 18, 2030 and the Series B Warrants will expire on January 18, 2027. At June 30,
    2025, all pre-funded warrants sold in this offering were exercised; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
    June 18, 2025, we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKTY8byf7pCd" title="Number of shares sold">14,310,000</span>
    shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0bWixmHz5u2" title="Warrants to purchase common stock">13,690,000</span>
    shares of our common stock. and accompanying common warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znWIqShlfNoj" title="Warrants to purchase shares">28,000,000</span>
    shares of our common stock for net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze4DwWpXikG4" title="Net proceeds">6.2</span>
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#8220;June
    PO&#8221;). We sold one share of our common stock and accompanying common warrant at a combined price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaOwSQUNP838" title="Sale of stock price per share">0.25</span>
    per share, and a pre-funded warrant and accompanying common warrant at a combined price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_ziNBP3SE0hQ6" title="Share price">0.2499</span>
    per share. The common warrants have an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_ztAFoLaJ5Ki2" title="Warrant exercise price">0.25</span>
    per share, are immediately exercisable and expire five years after their original issuance. The pre-funded warrants have an exercise
    price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_z0KRQNVa8MPe" title="Warrant exercise price">0.0001</span>
    and are also immediately exercisable. We issued placement agent warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zTReL2a8sQV1" title="Number of warrants to purchase shares">1,120,000</span>
    shares of common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z740UOGCXj95" title="Warrant exercise price">0.31</span>
    per share. During the six months ended June 30, 2025, warrants to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z3yAYDxF8uo3" title="Number of warrants exercised during period">400,000</span>
    shares of common stock for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_zQ87JitnQVs4" title="Proceeds from exercise of warrants">100,000</span> and all pre-funded warrants sold in this offering were exercised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__srt--TitleOfIndividualAxis__custom--EmployeeMember_z3Wdm3slowfc" title="Shares issued">74,804</span>
    shares of common stock to employees, net of <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20250101__20250630_zFSEIzwsIAog" title="Stock withheld for income taxes">23,768</span> shares of common stock withheld for income and FICA taxes owed upon the distribution
    of the shares; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_ziAFRD2giEmh" title="Shares issued">56,252</span>
    shares of common stock in connection with consulting agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqJqgJGrTKRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82F_z1bK6Pag2Kml">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20190619__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zg0FAI78MWeh" title="Maximum equity available for issuance under the plan">800,000</span> shares of our common stock. At June 30, 2025, we have <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zVIDy0G7TP51" title="Shares available for future grants">357,420</span>
shares available for future grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zpg4GeMkaCLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zgJgUxTUru47" style="display: none">Schedule of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250401__20250630_zcVscPdtSXu3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20240630_zNWAg5OJNjBa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250630_zz0NmpJrXoSl" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_zfeZ7cIRtR03" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXLMkInpisw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">45,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">55,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">76,704</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0KsLz1TPpK1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">194,635</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107,049</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">375,626</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">243,571</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zMEnZuIYZlhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">203,248</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zfCuakJXxNl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
stock options to purchase shares of common stock were forfeited or expired during the six months ended June 30, 2025. At June 30, 2025,
we had outstanding and exercisable options for the purchase of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdrtciP0MqL8" title="Options exercisable, shares">2,747</span> shares with a weighted average exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znDFGlwvGfZ1" title="Options exercisable weighted average exercise price">409.09</span> and a weighted
average remaining contractual life of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zipkqjoyNXvg" title="Exercisable weighted average remaining contractual term">3.2</span> years. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we did not have any unrecognized stock-based compensation expense related to our granted stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEpTZk5XqTjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zH7Q6Wk69Jp9" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvWyFtyJZn1" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">383,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3zFX1wdn3I5" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">19.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjJztqK9ZQnl" style="text-align: right" title="Number of shares, granted"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3gRvcQMP6Dj" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGhj3E7NGK11" style="text-align: right" title="Number of shares, forfeited">(27,547</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyxpE39co2y4" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">53.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zog80YNNHcec" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, issued">(74,804</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z95F34UP6Y89" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, shares issued">58.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP4ZmwMHp0d5" style="text-align: right" title="Number of shares, ending balance">281,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjAH2VNiTWka" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">6.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Vested and unissued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziTIyR2gCLf5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued">(229,905</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHaDFq8RaBr3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">5.47</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CjqvEplxCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">51,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3NRGzVU0gql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant-date fair value per share, unvested">9.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zawHTNnLT6Fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, unrecognized stock-based compensation expense of approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYJI1eVIK85h" title="Unrecognized share based compensation expense">148,000</span> for RSUs is expected to be fully recognized over
a weighted average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8TpAcBy1Vg" title="Weighted average period for recognition">0.7</span> years. The unrecognized expense excludes approximately $<span id="xdx_908_ecustom--UnrecognizedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zw9NujZV6Ctg" title="Unrecognized share based compensation expense">253,000</span> of expense related to certain grants
of RSUs with performance milestones that are being accounted for as though the performance milestones are not probable of occurring at
this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. While certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a stockholder
until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock.
The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2025, we sold <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryPOMember_zDVK6ZNgKbx4" title="Number of warrants exercised during period">7,019,700</span> pre-funded warrants, and accompanying Series A Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zntPkoTrz7t9" title="Warrants to purchase shares">8,050,672</span>
shares of our common stock and Series B Warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zJODoOZVYGG8" title="Warrants to purchase shares">4,025,336</span> shares of our common stock in the January PO. We also sold
<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JunePOMember_z9WnlBqm5767" title="Number of warrants exercised during period">13,690,000</span> pre-funded warrants and accompanying common warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JunePOMember_zUy6ePLiIkW3" title="Warrants to purchase shares">28,000,000</span> shares of common stock, as well as issued
placement agent warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantMember_zG9mA6VXD8N8" title="Warrants to purchase shares">1,120,000</span> shares of common stock in the June PO. During the six months ended June 30, 2025,
warrants to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJWnN8x1q594" title="Number of warrants exercised during period">400,000</span> shares of common stock from the June PO and all pre-funded warrants from the January PO and June PO were
exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we had outstanding exercisable stock purchase warrants excluding the Series A and B Warrants for the purchase of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zZQkbFSvfIDh" title="Warrants to purchase shares">30,495,784</span>
<span style="background-color: white">shares with a weighted average exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zcCf964kTF7f" title="Weighted average exercise price">0.35</span> and a weighted average remaining contractual
life of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_z9i5RAp8ze5i" title="Weighted average remaining contractual life">4.9</span> years. We have excluded the Series A and B Warrants sold under the January PO from the calculation of the weighted average
remaining contractual life since we did not receive stockholder approval for these warrants until July 18, 2025.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">W</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e
did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zC4JPyi708qi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211;<span id="xdx_82F_z4HeVi6HFmyl"> Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common stockholders by the weighted average number of shares of
common stock outstanding (which includes vested RSUs and unexercised pre-funded warrants) during the period. Diluted loss per share is
computed by dividing our net loss available to common stockholders by the diluted weighted average number of shares of common stock (which
includes the potentially dilutive effect of stock options, unvested RSUs and warrants) during the period. Since we experienced a net
loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and
six months ended June 30, 2025 and 2024 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3x6DRAv7bTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2025 and 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zccZWdZJXXg" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630_zBQyRflVH45h" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240401__20240630_zZEaQ7g6xDdd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630_zDGNYNqEkei8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630_z8g5bxqfgZi6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zysC6SZSmFAl" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,933,918</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,010,326</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,768,323</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(5,736,707</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zCb25uWbxYNc" title="Weighted average number of common shares-basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zTwDq125EzHc" title="Weighted average number of common shares-diluted">15,569,312</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zNvcgA0igiBk" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zp8zBZE0AUk9" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zF5fdQcoEg1f" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_z7eXylfBtfhl" title="Weighted average number of common shares-diluted">12,401,583</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zILRm64pui2g" title="Weighted average number of common shares-basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zAw1NI5SyFzl" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250401__20250630_zOIbgKOcOOPe" title="Basic net loss per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_zrFAWidrfQth" title="Diluted net loss per share">(0.25</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zeLZqFlt6owg" title="Basic net loss per share"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zI493FwhU0hj" title="Diluted net loss per share">(1.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250630_zxYOMev6ukTj" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zk2QVSTHEkDh" title="Diluted net loss per share">(0.55</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zPKr7WdquEI1" title="Basic net loss per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z4ndRW4hLfN8" title="Diluted net loss per share">(2.11</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WqXw0ZfFe3" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJknADl25iA" title="Weighted average number of common shares outstanding - diluted">15,545,266</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgkP1uSqdedl" title="Weighted average number of common shares outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWsER6WVKnf" title="Weighted average number of common shares outstanding - diluted">2,849,192</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2zRbvhZdN2" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47QsL2S95J9" title="Weighted average number of common shares outstanding - diluted">12,371,909</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbFuJgrOAz4" title="Weighted-average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVtH5Xkuytz2" title="Weighted-average number of common shares outstanding - diluted">2,590,530</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpW4HpMsiUr" title="Weighted average number of vested RSUs - basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znCVAMfgSTgi" title="Weighted average number of vested RSUs - diluted">24,046</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zXOEyX5ulBY" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5dk2uqVHA2b" title="Weighted average number of vested RSUs - diluted">134,091</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zauaD8l29EEl" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFQYUsMAJ4i" title="Weighted average number of vested RSUs - diluted">29,674</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zyBHiDAhQWkk" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z48afxRmNlcj" title="Weighted average number of vested RSUs - diluted">134,373</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zhiqQOUVgcie" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zqX8kaF32rAj" title="Weighted average number of common shares-diluted">15,569,312</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zw9Dc8wccNm5" title="Weighted average number of common shares-basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zqursHq06uda" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zn05tG4uxtJl" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zwCe6TGM7vCi" title="Weighted average number of common shares-diluted">12,401,583</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_ziO6dS7M7U24" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zLjZFflDinS2" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zJ6VASJqcMQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zT9Ny4TA34dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have
had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zRiN2IsB6Ra2" style="display: none">Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250630_zkrQzxy8BfSe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zrXmypGTbojh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhWcCfvVdS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,747</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,747</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zvbHiH5u0Ly2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units (unvested)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zkblzalKdfj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants for common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,495,784</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,778,284</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zKarluVH0ZL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,549,911</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,876,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zbUa6Bcf3lV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not included any potential impact of the Series A and B Warrants from the January PO since they were subject to shareholder
approval as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zNHpp80gTIe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_828_z6Z4iswNw9S3">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of <span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20250630_zoWTWsGCbHLl" title="Operating and financing lease borrowing rate">8</span>% in determining the present value of the lease payments based on
the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled $<span id="xdx_900_eus-gaap--LeaseCost_c20250401__20250630_zlfox7BaWTof" title="Lease cost"><span id="xdx_90A_eus-gaap--LeaseCost_c20240401__20240630_zWC0kftusKs7" title="Lease cost">22,461</span></span> for both three months ending June 30, 2025 and
2024 and $<span id="xdx_90D_eus-gaap--LeaseCost_c20250101__20250630_zwvZqTcZ9au2" title="Lease cost"><span id="xdx_900_eus-gaap--LeaseCost_c20240101__20240630_zIUd59PC94S6" title="Lease cost">44,922</span></span> for both six months ending June 30, 2025 and 2024. The weighted average remaining lease terms and discount rate for
our operating leases were as follows at June 30, 2025:</span></p>

<p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zFAc7SvHu3Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zrMCiHT3pKk8" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zfcTa1j3ilS4" title="Remaining lease term (years)">0.3</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUwp4wb4Xaq2" title="Remaining lease term (years)">0.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20250630_zO2uCxN12U9h" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zaD75zPXDL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmVtLUvJNSz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zLnf6mxeVquf" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_496_20250630_zGllg7MuoUrj" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z1RKsd2fhLGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; padding-bottom: 1pt">Remainder of 2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">23,347</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zAuyxQzpP0y7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,347</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zRJVVVEdP7uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,515</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zTDc6qM7A6cd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,832</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zxEYGDadTbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,832</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxJf5oAZUB22" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z99fXTTMdHN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zAcqy1RIXNMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zlq9vwgmocMl" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250630_z6TimV9Ft9Vf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zd98xICrM543" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_z5K4N946tx4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_z1PuDZpzRuGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,920</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI5BdRRkDQnb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(168</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_znuLvlP8E0x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,752</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIRPnAxV9MDk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zj5p4XKBN0li" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl0872">Less: current maturities</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,752</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z2lW7IFlz6e6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zpm6BpzM4316" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl0875">Non-current lease liability</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z75UR0DVH30i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Financing Leases [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LesseeOperatingAndFinancingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ze9gXe6LDYK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zdqcdT7GGcDa">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. Included in our general and administrative expenses is approximately $<span id="xdx_900_eus-gaap--RecoveryOfDirectCosts_c20250401__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zufJEqvmGxx7" title="Reimbursements received">31,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_901_eus-gaap--RecoveryOfDirectCosts_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zDtc3ZXNNerg" title="Reimbursements received">27,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of reimbursements from CorLyst during the three months ended
June 30, 2025 and 2024, respectively, and $<span id="xdx_90C_eus-gaap--RecoveryOfDirectCosts_c20250101__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zN4r3uud0nH2" title="Reimbursements received">60,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--RecoveryOfDirectCosts_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zBWYKFW0VEs8" title="Reimbursements received">50,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the six months ended June 30, 2025 and 2024. At June 30,
2025, we included approximately $<span id="xdx_90D_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpW91teHCuQ5" title="Due from related parties">29,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due from CorLyst as a current asset in Prepaid and Other. Our
President, Research and Development is the CEO of CorLyst, and CorLyst is a stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zyH0kcoMQvy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
7 &#8211; <span id="xdx_826_zmFIvSOykUZ9">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating
decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus
actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations
and comprehensive loss as consolidated net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zgLCF8aoESJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zZufT0nPmGGe" style="display: none">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zNWJzZLtLmsd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zlhsxvXSS1G5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_ztcVC35Ts9m6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zgt24ZWuv6g2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PreclinicalClinicalTrialAndOtherCosts_zCeH9ckbKyii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Preclinical, clinical trial and other costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,142,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,261,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,339,263</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,293,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zEGqH8EgqzUa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F4B_zhuy8nrNbSYi">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976,554</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zHOLDxoMw79a" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976,554</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zaYLf3fhut01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F44_zD8JbZyluxX5">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,302,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,409</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zfAsZjvssMqa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
personnel expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,302,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,409</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zxrqkYJC0j6k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4E_zQc48XVSEdv">(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">875,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">905,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,459,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657,658</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zHBW9TZKFWJe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">875,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">905,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,459,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657,658</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InvestmentIncomeInterest_di_zI9PgfScKSpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,865</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(71,698</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,450</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(154,915</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iNT_di_zsccqLLBMH54" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,010,326</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,736,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zi09RiT0x1C7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zkJPd2W63f79" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense">8,613</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense">45,583</span> for the three months ended
    June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense">55,333</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense">76,704</span> for the six months ended June 30, 2025 and 2024, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zOEEghvgeZNi">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zC8nYhvS8sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense">122,655</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense">40,309</span> for the three months
    ended June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense">245,310</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense">79,180</span> for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zhvE94uaLy0i">(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z3J02240kkA5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
    &amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.</span></td></tr>
  </table>
<p id="xdx_8A7_z5qUYBLAepgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PCS12852<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">PCS12852</a></td>
<td class="text"><p id="xdx_803_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z90mIn0BO6Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_824_zIc9hVjfT3Ji">PCS12852</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2025, we entered into a binding term sheet (&#8220;Term Sheet&#8221;) with Intact Therapeutics (&#8220;Intact&#8221;) granting
Intact the exclusive option to license PCS12852, a highly specific and potent 5HT5 agonist <span style="background-color: white">that
is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients.</span> <span id="xdx_907_ecustom--TermSheetDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zhgmgWiDn9cl" title="Description of term sheet">Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--TermSheetRemainingDiligenceDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zmexDf8czWCc" title="Description of term sheet">The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000.</span> There can be no assurance that
the Company and Intact will enter into a license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Term Sheet, Yuhan Corporation executed Amendment No. 1 to our existing license agreement dated August 19, 2020 (the
&#8220;Yuhan Agreement&#8221;), effective June 11, 2025, which, among other things, extended the deadline to dose the first patient in
a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial from 48 months to 108 months from the effective date
of the original agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmZkpPVBp9Sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_825_zUw8WCPkiWB3">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2025, we are contractually obligated to pay up to $<span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zzwPKqury4Vl" title="Purchase obligation">13.1</span> million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zmh30fozWaJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_826_zgP6ijFNE0Pa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">RSU
Grants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2025, the Compensation Committee of our Board of Directors granted RSUs for the future issuance of up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250724__20250724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn6iguZTRFA5" title="Number of shares granted">356,310</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to our employees and independent directors.
The RSUs vest over a 1-3 year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
Sales</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 4, 2025, we entered into a Securities Purchase Agreement with an accredited investor and sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdcAWabcectf" title="Sale of stock shares">5,467,181</span> shares for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc6eJE964wCa" title="Gross proceeds">1.3</span>
million in gross proceeds. We also sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNJJIZeIPJug" title="Sale of stock shares">4,597,612</span> shares for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMN5IAtxSOw2" title="Gross proceeds">1.1</span> million in gross proceeds under our ATM agreement. Following these
investments, we are exploring options to pursue a cryptocurrency treasury strategy.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_84A_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zmQ34fiLtj4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Organization</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation Cancer therapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications
of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known
and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments
will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmc2n4cY4vO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2024, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2hdvmOmWDs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all our efforts toward research and development of our NGC drug product candidates, including conducting
clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20250630_zNh9yWsIe164" title="Accumulated deficit">94.0</span> million
at June 30, 2025. During the six months ended June 30, 2025, we generated a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zFzXmnNyo545" title="Net loss">6.8</span> million and used $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zpQwioDX2aL4" title="Net cash used in operating activities">5.0</span> million in net cash
for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore
we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We expect that
we will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2025, we closed a public offering where we sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2IACKKI10E1" title="Number of shares sold">1,030,972</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, pre-funded warrants to purchase
up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z58Do0rJpmlc" title="Warrants to purchase common stock">7,019,700</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, and accompanying Series A warrants
to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZTmd28bUka4" title="Warrants to purchase common stock">8,050,672</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series A Warrants&#8221;)
and Series B warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCXIC3WoAcM9" title="Warrants to purchase common stock">4,025,336</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock (the &#8220;Series B Warrants&#8221;)
for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zioWwupi64G1" title="Net proceeds">4.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). On June 18, 2025, we closed another public offering where we sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYXePnTaJ6j4" title="Number of shares sold">14,310,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, pre-funded warrants to purchase up
to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--JunePOMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zXWIl4CjZbd2" title="Warrants to purchase common stock">13,690,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, and common warrants to purchase up
to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrNMa5jWEqYi" title="Warrants to purchase common stock">28,000,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zH31S1JuM2Z3" title="Net proceeds">6.2</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). As of June 30, 2025, all Pre-Funded Warrants from both public offerings were exercised.</span>
During the six months ended June 30, 2025, we also received $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6EycM3aubbj" title="Received exercise of warrants">100,000</span> for the exercise of warrants to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjpAP6rnKIa5" title="Number of warrants exercised during period">400,000</span> shares of common
stock from the June PO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On August 4, 2025, we entered
into a Securities Purchase Agreement with an accredited investor and sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGdBVoKFE98" title="Sale of stock shares">5,467,181</span> shares for $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgX2dT0HbjF3" title="Gross proceeds">1.3</span> million in gross proceeds. We also
sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxqId1oMYKpi" title="Sale of stock shares">4,597,612</span> shares for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaplZhOhCk9j" title="Gross proceeds">1.1</span> million in gross proceeds under our ATM agreement. Following these investments, we are exploring options
to pursue a cryptocurrency treasury strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2025, we had cash and cash equivalents totaling $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_z8sFX0LwBso7" title="Cash and cash equivalents">6.9</span> million. Based on our current business plans, we believe these funds, together with the $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250801__20250831_z7xMLlYVDhXi" title="Gross proceeds">2.4</span> million in gross proceeds we received in August  2025, will
satisfy our capital needs into the first quarter of 2026. Our ability to execute our longer-term operating plans, including future preclinical
studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or
debt securities, a strategic transaction or other funding transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_z5RcCwaqmVAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z2Ef04Iwn7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2025 and December 31, 2024, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2025 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z5mNCpgeT9r" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Concentration
of Credit Risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2025, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTwDrg7o1fOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Activities And Organization [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zpg4GeMkaCLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zgJgUxTUru47" style="display: none">Schedule of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20250401__20250630_zcVscPdtSXu3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20240630_zNWAg5OJNjBa" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20250630_zz0NmpJrXoSl" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20240630_zfeZ7cIRtR03" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXLMkInpisw4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">45,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">55,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">76,704</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0KsLz1TPpK1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">194,635</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107,049</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">375,626</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">243,571</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zMEnZuIYZlhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">203,248</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEpTZk5XqTjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zH7Q6Wk69Jp9" style="display: none">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- <br/> average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvWyFtyJZn1" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">383,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3zFX1wdn3I5" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">19.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjJztqK9ZQnl" style="text-align: right" title="Number of shares, granted"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3gRvcQMP6Dj" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGhj3E7NGK11" style="text-align: right" title="Number of shares, forfeited">(27,547</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyxpE39co2y4" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">53.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Issued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zog80YNNHcec" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, issued">(74,804</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z95F34UP6Y89" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, shares issued">58.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP4ZmwMHp0d5" style="text-align: right" title="Number of shares, ending balance">281,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjAH2VNiTWka" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">6.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Vested and unissued</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziTIyR2gCLf5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued">(229,905</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHaDFq8RaBr3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">5.47</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CjqvEplxCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">51,380</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3NRGzVU0gql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant-date fair value per share, unvested">9.84</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Basic and Diluted</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3x6DRAv7bTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2025 and 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zccZWdZJXXg" style="display: none">Schedule of Net Loss Per Share Basic and Diluted</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630_zBQyRflVH45h" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240401__20240630_zZEaQ7g6xDdd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20250630_zDGNYNqEkei8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20240630_z8g5bxqfgZi6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zysC6SZSmFAl" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,933,918</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,010,326</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,768,323</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(5,736,707</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zCb25uWbxYNc" title="Weighted average number of common shares-basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zTwDq125EzHc" title="Weighted average number of common shares-diluted">15,569,312</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zNvcgA0igiBk" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zp8zBZE0AUk9" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zF5fdQcoEg1f" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_z7eXylfBtfhl" title="Weighted average number of common shares-diluted">12,401,583</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zILRm64pui2g" title="Weighted average number of common shares-basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zAw1NI5SyFzl" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250401__20250630_zOIbgKOcOOPe" title="Basic net loss per share"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_zrFAWidrfQth" title="Diluted net loss per share">(0.25</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zeLZqFlt6owg" title="Basic net loss per share"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zI493FwhU0hj" title="Diluted net loss per share">(1.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250630_zxYOMev6ukTj" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zk2QVSTHEkDh" title="Diluted net loss per share">(0.55</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zPKr7WdquEI1" title="Basic net loss per share"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z4ndRW4hLfN8" title="Diluted net loss per share">(2.11</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WqXw0ZfFe3" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJknADl25iA" title="Weighted average number of common shares outstanding - diluted">15,545,266</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgkP1uSqdedl" title="Weighted average number of common shares outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWsER6WVKnf" title="Weighted average number of common shares outstanding - diluted">2,849,192</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2zRbvhZdN2" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47QsL2S95J9" title="Weighted average number of common shares outstanding - diluted">12,371,909</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbFuJgrOAz4" title="Weighted-average number of common shares outstanding - basic"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVtH5Xkuytz2" title="Weighted-average number of common shares outstanding - diluted">2,590,530</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpW4HpMsiUr" title="Weighted average number of vested RSUs - basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znCVAMfgSTgi" title="Weighted average number of vested RSUs - diluted">24,046</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zXOEyX5ulBY" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5dk2uqVHA2b" title="Weighted average number of vested RSUs - diluted">134,091</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zauaD8l29EEl" title="Weighted average number of vested RSUs - basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFQYUsMAJ4i" title="Weighted average number of vested RSUs - diluted">29,674</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zyBHiDAhQWkk" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z48afxRmNlcj" title="Weighted average number of vested RSUs - diluted">134,373</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zhiqQOUVgcie" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zqX8kaF32rAj" title="Weighted average number of common shares-diluted">15,569,312</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zw9Dc8wccNm5" title="Weighted average number of common shares-basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zqursHq06uda" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zn05tG4uxtJl" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zwCe6TGM7vCi" title="Weighted average number of common shares-diluted">12,401,583</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_ziO6dS7M7U24" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zLjZFflDinS2" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zT9Ny4TA34dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have
had an anti-dilutive effect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zRiN2IsB6Ra2" style="display: none">Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250630_zkrQzxy8BfSe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zrXmypGTbojh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhWcCfvVdS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,747</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,747</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zvbHiH5u0Ly2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units (unvested)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zkblzalKdfj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants for common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,495,784</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,778,284</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zKarluVH0ZL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,549,911</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,876,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zFAc7SvHu3Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zrMCiHT3pKk8" style="display: none">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zfcTa1j3ilS4" title="Remaining lease term (years)">0.3</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUwp4wb4Xaq2" title="Remaining lease term (years)">0.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20250630_zO2uCxN12U9h" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Operating Leases</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmVtLUvJNSz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zLnf6mxeVquf" style="display: none">Schedule of Annual Lease Liabilities for all Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_496_20250630_zGllg7MuoUrj" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z1RKsd2fhLGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; padding-bottom: 1pt">Remainder of 2025</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">23,347</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zAuyxQzpP0y7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,347</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zRJVVVEdP7uk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,515</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zTDc6qM7A6cd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,832</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zxEYGDadTbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,832</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxJf5oAZUB22" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Financing Leases</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zAcqy1RIXNMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zlq9vwgmocMl" style="display: none">Schedule of Annual Lease Liabilities for all Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250630_z6TimV9Ft9Vf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zd98xICrM543" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_z5K4N946tx4j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_z1PuDZpzRuGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,920</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI5BdRRkDQnb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: Interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(168</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_znuLvlP8E0x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,752</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIRPnAxV9MDk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zj5p4XKBN0li" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl0872">Less: current maturities</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,752</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z2lW7IFlz6e6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zpm6BpzM4316" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityNoncurrent"><span style="-sec-ix-hidden: xdx2ixbrl0875">Non-current lease liability</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zgLCF8aoESJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zZufT0nPmGGe" style="display: none">Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zNWJzZLtLmsd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zlhsxvXSS1G5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_ztcVC35Ts9m6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zgt24ZWuv6g2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PreclinicalClinicalTrialAndOtherCosts_zCeH9ckbKyii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Preclinical, clinical trial and other costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,142,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,261,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,339,263</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,293,001</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zEGqH8EgqzUa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel expense<sup id="xdx_F4B_zhuy8nrNbSYi">(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976,554</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zHOLDxoMw79a" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development personnel
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976,554</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zaYLf3fhut01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative personnel expense<sup id="xdx_F44_zD8JbZyluxX5">(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,302,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,409</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zfAsZjvssMqa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative
personnel expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,302,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">964,409</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zxrqkYJC0j6k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities expense<sup id="xdx_F4E_zQc48XVSEdv">(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">875,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">905,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,459,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657,658</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zHBW9TZKFWJe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative and facilities
expense<sup></sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">875,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">905,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,459,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,657,658</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InvestmentIncomeInterest_di_zI9PgfScKSpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(16,865</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(71,698</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,450</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(154,915</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iNT_di_zsccqLLBMH54" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,010,326</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,736,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F09_zi09RiT0x1C7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zkJPd2W63f79" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense">8,613</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense">45,583</span> for the three months ended
    June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense">55,333</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense">76,704</span> for the six months ended June 30, 2025 and 2024, respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0B_zOEEghvgeZNi">(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zC8nYhvS8sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense">122,655</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense">40,309</span> for the three months
    ended June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense">245,310</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense">79,180</span> for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F07_zhvE94uaLy0i">(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z3J02240kkA5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
    &amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2025</div></th>
<th class="th"><div>Jun. 18, 2025</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,987,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,987,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,219,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,933,918<span></span>
</td>
<td class="nump">$ 2,834,405<span></span>
</td>
<td class="nump">$ 3,010,326<span></span>
</td>
<td class="nump">$ 2,726,381<span></span>
</td>
<td class="nump">6,768,323<span></span>
</td>
<td class="nump">$ 5,736,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,253<span></span>
</td>
<td class="nump">5,394,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,758,802<span></span>
</td>
<td class="nump">$ 6,282,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,936,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,936,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,191,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,310,000<span></span>
</td>
<td class="nump">1,030,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,690,000<span></span>
</td>
<td class="nump">7,019,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | June PO [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Received exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Investor [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock shares</a></td>
<td class="nump">5,467,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ATMAgreementMember', window );">ATM Agreement [Member] | Investor [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock shares</a></td>
<td class="nump">4,597,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_JunePOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_JunePOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2025</div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,758,802<span></span>
</td>
<td class="nump">$ 6,282,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes', window );">Stock withheld for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=PCSA_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">14,310,000<span></span>
</td>
<td class="nump">1,030,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Chief Executive Officer and Certain Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series A Warrants and Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="nump">13,690,000<span></span>
</td>
<td class="nump">7,019,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.2499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock withheld for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=PCSA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_SeriesAWarrantsAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PCSA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PCSA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 203,248<span></span>
</td>
<td class="nump">$ 152,632<span></span>
</td>
<td class="nump">$ 430,959<span></span>
</td>
<td class="nump">$ 320,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">8,613<span></span>
</td>
<td class="nump">45,583<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="nump">76,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 194,635<span></span>
</td>
<td class="nump">$ 107,049<span></span>
</td>
<td class="nump">$ 375,626<span></span>
</td>
<td class="nump">$ 243,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Beginning balance | shares</a></td>
<td class="nump">383,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Beginning balance | $ / shares</a></td>
<td class="nump">$ 19.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(27,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, forfeited | $ / shares</a></td>
<td class="nump">$ 53.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Number of shares, issued | shares</a></td>
<td class="num">(74,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, shares issued | $ / shares</a></td>
<td class="nump">$ 58.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, ending balance | shares</a></td>
<td class="nump">281,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, ending balance | $ / shares</a></td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued', window );">Number of shares, vested and unissued | shares</a></td>
<td class="num">(229,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and unissued | $ / shares</a></td>
<td class="nump">$ 5.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, unvested | shares</a></td>
<td class="nump">51,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, unvested | $ / shares</a></td>
<td class="nump">$ 9.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 19, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Purchase Agreement [Member] | January PO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="nump">7,019,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Purchase Agreement [Member] | June PO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants exercised during period</a></td>
<td class="nump">13,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, shares</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price</a></td>
<td class="nump">$ 409.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable weighted average remaining contractual term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense</a></td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">8,050,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">4,025,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_CommonWarrantsMember', window );">Common Warrants [Member] | June PO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_PlacementAgentWarrantMember', window );">Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsAndSeriesBWarrantsMember', window );">Series A Warrants and Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="nump">30,495,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum equity available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">357,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_UnrecognizedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_UnrecognizedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_JanuaryPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_JanuaryPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_JunePOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_JunePOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_JunePOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_JunePOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SeriesAWarrantsAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (3,933,918)<span></span>
</td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (6,768,323)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">15,569,312<span></span>
</td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">12,401,583<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">15,569,312<span></span>
</td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">12,401,583<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">24,046<span></span>
</td>
<td class="nump">134,091<span></span>
</td>
<td class="nump">29,674<span></span>
</td>
<td class="nump">134,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">24,046<span></span>
</td>
<td class="nump">134,091<span></span>
</td>
<td class="nump">29,674<span></span>
</td>
<td class="nump">134,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">15,545,266<span></span>
</td>
<td class="nump">2,849,192<span></span>
</td>
<td class="nump">12,371,909<span></span>
</td>
<td class="nump">2,590,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">15,545,266<span></span>
</td>
<td class="nump">2,849,192<span></span>
</td>
<td class="nump">12,371,909<span></span>
</td>
<td class="nump">2,590,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">30,549,911<span></span>
</td>
<td class="nump">1,876,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,747<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">51,380<span></span>
</td>
<td class="nump">95,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">30,495,784<span></span>
</td>
<td class="nump">1,778,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Weighted average discount rate for our facility and equipment leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease term (years)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term (years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 23,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">23,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(1,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">21,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">(21,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Financing Leases (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 3,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">3,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">$ (3,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current maturities of lease liability<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Non-current lease liability<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Operating and financing lease borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 22,461<span></span>
</td>
<td class="nump">$ 22,461<span></span>
</td>
<td class="nump">$ 44,922<span></span>
</td>
<td class="nump">$ 44,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Reimbursements received</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Due from related parties</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development personnel expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,447,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,730,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,035,767<span></span>
</td>
<td class="nump">$ 3,269,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,503,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,762,006<span></span>
</td>
<td class="nump">2,622,067<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,933,918<span></span>
</td>
<td class="nump">$ 2,834,405<span></span>
</td>
<td class="nump">3,010,326<span></span>
</td>
<td class="nump">$ 2,726,381<span></span>
</td>
<td class="nump">6,768,323<span></span>
</td>
<td class="nump">5,736,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember', window );">Reportable Segment, Aggregation before Other Operating Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PreclinicalClinicalTrialAndOtherCosts', window );">Preclinical, clinical trial and other costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,142,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,339,263<span></span>
</td>
<td class="nump">2,293,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdministrativeAndFacilitiesExpense', window );">Administrative and facilities expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">875,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459,839<span></span>
</td>
<td class="nump">1,657,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,450<span></span>
</td>
<td class="nump">154,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,933,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,010,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,768,323<span></span>
</td>
<td class="nump">5,736,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember', window );">Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development personnel expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">305,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,504<span></span>
</td>
<td class="nump">976,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 628,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 445,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,302,167<span></span>
</td>
<td class="nump">$ 964,409<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Administrative
    &amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Research
    and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense">8,613</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense">45,583</span> for the three months ended
    June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense">55,333</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense">76,704</span> for the six months ended June 30, 2025 and 2024, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">General
    and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense">122,655</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense">40,309</span> for the three months
    ended June 30, 2025 and 2024, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense">245,310</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense">79,180</span> for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AdministrativeAndFacilitiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Administrative and facilities expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AdministrativeAndFacilitiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PreclinicalClinicalTrialAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical clinical trial and other costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PreclinicalClinicalTrialAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 203,248<span></span>
</td>
<td class="nump">$ 152,632<span></span>
</td>
<td class="nump">$ 430,959<span></span>
</td>
<td class="nump">$ 320,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8,613<span></span>
</td>
<td class="nump">45,583<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="nump">76,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8,613<span></span>
</td>
<td class="nump">45,583<span></span>
</td>
<td class="nump">55,333<span></span>
</td>
<td class="nump">76,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">194,635<span></span>
</td>
<td class="nump">107,049<span></span>
</td>
<td class="nump">375,626<span></span>
</td>
<td class="nump">243,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 122,655<span></span>
</td>
<td class="nump">$ 40,309<span></span>
</td>
<td class="nump">$ 245,310<span></span>
</td>
<td class="nump">$ 79,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PCS12852 (Details Narrative) - P C S 12852 [Member]<br></strong></div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_TermSheetDescription', window );">Description of term sheet</a></td>
<td class="text">Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_TermSheetRemainingDiligenceDescription', window );">Description of term sheet</a></td>
<td class="text">The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_TermSheetDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_TermSheetDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_TermSheetRemainingDiligenceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_TermSheetRemainingDiligenceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=PCSA_PCS12852Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=PCSA_PCS12852Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_CROsMember', window );">CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 13.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_CROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_CROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2025</div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock shares</a></td>
<td class="nump">5,467,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock shares</a></td>
<td class="nump">4,597,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>193</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - PCS12852</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Pcs12852</Role>
      <ShortName>PCS12852</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/SegmentReporting</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Net Loss Per Share Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/RelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails</Role>
      <ShortName>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical</Role>
      <ShortName>Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - PCS12852 (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative</Role>
      <ShortName>PCS12852 (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Pcs12852</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>pcsa-20250630.xsd</File>
    <File>pcsa-20250630_cal.xml</File>
    <File>pcsa-20250630_def.xml</File>
    <File>pcsa-20250630_lab.xml</File>
    <File>pcsa-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="493">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pcsa-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcsa-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 165,
   "keyCustom": 28,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 22,
   "hidden": {
    "total": 65,
    "http://fasb.org/us-gaap/2025": 51,
    "http://processapharmaceuticals.com/20250630": 10,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 135,
   "entityCount": 1,
   "segmentCount": 46,
   "elementCount": 419,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 493,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://processapharmaceuticals.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999013 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquity",
     "longName": "999014 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation",
     "longName": "999015 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock",
     "longName": "999016 - Disclosure - Net Loss per Share of Common Stock",
     "shortName": "Net Loss per Share of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://processapharmaceuticals.com/role/Leases",
     "longName": "999017 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions",
     "longName": "999018 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://processapharmaceuticals.com/role/SegmentReporting",
     "longName": "999019 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://processapharmaceuticals.com/role/Pcs12852",
     "longName": "999020 - Disclosure - PCS12852",
     "shortName": "PCS12852",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies",
     "longName": "999021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEvents",
     "longName": "999022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999023 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
     "longName": "999024 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables",
     "longName": "999025 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://processapharmaceuticals.com/role/LeasesTables",
     "longName": "999026 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://processapharmaceuticals.com/role/SegmentReportingTables",
     "longName": "999027 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-18_custom_JunePOMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LiquidityPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999029 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999030 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
     "longName": "999031 - Disclosure - Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "shortName": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999032 - Disclosure - Stock-based Compensation (Details Narrative)",
     "shortName": "Stock-based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "longName": "999033 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "999034 - Disclosure - Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails",
     "longName": "999035 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_FacilityLeaseMember",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails",
     "longName": "999036 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails",
     "longName": "999037 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
     "longName": "999038 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999039 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30_custom_CorLystLLCMember",
      "name": "us-gaap:RecoveryOfDirectCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30_custom_CorLystLLCMember",
      "name": "us-gaap:RecoveryOfDirectCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
     "longName": "999040 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)",
     "shortName": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember",
      "name": "PCSA:PreclinicalClinicalTrialAndOtherCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
     "longName": "999041 - Disclosure - Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)",
     "shortName": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-04-012025-06-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative",
     "longName": "999042 - Disclosure - PCS12852 (Details Narrative)",
     "shortName": "PCS12852 (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-06-172025-06-17_custom_PCS12852Member",
      "name": "PCSA:TermSheetDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-06-172025-06-17_custom_PCS12852Member",
      "name": "PCSA:TermSheetDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999043 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999044 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-08-012025-08-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LiquidityPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-242025-07-24_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "PCSA_ATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ATMAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Agreement [Member]",
        "documentation": "ATM Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r531"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r697",
      "r698",
      "r699",
      "r700",
      "r748",
      "r792"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of stock award",
        "documentation": "Adjustments to additional paid in capital settlement of stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AdministrativeAndFacilitiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "AdministrativeAndFacilitiesExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative and facilities expense",
        "documentation": "Administrative and facilities expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r580",
      "r590",
      "r615"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r583",
      "r593",
      "r618"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r611",
      "r619",
      "r623",
      "r631"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r281",
      "r282"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r69",
      "r82",
      "r104",
      "r105",
      "r106",
      "r141",
      "r153",
      "r171",
      "r175",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r304",
      "r306",
      "r332",
      "r368",
      "r369",
      "r372",
      "r449",
      "r513",
      "r514",
      "r519",
      "r531",
      "r537",
      "r538",
      "r550",
      "r715",
      "r716",
      "r757"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r86",
      "r104",
      "r105",
      "r106",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r304",
      "r306",
      "r332",
      "r531",
      "r715",
      "r716",
      "r757"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "AssetsNoncurrentExcludingPropertyAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-current Assets",
        "documentation": "Assets noncurrent excluding property and equipment net.",
        "label": "AssetsNoncurrentExcludingPropertyAndEquipmentNet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization",
        "documentation": "Business Activities And Organization [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "PCSA_CROsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "CROsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CROs [Member]",
        "documentation": "CROs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r80",
      "r497"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents - End of Period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48",
      "r103"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Decrease in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r48"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "PCSA_ChiefExecutiveOfficerAndCertainBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ChiefExecutiveOfficerAndCertainBoardMembersMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer and Certain Board Members [Member]",
        "documentation": "Chief Executive Officer and Certain Board Members [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDisclosuresAbstract",
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r83",
      "r84",
      "r85",
      "r104",
      "r106",
      "r130",
      "r131",
      "r134",
      "r136",
      "r143",
      "r144",
      "r182",
      "r204",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r224",
      "r227",
      "r228",
      "r231",
      "r234",
      "r241",
      "r332",
      "r408",
      "r409",
      "r410",
      "r411",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r437",
      "r457",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r639",
      "r693",
      "r694",
      "r701"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r143",
      "r218",
      "r227",
      "r228",
      "r229",
      "r231",
      "r234",
      "r239",
      "r241",
      "r312",
      "r408",
      "r409",
      "r410",
      "r411",
      "r520",
      "r639",
      "r691",
      "r693"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "verboseLabel": "Weighted average exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r107",
      "r242"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Number of warrants to purchase shares",
        "terseLabel": "Warrants to purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r63",
      "r373",
      "r436"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r202",
      "r203",
      "r492",
      "r711",
      "r712"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum equity available for issuance under the plan",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r697",
      "r698",
      "r700",
      "r748",
      "r790",
      "r792"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r437"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r437",
      "r455",
      "r792",
      "r793"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 100,000,000 shares authorized; 40,289,356 issued and 40,284,356 outstanding at June 30, 2025; and 3,707,628 issued and 3,702,628 outstanding at December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r216",
      "r223",
      "r375",
      "r531"
     ]
    },
    "PCSA_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "PCSA_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]",
        "documentation": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_CorLystLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "CorLystLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CorLyst, LLC [Member]",
        "documentation": "CorLyst, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18",
      "r96",
      "r498",
      "r499",
      "r501",
      "r503"
     ]
    },
    "PCSA_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Annual Lease Liabilities For All Operating Leases",
        "terseLabel": "Schedule Of Annual Lease Liabilities For All Financing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r247",
      "r276",
      "r277",
      "r279",
      "r523"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r564",
      "r576"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share - Basic",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r93",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r130",
      "r134",
      "r135",
      "r136",
      "r140",
      "r214",
      "r280",
      "r297",
      "r302",
      "r325",
      "r326",
      "r367",
      "r380",
      "r505"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r134",
      "r136"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share - Diluted",
        "verboseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r93",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r130",
      "r134",
      "r135",
      "r136",
      "r140",
      "r214",
      "r280",
      "r297",
      "r302",
      "r325",
      "r326",
      "r367",
      "r380",
      "r505"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share of Common Stock",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r137",
      "r138",
      "r139"
     ]
    },
    "PCSA_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "EmployeeMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee [Member]",
        "documentation": "Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "PCSA_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "EmployeesMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "documentation": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r73",
      "r74",
      "r75",
      "r90",
      "r91",
      "r92",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r142",
      "r183",
      "r184",
      "r195",
      "r213",
      "r243",
      "r280",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r301",
      "r302",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r355",
      "r379",
      "r401",
      "r402",
      "r403",
      "r416",
      "r479"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r580",
      "r590",
      "r615"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r577",
      "r587",
      "r612"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_FacilityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "FacilityLeaseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease [Member]",
        "documentation": "Facility Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r352"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Financing Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r692",
      "r696",
      "r759"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r692",
      "r696",
      "r759"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remainder of 2025",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligation",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350"
     ]
    },
    "PCSA_FinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "FinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability",
        "documentation": "Financing lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r619"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r619"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r619"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r619"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r619"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "verboseLabel": "General and administrative personnel expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r459"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r308",
      "r309",
      "r310",
      "r311",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r335",
      "r399",
      "r400",
      "r464",
      "r494",
      "r495",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r746",
      "r747",
      "r761"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r308",
      "r309",
      "r310",
      "r311",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r335",
      "r399",
      "r400",
      "r464",
      "r494",
      "r495",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r746",
      "r747",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r407"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r102",
      "r289",
      "r290"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "PCSA_IncreaseDecreaseInDueFromToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "IncreaseDecreaseInDueFromToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Due from related parties",
        "documentation": "Due (from) to related parties.",
        "label": "IncreaseDecreaseInDueFromToRelatedParties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r688"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r584",
      "r594",
      "r611",
      "r619",
      "r623",
      "r631"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r565",
      "r634"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r565",
      "r634"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r565",
      "r634"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r100",
      "r101"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r156",
      "r175",
      "r513",
      "r645"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754"
     ]
    },
    "PCSA_JanuaryPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "JanuaryPOMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January PO [Member]",
        "documentation": "January PO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_JunePOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "JunePOMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June PO [Member]",
        "documentation": "June PO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r530"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining lease term (years)",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r750"
     ]
    },
    "PCSA_LesseeOperatingAndFinancingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "LesseeOperatingAndFinancingLeasesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "documentation": "Lessee Operating And Financing Leases [Text Block]",
        "label": "LesseeOperatingAndFinancingLeasesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r692",
      "r696",
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remainder of 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term (years)",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r104",
      "r105",
      "r106",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r305",
      "r306",
      "r307",
      "r332",
      "r435",
      "r507",
      "r519",
      "r550",
      "r715",
      "r757",
      "r758"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r64",
      "r377",
      "r531",
      "r537",
      "r538",
      "r691",
      "r695",
      "r709",
      "r749"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r79",
      "r104",
      "r105",
      "r106",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r305",
      "r306",
      "r307",
      "r332",
      "r531",
      "r715",
      "r757",
      "r758"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity",
        "documentation": "Liquidity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Total",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r50",
      "r65",
      "r75",
      "r77",
      "r87",
      "r88",
      "r92",
      "r104",
      "r105",
      "r106",
      "r109",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r132",
      "r182",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r217",
      "r220",
      "r225",
      "r280",
      "r297",
      "r302",
      "r326",
      "r332",
      "r378",
      "r456",
      "r477",
      "r478",
      "r500",
      "r502",
      "r504",
      "r548",
      "r715"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r95",
      "r117",
      "r118",
      "r119",
      "r120",
      "r127",
      "r128",
      "r133",
      "r136",
      "r217",
      "r220",
      "r225",
      "r302"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NonCashLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "NonCashLeaseLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net",
        "documentation": "Non cash lease liability net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OperatingAndFinanceLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense for right-of-use assets",
        "documentation": "Operating and finance lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturities of lease liability",
        "documentation": "Operating and finance lease liability current."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liability",
        "documentation": "Operating and finance lease liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OperatingAndFinancingLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate for our facility and equipment leases",
        "verboseLabel": "Operating and financing lease borrowing rate",
        "documentation": "Operating and financing lease weighted average discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r500",
      "r504",
      "r508",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "PCSA_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "OrganizationTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r81",
      "r371",
      "r514",
      "r537",
      "r538",
      "r550"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense), net",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related parties",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r710"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r582",
      "r592",
      "r617"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r585",
      "r595",
      "r620"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r585",
      "r595",
      "r620"
     ]
    },
    "PCSA_PCS12852Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PCS12852Member",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P C S 12852 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r599"
     ]
    },
    "PCSA_PaymentsForSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PaymentsForSettlementOfStockAwards",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of stock award",
        "documentation": "Payments for settlement of stock awards.",
        "label": "PaymentsForSettlementOfStockAwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay taxes on stock-based compensation",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "PCSA_PlacementAgentWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PlacementAgentWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrant [Member]",
        "documentation": "Placement Agent Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "PCSA_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PreclinicalClinicalTrialAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PreclinicalClinicalTrialAndOtherCosts",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preclinical, clinical trial and other costs",
        "documentation": "Preclinical clinical trial and other costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r227"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r437"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r227"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r437",
      "r455",
      "r792",
      "r793"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 or December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r216",
      "r222",
      "r374",
      "r531"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "PCSA_AssetsNoncurrentExcludingPropertyAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "verboseLabel": "Net proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r408"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Received exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r366",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r496",
      "r499",
      "r502",
      "r504",
      "r521",
      "r522",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r640",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r713",
      "r714",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative"
     ],
     "auth_ref": [
      "r178",
      "r366",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r496",
      "r499",
      "r502",
      "r504",
      "r521",
      "r522",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r640",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r713",
      "r714",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "PCSA_PropertyAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PropertyAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "Property and Equipment, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r353"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r353"
     ]
    },
    "PCSA_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r696",
      "r759"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories",
        "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17"
     ]
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RecoveryOfDirectCosts",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursements received",
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r566",
      "r577",
      "r587",
      "r612"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r109",
      "r359",
      "r360",
      "r756"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r109",
      "r756"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r109",
      "r181",
      "r359",
      "r360",
      "r361",
      "r460",
      "r461",
      "r464"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r362",
      "r413",
      "r414",
      "r415",
      "r462",
      "r463",
      "r464",
      "r483",
      "r485"
     ]
    },
    "us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReportableSegmentAggregationBeforeOtherOperatingSegmentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Segment, Aggregation before Other Operating Segment [Member]",
        "documentation": "Aggregation of reportable segments before other operating segment. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "verboseLabel": "Research and development personnel expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PCS12852",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r493"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r578",
      "r588",
      "r613"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r568",
      "r579",
      "r589",
      "r614"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r586",
      "r596",
      "r621"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r57",
      "r376",
      "r404",
      "r405",
      "r412",
      "r438",
      "r531"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r183",
      "r184",
      "r195",
      "r213",
      "r280",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r301",
      "r302",
      "r313",
      "r315",
      "r316",
      "r318",
      "r324",
      "r343",
      "r344",
      "r401",
      "r403",
      "r416",
      "r792"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New right-of-use asset",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r530"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Loss Per Share Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r134",
      "r136"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r353"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r109",
      "r359",
      "r360",
      "r361",
      "r460",
      "r461",
      "r464"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r279"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r55",
      "r56",
      "r57",
      "r83",
      "r84",
      "r85",
      "r143",
      "r227",
      "r228",
      "r229",
      "r231",
      "r234",
      "r239",
      "r241",
      "r312",
      "r408",
      "r409",
      "r410",
      "r411",
      "r520",
      "r639",
      "r691",
      "r693"
     ]
    },
    "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases",
        "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r141",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r180",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r200",
      "r201",
      "r299",
      "r300",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r510",
      "r513",
      "r514",
      "r518",
      "r535",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r141",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165",
      "r167",
      "r168",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r509",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesAWarrantsAndSeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "SeriesAWarrantsAndSeriesBWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants and Series B Warrants [Member]",
        "documentation": "Series A Warrants and Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Beginning balance",
        "periodEndLabel": "Number of shares, ending balance",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance",
        "periodEndLabel": "Weighted-average grant-date fair value per share, ending balance",
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, issued",
        "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, shares issued",
        "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average grant-date fair value per share, unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants exercised during period",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, shares",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable weighted average exercise price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation, shares",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r76",
      "r141",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r180",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r200",
      "r201",
      "r299",
      "r300",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r510",
      "r513",
      "r514",
      "r518",
      "r535",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r83",
      "r84",
      "r85",
      "r104",
      "r106",
      "r130",
      "r131",
      "r134",
      "r136",
      "r143",
      "r144",
      "r182",
      "r204",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r224",
      "r227",
      "r228",
      "r231",
      "r234",
      "r241",
      "r332",
      "r408",
      "r409",
      "r410",
      "r411",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r437",
      "r457",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r639",
      "r693",
      "r694",
      "r701"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r42",
      "r43",
      "r73",
      "r74",
      "r75",
      "r90",
      "r91",
      "r92",
      "r110",
      "r111",
      "r112",
      "r114",
      "r121",
      "r123",
      "r125",
      "r142",
      "r183",
      "r184",
      "r195",
      "r213",
      "r243",
      "r280",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r301",
      "r302",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r355",
      "r379",
      "r401",
      "r402",
      "r403",
      "r416",
      "r479"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r142",
      "r215",
      "r216",
      "r218",
      "r221",
      "r344",
      "r366",
      "r406",
      "r417",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r502",
      "r504",
      "r543",
      "r791"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r142",
      "r181",
      "r215",
      "r216",
      "r218",
      "r221",
      "r344",
      "r366",
      "r406",
      "r417",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r502",
      "r504",
      "r543",
      "r791"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r570",
      "r581",
      "r591",
      "r616"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsUnauditedParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement, shares",
        "verboseLabel": "Shares issued in connection with license agreement",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raises, net of transaction costs, shares",
        "verboseLabel": "Sale of stock shares",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r39",
      "r57",
      "r408",
      "r479",
      "r487"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r39",
      "r57"
     ]
    },
    "PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock withheld for income taxes",
        "documentation": "Stock withheld for income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r42",
      "r43",
      "r57"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raise, net of transaction costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r39",
      "r57",
      "r416",
      "r479",
      "r487",
      "r549"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r38",
      "r39",
      "r57"
     ]
    },
    "PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor",
        "documentation": "Stock issued in connection with licensing agreement which had previously been recorded as due to licensor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r42",
      "r43",
      "r51",
      "r439",
      "r455",
      "r480",
      "r481",
      "r531",
      "r550",
      "r691",
      "r694",
      "r695",
      "r709",
      "r749",
      "r792"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r226",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243",
      "r312",
      "r323",
      "r482",
      "r484",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r364"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r364"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r364"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r364"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r364"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r365"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "PCSA_TermSheetDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "TermSheetDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of term sheet"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_TermSheetRemainingDiligenceDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "TermSheetRemainingDiligenceDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Pcs12852DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Description of term sheet",
        "label": "TermSheetRemainingDiligenceDescription"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r755"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfReportableSegmentProfitAndLossIncludingSignificantExpenseCategoriesDetailsParenthetical",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock shares",
        "periodStartLabel": "Treasury Stock, balance shares",
        "periodEndLabel": "Treasury Stock, balance shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 5,000 shares",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r39",
      "r42"
     ]
    },
    "PCSA_TwoThousandAndNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "TwoThousandAndNineteenPlanMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Plan [Member]",
        "documentation": "2019 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "PCSA_UnrecognizedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20250630",
     "localname": "UnrecognizedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized share based compensation expense",
        "documentation": "Unrecognized share based compensation expense.",
        "label": "Unrecognized share based compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r145",
      "r146",
      "r147",
      "r148",
      "r368",
      "r370",
      "r506"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfDilutiveSecuritiesFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r544",
      "r545",
      "r546",
      "r547"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted",
        "verboseLabel": "Weighted average number of common shares-diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r136"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic",
        "verboseLabel": "Weighted average number of common shares-basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r136"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001493152-25-011685-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-011685-xbrl.zip
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M9'O_=;W2=%D?'9&HB>4@&@]U83\/X3X%B9?]2:@GRREY_5:+A=46P 6N\'X
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MX9K*2TN^;9)SO0/IHCE=,/<WSNEB^C]02P,$%     @ B$8'6]"\>78&!0
M[2P   H   !E>#,R+3$N:'1M[5IM3^,X$/Y>J?_!5PD$4E]AN9>V6ZG0LMM3
M#WJT=Z?]Z"9.X\.U@^TL]'[]S3A)*2^WN^RU0%$J04ALCY]Y>=R9(>V/D]^&
MG6*A_;'?[<&5X*<]&4R&_4Z[EEQAM)8.MX_/>Y_(>/)IV']?"I2T3=*H1Y9,
M^)P9<L:NR86:4UE.'I3)F&D>E& A+!T]=5V+S*F><=DD.'7Y4^JT3\_/)JO2
M*@&=<[%H?DV>FVOX/RS9'B0==W;EU$2M=NT8]$6Y<!FM%W"+6'9C*U3P&0QI
M/@OMFG7HWX1\RFVQ<'A0;3R?*AZ3ENEUZI(YXSG0_QT;RX/%FEWQE^;6,EDL
MC"VU; X6(BH@-F3D).0L(/T;YL66?V;D/ BXQS2ATD_'3KFDTN-4+,=&L38Q
M!1E6D<;/Y(_JN'I2);N&>;;5.#RJY[Y^,5^/E6!B42P$2COW1K&.E $1X&Y/
MS2.QX')&KKD-'_5<F0S*;ETL?:8-H&3^?X8(B!QIY3%C*!F%5,^IQV"&1P4
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MYSI\(G0UG*<A?7_<' $=^A_J8U65SF45>7"7 #H5E[+0DQ7XIFM-%6W$'\Y
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MO@B,GT+=:I'0MKASBU;:MRIA/UEKR5+WCMBAN9"% 9E[7"JVMIFAV[;,G]E
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MOM,T4]5, +]'XS&_1'U$9=5'5"AJ]4?0JS\B !=<,?HC G 1XQ%T "[B/"(
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MVKJF(D=<&1, .N5CHH'4(^04^1409X(I$+C"=TZ\I\_P)H70M)(#CN*1!-^
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MX*,N*'B\)TIDF , 3;@X.=):]!YI[71)P<N-R>'6.WJ8NP])#[[]3Z% G,M
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M?^!2-UR?W;:&$/8Q\GW:$$RY#Q6-:A)35!$NKB;\T#O9!%NO 5T;X6O^T)L
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MU2+JD45=0CSN#?JX'E3&]T8#T$5NTM=3700AM#@V%(+H0T^XJ(.F"D@?0VI
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M4H$);\F*)@X03T!V)(:N*(%T !KQ2#G+L>@A#F@9.(BX03J6>-(M" L%5Z;
MZXEU_2 ,.Z;8P^I2"DTXH%>]DH@]KQQRBX=EGSU%@0_"/G98=2=*>E*_#ER0
MD\"NQC6S3..1)I:L[-^QF?IS81)LSE2M%U+92J\1;9P3@8)!X1SE.E<$NYP6
MVMU<XN[Z4BC"5%P,4^'#"6S%E+1JRJ2A A%\D5TT0<OKV.VRFP,3QB$L0?PB
M0D@BGV. $]CNN=6V%OJ:/0(NP7;-W25ZAJ(#X$^QVA6OUUS:6RCN">?F/&0=
MW,<6HBB] 048L_I,/)'::8XQ0;!XUQ73ZJI]KQL]/)$C8!,NF":)LG4-#1PZ
MBQX[+/=5-5"1LE>ES Z>U[;"US=D-2[&E$:P6<2PN@&M"7-2R(:2]8LR^'Z6
M@F!R,%L@'\XG. T",0V>,-VMU$0)RRV/'UJ(7]'Z0RJ<X3 9L+'D+A>1N0@L
M!CV3P*^2A^8:4,RV^ (#],'V:2-O2BZ[.GB"+0;_0?@SF#C20I$ GW\A$!QL
MHB3G!!Y"0#("[602Q%*<H6[DX" Z)@'B(U1BC.@J:W=GQ#=1U0C'!"385GNO
M]8H:+80ORXW:=A%O1+29=9OD1A(F8*+#<A!W5B5"VB #DI<C"&&BA] %ZD"G
M(&3(\#T#=2C)GB+ Q"A"R 2\MC03H'R(#O9XD8($L%;*+=<-(X(#\>^HRA=[
M")?GXL2![/Q#D<4\R)%DP 6?'/1+X] LW-0,LAQ_]3 1A21RB0SGC _"\.2P
MCY--I2(\TC(<.RH(/$0$TBDX#%F$Z@BGPR@\#V5SR92E<'"ANM#)&Q7%2M0'
M(1A HBC;&L5_(.@,EHI&%1,_"I'0EKN;V"T9A+=+%>K\@.#R\*.1TH&6RFA:
M$*.'0.SU?+C$T;>">$Q43:+TSQ%EU"8*Q':Q_,BA"5AYXW8FQ(RPJP@CX^LQ
M1V?F$F4<TL.AA3-OP3(_O51=-*I=38B",=]9F,@**T9$32L"9]<,A%?"#SX/
MR]=2\UU\[=TWU U!L2-@=; ,A"+S%K+%K%NC(W&BYR@,G6OU38.F3-%1&<I8
M &>6XHMB% T%)'%3?+A9ZGF9&*ZS&2X\9SJ:8N7H<"[^L&MI(P8HLV/!"%5<
M+B+C_''D#A/AQ*BFIG10SE+L3Q^J>1K4U!$  @)_NNMS,G6T+0II1'UV5#/$
MJ*:@]X%H64R4C',3L'EJ^N]002T%\B-YS$@#EP_UD:=+F%[J(="^C?JV3],E
MZ915 A,&-OL'L["M*-G0RN[UF5%A>G""I$L[IQ!'D2(OR>379%8Y4!\^,B_S
M3BRR I.V>L#'L6F!ILB= )RJ!@-B%KHHN6I/-26GAT:'A!-\("T0PA'IP'RI
M[L?+3H/H.CX' R',K O4*A%U2/6C!U(,ZV A0V-D]?0%%795LGU7=S(D[Q;+
M=0JM-])OBH+7W8H?X^%<@]D92:\\#PL'[7SIY%VOGA4V21/2!>5N\61NM> :
M:<$'Q04R9\#\O@2-ZP_0N&ERMT8?3DJUE.<Y;V<YLK.[N+7</@9\:'^!P&"B
MJ?BN@5^MP."EX1D"(,LNX*D&5'K88\<<>"X _J*EV.^(J8>O$ZA8+@SV&G0D
M\#.^^J8*D=SP."9X.JY*\/2E9'1T((V<"U/">QS\QPC4)AD@!L[[/;!6D:-J
MA<1",16&4!,CTIIK!!#0;/\%,J$<B^"B>RR[%,79L+4RH%EP[2SBSN]HZHNB
M#7; '-!W4!<3NX#$J5J*KK352 "!PN6Z7F7<% E^^)NJO -%V*V:1IT^$IY6
MW:@S!?P+!"0\C#\% 2/):JEC#<MUL6150G&,!(K:9U(OFRT-[C")*X>''([W
M3J&:CYYPK__?"4. OW8/%1Y]+Y_+:[= #$$2Z:'Q%(J3WU9D#VN86)TLT*!2
M0&5V[G($,)(<T7X?$>L]HQF#+#NVL4.B*QY,LQ\-PF-"90,)+-'<G(AUN!>,
M#+ YDJ)"W?"N=>@;.3(</4,8S&"F*YZ"$#R^)Q#BL3;9B7WW 3<#L)CP"?(H
MGG9_'113^A,=C]2)<+5M&^@%9KW5MEEOR\]Z6[CC48XZ'DT,@NHV]>FN5>NE
M26JV\$]C&IZ->>MY6.Y=-/L=Y;9N;HCW,;Z;1&BM:''1M7*XV&V#SXU&(O;:
M?.=4OVR6W0H9F-Q 8R7NW3#-K[ "G8FE(&^04E3*&Y@G04)H8-+B_7N/]M-Q
MH=V2;N]V<P\*YX"E#'.DJ2VDUV6PPV5+U%^H3Q+LBP9TM!T:E2$N6%?M=+VY
M$#N!6#,:RYG0,<D,#7!BB,'K#FM[A5;)(36\<OOLD1/=O71NN@U-L7?:X?Y)
M\QO#5&1WW]CA H-[!/S<)M?OL+ZNHI&Q<>5L]G84L@!$-;FEYG!4=Y#/8](L
M7JZ/]+2$^0;:49J&;N!%%F'P--TM&Z$&!-,-]3R\?=\W.U5#:%^*&Z("B*1'
M! EPJH/MQD.KW0:EUL@-Q8.2PQM[XO#!_VDZDR?2@UWC;VP0F*(I6]R>@7US
MW,:/AXV;/;_SHYN-9+&G.4NQR>LM@^3QDAMV\+[>PQTP@QRRF[OKRVY@GDP'
MOA _DV:@I3*[9NCU'+S^(+$NEK"DLL1M$L#2XT>BG_06U;BY<]=$] EM080-
M#'&*&#O" ,^X5;#K(J(:F-?-?%:6FL9N!Z:\$/-GXU^BF.3(H>-.$T.2YT13
M(3')C 24W'P)D_C8X(_[#1C9Y/0Q\XMK04ASO$;O.7;'B_* U"SO/P\?KSK6
MG[U>2?FYH-@[=? V7F'5HPKK)I#=1Z%,$'%IW[LW3=!4(2RCU&,\#X5.]_"F
M]KC_(K4V1T6U?N!Z<@4OPA8N/ZD5]IZ'/?7FN+=W(/;ZPI<?-S$IDY0PWG:W
MM@[,1JP*-I\XHP3JANPK-4>V^[?^M@K%&\BE!&]CJI!&B-VZZ'CTPW\^$Y7B
M]MV/O@:CK=%H[-2K#@5C$X.V7S#"&(C,IA\_)H;[A84K_;!MVN$62&-;7I-9
MU2O5>B;36EVH\%(G<_9:6X4^F?A6G2TZ</ZS14#/&K1_[^SA517O]8^3EPWM
M<E6?#_MV8I<KP@9S-*9:7:^>53:FVC?N3TN]ES/E>#SX^!HT)\F@%U5]/HR?
MB;VH)O)@<ONH6/SK>);<6Z/>.=FWCY+;IZWKQ[/2[VYE/#AX.ORIC6@<54\+
M#C1CXZ@)?,F%NCA-P8E+Z-JWPBY.@W:K,K@Z_W787?_&#-EV<:K/B2$[J8O3
M)'Y,A2Y?7I^62H\%O5J0Q%K-EC:GI5(]"U"1,2V5R";/#PCOU2,P'#.1:V&U
MM-*&N<,YC'8T"O;L8DX!F<C5I7?EX#H\F3E2&+9G> Z*[(N%OJG2*X2Q2/!T
MEXE8N\(7P!XGYRA)(,[*HT>-R\%/47"N+MH)@(YTOGV\B\$)3/0D$B:>RI9+
MP:"5_&P> _#EE2N)\KL5H3R606E"L7>33^[U*?H?9<>1O:LO?^_&HCIZ^.M=
M56D?$ @=]0V>:\-\3$2+HG64Y J.CN=U'GH[[%3$H^J!,]#6EB4\?/1IEQ?A
MI=DL_S O5>O5R<R$\J=)#7RO((E,GO-FS['ITVP4!@O2(G>D/;H$[KUK4/P,
M2>V+@5(Q5\[1W'#/>\"!]L@4/ .%]+D@]W[ OE[O@6295)MDR[G ]F1GO5]Z
MEHF0-=//X8P 7\0;04/Q^.KDZ,YZU!4E:M-%B#23(3>)1AD<A)1+C;#_; Y&
M1)2.9WY/2L3WP2(=5@)X'P%<$<PB-XTW4>,Q/B=UN7?18@A!>#D=2E /OH9X
M.Z1$%#L?:E3/N]T/(P?$.Q:DT ),"A7G2=]C[Q3S7HKXJ"\4?8V%&]G7JJ'Z
M$S(/OQ--7-R)!!O)D295,FXWQE 3FN]<,#)+,G^W@?$-F]6R,XRVC+*]09GU
M!F6D=VSLC4A^77K"_KS]76L-VM5^4][,GK"5_*)[PB[H2N1P+5JY+NQ*)-]Z
M4#]ZQ\.RL_YAOQ#/S7T_4LDONO7J!([<';T@&=\^-8X]ZTMLGYKLD2RH'9K^
M</)ZT]7:%\:?-;X=F;-I*FEL!D0/,Z>PZ.:IF42E2^O3\U0I[;\_]!_5EZ/2
MQO0\K0@+[GFZ!E%I,+0B(6G2AHB86PB<XSG1L?=T8Z0C%PE$)\9ZFE/%,+/A
M1O'R_>;7W<55K9C486W!P<;I63&+H$DA9="$Y0;$F&29[?IAM)\H(5O&^YR%
M#3=4+_:NBC<'^>XO/P> S#A=:,Y?W)+L)F$V2S["*:5Z8BN%,*_0V%;4,IHB
MUEO.+M:;,=/,:ED-[<:A<2:>EG^J(U;[*@.[B[&$9C/39Q9,6.W3ZRFR"GN#
M8&R4%B1'&&43"XNV\68#\3\L'V55!6?<5#LJN5=C)@3EWCC7,\K!="*)7#PQ
M#VIE7#R'Z,O_O/YU<2_6SJ_6ZH(B8X%9R.)J%P9*;(=&6,?%"B1@_0D<3$PO
MEOL?M?ZF<#J;BW<ZE\*5+@4:2("HC+V]5LX*8LWZ=2^,Z\6]EF[HA%NU<0N/
ML.Y\.:0"+Q2F\4+#]K^=4L$7-UHTCF7":BE_=WG4?/Q3+Z^M@,R,U[+P0(KC
MA63 JMQW\=E3%$S%'?9Q*05D/@39JQE D@TPTM[ ?^2*0L<VX"ORA:%?$EA8
M&G(X\2%#W*V2W;0#KY<7MEZ+L2GI"/A]<+/Q[CR%75D<-'[O?QS6'*,X3N9Y
MM[8NR#W%MT_EJ2R(*LDI@VZC,2P7'F><1IAQSJ30J8)O(X&W&9J&NXM9)'O\
MJE5/55O_=6_Y,39W-A3MUY-) 7:9K8F<^^W,-S:M.Y$?Z4<[?D^I 39/"L3V
M8GO39_579T!X):_YW<56[<ZU0=X<LR\M_@3I$5&]4YVY)#2L?]+D]![T^IHQ
M4!3/&'F0>T5+,][;4C@NRF!R%E[]&:=@PI,,JY;B?'=VU1)?RX\O,$@P&;"=
M*)L7;#K!;FV/V*<'SXJ70#J.,.27#ZK=15"U0\/T,. 3]G9X>'-P,GRW3AI&
MQ]\G,J]W-LH(I'?2SETU;QKCMVW,[,9M9!@S)K1I\WFXA2)?K=02;8*$#8LC
M#)H/AR?-!L,I-]X1TKK/@(&#G0P))[#F#G3\[_CR>BJ%]50#ZSFKO]IZ6,\M
MV1H($PP$(2,#(6W,K6GHB)\&@WOQ)L\]51N'U_N%CGK0ZZZ/P9 \X8@>FJ\J
MNESA"^6T)=$A741;1>D4=IY"NTK>G ,->W=CY09#Y\X<%VBI$$"IX>#K6SCX
M!<+!U[=P\(N%@__L2%X+1I2L%$<@D'W<Q\MV,*A]31/GFH9E6R,Q;2L)9S(8
MY9USY.?AZ^EKY_3(O/UY_3(?^F2J_27LE3D*93$1A?+P>2BT?E;@]!5^]C2&
M0LFZ]P7)M2H,RFUWZ@PK=FBU3AVOX_"_T4;MK*+2;12/O7]DHT\:QZ./3.X7
M+$ODKN"X]$1)<8BRL[@37=HE0W*7/1V<:XOAEN(O$)C_#=[58'G!?%9\/(<_
M];-9,<&'C$(>)GVK+,Z!I=)D6>J^F\R^8HFN%",:_K)/?H/U]Z1--EIFJFTK
M"L4=-MH\!G=(W\T.O4EP$TAS1I_U@'>[QK-^D8X>^(&?2>OB3OO'1'PGT,[A
MX!%MT.RV(E6\(FZ#%G'#$\PX%!E@<DYV5Q"E!.Z)*BN65R@N=L"8["".=!!R
M>AQ<!+W.(6>[2;O74WOW6K$4$S;\T# /25,C]]X(;_+[*KDC%>J8.Q;P+'!2
M:'*$'8K;=^.V:S@6+*6ARQ>JK@#U=7S6=2LZ^</&2;5V_J#X;L6Y^*'VG!YI
MK( =J+U&V22@XZ[.9X ^C#?QAG[:Q<;=S@MU<COOU5=/6EY$P<U7$E.;<$,V
MKA8FVM*.%.61'+G%7+2[^39D2@UW_X#&1WC. ADA(>]T5AZZ/]D?Y(^JMU=E
M(>J:AGF']>CJI+HY7=3JD],^?+]V.L8JS1<:+Y:K?*F0?)UN323EI^^BOB%M
M(L;W00I]A<Q#QFZ4A*W_H>)4 TYCYEXNR/7< :U1\:BRY*Y)*]CRK-V;TDC+
MX!NIJ\@.J3R)%S78*Q$4X"T>N@2OIA[,OY]MP.=AOU,Z4LY?Q.;98J'T5V?F
M/B@YK_-JT$H+MB+W6CZZ%I7=-15Z<S0^A8T\@BUA.=%B@-_6)\;U#ON*>V6P
MX4X[=Q^W=Z93JGK\(ZL6F&7P,3A$*%(8:Z)YDN1-C@B9"(!XBGA=>O*FB^Q%
M <1#JQJ]HZ%!K]%KFKCV'RY1,?;F/\G6Z(7/A"#]@W<:,%VDTO^^%+YXFU&J
M']"@?RE\ARS=6]*5;-\\.L5H9#,QF!HW91QQV@EGMS8!5U3RUE:B:[MX:'3*
MEZ<7?_;$>==66MW:#I_C[OZ'^8M>_]1\-&ZT#=ZW!MTM(;QO;>6I*IU<V]?Y
MN7ER^GT;O9==AY-<F8L0MT1;G5,M=1#24DO=^_E6<0.:-ILUK.<>%S;N(&^8
M3-U2-^VI\"1T*"C8 /.5=+"+=R&8B?;<]5Z@.6)>YON903OBT1B.]Q2&V413
MZC9T>5]Y4S2C3]+DZ6@>]O'9^<N)WE>M]]*7\8<VSM0W.ZVOA7R)+Q1K?*%<
M_C9ZL)EA5\(;V]$+6'>*K%&=-\DHC=DHA7_'[V[X*2'V4_]*&%.(/FYBI="D
M0%6Z+4M*K"B%$RO8H,\I-BSBWZ9-L1A)_:_Q%:$8$WV*)U$L0>-/Y&?:J9*W
M4Z6Y=ZHRZTZ5RGRYMMVJR8=*R.I0I2V4&MFJ,J+F;[=J\JD2LCI5M5FWJEKA
MJ[&IZ3-N5:R./UB\CC]2=.P[#A1KR#U5QZ1J$:\W(UH^_],Z&PJW5_V?P@Q:
M_H$&],;9[$B1[URL*<2F2*O)0I.<V9J;P8(;=[JF&6=UUD&JK0Z?#T0>F;$T
ML%[B*\4XC)&)6Y:>[MO]'F=CS++?:2\E8TI!JWR^% =@M-WO)1DJL^QW8=;]
M+E;+?*40U^%GN]]+LG9FV>^TI5TC^UTH%?ER-0Y*8N[]CC5]#J<W?8;G!_J3
M<_+[2>MV%A**B*ZML%M&AKPU;%&;1 ?V[+3,2U[C9,-I:4HJHWS*499NC43X
M<>;X0R%?Y NEN#+#%/LPNP3Z2[=QQ,B(;./,P0FA7  S,:Y*9[N-"[,=DDM_
MRS.'+DK8G;<\O?VWW<A,C(+(-LX<UB@6\GPAMLM5!ML8K9 ;+4\))$DURL_#
M=M,17TX?/RZTTD)SG+:9B-EG(E)X*FLUR8<;O:&KR[B[,'*T/()54L1 .8X"
M-R!B$PB;MJ)B>85A,CQ8#PEM,IQ<3*I[CJ2ZPW".;=FB3LHO*-:LCSWK3M)-
M_?-F.J&$8N8<<<;2!_X<:-9X4FH\>0D+/",Q5Q<QA1P4.JC7_=JT)?4J?_YZ
MYJ.DL\\&U\ZG!-;,?*EC\^!=QS1Q?6$M54D;7$S &>&KI>JDP@I2O"T"DZ)"
MQ@H?\ >Q/#4%AF9S,2SSP*;2H#,)X4UFR$CZ_N&1]OYVU'X2QC'2),HLD<'&
M$293MDL;\TH&U2SEZ[OY1+!VAN3O4C;G4M94>J*J4P!_W<:7L*&AIK;32:S6
M9"JWIJ;RM3NGIC^E6\7L"<^R_7L"+L4,7*GV7U[_&(.+QS<?&.E@'#?&T\R&
M&7Y)7\P\':\$>&/'4J1_0(TAJGF$B4HCA0'+WR,PU_U&)YX-S9B0(+'O9M_L
MNF'G1JO29%7F=,-V$=P'I.12,CHZO)@B>=]MJ@+F!I;!D?HDKU23J?EEEBMM
MM/FX=O[ M5=\FZ,@:'<@4S^I8Y!U 5*E,FT!DD]M0FQ":R)G4E4F'4Q1F33E
MEYZ'!_W;IY?RX^OMGSGQ%];6@7)7GB-V)]@*?=;M&,6:3R\N< ZXKZR._OKF
MSG)+Z-/[3J17\L)+F)96F%1X'AY7?U4>7BKUTWX]36'2-%1UMV=-BI5JH[5*
MFY_N[H.C_[=E_L=UQ#8H1=NUOG;8 EQ3E/Z-V"8[,D(VM$759#]]0P@L'TI_
M874/<Z505Y#=+H,!%=MO9$ZER0+2!B.;ZCDXM;T ^NJL7N0(^OTE8GK<=D6&
MCA]8[;-Z,Z,_$Z?G0*RX/LW)V\/@T!Z</NEQ75$H^_/<G@)2E3@R+5&C4!41
MZE6F2:.DL+!+(%NLYUW:$0H[12&8=YE,H8A!D_9J(@'VH%;D*\7):2>K3I'U
MV;RR7#:/^(X$O&(?I-4A""L"U(?G@.'!9'\6BL/#1^%=UHLG@>8LKCQU!6E4
MA$:$Y^:>E8FTS_HP56>+H 9#64)]MQ8719T_C7G>+.$?1S0,X,YEW*F<0NUD
M@I4SB2DL,G?K1*=PJ8LY;'].A_;KS_K3+UT;HWA8,.5+'*G<8Q.T[3'FM:-^
M['15&=RG?SB@6D']:)D:L%OARX^=$.9I^AW(:/?V5[![DT7J8F1IY_I-^G5^
M5=G_,X<LS7+[2[-N_V+,VQ^'[JUCQDQ67PJ3>;/WI(1Z\2RKBV&FH^Z?XD'U
MXNBG,,Y(]:YQQ['+UP7="$U/L.D+N5(KUK0);0E7DU6^''LW.>G0?,N8DTO+
MY&0'UKXB63GXZ!\4ZY)1&)3FD)6IV'_%W)^*R L\&+.Y;T&+LUS<S4_.VUV:
MF3DV1D.1[U=>EK!<;]*BJUZ&6C(ZM?SOBXMC29'&J"76JF".ZHP$G;58SS!"
MQ\4=RMI\B32)799FJNSXMD:GI;[\T[(B!5@O'Q9+=U>5W[7Z' K0"K4&R;P:
M:JG';85*LC9_AE&YMEN=OKAENF*K+%VQZ+5"\(HR8YOV<-GW!@>+BY=>E9YZ
M[^?'_;Q<'J/_%$K7:#!T3<[=I,N">0Y2:3XWK";PA=KD8H;EQ:[6["9@@9S]
MIW%<N+]0;Q]>Q#D4TL9P_FRA_WF.QFP1BJ".J>P69HE1+-@/2PD*<@^D\MH[
MJ.OFIE6787A2$C1T^8X18-KT\0E'6+T]&5P7.LVS]CCE]#:Z$9OGJ8V0,O/C
M.E7<Q **_._+3IQ**]3Y>CXS6)5U<M;**SDS*;1DIH?J6-P_?*U=BWMF<0Z]
MF/&A6X\SMW0=6I__^KR\FR+.OSYN6H9V;;(I-OG!S(WL;">SA.@RJUN_T]V3
MG. S+[GN?5S<>0D721<&HX=;5WFP&.>DVOSS^G;0USZ:G3&6C<,F,UZRS@D"
ML#1B9BX\9PMR>8)3X(NUN/9%FPT7$4IO7>:)2>7M+R9/Y>+Z:'A_E^^\:G-8
M-)_EL"W?B)DM1A8T8NJ[M>FO?Q: ^-%\'HKOQ[<7^MEMY5#=9,2/U.VSA?RV
M?W9214L&_;.%_+:!]C*KN38?'26NP'FZ8F:P($GWW0^0N[:B#<8C2WB%Z(KY
MIDI*O(;RM M11A8!' S^'EM?7QCV;P5DNSO1C.,6OT]/!.7^Y&>M[+=\O0O1
M!6?.)=-EDFY>&"$R5[BS@]V5:F.;P2*0#=8K<JI%J":QFO@6&$V.!IP4(+<!
M$C87 VS2)Y??<8 2Y65P';U[/S1,]B-\;AXLB0E<V:W=]AO2WD"X[XS8GE&2
M('5-?U;SX4=,X)=4&!+U6K2V>[G;\N5'?K<Z 3X"^U>'Q)\KY9A:LB;)NIH?
MU0V*B_%(K@OAE??ZA?/GZ;[2M#O92C 2)TV]N(6EG53S,X.U%\K%L8()I$D,
M5(<$-IZHZJR=< YKL5%XD=)W.'-D*FAL@1J&11@Z,(O=%6V.4%DAF2*29#@$
MZ@,/IXB_-YQ.EZ)YQ8^ +R/2"#!=BZ* M3E#DAS3I*DG.;L+TM,&%;_M;[S&
M*QJ#H7!L:.!^$'Y"U 06(&6LI6FH#>E]P9CFZ9S3AS_V%,5V411DA,=66PXY
MMR8[5 0-"X\CL#&,![P,CZI!I(8 8@E'Y [7Z)@*B150X9@\+G*JK+;;B@D/
M<U\U0^\HYC<\ N0S9&$X.XN!&?"<VNL;%D6ZX]!-PW%$+3AJSJ#O=@F-=C':
M3/PZ>A 5ICXLV.<!>8;9#0$:\N1]V%;U39412TDVX'F"W8//(W:/2U;3A_,A
MT15":9$2F$X@!X=7U2;0%^G04X!<=[@GH>= B."[[KQY3A&E+DX3-P5=2#"%
M=$3/T!G\8-Q>[^9P'PA_L*WDR.(4A M\==0W4<,-H$O8"H7UB)ID!"WT()I$
M^7Q.,*%-YLXQ&[Q/L&URD[%M"+28A6(I:E46LPBN@R%-H[<CT5T7>W!2;EQ3
M$RWP)QD77IK7*&.H5>H:O5>F<H@,*[NLRLQ1?Q"T9"_;@?E&!F"HII[>&1G@
MQFE9JJR*YN!&)&A-*!7#@S"8CZM+UQC>O_]9>;KH_&Q]E&)NP-[97#TP2 _,
ME?I2"XNSI]B2E/8S7?ES$OG=7R<0E_TZ0K:(N3W?!5B5SPMUOCK&ZNZ;RDZ;
M3-[;$)YB2TKHGH!>QAW!XP?GLL&Y*PR!]CI]_.LX;,E8'J:L *P$SIL)=HAB
M-45-4^2]@?L5]J"5,LSD9?:0V38BNS'4[:L7X]8<5NU ^4+<>M+!WLZYIK$1
M(\8:L0N),,A\V<LU/E_.\Y5J7',$PB"Y,?8OL@GCC+UI."._8L[8BW+&Z>6^
M<?ET__OHJ+91G+$WEC/F*R\N\:@<B[$P."'TXSC.H$Z.!_QT=0E>!!CYFF40
M59O;JMHY52U8,+Z>K3_HVMYKKURM5+=Z-EG/!F@6.2GSP44)1;Y2SX^-;<5H
MV5$ERT[0>WI!VER9(&V2N<YZ!L+L>S>H*%=GZLG+0W%#I&_LZB>RF3 G%#VY
MUQG+9KY$#DIC'H.>[XJFX?]I5"O7UT2); PG=O"_4S#=P<J8[LJ== /GS ;S
MP$?JO4;E_G&_=K$I.GS,<B*,,Y\3(/ @2V?@&T^+H[N,*GP_+5XLGXOEIX7T
MRYA?ZWO=B^D(^'U#QP$B5S_TU!-MG)72'YX^Z!>U#^&U7/^D+K)[Q31*O/%:
M.W("YO-R2C/)3:X-BPJ> *JR08[&J7/_8<_H)<^[[V(+FYRWC]L0\5JO*+;_
M0+154+##"6483](%#B[>8+M2TPNC(&,$7.9IFPNM-)S2T.4$-_KIUTOK\.:M
M?;+?W1 5G')I$6$TGV,-/%6JE_EJ;#HLC;F$&#DQQ,VDUAS=AQJ3>"K4'\?[
MI4=B85&<)#7;]4KIY?:PVDY.N9FNB=!,ZUL<#\T/<97?C>U\']<=:'RGFUQ2
M=Z#J4JH+D@O<DWK26-/G>DW-@76U?-WHUX9*64WFP.1F2[,E?DW+46DRP*J%
M?&P7H7792[#.=NL3$L0>%)HEP/+!Y+'*E-SED>O;J#GFF6B2J$F.1O.N@._Q
M1]&CDAO32,M2,5\HT)'(5"1%?5."60LT9>T-7F'*/6@5T(R&4T<;<$*-M2?T
MS*?/8T5]-KMPS'7S0^8ML)3<(OM=C5JJT>+03^^A1$5.QEV5JH7"2.:M:*)
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MR]OA$0"I=#M<FQU8JKK<'0:98(:)2+"!V?(XV3%=6+PH9!6(EGB$(1Y&M/I
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M+M)(2;>%,V>%UZNPA>5YMS#67!%6:JX<7Y[M?QCG[]6Z&'^Y.0UFWEI:+[F
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MI^]6Y\-C&O4(F>%%O(R^J>QXM4P!2"%:2H56S@XX1ZPPSKWLP'=MKP)FD/,
M#:3@*E!$O1/P#/QH#ZQU45>M'@%[HI=;*EH)L":BI<'E,AAL!]I0M$#/U,DO
M=);D1Q<8   SE0YLF0Y[UG)LLCD,I<PV/E2)53]:")E$JPDM?W"CC?4;_E#$
M"R0030^(A4!L@Z#S0@S(+MX7DO6\B]0K:!GR !8'/J !O@FJDZ[2XSDFFME3
M-*PA(S2EVB+0$![2%!V!)_3LH;.F,+AX#\R-39W5HX%;I=#5@5%+YFIC-$=!
M%$V5[GZH3#0MS^$*X6L!_PJ-<= S-II8USZXU U^!N;00-=21&0)RH#@!;'
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M>OT;S1R*O2!W&34X%,>8FPH%Q&QR^R(9CKWC5\1A-3AX6BC?NVH?AD1G"Y,
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M 37C=V:Q1O'TR&*OR6(-9:R;ORMWM;MG1^YZ3>YJPZ1*R_N-M>0Q[?KSI)8
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M$$!)A&/^J! 7YQG@$24.+B7._2B '0# P?^? P#_;\-YA(N'3T!(1$SR^&%
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MF.\X-@[-ZF-IUNL6#V&W?$&%:+D80,FDH67Y7[)O#2(*;=K'2B5^#SGMY:2
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M=?Q,AWJ03]T6CO-[7$F6[*TV5A/SUGA-3KOTP J 26U LA,0MF$*LV$F!_<
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M4$\]G8*,S)T.-3%E!>?K?'AF7DQ"\.BXGLB;3M=0J<YBJ@Q:1GQ6]49)4+-
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MTH-'P;(3LB6&^!_P,S\HDKRT0(N,2T\29OB&LH(61X>6:O\8%A@S]E1*C?V
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M]LUYDU6>L&]9LLKEQ3_LDRCK82_1=YD_F]"$AG81K/HARIKS3OR!X. 7K)<
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M>#]:L#,QL!.RKA(VAZ^(]('1!KBKX=L2J)+?G@DC[IB%B-Y/1KFZLZE%^$%
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MJ;A4[M99HTH@/U4ODRI%HUX@BNYV1%1BRR'GM5"79]*8C)"_Z<]OVEY7Y_)
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MWH.]=-S);*&X!% JQ=8KV$Y^KK)VW4&*G/'_<2UJ<MMQRY_<,BF#9EME3Y_
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MG\!*6"CL,2"-LAQRE$\Y-HL__$[ZV][6GL/]O_.&@PHZ#GF2B_[O,(7_?0*
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M&M.-[$);]E(#FO\NY(['LU3BYQM/TE1:^[^G%R^HB4.@7PZMXR 0IZ7E=ES
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MTKB+5^9.Q>)]4FU#P:VFIU*2-3\9U)"RGT_D+"4PN@PI1D]3]+@9[DX^O6S
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MYDZ3JL;Z#5-/[\QCS_&JE!XY)N; %_%(C(4W2!E ?Z7'_B_M3:TW'\%'46T
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MH;L#5Q:TJFOPS@_U*LD(<?P50KA)!O1(@#Q];HY#JR'Z>)GN*G^24V)7/72
M!B*,0C;ZH1WL^N'77Q2: CW"@I+ CBN+O77@-HPUW* A>NZ1)^1+B'5J3['6
M$)H,((B,[\NNP6!M<*27(S0&SM8A5$W8Q+PL\<1E(!T5\%ZE:>AV'\[E;:ZX
M&$R*M.F>E-[DI:)&<"69M$Q=RSBE?7(UOS"HM(BRY?$?BH!_3@&\R&ZH) -X
MMTD2^&E'1CQ#7THP'94-KCE14EIAE7G%R<D1D5=L[X:R_^8=1"L5N7_/77Z
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M<\EF!4]LS3,%3+-9/LT;4=VSZK1-RO;/9/&TZ?)##N.#UY,F972##[]/@6A
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MYPV?S]X+3!RO2DUI3WYH2)$LDN [.XVV/GV%']]_C5ZE)VR>OB?,?6GNA\=
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M]F2L3.3X@O]5%>*YBOP<IZ B\S(5:.5#-I42^2H!H,>Q+_>E,Z!(ID4NE0G
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MLO)7&9DZTIM.MCHP\>=K&>K%O$S0Z([1?4U]OS[RSA/&SI$ 0T^ON/RHGKJ
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M0E>$:L2*$:M5\@FGUBPR:Z7Z,:>- A/&1:^<IKTWF@1F ANRE592+ N2OQ(
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M$.+YK">E^SVAF YJ#9FFH0/R%V!!W0LJ3I?VWX&2OI8&W;LNL/7ETF6;;P3
MHC%^^5!Q9/YK^Z6(A]?9F_+]J_(&%T$?%Y'-*MC?HGICBV&(TY#0OO#^V?\
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MG[^] =S"X/ /,P5*"G,T27R=)YC/A[CHLW77C\*N^EG[R .\]Q['&X: Z+&
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MMDT.&K Q) !9(Z(_(\%G_!H2XU;=XCU999I9$ 2<MR;&(]LTF^^4U \Y[-T
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MDP 1!)IW=9_JGJ7S*%3/#GE7T_-HT'HQ9IY6U=3< -3PSX))<4I88\32]<+
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M D"^1%\-^WC4K-28ADEW5Q8J@DEG3@Z#SL)P+)_WYF5"B\M<K1\TAP?9!T=
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M'8N?4&APB[2_E!IT!VP?O'Z 2"B_(T\V>N&C?IWT1ILXJYQPY!8K9(/1R_Q
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M9<\)H,PTE>'",1T%P[8_P9K)!62P"C3W]D V<M1^#EJ>_$]Q?[VGJC8<]7P
MST=%_[><)UB\YD'- JM)PDIN/#GY'6CL_T:A.E,!*]P(P-X V+W>4ETX)?84
MWEI4SZ)_;L'!,CNE GIBO4Q58>\<#7[=^29]Y@:@6]&<8OU7W-V\L:4Z/>4&
M$!V0?J(]?M+&;E>=>4W#9%338?EU(:-J=?IORR1:^O+^H*NESKM.(YW/.'N+
M)25&0:I?)/=\.FQYH6"[3[?6&I^.R8R+.2H@WS=9#2/E.N!R.>%T2/2"W2K)
MKI'#QNX\/[$!58-2+Q#TJ/@".G-\)[QTZ0&ARQE+#(ES<QCK<?-'K@U*Q0G1
M^ CG4#%-57PQ<KD[\X?DPN?V=HV%QH6:87S,+PKKB_-8XR!XE>ESS=8"4S._
MGH!.C^0KQUNG&@K_WT HGC!BUAK]ZPQ'9& 35!:4ZD<:$B(/R6\ 0X]0$VI$
M'!004T:PL/S "!,)V.&.EP[==18;_^ M CJ98&2N4U98-S:VQPCE.L+>GFS@
MQQKVKPO*#T<Y0Q+)V758590 !+LC_\IOX22] WX[$%T+5_RM)U/-YX'I!\TZ
MCCW0VY[#=P;&!>SC*[;(RB%/<@;WM[Z?+GXQP8NS/,?RG:M&7NDI@E.171">
M),[(ZWRR^Y-<"X2<?[=^@C7@MQ3MW+<'EJQ^RNE0JUB_?;>I;0M- C8^L_,=
M?SAYYA>&#A,L)$PD>0S.%Y.9IA >I+[5B.4[<A2YO#,*?T<2H4FE5,/J0O!9
M,WI+>/.99?J,_])EZZD;SVU5E^#8?+1QA^,-@#%?8]J_R?]B_L_%[DZ**C;;
ME^-A-\&MRQ.3#8-!U:DCI_1,IXPG>U+':DLD,1?_&5B_$F(<6>/Y)]XFUX1=
M?728Y%62_G76#<#Q%WN[>Q+2!4!8;OO@:')'Z^ET-72XP X$H&I\@4O]@&BK
M53 KP,5/WP ^/T[,@?=_,9J9:<U.P<=\\VD,#HK[STLO%OUN )"_,^7:"&SR
M=3@*?D$+MKRMY'S;#6#LPO G^%7@_^KZ"70#R HP/3P\>P =#GJ;?>OKC=4Z
MQ @=]AN 0_3,POBM]CSYZ)+!#2U?9/U'[W_E-SJ:!':@S%-]+:Z#YY*X_3D]
MOO\^HTQ-0Z;L;N5/<_SVS!IJ%H!DS8(LW0#,UL=];MV()*9>]>HQN\"V'%BV
M^B'.;EP.H12^^X-_AYT+S$&*:PGGAH\T5>?#>A5V%*,8A]^&SSK<<IG$^!T5
M04&?1*6F2.#19.8,(=-D*VA$YZ"#&RCCEX)166]8_CCHSAW9A %<NX@P<5P_
MF-5WL82[:IC)GFR96;K.<%QIO+&J"P4/6\+GN%+=Y^K..EPS$@1XNR;1PG(D
M0XIW@CE0G385R\@N3^"V0%(#>7A2UTX@8,9<$2M%',R%FBA\)L\R7R\&>A05
MPYNHH__3Z1;':C,=8,PAX0(=A ?^&W>*8(@,Z$>?"?&%;I>:4I--AADW@VT7
MZT9%)81<<*,J0/H5=4&1-9;)WH_CE#_B;6M/BZ-_YC\+PX-;Z1KW_\$Q)7Z7
M=N7K-A,=FZ<P]6@=[?4AOFUQM<NCSN',>MCXC"2&E4^>&NOA$_9?J"&_8Q,1
MV, TH2T;CY$EPO=BI>2M27&==PI9;U$(M)&HV+#A&$<P"OBHSD5WG5V6;K,N
MMCLOYZW>%!D%G'S"J8'FZO89IC*E3'"@NHH4I++X/;V2&P9#BL'Z_AW&O[YZ
MH^M_6]"GBQJ[U?.E.1K_-*#NEI*?ER865B [61$M-X"%:GVM)SWH!Z/ILZUM
MESK]\Y5M<#FWGOCP0EBRXN2[8#,E$! SW&R20L+ZRQ= XZW*#=4.(1D,CT @
M1>BN5Z[6F!9$$PHKEEI)4H\?#LLZ)5LO%DVYT]Y9"HDD6'#/:V :!BBT'X@%
MY>=]*TMX_,N>V3TVU_MN7AN 4D:%[ Q-\+4(-\EN??[8ZU^[2^>TUF%H0U-'
MUYGK_/09!,_#>_<&H#POL]!AO9>AXRXU9:>O)2M;PZ)9='4[H+:X3Y6WKHBK
M:8W/Q3E9,/&FT-XG#P, 'H;GZ[R:9B,<# 1AX''M?K<A]S@Y-WC=;H<67;0]
M\U^*7?]U]NX6S=!R%&E,Z'*UOC\A"F ]N+WI#>"GU/>@Z]A;&=RA+4@@DPPE
M&=@-:3+ZMW:XNGK>/=^H#!\LV<B/2\1671Y[9;Q:36FST!&S_N+N68Y-OXY"
MO8*/%*&^']\ Q-::)MDF?ZF/@IWJR_)(!A%X1Q'Z?!UKRGTY.04TXKCN8/OR
M\0(^?!Z.(_1$X%_@ XLOV6=O -]EQK&-+1P3,@HH2?@<W8L; &5C=WZRPRW[
M%&_<5BL>35=WK0>2SR\X? NWI$*S7!(.]I+C7@Q]/95GG0]C0NB</%#(<('?
M8A?B2H^=?T*,ZHK+;(KM!M!A%W@V,@&04X:_0:NUW@ *0V+DYXU6NU2^HT';
M7&TUO&?*=2HSU9GK!QGKF=3HV0MLDBL<RTRW<&5+:_[WA^."^T;/EU\**+UG
MTL;H7*?RBZ(TR3;'V%LW5(B/^MGY2OY6?<"FB4K_/34P P'L2:Y)6HF?A8Q,
MFC+<"KK7K: ;$<]$W#HR1FV;J7Y8;<,!+:=-5G?PTT6J/.E@GX;D&F2>FEB"
MMCF@"NUN+E=K _]G-=NW@0J1_HV0":C0WHN6DVM0O5+QS=:)>#9NZ9D]VEI[
MLC1JKM5#![W=GY*-4!X$XR :?E[2&!4DGPS+.)MIR?]Q>&MZA(/K_TV<$70B
M6+HF/KBD]OFO%'\TXP@K>Y"^0GWG*[J&6W"64N/%\^5!N+>4@,Q!=(1 [H\^
MN2F@NH,-Y[/BU/+%@(U%\U,0^D,T&#H#=I)@8Y\!X2<:*(9-3):=&H#G@ ,2
M-NQ*+$?\E/="A/.3Z2;\7'[MI33CVI(06\H>!Y8/IEJ%SK6;/X17@:1:M2 _
M8MP]0\!=5&CNG5!>N5O-^I[KAYEO5B=A+3BA$4<T(!N!&[=B\$BQO%]>F 0$
M@-F;/2T&;?W(N,IE!903$H+_R[A!]O&[9[PN@-]C*]AEQKC$=]CKHU'M)$C!
M.<FOC0?B9P+>T)4P.]ZR0-[C/R),F=)7R8Q!)Q#Q /=UI^4WS9HA;"<<4R*$
MCC\0P+4O>'76+(_V\@]S;I=^';_P8BJ1*-V%?GE!PTEKG$I+3T>$\3U!G\A?
MZ)0@>P(6)2S9"AQ)BW7AW'3'=+>DD('K+DB)['=GDG\NG+E?)[SQ5FAR\Z*"
M"$ GM;'A5[A"YU:;&\"(S&#B-WHOPA$Y>$ 8#+%)I7';8(]3>XB0RXWNX!^U
MYLOMM_'?>=WRWG^NT[M[ V":5W"$>&5HU)4EJMM)MKV<2_Y?-6U5P%RHX;$$
MQ&T0<M%6X@+_HC3)%U,B*1H2.6.(*7!AI\;:Y=J[W@JHG.Q'MS @H3_#[U/V
MGL6JG;,\XAP[,7^LDV?"+Z;)$;)>]A)?,'L=LU#9^CF)B=>8.D3 6^7 B5PW
M;)0DWA]Q)S?8V<,XFL3660<VGV$O\['\+"==DKXLQ4A]:._,K5WAY7=!_O[7
MZ._>N68NW8QC?"XNJKA9K/!K%SF+QZO-K=_QSVJO%% ^1*7!O*@%8GI9_0'F
M9;6ACQ2%]Z7N>8,F3* ?J:SW>LXT8U]>YW;3F%DOKB[J>")EZ2"03T_:OL:D
M Y*?1)C,JZTRAK]/("/ABKT -;/06R:4N0QI)* /I,IKO0H_7-+(D&- 3]+=
MMA23!]I%F>\JT51#JYT^\X<W$\1O$,3'&X]"DSZ83(B_I\][1<Q 7J\UD=.1
M(/V#CF(5^,T;H:G!,G9Y>-$3U4VIVG^@HD#](@[*N%[W(B5@W&6F^?S;MV_.
MQQ.ZZA(%@WDK*<HYF8:O#PKYGW$(!Q +TMIS0D>W5SCJ?JPW>R(4*/ _;@#D
M?O"X4/[ITU6(>N/<E70)W!%F->0GY'_QSQI[-R.ZS-QDJ;F>C%US^1>]VXC4
MH&E#<N2)^XRC%(TW(E2'B:7-*T0&V4X9.%H7<P/PZ(EDE[PN5'!R#T#"!_:_
M6"H,+JP)X *K^D+\?'@^+YGNY$M,MW1I["WMTF6)V#4V?EKV)79\#1VM2QGE
MLX'8_X77[J9/=#U%.=+Q/$4N9Z=5Y\T6W_5S7L/O64P;79,DB((F'D;AXJ@'
MZO->[27J9QOT#:2K:SYD55%E5.*E/Q(.7$9IIH^6,S9-NO=L?.:X*]1<QV )
M6Q^X!5MY)HC\@QE!R9R"^[#B@>KLWTWEKG_/I2B*S$U_0-DV%]H$SIS1-%\"
MUP4 G;/Z^#4\"081]0=LC8)'W@!8@SF7)MH^[U@]F K61#J['5U9!M68M6R5
M9-]I.?IH1)K>O;RM$1__W!XX28*^ >!X3Y:2^K0T53!M,0IMH>+J%3!]JU9L
M0&(+\:S#UV^8FB57^C6VC ./['75O.2!JLCWJ= 7RP&(-;KKTF[^8'XXZ94>
M[BZF8%AL)W/)9%K"&J==5]2EI;&VB))_4C_K?C#7/'FP&ZM)1'8Y^CB8GDGR
MM&?QZJ'>ET3#Z')!KJ%V8+M)_#F2]VFY+R;MB[Z'A.M\<Y7J0_TE;Q7?V8T\
M$$>B)AB+H-)DR?S=4@]ST[DHUQ<?][%@N#<.'!45L@?M;UYI9MGL!9F!.I]-
MW=K$'I,*&X+JPZ!M@Y]C7"[$EN]")TG!G8,PF!>S,#!)#]OOZWG8/(Q+JE@T
M-=^-05:VP?R.ZI S[IL+CC0LYAQ2D$^K9%F=L^?%*VITT\'ZUW5@.HP3HITA
M FR\D13SSRRT)Z1XUPMW@1@H\[QKNL?\N\\6 JU@"OCS?*=-3/6A*FM-<SZE
M/"\NZA*(7V N.%C _-M86MHI> BV=$%;<@U;\2R E5#F'QB4FC#X'I?JW5"*
MYH[L><V<99665G..M@;%0@].-->,O'2PV'5Y9PCVZ/](>^]HMN.X;3@MI7;M
M+5JK-K5GJH.B:%%[M$45)441A!A%[:)&K;2UJE:+H%9L5;57S8C0U$[,()(W
MO<_S/.>^[_<^YSGO>?_++_*[OI_]N:[(2=#];R1P\K&'J&BGB^,'CG[SG4,K
M&+!0$4;#)>U0J\ 541Z[,W&WX-WZ3\MXT3>*-YDOW8Y3-T5.+2Q=3#WC9O_9
M)M'#*4+WJ,0J8V!:*-]91TU,\E:,YO:MRB>:PY_BKD&GU(][WZS-KEZ-7&%L
MY-F$F$2B*\7=.Q-5^]QJ1UY"XGW=&$?8C8RRW.C]2AA-7@3R53KQ94)EI;Z6
MO2FS4]QH?40&7&(@R)9"5O;O?<-A>Y+M0 R0U%LX@WAM8_>/)R%RB160.L=&
MW%'>&Q_7V#T\\$&6<OJ?/OXW*Z_?VS-D.(TL[\Z5&>+[>Y/!Z+@XXB6,B;G\
MY8WF@A3DRGKEBZ>CV]4R6YBV>QB@3^BXH)O-P^*&!^-1-#=K*/- @-2+0H 2
MPT4AJ8Z9VI>XRE=J! C6/>'LA.@GE0.NNH)_G8!XT9#SM7?MW/;^'BLZ^O8\
MA7T:STS&ZDE^S:]_G%J!9C<QG,?;8NB1-T) 7.IK$K\- 6R%G($&KPRQ]\X,
M?89:2A:+%2175WWHIPY4'=M0NY[AJ+1SIBG_TYC=[H^&&JW%Q[A8+HCF<*%Y
MML[]P^DCF]D'G[#F+WTX/<//5UX>%/&;YA=HF+(5L7C)R0!Y(;/GY9JVOR!9
ME=:\;NKT#SMQH@IUY=WO\!""5:?K[TRK*L9&!E.%0O>"IW67S-6)EYRWB%R:
M*>YONBWBQN&705Y@.J(^ ;G"$AVT1$M(70;R>C3S0VI,4OOF[@0&VOV)#5 ;
MSSKM6F&(G\Q^?[NO]O+OCD%Q=3>@F[[2U1Q<93SQ#N?>_"=BJ^1O0Y'//_J%
M4W^9S3JCG;>YT: 4&&NX&-0/YQX74 !;H88_J\4C:A)H/@)CM)G*G!R,BR"W
M#<;M%F2XOAIK'Z<O2,<6&F8Z?$MR.=BYMI:A%7CB#KT9M2JIQ7M/_>K >J'!
M"[RS2.$3G+J#Z]<3V%?(\X==ZJVJXC:M6A7:RA*VXSTF^P-2>>4EURV3W5P+
ME"E\#(>],;(/3;$AB::X,0Z7@N$62?Y)I;Q"8,:&6/";LLS;-P:O2Z*?K[1_
MY+&S,4*\/%2H&\1*9?2T>B4?2;%>^<+VN6EU?^)JA$!$\#)VOLV__1J>*PX=
MQFZ)YWZ#D&;BUQN3%9M4\;8V;TH8[OHYOL@PJ#+TZU>Y@-&5=+-+$0ZK20<F
MWY[RBJS=Z9R[58Y9$XU.PN<?8//_M)N?U\/<[>%SC4=/"6TXFN[>(%V:=D(V
M^OV!L1F;?=>,A&F!C^SNM: $C:NRU%7@U>&*:^S4Z7PX#+U% :?ZG-"2[KB'
MRJ"7)USI.-UD\?ETLG@N+%3>,^^=ZS:GEXJ@?8O5,=AK3JMA<6O\^2J)EC2'
MI-'5(J3:3T"O:'NX>)>L[WNQ$O)Z2?0S1+'E19A>8W-HL(HS(R'.JC[:9,H[
M2R_-'ZPETG4G<>^*V12.@.P*T@QK+_=>*: )4SU%R\@<7D8D<M<WM;JLG:?S
MQ^04SUSXP<"6?H:*$9U9P4:VTX<O[*JE*&];=Q9RCM4S@8Y@<6BKF&4FL]ZT
M#1ASJ]Z*]S4M0:D).]S2>V]WL/^GWYZ:;N\::P3V>45:FNDDW<S[_P"C8#@S
M^7D@.I6RO1AMO7)?V#6TH<F N;->9QZHX$<'PJG7" ,$W&&W%(W.LW?D[]%T
M^9)X)C8M<QB::,_O%][Q*[W'^-[4;FN9;(%='63.)MBTZG+3]Z[:<KK1JH>/
M,@.D/,XDZ%\MKGP/*PH\UG 6_=:4*5X45_"(Q\BDUT]]P(C.XF&^X\EDB>C$
M1)I$,^@#G!'ZD!" 25L9A-,34-VG-41AS</C6*B%2FR9CW>]8) I:]ZBEK78
MZ&W9YA^Q)FLW%_-QTJT->'!,M=RK01MM _198MO36;F#BGL(>S6X.>+QO(\R
MX4Z?<8XV0D8TT4^=4:]K9B6KZ(R1^.3?TD4$=9$!+!"#;B&AJ7 ETF@#DEUL
M!BJ]8KPM)<\.L;:>5&88"NG:0]]KKFVU]S+1'ZH:ZQKB[\OW44>NC/R>QYC"
M\63  WBG,Y.V#DN4")+@_9FH2ACC3@VP=_1'@Z*(8F@3X/T9*&T905DR5L\W
MN&3#^J&#: PXSR&SNELYF'=R\"7;:E1?K^2^FCB:IT\Q6?2+1G-BX=Z[DH'+
M4AE%)DWR'F+<9JP);:0*'TN$^?%"R:\%!T>M6PY?I&W5^_P2,U;;D,]I$UH5
M9:<_/BN\.IJ[>;\N_=BR(=6R+OC@[-Y@<7:0+UW0O/U':UOQ=U)7-[IIZ6B3
MB&*J[[V_W%Z!L9B4. PW-,SEA[0E-5@L:''8VU1S^0O,,/[ZH!_GS[7LFD0&
M:"%KL9W.<^S]@60 FZX8Q+F##Q93^A6'W%9:/@-Q0"IZ^0J(%%J.0+)!8I=8
M:/Z&BX_)=3G:>-@%?VMO4C)H5B?^9OLE92AY(_P7#&<*GPOM]B6 S B]S'"/
M94%Y3 RJQX(B&WK/%PLSW7S1SS\V0+R?O+*V=V:3F)>MCQCA^Z3_JR7^2Z%>
MEL&\>47!Q(?/CTKS$H^_[-^"[ADIO7.66BWGD724W)M<^_*=<5J)Z[MW9+DX
M6F-?PZ*V(./AM/9 2U/#C.S*&L?*V#EG9\WS[*"9.9.&NA*SSQ[?].<RWUE/
MCSO-TB89505=_)9U";(H:I4)N-Z1<EFEPPO$"N4'5T(L[B=:>ALYLVTTSMU%
M_'F-G+.#JH4X5F9;O_3B2Z[0Y@OI>G-;9?#Z/N#6A:?2>+/EF2W)LUL$I:,H
M_''/"'#321DON_D;:C8^83E.A+[05L%+Z^/A\=G6N+J-$+L>\%8 DNYO[/PM
M1(I#O[>W*Y=VWZ%$+-+%;,YS9-DG;5G+^]KFK;I1XA.\CU<;\#Y^LF%)=4I;
M<>6<)E1'+A3.>DL R,ID_G+:NNGB'(>% FW ';_[>2Q629C"VU>^_YVU,\ZJ
MQ#R4_/S3>\ \-SF[>3SCC\?2<(H2K[D/6Z=I7(NYPUX^L'OP^3JPH<:](4\V
M==$$:#FN$OJL?0S![V@ULLVFQSF4/,FM6FKL84>#L(Y<-<']*)6D67XTF<1\
M%UJ.J9E/7)9_39+]363/(@-Z=:_B\YNSWG_RLH#(=]G-Q&N#T+)>SDWV@A+W
M\59MI?8.'J=,VY/ITI5JX_KK5SQ<+1WX3B:.6"=T-:&T.&P7<!:^ N[.\'EQ
M .0A)&!Z0QRWAXN88] F$A:-B=VL!(P=Q&["EI!1<UXS/+TT;8-^C\G=4-&
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M_3_W/K"GOHO.F*G62@H)OQB1[G+NXE;7K\'3L;J:A.49\2EVX23(DP&L_&1
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M^X>[=31>9!S,W>O3(P/4:SHS*%N1%]:I]D9*^Q'^/CZKO[OJ\970J%L!/%0
M7+#&D"0EL!0]LYPW])82.(MJ=4)P9=3E53( @)W9TQDR6M'E-X1U_:$_6K3V
M6?<^4MLN(U*=!Z+=D5RK=(>(>\<^PZ-G.^W;9DM6;/EO1PKSLT3>ZH?OJ*L3
M.]>G?F> @IM="%]#!+"\M*FW#P^(7)0L)8&6\X$'RE#K_O.,17==5/?A"-J
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M"X?:)$"*OSR%9H.P;1Q^5>&D7"U[$^4)1.M.KP\22W*AES1OZL TF@:+1 \
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M"T^PBY1%6=9>26RF9LY?\WY3I80JZWD7R?$:<YN$]'*CO%<8("UKSC/;!K#
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M$E;^[BSV7%)/E<PU1CM7VK5_-S,&W+!J"G]3I\E; [@GX/>5C+OR67E?GY"
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MI<I*1Q[4W"EF5R]I913\LS",$5+^>]JB6\%:4,F0I L. ?X*',AE0%J#0\&
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MJW.7-RX@_YALDG1X;X3K*KV#FF,W^6O46+OD #>#'-N6SGZP2NJ,W)0$K'\
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ML:OFW+I;\RF:SL"7AVOI<A+<1+NG^&V!@-7"5P[^T3@76U([@=/^6<<5I<<
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MRRERBPH$:-;K%N!Y+K(Y'9>B;X$=2BW,<!H']9<$&>8T![1)(<W#F'B9EX5
MQYOI'0]7$(;[^^D[QM^=7_UX5D'KJK3]9[F9/G&O'RJPQX&O[UVMC^QVB\KE
M: >[5(!_\]"V _VK+1<<)LTFRI8>?*1X[4(ZUE]9GZQ06V,B;LVAS-#[T?+\
MZ23;\E*"_V[6$7>'W-[,_ BR2:9K&.X(7\C$TG93!ND[-',KXN+WDR%E=.SR
MD,IA#V<.4O<DC9N#V4LB/MC;@L-! 5E. [_LGUG.!0B)C,_RLGE?+!<5E^T&
MAZL3ZS9\4XM<Q)/KZ^<KKP"\FU< VLN5ZY]V9NMS(-0>:]C(AV3J? JU[UWA
M#72CV:9HU8X0;3<=?OA1O$-TWOK/S_H)FJQ*YW0&CB)'MENOI)V(?-<H'G-Y
M;0@YD(Y<;B?FN-MY&$WKP4Z>NKE&^4K#('HQ!1$_VX(=(W:[:HA5$/_!(C=$
M9-%1C-OC?<U0K_>K,C[8,!I!$(AHP6@S$94($QB"E*;J7WC(*K4".18)@-8%
MXE!:S3@,$YTEP5.#=Z-+?+_2Z@N=E,>7IJ'^CTYG;2?B%QEP)V HG([HB%$$
MKE5E"_1I,_PBG R^(B1BCB/?(-"^R66$C%V=J?9'A5&I2#1?PXQ 2\ML=?6R
MYKAMPH--)9&=O ]#(FMX:<F%<'P#;NEO_@8[W;\?6S*L_=\[;5^&Z&:X'M]M
MN#BUW=3K?[_]WDJ]D$N=P5.G-*EL]$Z/0OOY=3<P'Y974:DRVJ_(+>=IFA^<
M8"&2XMPBR7HU)7HIL=KLA%CM:YROAJ[J?&_ )7ST"BPS-G[M]ZT? O'Q4:R%
M[)NRQI8B!!2L-\&W@Y> G-5P)P3)Y0BW**ZYUP+89RK0L\R+&>RG93/;1442
M'W0J3OD8SMYJ M]A\S:$[%[0_J%7Q$#$BJ2GU7[7/KB7VOGYHA!H$WL-O2""
M=![LY=Q1_&MMG'ASP:ZETC1?R*8\[=U1>__B%4LSY1-'JZ09>1.U!_(#O0^V
M\I@W<IF![Q#TT"T,O)<,5U6RQD,&>T"P",RW)+P,Y +J7G->"7I4PZ;5PNWE
MM(+&5GHN:"YM4ZVP"9FTR9J7V*-:I#]_FZ9*1T'QF4$):(3'Y.1[1DI'Y0[_
ML*9*(]LXR$MVJL%1W&'6T\"Q8MO *-6I+FXG<&4B*<M)/<N?T7S"]=7ZGO_#
M=4P+\]H^XD;P]!6@D2=>.G B#H@KO>3>!M9GKT1B*A#44!X=?%<S8:-B$)U9
MD<<2>V_Z_F3QSPV$24C_U_I)(].5>'\WON92G<G *\ OY9,4_.F>)@[;!V;^
M;^?"'7:HGQZ>?YV;]F<[;ZF3%R&W)PTW,NJ!!G*C=I[9AKW=_?<J]B1P^(]=
M:UV.PX8#7]*]JBN T$XN[LT!(F,0H41NN0P+G++"S?\YPR><8F1"%%Z4F#BA
MX'&-X!N@D[.]8"I",:7\;^\@[9ZZY145Z8NQL8[^V9Z%O@(' 2YDK_:"R$D\
M@03/TP>D5V)']II9:&"V8F%R+'T("NA+^666KI_;OO]2YKGY"*$/DP-%AW(D
M9_YL2$J9.OO.3:F_B6MKD=JVF75XK^_TL\#P46B1;(_Y.-..^L_4I8ZL;#EA
M!!VJ;._]]JS6XU ML$68F]:Q6=P5P.]AEK40_T&)S9[/*+LK?L,WH5F[F7!X
M'K@+OHETI0V#UY=$!7,6S?=H<\-DN>_A6?I9I<U>M>#2HX^YM T;)Z5V*Q\8
MSYG\D;":K)JMVMN2%^>6>@30H&I#$@3G,HN"YZX +)UTN]PL3=.7MV%L!%4%
MOVJ8B<LK#7\/#(=_G@Q**[N0OY[M?@3EJ+%*K^5M2&CM>Z'(\M5&,)$Q'XPJ
MP5XVXI7U"1$*0'1T)YDCF/+HXBY'8&+Y=N>3GS#M,D+,8/\G\\*H"-:UF<[Q
MTJ^/C#[=O5\+EC6]=LC<,%L/'-(2QQ.-=-"KVND4(8""UE99"&F:_%\[YX@0
M#TSE$W#3_.87<S6ID\:I2JFV3+<G#,_!E(=>"V$(*@5Q;EFBA9./_<<LIV:6
M(7SPBG#6S%G03D[WV*K^^G1K4^&.G>/WGCA;9B6'ML(,_0/![<J. E!31IQA
M!20HJ/3Z#?21-EP2:W.)^&9#O"'2ZJN3)6]FC[(JNV@](6W:HJGQ^\QUT9$Z
MEQ.(N"?UF_W<#V7"??,F<;T4#XY&X@RO:RBJNBLW%LD(MQ]3U6: (M"*Z;VY
M=Y=0A(+7[5-_&L$ :$G_/]7(BIT 24JI9FV:;*]2L\5>/AVYF20F]ZB5=TLX
M!)&1 S0-DT:/6EAK$QR+(7.7#V=AFMB*;!FUMCGO*P#KJCGT,;;GF5VE8EKM
M9C>D]#5GOLGE\*U'CT.^BQWF/L5O$1GL#>;;I;D_HL$\A-<]!RQ_K@"VN#3I
M1MR/M\9+! 2(4%0 4YEJ7%:?$XOV*RF=BDB;T^.M,?OB"ZN35-B/I.JIC^=T
M44^$9I2GV,NI$DSU8N,*ESA<O5M2,2WYT[G"3E/A1E(ZFZG"CL_<MW3\+G9U
M-^<A0J4H\=VB\Z"G\+52<)UK[IH\+3<8&MOG.R^C]+B1X)W#9D&QJ4VG@MF-
MM6G7E/Z3BF) W,K?%,KQX$F,'T.*F/TS(C+9G\#<F*&A/4KWW5BA=EA5G&4]
MGEO3JR^ X461^>_6NW'2%[;.83+S,IJ!A=OD_#.UF<8S858D]>XPB2XP3HO+
MLQ<[ECN C+(4PMVN"/3 \RL$8GCN. ;?!?]AR>GMH8=JOV:W85'']\,Y/8+J
M,$=?TT"Y_,W4L]%XC4OR,KP99C"!J%,-K<"J1I=O-]<3'9MP1Z>F?)*6OR_I
M"46X2_CM;26*3*W:"$HY[P,J#85F1S_>4<5US8VA%S=3W(E/GJ4RU<X*76(,
M9AWFRIYY[P9JO$0(E] ZLKN?%ID,R$POS^:7S_[0OZ^;S:JE7BA7-JSZ.%L)
M[%^\CB4?\=W0;#/9V0\H"4.N5:[6^L4',Q*VL(;)V" '@GQ70$)TOF71:J3;
MU]GC>(W^$ -<46>HG:?X8)1=/*8NR2[\[DND(_1M6K45P>_<+_BZD]/#Y-;@
M3([L)W7W\5MA"HY8RD#Y"Y$_J(1HZS7F^':C(FC$G-RZ).29:%(FB('DL8:H
M+FLA=*0-QG%=)+MYCA&$%T3RKP0]#&V(=Y R>B_W#][?RN6ZZH91HJ^?#KD"
MD(AG[/LKJ%@QB!KY=M[KZ;--D[-OUAVG9&_^[_21!D(%NM+H+?XT)%@:ZCH]
MJ/0,SS+0 >[_)UZ6;VX.E0?5$_HZ+?.*H4IC)GP-D6HVU*S>!IWIWH?BFP_#
M(] QHU_L7,;?>B(4-J15\W/%GAGX"S4+CHB@6FL=A4!O=1Q;^':P!_RBCS5!
M15+YR;&@UII9P6%UO/?4W+CZZ^5<&J3KZL(T!MF_2@YCPZE65^YR2^+=PI'H
M![7MH:!4[TQY@89T?0VNESL@F855[9*^^3L1]SD3F5\(VBV"(8U9\IV_[>,>
M#BP9%-SX#MCBLW?5DW6VESYCP0$OR2?P,FN(/7*<!@8>WBD(!;_"@3\V4,8_
MP0S$%S@HG[MAF7N@JG#:WV/?S)<'96LT:?Z^:FT(DMMCJ\28^:=IM\/!'Q,4
MTGG3WAIXS= /#2K@QY_,D]V:3_PLRL5>O?/KRXBP$*@'5CD\7)ABD]Q08,^*
M&CEIK9U5U]NPG!)K.O)-2--Q&1FK:'E:'?B[NCB4?9C__I?<@*0?T!M+3T'W
M$MB,>/R$595MWN><#.THDY%QZ'^X\3:4#_#HPY(06_?P[V>.7ZF8UK)[^?9Y
MK>YA2>2V9(<4ZP?5/POJ-"?=#LC*"=(.P,13N ;/IYL)W-V2\6MUD9/*U2BJ
M=QIS:TP]L(6KP'</V%B%8VB6UFA3WGG_]Q6%TS)!$A*2KVMZ(,JX+)N/X_Y_
MR)KYC%0:)D]7S8"]KPY*7&[;:EX!>*BT/+[?2 Y_3W;/"L0Z='"0''.I=@58
MVZ:EVM59N.SO!-[!]K+S1"L)$+3UOLBH2UU8]Z/@D463Q^1K+DT3@.8I'PXC
M?_X$X\N9?&ZN>+@Y@R0DFN76WL3*P$_W9QZY;T'CY+\A6]HH^1-K@N*Y,4QN
M7HF!Z(&+R,4"27:=XKS/Z_F,[@9DD<875Q1;]FS[E*R@9&_+N2RS#3"/BNN?
M?6D"B\Z+#JR]GV7#.*HGE6Z(FY4)J1Q#]*?K3OTZDI7@T7];MLYN.Z;J9835
M0AW?ZGFFZ)MF9&RZFX]YO5 I"N*KAAX*7#I? >JW!JGEU^)X6(ZIM=4[YJ21
MS+"G;;CY4*N(!=(P)3Z-_J217?,DCE'(9^?WMB ZXV'1.":1N[HJ@:K5YPYF
MA).)GG_@?@2U4S O+KLZE.<-_N>4 @>:MTP"L=^H:7FH,PN3+[=<[2Y%_2JW
MV ZYD^%]8Z^0_XYUVVGRP"K.6;%H,%JBZI+G<J9U(!2]O?4=PL5KC#MN*O J
M1M77-C7$[&4I[#JTZ=@FBY_?< 5-2*[B(/L=)W A.,1Q24[U^RH:RFSKJ:PA
M(CQ"HG;0OGYT0]6=-!BH$?J]GNR.E3L!.E/T\JAL)O6-HE: 7VJ1?Y7=QICW
MXE;\?L[@X5,+='74F:9 :/<[R5E)[[-MO=*-T)0*'5<7KYGL'8L61S\? 3^;
M;\$*T-V3KQ?Q/I6>$$I@Q*5<*PY ,'!!:[,[-G-3X(HBKQF/$#%H6C_;X.^M
MS;@ #=$($I8*H7<I7U80\_!Z7^V4F/P0CT6R=\K"* A?\#Q=[,CP=CG,0>0J
M%4P,[N;SS<F2Y9K5\XGJM;CU:,9L\JUZ_/W&.0D7AJ?UTXTWO&P?Y#U68ET+
M/LPE2&^9TPP 4;-K7N<3DM"GLUF/UT4^'2;>!X1U [VMF>]= 4(M?9CIK^.7
MVDAF\>DW+XWK*OC#(2EJ4E>HO5;V!9\6Y9ZP?NU9ZPTC&@9,LYMC2.&6;^96
MWBA_A?KRMR1DW\J?G?3(R_M:V;*C_%VR>IDI0C-0D."(84IV@8CLH3BDQ4O&
M=RH^\8P6H[T8V\,MB&.))9)@N"!].4_2#?&(J..]Q[*7S%"M0"XP>K,$=_@*
MY]9[!2#;9:\JPX#W:&FA%;W-ST11$<BJ[8H@L5[SR!@,NEOG;TXH7J3KY[6#
M\>L-,L/P]$]$KO#BTFHKG5B:5FY,_SD@RF"CJC<C'"HEW/CP--&ERG"&0;'L
MOM.[\Y+^KA&/?TE?T/$0I _,XM1CS\W4:]I'G[SL9&A6^9Y"TJD1F>".WK2[
MGTT1IM_S,0.(88DW&WL\?&[\PX/Q&^7U]'SC>&^/TA!B%#PSAK60(O"<LQ/A
MLI43F3M2C!LA3H1@(]N1#8B7T/>%ID;/V>-:LP\P4$64@:7.A_:R@4R/!,J%
MO],A)=]L%C<]0$V=T\C68R"_3_6BUXE#D(P!/ )(WE@19*8YW<"+BQDU)-BN
M:=?#6!HC>@9&!TZ>]2_NLC 01L <A"0NLS[)E>77?"AWI#'+!@>+-GIB3QZG
M;3S5*434P1N&Y-#A2WJ76;K3C5 -2(IVMM)EB"7[3.>#WY,3Z -*: "7@51!
MJ1,WV^7\5/6QR<H<1E:BO<O\H<BQ#GQMOIK^0R80,AQ*^\B5'4B&>ED?]DML
M=I:?S7C8UYLOTI?*8ZH0B(,<1*V.&EY4%AN8F(])$!]\&A:M8;[O4AR_KU"&
M#O^0M/Q0E0XYP4K5PD6'SA%!R"?0TE1AH>JR)J^702JEWQN9;?U5Q51U8?M_
MG7>N +H*RF$SO]>_>#.^C=ON7YO2+7$8T'K6W?,6Y(F:RM[1]&J&#VHS7/Z"
MUU^6%8)1U_0-TRO<W4-/HW-)X3W::#=J2 !_<;27?R TATY0^E \LWB4<^YO
M[*A/8F6QMIBUX U%TBO 7OKYLYV NZVNG=Q@0OK@L_#3B,(.%R\T(BQOTD?B
MIC$4YK#5E<^A38^H=7KVL)IKLZ 8&O*(+QVD8(>177@ZO_LF%P<9Z%Q_$CS/
M>!9R&P'+86Q*IJ_W8JCX<5?ZW6-;\$H>^HZE4.(U9E3]Z_)/O0) Y'+FC.,B
M[J,=4N=^/QU"H&YAE)VCAV+OB88G:&%U],*_UWEH[-34=6;],B[.J5:;-BT\
M<M-?/G^2C1.(-H2UV%$\DS/1('^8X3H,VJT\L_:SJ3KJS(T!LL.=JL-YZ# $
M'6M<9L_*0]QX(JY@<(4:?W$0XJI B]9DT<"ML[.C5*I$V;,3&@,N1=KG7/,S
M(&H^',:\84R/U>^,!3S-.W>!D<\?5T>E7P'HVEDPM R.EE)X9'P[^!M4%QZI
M1#4C?EPXWZ[5BOA(-/+#"DF/!JGWP,FA=B)@6DN"TQQ9?>*?4V6/!S\FP)4>
M\.[JSGLQ=-'G%EH(SH_3;F$N* '48GMF.&-$QH-O\#GY=\3>(C[P]?PU4]$R
M!,\]%CF+7D]&"W(I= R\3G#(L3^\C7E.>E(#J!FS^:X7Z^^,2\ENJ,\FE^<[
MVH!8NDB[@?BF-$G6P QGME< <EF0P"BW*DX3I?XW=7%QI<VT8=IC'MZ]2GXY
MQ4-[5!T+;X#'$QWSH)$:!#B^&BV0T$E)$"68]?P#S"C0NF I[XC"GI1;0JU\
M(&)*+C):!DF0LG<S'&]);^:WR?%.BP$AM*$G34)%JU!(_WM:<D(@"+<52K0H
M)8![.^]_,'-$J2:B%^/?$M[OFB3<<6W7N)WI?TMM>N2?J<6@NTV:BFWUPJ_K
M/+KP%&FIXCFI]?_1A+C9=\D8Z:RGIF26<O-]7MXG1B9^]8?/N<J9KVNP12.A
M]PS8V#?Z<"UOM?MDZG;TQ]<,(N,ZG^/JOK^(?M+L6!Y)X:'>@9.2\#W+JOGK
M>N*B%,_WK6&RQ>\A D! O,[0]\QB?I;4ENTP<:M(R:ZJQ$<0)4PADOK:PL=E
M$3\QF-OH]V="J0Q7=XJF[3H_(%\@ $V>I=6BL^'=EDPS#S/[]!PR+BI+HJ1V
MHWQZ;?VL2G?2 YSG_P47D?")E)2DQ'6Y_E:@/H=<CG-3$#@$PJX :"I\%^&T
MPF2WB9N7$%I!E,3=KD1?2/2;HF[[2Q&0Z'L)V//;(H717YO-^*$?SO0:@^M?
M7P%NM^S67F31HJ8\'RQW(-$L40IQ1>O1O>2G>7'U7#'JN#N<LQ'7LP&6G@M1
M@:/Z?PR*IE.C9<G3 4PR=Z9=4GMMFW,_8ZMDBPEZ,3S"QL*//':*(K5032V-
MTQ8HU.2BOA(I7B#'X*YVZ%;LE/FOUT!_B&/SF.#R+IO8'I>U-1ZB?%$*MQ/Q
M_C[;[H^3Z.,6)2" <7^D%8&6]9/M<L6_6TMZ*RI9E!OPJF6EV[ME0S6[.M!0
M]?9VW$6(JI6&1C*C)LVFSB#4[*0 EWO=I!"K#$K2A,!>F:96OZA.9D)N]R6@
MZ2=1HO"7]L..\F\0-YG8HV@?$V>;IH[)@O;IQD<NO&QAW5/\[]G@/@_^-YE7
M "%L[DES]NEG$SLP^0L.54;2^SI;=/=B-#<>W+K/\'1-Q3S]DCITSA)M@SBI
M:XDC)M5= 7J>D/!:JM[DR"[6C/[+T&D*^,HXGY5",(I!/_-*H GC)RV(J]DY
MZ<A*WNQ0+;(78S2,[UAVP<E$@P86M*@%59^^3:-YG!R^*K4UYB?2E&G8&?LJ
M6(7X_*(6:(VD5SR'/2'(8Y=O_H_VWC.JJ6][&PVBTJOTKC1I(M([J'3I34"*
MHD) >H= 4*1W0I$6!(30 E)#D] C(J"T"$A)0I&>B$"$ )??N>.^XYSSWC+N
M]_^'/<9:*VO-.3/7DSF?N7?6V(/$6RB#;U-#YYSX]6:OC185#T\5IM;T08_.
MJ))PPI,AKY!78_*="1S#P4WH8L7=!WC8(T(N IO*WJ=X?'(EU+./CQS?\*:^
MAYMX3X08 /NQW:D!QY7056Q[6L(2@J1O$/VG')(&G#N25-O/%UF+(/???T:V
MN9[3@6:6;C"=U7FS]OE(?\'7T;#HO%;->5@>?(_CBE\7A;HLTS^$14VKEEOG
MU-&IKG]U3&@,\]AA/)-B[XX=[0]VWZ8RR=5FRF010TAQQ0#(9CK[8VAP!4&7
ML5]71?5#.4>M:,2BW!+<;G[LTB',V1]^O[K*4JQL6*1182*E^X20E.0/=,AW
ME)<867CPV^WQ64</623"1H-I"F2T,C3C,B67C&1!]NV3.P-/*E.?UD9VAZI:
MX\T(C$W!B"F#25?TM<%FH7$WJA2N]6[^4Y>HL7/VR3]$%Z(GMH1>_T0G#E+O
ML$@D[W>2,G;635L_4OWG-=04%@1:UX%,#W;+!WY'"UK+;G&R')S6K*>,2+PG
M,J%[0L5T?FXUQ$8BG<(^71+)S)1HV*4:L-[T-WJ#(L4ZG1A',>CFJ;CK(]XC
M]-.VW^8K(-='1>N!?HC,8KKB3;22A83TH67B#GJZRF,U&_)^J5JJ> 9>YBC?
M:/I&S? 8\L7WAG%+Q5B,4:YY<[*-H5D2J,T#GW6L(3(Q[*5XE'>6WZV^<G:?
MUPUSG%3?(^D1Q80FW2Q[0HSHC^(SC2_PFFTXZL.XS?ZI)CVXMKMQ% KM"^J*
M=G3[7?]0)F,D79( 'EY^TXD:-F4./=!I)$S$=<O@I-^$+#.0=*KLB8H#W^U_
MD/20S6S'*A.Q) F*Q#>/0S4GS&:_CU9IE+(\C]I-V#A^?YE3YJ>9;KB=VAFQ
M3J>-!@2)OL7F5+8\"_"H%=JY]<I%:C TYRX'8T"6,U%^V]YM"=E:T?_4=P\D
M1M-YZ%@BMWZO&\!1B8N!/-F/"2VVJ[O&+N5U^D7B9<.YR*3-7^?2&/SQ(-_C
MBJRUW\!-<,VO,ESYDR.#W8J?)=*R>JO(WN64DN:\@>7HD!XI@D)Z4-T\,6(H
MZ@;1&+YY7,( 4FT@(K#>Q=)O6UFZ6[YAIUO;L7AH<E"#5!LLHB[UOM&O@N5G
M]NW!K*_!IW91XQ:_.BO3JTC2!(U&S&FRHZ(QGO]UX/X5HJI^.]&3K<#+!%FZ
MI7$[WMFH@:78(G2M)PGK[II"Q<8^;*+IXG!.%T(0CWN,]"Q\G=4;C^^.,I=J
M"8.:SM-J^*9DVUV-\JC&H.S_J3;1#3>N6UT XA 9 T@A<+\$^[L8=Z'>,1DQ
MN119H0[IUVGOZF'])&/T-9WAA0.SYKD1A=V7\W_"/^Q8K/@P*CLKTKLTT&5[
M8)B#U[S169[YM7 ?MC5C>S'^7#Z6LT[-EX,%8STB1--+PKVMJGF-".N?ISM*
M7)&F"&4>T%=!)M0?JG,/ #$+THQPR!!F5\$S@N;,O.BGA^+MO3'QJLR.=.JH
MV>6FL38X(<"6F(/QX2/.HH>@7--JFBN:](])$GCZF#*BCW[A &)>-[UL*THO
M,>7WXJ\>H1(3I)?)SQ8TE?L43QOC>>?(92KI"2T+IA/=]>*T:-Q+/V>B"=0B
M-)__EC?(L3"NJ_E=LY=1ORXT.7HY$1E: (*<V@G2_NUQ(!J*F;_XLAKM1I9C
M%99$#XYH.=J@PI>P6I>H/T'2B2F+^2-K(X3G(M1OE;5X2^A5[#7XP\B(R?8M
M-58C_A> *!"I.>W:I,EWFT!(2IAC'88;5=ZIF3W*'6DX/SZY;'OOB4<NOBX\
M9_ASOW$@.>,O9JTKE/9RO>0!Y0I40Y%S%X"KHX2TQ!5^XFV]G7QL.HM#)$P[
M'JM0BMDN#/7"%FR<F@XY<<P$?J+730MS3626TL86_92K^Z[#S9):<@7IM_)/
M\.M^5)4$]LQ_&>1UNM#O>^?/Y_DGG"49,.^ +,">N+'F.5T*H3(1;K?=R;#[
M.NQ#:/+#:;G%"-V95Z1[&4N;)^-Y8GG&R#AG5>JCG4?:V72-7_Y2)*%H^M1T
M8K]N/H.]+K=X6W._PD.FF -%3+),EWP.3>Q2:H&L-;68J#7T+\GW^O$YYF/O
M?97#MP10OK2^^Q'*:P9+#(K\4$%M *. =5&>9AJ*N:<O@!?R5HJ@PHU3/4).
M).EOER4Q.6;2PTFDDVA:YRQ?"1=-$5VXEM912E/K"5<@O(\S>)B+:)HOJ[JG
M=_,5^=\7I_^4T$FS/0*>- 3RX;L+CXFH1]^[_7#*^U+S![9$TQ5I%CH3%&:Y
MES]F7OU3+;"3/?F/IY%1?K<S5OE%TN)J]T<%A.)UNN]1[XD^1T.FT;A^Y#7P
MJS\=>(KT7!K'&P;$6+:\D/I0?FQ.?8F[%!CQ<AH._]#R7;KAJ\CZWOC?LA][
M]YNO7(O8@VJ^2!7Q<D5QV2:>LP)E/2$ZM9[AB]#6,J80J2*[U@Z^R,$JB+:W
MH>Y-_2]Q2NG!,B?KVGEX;W/+>U]K?"LI^ NQ?C)P\1:_#&M\Z+M.DZ*MI\V=
M[477.)_B3*RY1_'3?QV"7#I:P;,\#X:Z Q*^_/Z*%!I3<I!*X\[*E6 O6=E2
ML^$K$A0;#G6?/'JL0ASB-)J?'9JML&4W214/XM6_SP2Z .Q4X"5Z2\@"G9FV
M>ECP0\LQKT &?*58WI>C3]"'#"RA>5;Y@EGK7JY#7$L5?K)/G)_HIFQ>&152
M^*Z8D75U6"WOB*:E@&$.^6B6B_)]&V%YR#1-D[E;W;MC7DT*!T[LN8E6T\ J
M8+^./ VAA;O'/2Y[5:,*H L ,T;=]>!O2\O$@N=.CPQ["+HEF'3F;B@7L>14
MKX_GQ#K]C9S<!2#C*Q\#]$0(XH0.TF?]LV#G966_0 4%R[X*.@YY$T6YV4.)
M]WFK1H;I0G[\!:7 MZ5B/O'2K^>TC'&-<W.'B0KR;][X*[(5,!)6$>QO,#*?
M*\M:8-@FRY04BK9E33"O/4QZUVJ25%.J1W58D_FV)M(BQ=7HV,^J[-.\U%22
M$6JDNDO7E)=GW*+8@U@WS%2LHE3GZ.-V6)/M_H4%8Y)=HVT$H>.OZ1NS'##H
ME_6J:7+SU6]/+<[1IZ7F8U#Z_+.&NX'G-?1!;T9JY>UH@2S:HK5$U,WK?A-.
M);%!R_C:O0\4W@T'(?X<ST%OI2F*>*"APHG;27Y$ZU#P^IU>'.??$9Z@M?1J
MC9G-S= YH0[!/3B+O8VG24.(-R+2]'V2X:97R-+QWH(78O(LITV91Y/T._[\
MG/_\5LK_:G42+@D[N4K'1!0WR?T"$&L7<0'0#OBK2/QF_OGI!6 C6_,8?P$@
ML/Q;FQ5]21#K/ET WG>0"O]K$<7-^ L U.P"L'Q)7@?-_[UCZWP!H&XZ/G^S
M\=N'4'[.^F+_[-K$ZC).BR>._SSLP04 S' !8-+]M[8CF"0^NGQ"4S*"'$XG
M6N<A_[!K0L"I #\B:.-+_/)Q_#3#WFEZ;X2E4*8KK2.+7TD.0HQ<$.KO:RKP
M.N7&N)]C)M$VW.\"<"-@?R"<:7M?CR2^/?.7W<;"]&N(( ] ;W%+94.P)T"+
MSR_(M^GATRP%K?%V*VJ#%Q8HJ0Q?LFM^:60</&X92)V>[H^(YA2U735/3HZ4
MVGUK6@.AH&N)?0*!#;[M1-OJ4>Z:;:8X%YA? E.&GE+?,&!83\BO8!F_/R E
M:^3N+9T?1%/U4U_X::R-9889;<CNYPE[P-Z?7\4"C4F/5!^\8 FXN\+V>]J%
MF5Q166"%)VC?@?7A V5?HVMF?W$->9!62MPU%IS >6MXM QZ+?'+6Z& S(Q>
MGMAG9$(=9E2\'*O0\/.@"T"?3A0CR8J(P8N,8D+Z>>^H3G!N.S.KL=<#H<(E
M5EQ!\=%[(-GZ^>U9C=L$/HB !':9=B "-N0&#XV$WHAT#;HEPD/!7YZZMGNU
MN")C _#"E.-O>);V/,N57D9ZB0//<VI! C^*RW1@@HQTFVB _4SB)QCA&H8:
M:$+Y!]!11FU=89BQ>W9JU@0Z-56R :G5*-9OASJ*L@F8UT) 5Q&SZ,W7%=8O
ME4 ZU$DY]O(WQ0W++"NN5X09FI7L_73!2''Y93N8;"X&/.-QC8-S91;A+(JR
M%T5O6Q7C6EX8!X@L%H79K\VBFTP/0H9+FBA(K&\B75'VG>>3TFY8.NE>!0U^
MO'I)?R3?:#^2QEON=.'U9>U^:Y[X\NA\?4^3LX6[Q&CF97O2%\XV=A,Z7ULP
MWD1S87+A"6$65@%Z/"V]VQVP H[O89Z2!W-LH[GBDYYUXL<+RYRVSF\1<WP\
MF%&#][9"CD[2DBN!G8Z+*2J6.=-.$:AG.?O+-$@OA@7$4&=])K[K,CX*=;_Q
MX01&,1>B>FY/RG<Y^%S9;%,D.]PD64A/_MP**:@O$.J<7&^4!G*^,!!:"D:+
M$0:._OE'?<+<.=J978T<?X"Y "2UFD:;A98/E-!U7ZL!\M&G!^<UA)KVMH$9
M04^Q-,46A+)3IW2LT6P7OCBEMTDGY(;D\PX+L+;U0;>W2"Z?'-$I%2>>6<WA
MXOL'9I*-,XAPXW/OFZD6PIA8F 3[Z(L*]M>^'6F4 YZY2M<F6SWA>9$P^-(R
MJT3R0_83&:)WF+;"(N2M4ZX_"#9>TF*[@[L 7-,F2F!251_B\X89DDHXUHDE
M066;S;^B&&?V=UJ=Z8@U$H7R3>@_9Y&!"Z.77;T!?3:C1:Y0F$K%I]JAH_;Y
M1^D(3: /412]*T-H/HJ;.5<.]<3IYF-HD.0D-KQ(#+[+M//;7JNCJ14QLU3X
M[ A>[[CUS2.WT?W;I\.O;.@,N\T0NM".,"%32=VEL _@/GWPJ]%J$&OI90QJ
MQ)LTX"(-)T^'"A #RW3 *!$D 5JQ@NKI^!CW/6,.GAY+TH8-^4BM'FS;,CYV
M[!:66O/=8E#%(X\:_CD9 ^+'TVIP$%"]V\MI3H+?]M0>$"1L";J0]UN,CAX]
M5V>T"7RI*V?RUH*(#H)N/K#ZQ^8QTP#R./?@/NN'^^(R/^X('+54[(2&%^&S
M"=0!Y:F]%K'N3EE%GPHL+ W3A97:[S_Y7NCG7;-N_U0T;RK'_K&'4J=OM;7R
MJ1@6+81["[U.G:IG82V&VCH4UX;9V-2>C@18&98VXQ>.U"ZM2]D^N8,H)>D0
M:W%2- -1 NT$$SA671R<=%PP# /7+(3J/6G&'Z:E5^EA3@T"&6@]3LYA;D&1
M;OSSWEZV1J]=W823""4,R*?\1+'X 09J=P5-2@UE)R+U0A^4,D\+'_*FVQ:;
MO,_K/A]5&DFWBTH*<@36"S1UH ]372TZLR*O'VWM79MBQ=Y[B%6O!!-#T;M=
M-0ON!2W+Y/*G;R</'99Y#$3CNQFPW-R>$]3U)7?B@S#+C//+"T.AIF_W2=J5
MH;7V;(WR8WO%'QS[7++&3IOG'<!]QA< (!!DCM&,9^=GZ.9^'[IAWH@^](PT
M&IQ_B?@ =&8#296Z(U1V]U- W&Y^U,N_.J,@0"])=ILE@:0O6\!^CEN9CIYE
M=['0\!\=*^W6,%WY,&')'BN,;K&R13;,>$C)Q"_[IL6]LS_3[C-K!H8^'A:]
MF.JIMX*IV>ZB)@4-B4/HHBRGK>RM:8L:".AC]NHN4$?^>23XE"9J%-S2,(#D
M'L*:IB/9SP5#]P>BN(FF&"_!?B[V5#4#KZHEQ""=I1U:7CHA?+;AK,23]L80
MC]\OMBA>2\%6.,1QX+:_.6J;KHY91Z;O[,L;Y5<=+X7SDU>8WZ?<IN#@.:;
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M4I@6W"OI;.M^AJU<+?XPLP=1!+:/Z!I*P=R>SW^'0T]:#G<K=TB+1+K+6"4
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MZU[A*W]\\(.9'M"WT"40LUP*.!;-4NZ;^AU_7!3T:PD9>SN%-L/@&>7/91G
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MDA"SF[?9FC(\LS==LIW<6"GI35_8QRI&JXET2N_28*5LA\',/5>COH:CARX
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M67]9F7M9[B+&'C.HG_^<#;\ ]$M5N:''8TBW+[O(7S;3FOM_-#%.L3H2H L
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MBQ#Q&?AT-(9@.-0 ^QOR;$P>[Z\3L"O?W]"ST>CEY>7(PUOX@LEW>F3AM1[
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M+D^OK4N5#54 V86Y&?"0@M(*#9D#$8U>;,^G#@&1F]U<Y_A$+8VX?S;6KJ;
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M,0GGCRJAXV\7)%D1YU&R;APU[::!6MKAUH$)<F<#024*@PI&?.)F0JW0.M:
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M85HQ>'01L)G(PA28/\-4?-*$.U9W9$[2YRA9JEUFE;@7PBA 2UDSD(5''3E
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MA)@!>%OP/K9^39]<"?*SWH0'2'XSV%>W!5\%5]VMSH/LZ2I./YG2.>A5O,3
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ME'1.%OVFO$(,%E&LMM[[-/&QTU[CG1,<YF23A%=QL-;4:R#GFAE2F$->](1
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M:_2I*@;5<SV(*94?S5_L<?07N\>;(&(GPL_3)"?!,B^">(')1I5IW L2YW;
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M@Y0AVX6<@%_HGC7Q!0;;$W%3ZB=L6;JET>K*"=PT$/CF38A7(K$+KMM_O'M
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MMR/L2KR;'-^%BLBJ(\_8-TT\8_E71GXX*G[GK\XZBG\:99_#]YD5W*'-LFQ
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MS/U?D?<>*&3'D^F(@V[/R7ID;UZ(RPS1#;EB<WX1T:WD,,;:2II:@'E).PK
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M>E9_TL6U!8N;241B9A ]DC]3G^XYU:RS)OUQ<[4ZDJ Y8);<68M;YIF_RE[
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MG1,_X4^<X:WH-41@YTN<H')+16E^FK'I@;J^\>(5[JW<$,SHP[Z6/]T)8Z0
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M/1A@?H$TQJ82@*AUXGIS14-U&:/F6VN1/9#D+G2C%>$.@GTL["PJ;&S+*&
MQV)YDPO1>"#DL'>8&5>2:4.TT*5<\I$=1T 7?&D:&1L.@QUZWDC$C: Z::^]
MA./<,5AAW%@]Y -AQXAWJ2 ZN$Y:16J!,G1UX4==-Q*WDO57)=1<@^%BW7?
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M#@;#Z+HM_PO_GV>VZ+#?_']02P$"% ,4    " "(1@=;T%!#!X@'  #>+P
M"@              @ $     97@S,2TQ+FAT;5!+ 0(4 Q0    ( (A&!UMU
MB(A7B@<  )\N   *              "  ; '  !E>#,Q+3(N:'1M4$L! A0#
M%     @ B$8'6]"\>78&!0  [2P   H              ( !8@\  &5X,S(M
M,2YH=&U02P$"% ,4    " "(1@=;HGS30RK\  !F_@D #
M@ &0%   9F]R;3$P+7$N:'1M4$L! A0#%     @ B$8'6_;SKY=J.P( <U "
M !               ( !Y! ! &9O<FTQ,"UQ7S P,2YJ<&=02P$"% ,4
M" "(1@=;\4!2@K(-   XC   $0              @ %\3 , <&-S82TR,#(U
M,#8S,"YX<V102P$"% ,4    " "(1@=;S3"_6PL-   #EP  %0
M    @ %=6@, <&-S82TR,#(U,#8S,%]C86PN>&UL4$L! A0#%     @ B$8'
M6U=AOVT\(P  /%H" !4              ( !FV<# '!C<V$M,C R-3 V,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( (A&!UN%M);<TE4   'I!  5
M  "  0J+ P!P8W-A+3(P,C4P-C,P7VQA8BYX;6Q02P$"% ,4    " "(1@=;
M9N;%S7\]   (_0, %0              @ $/X0, <&-S82TR,#(U,#8S,%]P
<<F4N>&UL4$L%!@     *  H :P(  ,$>!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PCSA="http://processapharmaceuticals.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcsa-20250630.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2025-08-05</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-292025-01-29_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-29</startDate>
            <endDate>2025-01-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="From2025-06-182025-06-18_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-18</startDate>
            <endDate>2025-06-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_JunePOMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:JunePOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:ChiefExecutiveOfficerAndCertainBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-29</instant>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-18</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_EmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-19_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-19</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JanuaryPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:JanuaryPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JunePOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:JunePOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonWarrantsMember_custom_JunePOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:JunePOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PlacementAgentWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SeriesAWarrantsAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember18079015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-06-172025-06-17_custom_PCS12852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">PCSA:PCS12852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:CROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-242025-07-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>PCSA:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-06-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-06-30" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-06-30" id="Fact000006">0001533743</dei:EntityCentralIndexKey>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:IncreaseDecreaseInDueFromToRelatedParties
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:FinancingLeaseLiability
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2025-01-01to2025-06-30"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2024-01-012024-06-30"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0672"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0674"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2025-06-30" id="xdx2ixbrl0872">http://processapharmaceuticals.com/20250630#OperatingAndFinanceLeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2025-06-30" id="xdx2ixbrl0875">http://processapharmaceuticals.com/20250630#OperatingAndFinanceLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="From2025-01-01to2025-06-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-06-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-06-30" id="Fact000016">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-06-30" id="Fact000017">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-06-30" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-06-30" id="Fact000019">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-06-30" id="Fact000020">Processa Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-06-30" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-06-30" id="Fact000022">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-06-30" id="Fact000023">601 21st Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-06-30" id="Fact000024">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-06-30" id="Fact000025">Vero Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-06-30" id="Fact000026">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-06-30" id="Fact000027">32960</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-06-30" id="Fact000028">(772)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-06-30" id="Fact000029">453-2899</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-06-30" id="Fact000030">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-06-30" id="Fact000031">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-06-30" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-06-30" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-06-30" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-06-30" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-06-30" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-06-30" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-06-30" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-08-05"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">50349149</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">6936620</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">1191325</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000050"
      unitRef="USD">217201</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">682294</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">7153821</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">1873619</us-gaap:AssetsCurrent>
    <PCSA:PropertyAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">4414</PCSA:PropertyAndEquipmentNet>
    <PCSA:PropertyAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">5016</PCSA:PropertyAndEquipmentNet>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">993701</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">1274442</us-gaap:PrepaidExpenseNoncurrent>
    <PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">993701</PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet>
    <PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1274442</PCSA:AssetsNoncurrentExcludingPropertyAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">24318</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">70677</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">5535</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">5535</us-gaap:OtherAssets>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">29853</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">76212</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">8181789</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">3229289</us-gaap:Assets>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">25584</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">73020</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000092"
      unitRef="USD">785754</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">880880</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">1263243</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">578731</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">2074581</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">1532631</us-gaap:LiabilitiesCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">487</PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000107"
      unitRef="USD">2074581</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">1533118</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000121"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000138"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">40289356</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">40284356</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">3707628</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">3702628</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000135"
      unitRef="USD">4029</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">371</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000154"
      unitRef="USD">100390701</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">89214999</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">-93987522</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-87219199</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">6107208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">1696171</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">8181789</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">3229289</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">2447286</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">1730444</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">4035767</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">3269555</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">1503497</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">1351580</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000185"
      unitRef="USD">2762006</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">2622067</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-3950783</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-3082024</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-6797773</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-5891622</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">16865</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">71698</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">29450</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">154915</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-3933918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-6768323</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-5736707</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000205"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000211"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000215"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000217"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000219"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000221"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000223"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000225"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000231"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000233"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000241"
      unitRef="Shares">1291000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">80658111</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000243"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-75369081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">13176</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000245"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000246"
      unitRef="USD">167642</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">167643</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000259"
      unitRef="Shares">1555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">6282274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">6282430</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000267"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000261"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">188999</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">189000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">3750</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">1</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">9923</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">9924</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-2726381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-2726381</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">2860981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">286</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000290"
      unitRef="USD">87278542</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">-78095462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000293"
      unitRef="USD">8883366</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000305"
      unitRef="Shares">14167</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">152631</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000303"
      unitRef="USD">152632</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000313"
      unitRef="Shares">1265</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000308"
      unitRef="USD">2008</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000311"
      unitRef="USD">2008</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000327"
      unitRef="Shares">2873883</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">87429165</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000329"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">-81105788</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000325"
      unitRef="USD">6023664</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000337"
      unitRef="Shares">3707628</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">89214999</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000339"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-87219199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">1696171</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000347"
      unitRef="Shares">11721</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">227710</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000345"
      unitRef="USD">227711</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000355"
      unitRef="Shares">1556672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000349"
      unitRef="USD">156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000350"
      unitRef="USD">4438414</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">4438570</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">1781</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">1</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">1438</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">1439</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">-2834405</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-2834405</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">5274240</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">527</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">93879685</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-90053604</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">3526608</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000387"
      unitRef="Shares">5274240</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">527</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">93879685</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000389"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-90053604</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">3526608</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">143103</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">203236</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000395"
      unitRef="USD">203251</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">34894000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">3489</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">6316743</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000403"
      unitRef="USD">6320232</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000413"
      unitRef="Shares">21987</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">2</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000408"
      unitRef="USD">8963</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000411"
      unitRef="USD">8965</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">-3933918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-3933918</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Shares">40289356</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000421"
      unitRef="USD">4029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">100390701</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-93987522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">6107208</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000437"
      unitRef="Shares">40289356</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">4029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">100390701</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000439"
      unitRef="Shares">-5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000433"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-93987522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000435"
      unitRef="USD">6107208</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-6768323</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000445"
      unitRef="USD">-5736707</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000450"
      unitRef="USD">602</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000451"
      unitRef="USD">278</us-gaap:Depreciation>
    <PCSA:OperatingAndFinanceLeaseExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000453"
      unitRef="USD">46359</PCSA:OperatingAndFinanceLeaseExpense>
    <PCSA:OperatingAndFinanceLeaseExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000454"
      unitRef="USD">42670</PCSA:OperatingAndFinanceLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000456"
      unitRef="USD">430962</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000457"
      unitRef="USD">320275</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-745834</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000463"
      unitRef="USD">980554</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000465"
      unitRef="USD">-45073</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">-41228</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-95126</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">641469</us-gaap:IncreaseDecreaseInAccountsPayable>
    <PCSA:IncreaseDecreaseInDueFromToRelatedParties
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000472"
      unitRef="USD">39</PCSA:IncreaseDecreaseInDueFromToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000474"
      unitRef="USD">684512</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000475"
      unitRef="USD">359123</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000477"
      unitRef="USD">-5000253</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">-5394713</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000483"
      unitRef="USD">10758802</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000484"
      unitRef="USD">6282430</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000486"
      unitRef="USD">10404</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000487"
      unitRef="USD">11932</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000490"
      unitRef="USD">8561</PCSA:PaymentsForSettlementOfStockAwards>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">2850</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000493"
      unitRef="USD">2301</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000495"
      unitRef="USD">10745548</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000496"
      unitRef="USD">6259636</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000498"
      unitRef="USD">5745295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000499"
      unitRef="USD">864923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">1191325</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">4706197</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000504"
      unitRef="USD">6936620</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="USD">5571120</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000510"
      unitRef="USD">1880</us-gaap:InterestPaidNet>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000520"
      unitRef="USD">189000</PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000525"
      unitRef="USD">11804</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <PCSA:FinancingLeaseLiability
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-11804</PCSA:FinancingLeaseLiability>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000533">&lt;p id="xdx_80E_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zIZIjLFBErTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82D_zFIjwmIv4qfb"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zmQ34fiLtj4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation Cancer therapy (&#x201c;NGC&#x201d;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications
of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known
and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments
will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmc2n4cY4vO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2024, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2hdvmOmWDs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all our efforts toward research and development of our NGC drug product candidates, including conducting
clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20250630_zNh9yWsIe164" title="Accumulated deficit"&gt;94.0&lt;/span&gt; million
at June 30, 2025. During the six months ended June 30, 2025, we generated a net loss of $&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zFzXmnNyo545" title="Net loss"&gt;6.8&lt;/span&gt; million and used $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zpQwioDX2aL4" title="Net cash used in operating activities"&gt;5.0&lt;/span&gt; million in net cash
for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore
we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We expect that
we will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from its operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 29, 2025, we closed a public offering where we sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2IACKKI10E1" title="Number of shares sold"&gt;1,030,972&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock, pre-funded warrants to purchase
up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z58Do0rJpmlc" title="Warrants to purchase common stock"&gt;7,019,700&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock, and accompanying Series A warrants
to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZTmd28bUka4" title="Warrants to purchase common stock"&gt;8,050,672&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock (the &#x201c;Series A Warrants&#x201d;)
and Series B warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCXIC3WoAcM9" title="Warrants to purchase common stock"&gt;4,025,336&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock (the &#x201c;Series B Warrants&#x201d;)
for net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zioWwupi64G1" title="Net proceeds"&gt;4.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). On June 18, 2025, we closed another public offering where we sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYXePnTaJ6j4" title="Number of shares sold"&gt;14,310,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, pre-funded warrants to purchase up
to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--JunePOMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zXWIl4CjZbd2" title="Warrants to purchase common stock"&gt;13,690,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, and common warrants to purchase up
to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrNMa5jWEqYi" title="Warrants to purchase common stock"&gt;28,000,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zH31S1JuM2Z3" title="Net proceeds"&gt;6.2&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). As of June 30, 2025, all Pre-Funded Warrants from both public offerings were exercised.&lt;/span&gt;
During the six months ended June 30, 2025, we also received $&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6EycM3aubbj" title="Received exercise of warrants"&gt;100,000&lt;/span&gt; for the exercise of warrants to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjpAP6rnKIa5" title="Number of warrants exercised during period"&gt;400,000&lt;/span&gt; shares of common
stock from the June PO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;On August 4, 2025, we entered
into a Securities Purchase Agreement with an accredited investor and sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGdBVoKFE98" title="Sale of stock shares"&gt;5,467,181&lt;/span&gt; shares for $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgX2dT0HbjF3" title="Gross proceeds"&gt;1.3&lt;/span&gt; million in gross proceeds. We also
sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxqId1oMYKpi" title="Sale of stock shares"&gt;4,597,612&lt;/span&gt; shares for $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaplZhOhCk9j" title="Gross proceeds"&gt;1.1&lt;/span&gt; million in gross proceeds under our ATM agreement. Following these investments, we are exploring options
to pursue a cryptocurrency treasury strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2025, we had cash and cash equivalents totaling $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_z8sFX0LwBso7" title="Cash and cash equivalents"&gt;6.9&lt;/span&gt; million. Based on our current business plans, we believe these funds, together with the $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250801__20250831_z7xMLlYVDhXi" title="Gross proceeds"&gt;2.4&lt;/span&gt; million in gross proceeds we received in August  2025, will
satisfy our capital needs into the first quarter of 2026. Our ability to execute our longer-term operating plans, including future preclinical
studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or
debt securities, a strategic transaction or other funding transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_z5RcCwaqmVAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z2Ef04Iwn7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2025 and December 31, 2024, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2025 and the foreseeable future since we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z5mNCpgeT9r" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Concentration
of Credit Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2025, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTwDrg7o1fOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_zXPgsjBm4eK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000535">&lt;p id="xdx_84A_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zmQ34fiLtj4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next
Generation Cancer therapy (&#x201c;NGC&#x201d;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications
of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution while maintaining the well-known
and established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our NGC treatments
will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000537">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zmc2n4cY4vO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2024, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <PCSA:LiquidityPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000539">&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2hdvmOmWDs5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization
of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,
currently devoting substantially all our efforts toward research and development of our NGC drug product candidates, including conducting
clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20250630_zNh9yWsIe164" title="Accumulated deficit"&gt;94.0&lt;/span&gt; million
at June 30, 2025. During the six months ended June 30, 2025, we generated a net loss of $&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250630_zFzXmnNyo545" title="Net loss"&gt;6.8&lt;/span&gt; million and used $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250630_zpQwioDX2aL4" title="Net cash used in operating activities"&gt;5.0&lt;/span&gt; million in net cash
for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and therefore
we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future. We expect that
we will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from its operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 29, 2025, we closed a public offering where we sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2IACKKI10E1" title="Number of shares sold"&gt;1,030,972&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock, pre-funded warrants to purchase
up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z58Do0rJpmlc" title="Warrants to purchase common stock"&gt;7,019,700&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock, and accompanying Series A warrants
to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZTmd28bUka4" title="Warrants to purchase common stock"&gt;8,050,672&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock (the &#x201c;Series A Warrants&#x201d;)
and Series B warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zCXIC3WoAcM9" title="Warrants to purchase common stock"&gt;4,025,336&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock (the &#x201c;Series B Warrants&#x201d;)
for net proceeds of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zioWwupi64G1" title="Net proceeds"&gt;4.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). On June 18, 2025, we closed another public offering where we sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYXePnTaJ6j4" title="Number of shares sold"&gt;14,310,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, pre-funded warrants to purchase up
to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--JunePOMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zXWIl4CjZbd2" title="Warrants to purchase common stock"&gt;13,690,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, and common warrants to purchase up
to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrNMa5jWEqYi" title="Warrants to purchase common stock"&gt;28,000,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zH31S1JuM2Z3" title="Net proceeds"&gt;6.2&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting placement agent fees and offering-related
expenses (see Note 2 for additional details). As of June 30, 2025, all Pre-Funded Warrants from both public offerings were exercised.&lt;/span&gt;
During the six months ended June 30, 2025, we also received $&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6EycM3aubbj" title="Received exercise of warrants"&gt;100,000&lt;/span&gt; for the exercise of warrants to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjpAP6rnKIa5" title="Number of warrants exercised during period"&gt;400,000&lt;/span&gt; shares of common
stock from the June PO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;On August 4, 2025, we entered
into a Securities Purchase Agreement with an accredited investor and sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGdBVoKFE98" title="Sale of stock shares"&gt;5,467,181&lt;/span&gt; shares for $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgX2dT0HbjF3" title="Gross proceeds"&gt;1.3&lt;/span&gt; million in gross proceeds. We also
sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxqId1oMYKpi" title="Sale of stock shares"&gt;4,597,612&lt;/span&gt; shares for $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaplZhOhCk9j" title="Gross proceeds"&gt;1.1&lt;/span&gt; million in gross proceeds under our ATM agreement. Following these investments, we are exploring options
to pursue a cryptocurrency treasury strategy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2025, we had cash and cash equivalents totaling $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20250630_z8sFX0LwBso7" title="Cash and cash equivalents"&gt;6.9&lt;/span&gt; million. Based on our current business plans, we believe these funds, together with the $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250801__20250831_z7xMLlYVDhXi" title="Gross proceeds"&gt;2.4&lt;/span&gt; million in gross proceeds we received in August  2025, will
satisfy our capital needs into the first quarter of 2026. Our ability to execute our longer-term operating plans, including future preclinical
studies and clinical trials for our portfolio of drugs depend on our ability to obtain additional funding from the sale of equity and/or
debt securities, a strategic transaction or other funding transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our
projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial
doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements
are available to be issued. The accompanying consolidated financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might
be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000541"
      unitRef="USD">-94000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact000543"
      unitRef="USD">-6800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-06-30"
      decimals="-5"
      id="Fact000545"
      unitRef="USD">-5000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">1030972</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">7019700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000551"
      unitRef="Shares">8050672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">4025336</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000555"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">14310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-18_custom_JunePOMember_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">13690000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">28000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000563"
      unitRef="USD">6200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000565"
      unitRef="USD">100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078109"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">5467181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000571"
      unitRef="USD">1300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Shares">4597612</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000575"
      unitRef="USD">1100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000577"
      unitRef="USD">6900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-08-012025-08-31"
      decimals="-5"
      id="Fact000579"
      unitRef="USD">2400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-06-30" id="Fact000581">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_z5RcCwaqmVAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000583">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_z2Ef04Iwn7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2025 and December 31, 2024, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and is maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2025 and the foreseeable future since we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-06-30" id="Fact000585">&lt;p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z5mNCpgeT9r" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Concentration
of Credit Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (FDIC) up to specified limits. Total cash held by our banks at June 30, 2025, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000587">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zTwDrg7o1fOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000589">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1ghFS8XDkcb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82B_zmiSHmBEamp1"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2025, we issued the following shares of common stock:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
    January 2&lt;span style="background-color: white"&gt;9&lt;/span&gt;, 2025, we sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBLWqiaVnxIk" title="Number of shares sold"&gt;1,030,972&lt;/span&gt;
    shares of our common stock, pre-funded warrants to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDoVJ4mkLeH2" title="Warrants to purchase"&gt;7,019,700&lt;/span&gt;
    shares of our common stock, and accompanying Series A Warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zdfJbRXL4Yh6" title="Warrants to purchase shares"&gt;8,050,672&lt;/span&gt;
    shares of our common stock and Series B Warrants to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250129__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyfb6yPMQFh2" title="Warrants to purchase common stock"&gt;4,025,336&lt;/span&gt;
    shares of our common stock for net proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250129__20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zX2n72ca88tc" title="Net proceeds"&gt;4.4&lt;/span&gt;
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#x201c;January
    PO&#x201d;) &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at a combined purchase price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAOyKa1uPNf" title="Sale of stock price per share"&gt;0.615&lt;/span&gt;
    for institutional investors and $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndCertainBoardMembersMember_zvFg6aG7Euyl" title="Sale of stock price per share"&gt;0.7975&lt;/span&gt;
    for the Company&#x2019;s Chief Executive Officer and certain board members who participated in the offering. The Series A and B
    Warrants both have an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250129__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zaHPIGUsXnee" title="Warrant exercise price"&gt;0.65&lt;/span&gt;
    per share of common stock, and were subject to stockholder approval, which was obtained at our annual stockholder meeting on July
    18, 2025. The Series A Warrants will expire on July 18, 2030 and the Series B Warrants will expire on January 18, 2027. At June 30,
    2025, all pre-funded warrants sold in this offering were exercised; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
    June 18, 2025, we sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKTY8byf7pCd" title="Number of shares sold"&gt;14,310,000&lt;/span&gt;
    shares of our common stock, pre-funded warrants to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0bWixmHz5u2" title="Warrants to purchase common stock"&gt;13,690,000&lt;/span&gt;
    shares of our common stock. and accompanying common warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znWIqShlfNoj" title="Warrants to purchase shares"&gt;28,000,000&lt;/span&gt;
    shares of our common stock for net proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze4DwWpXikG4" title="Net proceeds"&gt;6.2&lt;/span&gt;
    million, after deducting placement agent fees and offering-related expenses under a best efforts public offering (the &#x201c;June
    PO&#x201d;). We sold one share of our common stock and accompanying common warrant at a combined price of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaOwSQUNP838" title="Sale of stock price per share"&gt;0.25&lt;/span&gt;
    per share, and a pre-funded warrant and accompanying common warrant at a combined price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_ziNBP3SE0hQ6" title="Share price"&gt;0.2499&lt;/span&gt;
    per share. The common warrants have an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_ztAFoLaJ5Ki2" title="Warrant exercise price"&gt;0.25&lt;/span&gt;
    per share, are immediately exercisable and expire five years after their original issuance. The pre-funded warrants have an exercise
    price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember_z0KRQNVa8MPe" title="Warrant exercise price"&gt;0.0001&lt;/span&gt;
    and are also immediately exercisable. We issued placement agent warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zTReL2a8sQV1" title="Number of warrants to purchase shares"&gt;1,120,000&lt;/span&gt;
    shares of common stock at an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250618__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_z740UOGCXj95" title="Warrant exercise price"&gt;0.31&lt;/span&gt;
    per share. During the six months ended June 30, 2025, warrants to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_z3yAYDxF8uo3" title="Number of warrants exercised during period"&gt;400,000&lt;/span&gt;
    shares of common stock for $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember_zQ87JitnQVs4" title="Proceeds from exercise of warrants"&gt;100,000&lt;/span&gt; and all pre-funded warrants sold in this offering were exercised;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__srt--TitleOfIndividualAxis__custom--EmployeeMember_z3Wdm3slowfc" title="Shares issued"&gt;74,804&lt;/span&gt;
    shares of common stock to employees, net of &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20250101__20250630_zFSEIzwsIAog" title="Stock withheld for income taxes"&gt;23,768&lt;/span&gt; shares of common stock withheld for income and FICA taxes owed upon the distribution
    of the shares; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_ziAFRD2giEmh" title="Shares issued"&gt;56,252&lt;/span&gt;
    shares of common stock in connection with consulting agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000591"
      unitRef="Shares">1030972</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">7019700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_SeriesAWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">8050672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-29_custom_SeriesBWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">4025336</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-292025-01-29_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000599"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000601"
      unitRef="USDPShares">0.615</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_ChiefExecutiveOfficerAndCertainBoardMembersMember"
      decimals="INF"
      id="Fact000603"
      unitRef="USDPShares">0.7975</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-29_custom_PurchaseAgreementMember_custom_SeriesAWarrantsAndSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000605"
      unitRef="USDPShares">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">14310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">13690000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">28000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-06-182025-06-18_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000613"
      unitRef="USD">6200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000615"
      unitRef="USDPShares">0.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000617"
      unitRef="USDPShares">0.2499</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-18_custom_CommonWarrantsMember_custom_PurchaseAgreementMember18078250"
      decimals="INF"
      id="Fact000619"
      unitRef="USDPShares">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-18_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000621"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">1120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-18_custom_PurchaseAgreementMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000625"
      unitRef="USDPShares">0.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-06-30_custom_CommonWarrantsMember"
      decimals="0"
      id="Fact000629"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-06-30_custom_EmployeeMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">74804</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">23768</PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-06-30_custom_ConsultingAgreementsMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">56252</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000637">&lt;p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqJqgJGrTKRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82F_z1bK6Pag2Kml"&gt;Stock-based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#x201c;2019
Plan&#x201d;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. The 2019 Plan provides for the aggregate issuance of &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20190619__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zg0FAI78MWeh" title="Maximum equity available for issuance under the plan"&gt;800,000&lt;/span&gt; shares of our common stock. At June 30, 2025, we have &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zVIDy0G7TP51" title="Shares available for future grants"&gt;357,420&lt;/span&gt;
shares available for future grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Compensation Expense&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zpg4GeMkaCLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zgJgUxTUru47" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250401__20250630_zcVscPdtSXu3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20240630_zNWAg5OJNjBa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250101__20250630_zz0NmpJrXoSl" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630_zfeZ7cIRtR03" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXLMkInpisw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;8,613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;45,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;55,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;76,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0KsLz1TPpK1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;194,635&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107,049&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;243,571&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zMEnZuIYZlhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;203,248&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;152,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;430,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zfCuakJXxNl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;No
stock options to purchase shares of common stock were forfeited or expired during the six months ended June 30, 2025. At June 30, 2025,
we had outstanding and exercisable options for the purchase of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdrtciP0MqL8" title="Options exercisable, shares"&gt;2,747&lt;/span&gt; shares with a weighted average exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znDFGlwvGfZ1" title="Options exercisable weighted average exercise price"&gt;409.09&lt;/span&gt; and a weighted
average remaining contractual life of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zipkqjoyNXvg" title="Exercisable weighted average remaining contractual term"&gt;3.2&lt;/span&gt; years. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2025, we did not have any unrecognized stock-based compensation expense related to our granted stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Units&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEpTZk5XqTjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zH7Q6Wk69Jp9" style="display: none"&gt;Schedule of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted- &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvWyFtyJZn1" style="width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;383,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3zFX1wdn3I5" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;19.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjJztqK9ZQnl" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0672"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3gRvcQMP6Dj" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGhj3E7NGK11" style="text-align: right" title="Number of shares, forfeited"&gt;(27,547&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyxpE39co2y4" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;53.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zog80YNNHcec" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, issued"&gt;(74,804&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z95F34UP6Y89" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;58.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP4ZmwMHp0d5" style="text-align: right" title="Number of shares, ending balance"&gt;281,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjAH2VNiTWka" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;6.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziTIyR2gCLf5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;(229,905&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHaDFq8RaBr3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;5.47&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CjqvEplxCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;51,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3NRGzVU0gql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;9.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zawHTNnLT6Fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2025, unrecognized stock-based compensation expense of approximately $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYJI1eVIK85h" title="Unrecognized share based compensation expense"&gt;148,000&lt;/span&gt; for RSUs is expected to be fully recognized over
a weighted average period of &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh8TpAcBy1Vg" title="Weighted average period for recognition"&gt;0.7&lt;/span&gt; years. The unrecognized expense excludes approximately $&lt;span id="xdx_908_ecustom--UnrecognizedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zw9NujZV6Ctg" title="Unrecognized share based compensation expense"&gt;253,000&lt;/span&gt; of expense related to certain grants
of RSUs with performance milestones that are being accounted for as though the performance milestones are not probable of occurring at
this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. While certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a stockholder
until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock.
The RSUs contain dividend equivalent rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the six months ended June 30, 2025, we sold &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JanuaryPOMember_zDVK6ZNgKbx4" title="Number of warrants exercised during period"&gt;7,019,700&lt;/span&gt; pre-funded warrants, and accompanying Series A Warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zntPkoTrz7t9" title="Warrants to purchase shares"&gt;8,050,672&lt;/span&gt;
shares of our common stock and Series B Warrants to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zJODoOZVYGG8" title="Warrants to purchase shares"&gt;4,025,336&lt;/span&gt; shares of our common stock in the January PO. We also sold
&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JunePOMember_z9WnlBqm5767" title="Number of warrants exercised during period"&gt;13,690,000&lt;/span&gt; pre-funded warrants and accompanying common warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--JunePOMember_zUy6ePLiIkW3" title="Warrants to purchase shares"&gt;28,000,000&lt;/span&gt; shares of common stock, as well as issued
placement agent warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--PlacementAgentWarrantMember_zG9mA6VXD8N8" title="Warrants to purchase shares"&gt;1,120,000&lt;/span&gt; shares of common stock in the June PO. During the six months ended June 30, 2025,
warrants to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zJWnN8x1q594" title="Number of warrants exercised during period"&gt;400,000&lt;/span&gt; shares of common stock from the June PO and all pre-funded warrants from the January PO and June PO were
exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2025, we had outstanding exercisable stock purchase warrants excluding the Series A and B Warrants for the purchase of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zZQkbFSvfIDh" title="Warrants to purchase shares"&gt;30,495,784&lt;/span&gt;
&lt;span style="background-color: white"&gt;shares with a weighted average exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_zcCf964kTF7f" title="Weighted average exercise price"&gt;0.35&lt;/span&gt; and a weighted average remaining contractual
life of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsAndSeriesBWarrantsMember_z9i5RAp8ze5i" title="Weighted average remaining contractual life"&gt;4.9&lt;/span&gt; years. We have excluded the Series A and B Warrants sold under the January PO from the calculation of the weighted average
remaining contractual life since we did not receive stockholder approval for these warrants until July 18, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;W&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e
did not have any unrecognized stock-based compensation expense related to our granted stock purchase warrants at June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2019-06-19_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-06-30_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">357420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000643">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zpg4GeMkaCLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zgJgUxTUru47" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250401__20250630_zcVscPdtSXu3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20240630_zNWAg5OJNjBa" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250101__20250630_zz0NmpJrXoSl" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20240630_zfeZ7cIRtR03" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zXLMkInpisw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;8,613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;45,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;55,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;76,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0KsLz1TPpK1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;194,635&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107,049&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,626&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;243,571&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_zMEnZuIYZlhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;203,248&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;152,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;430,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000645"
      unitRef="USD">8613</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">45583</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000647"
      unitRef="USD">55333</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">76704</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000650"
      unitRef="USD">194635</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000651"
      unitRef="USD">107049</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000652"
      unitRef="USD">375626</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000653"
      unitRef="USD">243571</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000655"
      unitRef="USD">203248</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000656"
      unitRef="USD">152632</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000657"
      unitRef="USD">430959</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000658"
      unitRef="USD">320275</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000660"
      unitRef="Shares">2747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000662"
      unitRef="USDPShares">409.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact000664">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000666">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zEpTZk5XqTjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zH7Q6Wk69Jp9" style="display: none"&gt;Schedule of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted- &lt;br/&gt; average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Outstanding at January 1, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIvWyFtyJZn1" style="width: 16%; text-align: right" title="Number of shares, Beginning balance"&gt;383,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3zFX1wdn3I5" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;19.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjJztqK9ZQnl" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0672"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3gRvcQMP6Dj" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGhj3E7NGK11" style="text-align: right" title="Number of shares, forfeited"&gt;(27,547&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyxpE39co2y4" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;53.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zog80YNNHcec" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, issued"&gt;(74,804&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z95F34UP6Y89" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;58.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP4ZmwMHp0d5" style="text-align: right" title="Number of shares, ending balance"&gt;281,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjAH2VNiTWka" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;6.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziTIyR2gCLf5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;(229,905&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHaDFq8RaBr3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;5.47&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CjqvEplxCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;51,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3NRGzVU0gql" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;9.84&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">383636</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000670"
      unitRef="USDPShares">19.87</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000676"
      unitRef="Shares">27547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000678"
      unitRef="USDPShares">53.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000680"
      unitRef="Shares">74804</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000682"
      unitRef="USDPShares">58.78</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000684"
      unitRef="Shares">281285</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000686"
      unitRef="USDPShares">6.27</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000688"
      unitRef="Shares">-229905</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000690"
      unitRef="USDPShares">5.47</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">51380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000694"
      unitRef="USDPShares">9.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">148000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000698">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <PCSA:UnrecognizedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">253000</PCSA:UnrecognizedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JanuaryPOMember"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">7019700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">8050672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">4025336</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-06-30_custom_PreFundedWarrantsMember_custom_PurchaseAgreementMember_custom_JunePOMember"
      decimals="INF"
      id="Fact000708"
      unitRef="Shares">13690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_CommonWarrantsMember_custom_JunePOMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Shares">28000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">1120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000714"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">30495784</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember"
      decimals="INF"
      id="Fact000718"
      unitRef="USDPShares">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-06-30_custom_SeriesAWarrantsAndSeriesBWarrantsMember"
      id="Fact000720">P4Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000722">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zC4JPyi708qi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013;&lt;span id="xdx_82F_z4HeVi6HFmyl"&gt; Net Loss per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing our net loss available to common stockholders by the weighted average number of shares of
common stock outstanding (which includes vested RSUs and unexercised pre-funded warrants) during the period. Diluted loss per share is
computed by dividing our net loss available to common stockholders by the diluted weighted average number of shares of common stock (which
includes the potentially dilutive effect of stock options, unvested RSUs and warrants) during the period. Since we experienced a net
loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and
six months ended June 30, 2025 and 2024 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive
effect on net loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3x6DRAv7bTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six months ended June 30, 2025 and 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zccZWdZJXXg" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250401__20250630_zBQyRflVH45h" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240401__20240630_zZEaQ7g6xDdd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250630_zDGNYNqEkei8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630_z8g5bxqfgZi6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zysC6SZSmFAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(3,933,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(3,010,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(6,768,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(5,736,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zCb25uWbxYNc" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zTwDq125EzHc" title="Weighted average number of common shares-diluted"&gt;15,569,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zNvcgA0igiBk" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zp8zBZE0AUk9" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zF5fdQcoEg1f" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_z7eXylfBtfhl" title="Weighted average number of common shares-diluted"&gt;12,401,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zILRm64pui2g" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zAw1NI5SyFzl" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250401__20250630_zOIbgKOcOOPe" title="Basic net loss per share"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_zrFAWidrfQth" title="Diluted net loss per share"&gt;(0.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zeLZqFlt6owg" title="Basic net loss per share"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zI493FwhU0hj" title="Diluted net loss per share"&gt;(1.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250630_zxYOMev6ukTj" title="Basic net loss per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zk2QVSTHEkDh" title="Diluted net loss per share"&gt;(0.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zPKr7WdquEI1" title="Basic net loss per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z4ndRW4hLfN8" title="Diluted net loss per share"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Weighted-average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WqXw0ZfFe3" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJknADl25iA" title="Weighted average number of common shares outstanding - diluted"&gt;15,545,266&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgkP1uSqdedl" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWsER6WVKnf" title="Weighted average number of common shares outstanding - diluted"&gt;2,849,192&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2zRbvhZdN2" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47QsL2S95J9" title="Weighted average number of common shares outstanding - diluted"&gt;12,371,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbFuJgrOAz4" title="Weighted-average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVtH5Xkuytz2" title="Weighted-average number of common shares outstanding - diluted"&gt;2,590,530&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted-average number of vested RSUs&#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpW4HpMsiUr" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znCVAMfgSTgi" title="Weighted average number of vested RSUs - diluted"&gt;24,046&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zXOEyX5ulBY" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5dk2uqVHA2b" title="Weighted average number of vested RSUs - diluted"&gt;134,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zauaD8l29EEl" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFQYUsMAJ4i" title="Weighted average number of vested RSUs - diluted"&gt;29,674&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zyBHiDAhQWkk" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z48afxRmNlcj" title="Weighted average number of vested RSUs - diluted"&gt;134,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zhiqQOUVgcie" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zqX8kaF32rAj" title="Weighted average number of common shares-diluted"&gt;15,569,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zw9Dc8wccNm5" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zqursHq06uda" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zn05tG4uxtJl" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zwCe6TGM7vCi" title="Weighted average number of common shares-diluted"&gt;12,401,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_ziO6dS7M7U24" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zLjZFflDinS2" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zJ6VASJqcMQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zT9Ny4TA34dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have
had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zRiN2IsB6Ra2" style="display: none"&gt;Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250630_zkrQzxy8BfSe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zrXmypGTbojh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhWcCfvVdS4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zvbHiH5u0Ly2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units (unvested)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zkblzalKdfj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,495,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,778,284&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zKarluVH0ZL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,549,911&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,876,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zbUa6Bcf3lV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have not included any potential impact of the Series A and B Warrants from the January PO since they were subject to shareholder
approval as of June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000724">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3x6DRAv7bTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six months ended June 30, 2025 and 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zccZWdZJXXg" style="display: none"&gt;Schedule of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250401__20250630_zBQyRflVH45h" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240401__20240630_zZEaQ7g6xDdd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20250630_zDGNYNqEkei8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20240630_z8g5bxqfgZi6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zysC6SZSmFAl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(3,933,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(3,010,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(6,768,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(5,736,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zCb25uWbxYNc" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zTwDq125EzHc" title="Weighted average number of common shares-diluted"&gt;15,569,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zNvcgA0igiBk" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zp8zBZE0AUk9" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zF5fdQcoEg1f" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_z7eXylfBtfhl" title="Weighted average number of common shares-diluted"&gt;12,401,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zILRm64pui2g" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zAw1NI5SyFzl" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20250401__20250630_zOIbgKOcOOPe" title="Basic net loss per share"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20250401__20250630_zrFAWidrfQth" title="Diluted net loss per share"&gt;(0.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zeLZqFlt6owg" title="Basic net loss per share"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zI493FwhU0hj" title="Diluted net loss per share"&gt;(1.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20250630_zxYOMev6ukTj" title="Basic net loss per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20250101__20250630_zk2QVSTHEkDh" title="Diluted net loss per share"&gt;(0.55&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zPKr7WdquEI1" title="Basic net loss per share"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z4ndRW4hLfN8" title="Diluted net loss per share"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Weighted-average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WqXw0ZfFe3" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJknADl25iA" title="Weighted average number of common shares outstanding - diluted"&gt;15,545,266&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgkP1uSqdedl" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjWsER6WVKnf" title="Weighted average number of common shares outstanding - diluted"&gt;2,849,192&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2zRbvhZdN2" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z47QsL2S95J9" title="Weighted average number of common shares outstanding - diluted"&gt;12,371,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzbFuJgrOAz4" title="Weighted-average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVtH5Xkuytz2" title="Weighted-average number of common shares outstanding - diluted"&gt;2,590,530&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Weighted-average number of vested RSUs&#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpW4HpMsiUr" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znCVAMfgSTgi" title="Weighted average number of vested RSUs - diluted"&gt;24,046&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zXOEyX5ulBY" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z5dk2uqVHA2b" title="Weighted average number of vested RSUs - diluted"&gt;134,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zauaD8l29EEl" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFQYUsMAJ4i" title="Weighted average number of vested RSUs - diluted"&gt;29,674&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zyBHiDAhQWkk" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z48afxRmNlcj" title="Weighted average number of vested RSUs - diluted"&gt;134,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630_zhiqQOUVgcie" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630_zqX8kaF32rAj" title="Weighted average number of common shares-diluted"&gt;15,569,312&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zw9Dc8wccNm5" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zqursHq06uda" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630_zn05tG4uxtJl" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630_zwCe6TGM7vCi" title="Weighted average number of common shares-diluted"&gt;12,401,583&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_ziO6dS7M7U24" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zLjZFflDinS2" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000726"
      unitRef="USD">-3933918</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000727"
      unitRef="USD">-3010326</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000728"
      unitRef="USD">-6768323</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000729"
      unitRef="USD">-5736707</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000739"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000741"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000747"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000751"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000753"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000755"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000757"
      unitRef="USDPShares">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000759"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000761"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">15545266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000765"
      unitRef="Shares">15545266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Shares">2849192</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">2849192</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">12371909</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000773"
      unitRef="Shares">12371909</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">2590530</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">2590530</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">24046</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">24046</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">134091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">134091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">29674</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">29674</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">134373</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Shares">134373</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-04-012025-06-30"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">15569312</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000801"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">12401583</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000807"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000811">&lt;p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zT9Ny4TA34dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have
had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zRiN2IsB6Ra2" style="display: none"&gt;Schedule of Dilutive Securities From The Calculation of Diluted Net Loss Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250630_zkrQzxy8BfSe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zrXmypGTbojh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhWcCfvVdS4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,747&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zvbHiH5u0Ly2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units (unvested)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zkblzalKdfj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,495,784&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,778,284&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zKarluVH0ZL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30,549,911&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,876,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_EmployeeStockOptionMember18079015"
      decimals="INF"
      id="Fact000813"
      unitRef="Shares">2747</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">2747</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember18078937"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">51380</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Shares">95028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">30495784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">1778284</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-06-30"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">30549911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30"
      decimals="INF"
      id="Fact000823"
      unitRef="Shares">1876059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <PCSA:LesseeOperatingAndFinancingLeasesTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000825">&lt;p id="xdx_806_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zNHpp80gTIe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_828_z6Z4iswNw9S3"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of &lt;span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20250630_zoWTWsGCbHLl" title="Operating and financing lease borrowing rate"&gt;8&lt;/span&gt;% in determining the present value of the lease payments based on
the information available at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs included in our condensed consolidated statements of operations totaled $&lt;span id="xdx_900_eus-gaap--LeaseCost_c20250401__20250630_zlfox7BaWTof" title="Lease cost"&gt;&lt;span id="xdx_90A_eus-gaap--LeaseCost_c20240401__20240630_zWC0kftusKs7" title="Lease cost"&gt;22,461&lt;/span&gt;&lt;/span&gt; for both three months ending June 30, 2025 and
2024 and $&lt;span id="xdx_90D_eus-gaap--LeaseCost_c20250101__20250630_zwvZqTcZ9au2" title="Lease cost"&gt;&lt;span id="xdx_900_eus-gaap--LeaseCost_c20240101__20240630_zIUd59PC94S6" title="Lease cost"&gt;44,922&lt;/span&gt;&lt;/span&gt; for both six months ending June 30, 2025 and 2024. The weighted average remaining lease terms and discount rate for
our operating leases were as follows at June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zFAc7SvHu3Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zrMCiHT3pKk8" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zfcTa1j3ilS4" title="Remaining lease term (years)"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUwp4wb4Xaq2" title="Remaining lease term (years)"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20250630_zO2uCxN12U9h" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zaD75zPXDL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmVtLUvJNSz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zLnf6mxeVquf" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20250630_zGllg7MuoUrj" style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z1RKsd2fhLGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; padding-bottom: 1pt"&gt;Remainder of 2025&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;23,347&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zAuyxQzpP0y7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zRJVVVEdP7uk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zTDc6qM7A6cd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zxEYGDadTbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,832&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxJf5oAZUB22" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z99fXTTMdHN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zAcqy1RIXNMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zlq9vwgmocMl" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20250630_z6TimV9Ft9Vf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zd98xICrM543" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_z5K4N946tx4j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;560&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_z1PuDZpzRuGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI5BdRRkDQnb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_znuLvlP8E0x5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIRPnAxV9MDk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zj5p4XKBN0li" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;Less: current maturities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z2lW7IFlz6e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_907_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zpm6BpzM4316" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;Non-current lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z75UR0DVH30i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;






</PCSA:LesseeOperatingAndFinancingLeasesTextBlock>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000827"
      unitRef="Pure">0.08</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LeaseCost
      contextRef="From2025-04-012025-06-30"
      decimals="0"
      id="Fact000829"
      unitRef="USD">22461</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000831"
      unitRef="USD">22461</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2025-01-01to2025-06-30"
      decimals="0"
      id="Fact000833"
      unitRef="USD">44922</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-012024-06-30"
      decimals="0"
      id="Fact000835"
      unitRef="USD">44922</us-gaap:LeaseCost>
    <PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000837">&lt;p id="xdx_899_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zFAc7SvHu3Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zrMCiHT3pKk8" style="display: none"&gt;Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zfcTa1j3ilS4" title="Remaining lease term (years)"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUwp4wb4Xaq2" title="Remaining lease term (years)"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_pid_dp_uPure_c20250630_zO2uCxN12U9h" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2025-06-30_custom_FacilityLeaseMember"
      id="Fact000839">P0Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="AsOf2025-06-30_us-gaap_EquipmentMember"
      id="Fact000841">P0Y7M6D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000843"
      unitRef="Pure">0.080</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000845">&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmVtLUvJNSz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zLnf6mxeVquf" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20250630_zGllg7MuoUrj" style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z1RKsd2fhLGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; padding-bottom: 1pt"&gt;Remainder of 2025&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;23,347&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zAuyxQzpP0y7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zRJVVVEdP7uk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zTDc6qM7A6cd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,832&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zxEYGDadTbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(21,832&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zxJf5oAZUB22" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000847"
      unitRef="USD">23347</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000849"
      unitRef="USD">23347</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000851"
      unitRef="USD">1515</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000853"
      unitRef="USD">21832</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000855"
      unitRef="USD">21832</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000859">&lt;p id="xdx_894_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zAcqy1RIXNMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at June 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zlq9vwgmocMl" style="display: none"&gt;Schedule of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20250630_z6TimV9Ft9Vf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zd98xICrM543" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_z5K4N946tx4j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;560&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_z1PuDZpzRuGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI5BdRRkDQnb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseLiability_iI_znuLvlP8E0x5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,752&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zIRPnAxV9MDk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zj5p4XKBN0li" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;Less: current maturities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_z2lW7IFlz6e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_907_eus-gaap--FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20250630_zpm6BpzM4316" title="::XDX::http%3A%2F%2Fprocessapharmaceuticals.com%2F20250630%23OperatingAndFinanceLeaseLiabilityNoncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;Non-current lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000861"
      unitRef="USD">3360</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000863"
      unitRef="USD">560</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000865"
      unitRef="USD">3920</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000867"
      unitRef="USD">168</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000869"
      unitRef="USD">3752</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000871"
      unitRef="USD">3752</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000877">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_ze9gXe6LDYK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_825_zdqcdT7GGcDa"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CorLyst,
LLC (&#x201c;CorLyst&#x201d;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred,
which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated
statement of operations. Included in our general and administrative expenses is approximately $&lt;span id="xdx_900_eus-gaap--RecoveryOfDirectCosts_c20250401__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zufJEqvmGxx7" title="Reimbursements received"&gt;31,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_901_eus-gaap--RecoveryOfDirectCosts_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zDtc3ZXNNerg" title="Reimbursements received"&gt;27,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of reimbursements from CorLyst during the three months ended
June 30, 2025 and 2024, respectively, and $&lt;span id="xdx_90C_eus-gaap--RecoveryOfDirectCosts_c20250101__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zN4r3uud0nH2" title="Reimbursements received"&gt;60,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90F_eus-gaap--RecoveryOfDirectCosts_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zBWYKFW0VEs8" title="Reimbursements received"&gt;50,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the six months ended June 30, 2025 and 2024. At June 30,
2025, we included approximately $&lt;span id="xdx_90D_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpW91teHCuQ5" title="Due from related parties"&gt;29,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;due from CorLyst as a current asset in Prepaid and Other. Our
President, Research and Development is the CEO of CorLyst, and CorLyst is a stockholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="From2025-04-012025-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000879"
      unitRef="USD">31000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="From2024-04-012024-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000881"
      unitRef="USD">27000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="From2025-01-012025-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000883"
      unitRef="USD">60000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="From2024-01-012024-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000885"
      unitRef="USD">50000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">29000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000889">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zyH0kcoMQvy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_826_zmFIvSOykUZ9"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating
decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus
actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations
and comprehensive loss as consolidated net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zgLCF8aoESJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zZufT0nPmGGe" style="display: none"&gt;Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zNWJzZLtLmsd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zlhsxvXSS1G5" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_ztcVC35Ts9m6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zgt24ZWuv6g2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PreclinicalClinicalTrialAndOtherCosts_zCeH9ckbKyii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Preclinical, clinical trial and other costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,142,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,261,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,339,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,293,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zEGqH8EgqzUa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel expense&lt;sup id="xdx_F4B_zhuy8nrNbSYi"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;976,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zHOLDxoMw79a" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel
expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;976,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zaYLf3fhut01" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative personnel expense&lt;sup id="xdx_F44_zD8JbZyluxX5"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;628,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,302,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zfAsZjvssMqa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative
personnel expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;628,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,302,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zxrqkYJC0j6k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities expense&lt;sup id="xdx_F4E_zQc48XVSEdv"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;875,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;905,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,459,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zHBW9TZKFWJe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities
expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;875,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;905,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,459,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InvestmentIncomeInterest_di_zI9PgfScKSpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(71,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,450&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(154,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iNT_di_zsccqLLBMH54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,933,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,010,326&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,768,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,736,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F09_zi09RiT0x1C7"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zkJPd2W63f79" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense"&gt;8,613&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense"&gt;45,583&lt;/span&gt; for the three months ended
    June 30, 2025 and 2024, respectively, and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense"&gt;55,333&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense"&gt;76,704&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0B_zOEEghvgeZNi"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zC8nYhvS8sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense"&gt;122,655&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense"&gt;40,309&lt;/span&gt; for the three months
    ended June 30, 2025 and 2024, respectively, and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense"&gt;245,310&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense"&gt;79,180&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F07_zhvE94uaLy0i"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_z3J02240kkA5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative
    &amp;amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_z5qUYBLAepgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000891">&lt;p id="xdx_89B_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zgLCF8aoESJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zZufT0nPmGGe" style="display: none"&gt;Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zNWJzZLtLmsd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240401__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zlhsxvXSS1G5" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_ztcVC35Ts9m6" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zgt24ZWuv6g2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PreclinicalClinicalTrialAndOtherCosts_zCeH9ckbKyii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Preclinical, clinical trial and other costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,142,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,261,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3,339,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,293,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zEGqH8EgqzUa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel expense&lt;sup id="xdx_F4B_zhuy8nrNbSYi"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;976,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zHOLDxoMw79a" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development personnel
expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;696,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;976,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zaYLf3fhut01" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative personnel expense&lt;sup id="xdx_F44_zD8JbZyluxX5"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;628,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,302,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember_zfAsZjvssMqa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General and administrative
personnel expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;628,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,302,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;964,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zxrqkYJC0j6k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities expense&lt;sup id="xdx_F4E_zQc48XVSEdv"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;875,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;905,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,459,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AdministrativeAndFacilitiesExpense_zHBW9TZKFWJe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative and facilities
expense&lt;sup&gt;&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;875,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;905,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,459,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,657,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InvestmentIncomeInterest_di_zI9PgfScKSpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(16,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(71,698&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,450&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(154,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iNT_di_zsccqLLBMH54" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,933,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,010,326&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,768,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,736,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F09_zi09RiT0x1C7"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zkJPd2W63f79" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4" title="Stock-based compensation expense"&gt;8,613&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7" title="Stock-based compensation expense"&gt;45,583&lt;/span&gt; for the three months ended
    June 30, 2025 and 2024, respectively, and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6" title="Stock-based compensation expense"&gt;55,333&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a" title="Stock-based compensation expense"&gt;76,704&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0B_zOEEghvgeZNi"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zC8nYhvS8sM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative personnel costs include employee stock-based compensation expense of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh" title="Stock-based compensation expense"&gt;122,655&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj" title="Stock-based compensation expense"&gt;40,309&lt;/span&gt; for the three months
    ended June 30, 2025 and 2024, respectively, and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl" title="Stock-based compensation expense"&gt;245,310&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7" title="Stock-based compensation expense"&gt;79,180&lt;/span&gt; for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F07_zhvE94uaLy0i"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_z3J02240kkA5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Administrative
    &amp;amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">2142229</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">1261720</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">3339263</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <PCSA:PreclinicalClinicalTrialAndOtherCosts
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">2293001</PCSA:PreclinicalClinicalTrialAndOtherCosts>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000898"
      unitRef="USD">305057</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000899"
      unitRef="USD">468724</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000900"
      unitRef="USD">696504</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">976554</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">305057</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">468724</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">696504</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">976554</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000908"
      unitRef="USD">628330</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">445620</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000910"
      unitRef="USD">1302167</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">964409</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000913"
      unitRef="USD">628330</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000914"
      unitRef="USD">445620</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">1302167</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000916"
      unitRef="USD">964409</us-gaap:GeneralAndAdministrativeExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">875167</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">905960</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">1459839</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000921"
      unitRef="USD">1657658</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000923"
      unitRef="USD">875167</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">905960</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000925"
      unitRef="USD">1459839</PCSA:AdministrativeAndFacilitiesExpense>
    <PCSA:AdministrativeAndFacilitiesExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">1657658</PCSA:AdministrativeAndFacilitiesExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">16865</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">71698</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">29450</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000931"
      unitRef="USD">154915</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-04-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">-3933918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000935"
      unitRef="USD">-6768323</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">-5736707</us-gaap:NetIncomeLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">8613</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000941"
      unitRef="USD">45583</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000943"
      unitRef="USD">55333</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">76704</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-04-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">122655</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000950"
      unitRef="USD">40309</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">245310</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember_custom_EmployeesMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">79180</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000957">&lt;p id="xdx_803_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_z90mIn0BO6Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_824_zIc9hVjfT3Ji"&gt;PCS12852&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 17, 2025, we entered into a binding term sheet (&#x201c;Term Sheet&#x201d;) with Intact Therapeutics (&#x201c;Intact&#x201d;) granting
Intact the exclusive option to license PCS12852, a highly specific and potent 5HT5 agonist &lt;span style="background-color: white"&gt;that
is Phase 2B ready as potentially the first meaningful treatment for diabetic gastroparesis patients.&lt;/span&gt; &lt;span id="xdx_907_ecustom--TermSheetDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zhgmgWiDn9cl" title="Description of term sheet"&gt;Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--TermSheetRemainingDiligenceDescription_c20250617__20250617__srt--ProductOrServiceAxis__custom--PCS12852Member_zmexDf8czWCc" title="Description of term sheet"&gt;The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000.&lt;/span&gt; There can be no assurance that
the Company and Intact will enter into a license agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Term Sheet, Yuhan Corporation executed Amendment No. 1 to our existing license agreement dated August 19, 2020 (the
&#x201c;Yuhan Agreement&#x201d;), effective June 11, 2025, which, among other things, extended the deadline to dose the first patient in
a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial from 48 months to 108 months from the effective date
of the original agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <PCSA:TermSheetDescription
      contextRef="From2025-06-172025-06-17_custom_PCS12852Member"
      id="Fact000959">Upon execution of the Term
Sheet, Intact agreed to pay a non-refundable standstill payment of $20,000 and upon execution of a license agreement, the Company will
receive a 3.5% equity interest in Intact and a payment of $2.5 million, with $1.0 million paid within thirty days of closing and the
remaining $1.5 million paid within twelve months of closing. The Term Sheet also provides that the license agreement will provide for
development and regulatory milestone payments, commercial milestone payments based on net product sales and a 12% royalty on worldwide
net sales of licensed products, excluding South Korea.</PCSA:TermSheetDescription>
    <PCSA:TermSheetRemainingDiligenceDescription
      contextRef="From2025-06-172025-06-17_custom_PCS12852Member"
      id="Fact000961">The
obligations of the parties to enter into the license agreement are subject to additional diligence by Intact. Pursuant to the Term Sheet,
the parties have one hundred and twenty (120) days to finish any remaining due diligence and enter into the license agreement, which
period may be extended for an additional one hundred and twenty days for an additional fee of $30,000.</PCSA:TermSheetRemainingDiligenceDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000963">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmZkpPVBp9Sc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_825_zUw8WCPkiWB3"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Obligations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2025, we are contractually obligated to pay up to $&lt;span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20250630__us-gaap--TypeOfArrangementAxis__custom--CROsMember_zzwPKqury4Vl" title="Purchase obligation"&gt;13.1&lt;/span&gt; million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2025-06-30_custom_CROsMember"
      decimals="-5"
      id="Fact000965"
      unitRef="USD">13100000</us-gaap:PurchaseObligation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-06-30" id="Fact000967">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zmh30fozWaJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_826_zgP6ijFNE0Pa"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;RSU
Grants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 24, 2025, the Compensation Committee of our Board of Directors granted RSUs for the future issuance of up to &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250724__20250724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zn6iguZTRFA5" title="Number of shares granted"&gt;356,310&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock to our employees and independent directors.
The RSUs vest over a 1-3 year period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Equity
Sales&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 4, 2025, we entered into a Securities Purchase Agreement with an accredited investor and sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdcAWabcectf" title="Sale of stock shares"&gt;5,467,181&lt;/span&gt; shares for $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zc6eJE964wCa" title="Gross proceeds"&gt;1.3&lt;/span&gt;
million in gross proceeds. We also sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNJJIZeIPJug" title="Sale of stock shares"&gt;4,597,612&lt;/span&gt; shares for $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250804__20250804__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMN5IAtxSOw2" title="Gross proceeds"&gt;1.1&lt;/span&gt; million in gross proceeds under our ATM agreement. Following these
investments, we are exploring options to pursue a cryptocurrency treasury strategy.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-07-242025-07-24_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">356310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Shares">5467181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000973"
      unitRef="USD">1300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">4597612</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-08-042025-08-04_us-gaap_InvestorMember_custom_ATMAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000977"
      unitRef="USD">1100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-04-012025-06-30" id="Fact000978">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-04-012025-06-30" id="Fact000979">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-04-012025-06-30" id="Fact000980">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-04-012025-06-30" id="Fact000981">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000898"
          xlink:label="Fact000898"
          xlink:type="locator"/>
        <link:footnote id="Footnote000937" xlink:label="Footnote000937" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Research
    and development personnel costs include employee stock-based compensation expense of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zFm8h5j7ygU4"
  title="Stock-based compensation expense">8,613</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqVbJy3R6SB7"
  title="Stock-based compensation expense">45,583</xhtml:span> for the three months ended
    June 30, 2025 and 2024, respectively, and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zgFKD6LdgEw6"
  title="Stock-based compensation expense">55,333</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z0uuRgt6Ql8a"
  title="Stock-based compensation expense">76,704</xhtml:span> for the six months ended June 30, 2025 and 2024, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000898"
          xlink:to="Footnote000937"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000899"
          xlink:label="Fact000899"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000899"
          xlink:to="Footnote000937"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000900"
          xlink:label="Fact000900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000900"
          xlink:to="Footnote000937"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000901"
          xlink:label="Fact000901"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000901"
          xlink:to="Footnote000937"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000908"
          xlink:label="Fact000908"
          xlink:type="locator"/>
        <link:footnote id="Footnote000946" xlink:label="Footnote000946" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">General
    and administrative personnel costs include employee stock-based compensation expense of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDdNE4Q13JKh"
  title="Stock-based compensation expense">122,655</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240401__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zjjJrGzVvltj"
  title="Stock-based compensation expense">40,309</xhtml:span> for the three months
    ended June 30, 2025 and 2024, respectively, and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zLH7NkXKB6Xl"
  title="Stock-based compensation expense">245,310</xhtml:span> and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zydGpiYCQ1m7"
  title="Stock-based compensation expense">79,180</xhtml:span> for the six months ended June 30, 2025 and 2024, respectively,
    and are net of reimbursements received from CorLyst, LLC.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000908"
          xlink:to="Footnote000946"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000909"
          xlink:label="Fact000909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000909"
          xlink:to="Footnote000946"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000910"
          xlink:label="Fact000910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000910"
          xlink:to="Footnote000946"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000911"
          xlink:label="Fact000911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000911"
          xlink:to="Footnote000946"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000918"
          xlink:label="Fact000918"
          xlink:type="locator"/>
        <link:footnote id="Footnote000955" xlink:label="Footnote000955" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Administrative
    &amp; facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
    and other administrative costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000918"
          xlink:to="Footnote000955"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000919"
          xlink:label="Fact000919"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000919"
          xlink:to="Footnote000955"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000920"
          xlink:label="Fact000920"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000920"
          xlink:to="Footnote000955"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000921"
          xlink:label="Fact000921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000921"
          xlink:to="Footnote000955"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
